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ABSTRACT 
 
The pre-erythrocytic stages of malaria are the preliminary steps to a disease of massive 
global health importance. Following transmission of sporozoites by mosquito bite to a 
human host, a clinically silent period of parasite development in the liver preludes the 
harmful blood stages that characterise malarial infection. Creating a vaccine that targets 
these stages is a very attractive notion as it would prevent this burden of disease. 
Protection against the pre-erythrocytic stages has been shown to be dependent on CD8+ 
T cells. However, very few antigens that induce anti-Plasmodium CD8+ T cell responses 
have been identified, especially those expressed by the parasite when developing inside 
hepatocytes. Using mouse models, experimental genetics and bioinformatics tools, I 
present work that has progressed our understanding of CD8+ T cells induced in the pre-
erythrocytic stages of malaria and assessed the ability of antigen-specific CD8+ T cells 
to protect against subsequent challenge following vaccination. 
 
I have investigated and compared the differences in CD8+ T cell responses to a 
sporozoite (Circumsporozoite Protein) and a vacuolar membrane liver stage protein 
(Upregulated in Infectious Sporozoites gene 4) and showed that despite a divergence in 
immunogenicity when immunising with radiation attenuated sporozoites, both types of 
antigen are equally protective when mice are vaccinated with viral vectors to induce large 
antigen-specific CD8+ T cell populations. The natural immunogenicity of the liver stage 
antigen does not improve when liver stage development is extended by using drug 
prophylaxis. Additionally, I have compared the protection induced by liver stage antigens 
expressed constitutively after hepatocyte invasion and those expressed only after at 
least 12 hours post invasion. I have shown that some protection can be induced by the 
mid-late expressed Liver Specific Proteins 1 and 2, suggesting that these antigens are 
effectively presented and recognised by CD8+ T cells. This highlights the potential for 
the incorporation of liver stage antigens into next-generation malaria vaccines. 
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Additionally, I have investigated the role of the immunodominant CD8+ T cell epitope of 
Circumsporozoite Protein and showed that a significant level of protection is mediated 
by CD8+ T cells specific for this epitope. Nonetheless, following multiple immunisations 
with a parasite lacking this epitope, sterile protection can still be achieved, suggesting 
other antigens are important for parasite-induced protection. Thus, finally I go on to 
identify a number of novel CD8+ T cell epitopes from antigens expressed in the 
sporozoite and liver stage parasite, to further broaden our view of the CD8+ T cell 
responses induced during the pre-erythrocytic stages of malaria. 
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INTRODUCTION 
 
Malaria is a major global health challenge and remains a deadly disease with 3 billion 
people in the population at risk of infection1. Malaria is endemic to 91 countries in the 
tropical and subtropical regions of the globe1. There were around 216 million cases 
reported in 2016, resulting in around 445,000 deaths, with 80% of global cases occurring 
in 14 countries in sub-Saharan Africa and India1. 
 
Malaria sits on the world stage as one of the most high profile diseases and is one of the 
most heavily funded organisms destined for eradication although the resources are not 
always spread evenly between endemic countries2, 3. Reports indicate a general decline 
in malaria over the last decades however there are recent cases of countries rebounding 
from the brink of eradication as has been seen previously4, including an increase of 5 
million cases worldwide from that seen a year before in 20151. The global reduction in 
malaria prevalence and related deaths is likely through an increased use of insecticide 
treated bed nets, indoor residual spraying and improved access to and availability of 
effective anti-malarials. Nonetheless, to achieve the World Health Organisation (WHO) 
vision of “A world free of malaria” a highly efficacious malaria vaccine is warranted. 
 
Malaria in humans is caused by five species of the Apicomplexan protozoan 
Plasmodium. Plasmodium falciparum is the most prevalent human malaria parasite in 
Africa5. P. vivax is the most widespread human malaria parasite, constituting the majority 
of malarial cases in Asia, Central and South America, though it is often wrongly deemed 
to be of lower importance in terms of mortality and morbidity compared to P. falciparum6. 
Less common species include P. malariae and P. ovale which cause milder forms of 
malaria7. With importance to morbidity, P. vivax and P. ovale can form hypnozoites within 
the liver; metabolically active parasites waiting for reactivation by some as yet unknown 
trigger8. Relapses can often occur years later, if only the intermittent blood stage 
infections, and not the liver resident hypnozoites, are treated9. Finally and relatively 
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recently, zoonotic P. knowlesi, first surveyed in Sarawak (Malaysian Borneo)10, was 
identified as the fifth species of Plasmodium that infects humans, though the natural 
hosts are macaque monkeys. Prior to this many malaria cases in Southeast Asia were 
microscopically misdiagnosed as P. malariae. However it has been shown that the 
severity and lethality of P. knowlesi infection is much greater than that of P. malariae 
infection11. 
 
The Plasmodium parasite is transmitted by female Anopheles mosquitoes and seeks to 
continuously cycle between the mosquito and vertebrate host. Many vertebrates are 
susceptible to malaria. Plasmodia species are known to infect sauropsids (birds and 
lizards), primates, bats and rodents12. Transmission can occur anywhere where the 
Plasmodium species, preferred vector and preferred host reside. The life cycle of malaria 
(discussed below) can be divided into three broad phases: vector stages, pre-
erythrocytic stages and erythrocytic stages. Symptoms of malarial infection in humans 
are only exhibited in the erythrocytic or blood stage which can include cycles of fever, 
headaches and nausea as the parasite asexually reproduces. Severe malaria can result 
in anaemia, organ failure and cerebral malaria in complicated cases and- in non-immune 
individuals- will often result in death if left untreated as acute parasite infection is non-
limiting. 
 
THE LIFE CYCLE OF PLASMODIUM 
The initiation of the life cycle of Plasmodium in the vertebrate host (pre-erythrocytic 
stages) starts with the injection of infectious sporozoites from an infected female 
Anopheles mosquito. The mosquito probes the skin before taking a blood meal which 
involves injecting saliva, which contains factors that help locate a blood vessel through 
vasodilation amongst other mechanisms13. This probing and salivation release the 
parasite from the mosquito salivary glands. The parasite in its elongated sporozoite form 
then glides in the skin, trickling out the dermis until it finds a capillary blood vessel14. 
Finding a dermal capillary, the parasite traverses the endothelium and passes into the 
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bloodstream15. From here, the parasite will travel to the liver to seek a hepatocyte to 
invade and develop into its liver stage form, an exo-erythrocytic form (EEF).  
 
The sporozoite must cross the liver sinusoid, made up of fenestrated liver sinusoid 
endothelial cells (LSECs) and Kupffer cells (KCs), resident macrophages in the liver, in 
order to reach the parenchyma and hepatocytes below16. Sporozoites traverse several 
hepatocytes before invading properly17 and initiating EEF development. Sporozoites 
traverse in a transient vacuole18, whereas genuine invasion results in parasitophorous 
vacuole (PV) formation that protects the parasite from the cytoplasm of the hepatocyte. 
The PV is enclosed by a membrane, the parasitophorous vacuole membrane (PVM), 
composed of host cell origin which is then rapidly modified with parasite-derived 
proteins19. The EEF grows and undergoes mitotic division of the genome without 
cytokinesis (schizogony) within the PV to form thousands of merozoites inside the 
hepatocyte20. Membrane encompassed merozoites (merosomes) bud into the sinusoid 
of the liver and release merozoites into the bloodstream, where upon they can invade 
erythrocytes. This is the initiation of the erythrocytic stages and up until this point, an 
infected individual is unaware of the parasites in their body with the erythrocytic stages 
of malaria being the only stage responsible for the pathogenesis associated with malaria.  
 
The merozoites replicate asexually, with invasion, development and rupture of 
erythrocytes occurring every 24, 48 or 72 hours, depending on the species of 
Plasmodium21. Merozoites invade erythrocytes through a variety of redundant 
mechanisms, utilising different erythrocyte and parasite membrane proteins.  Erythrocyte 
proteins acting as receptors include glycophorins22-24, complement receptor 125, basigin26 
and duffy antigen receptor for chemokines (DARC) in P. vivax invasion27 with the parasite 
interacting via different erythrocyte binding ligand (EBLs), reticulocyte binding protein 
(RBPs) and Duffy-binding proteins (DBPs), released from the micronemes and rhoptries 
of the parasite, though many interactions have still to be resolved28. Once inside the 
erythrocyte, the merozoite replicates to form a schizont of 16-32 merozoites. Parasites 
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rupture their host erythrocyte synchronously before subsequently invading new nearby 
erythrocytes21. These processes induce a milieu of inflammatory cytokines and 
molecules from the immune system which induces the bouts of fever which are famously 
associated with malarial disease29. If left untreated this replication will continue, which in 
non-immune individuals can result in death by anaemia, organ failure and/or cerebral 
malaria as parasites sequester in different locations in the body. Cerebral malaria has 
been proposed to occur by several different mechanisms and the pathogenesis of severe 
malaria has also been found to vary depending on endemic location and age of host30. 
 
At some stage, although it is not fully determined what the trigger(s) are, some asexual 
blood stage parasites change and commit to development into gametocytes, the sexual 
stage of the parasite. This switch requires the gene ap2-g to be epigenetically 
derepressed31 and through a positive feedback loop32 produce increasingly levels of 
AP2-G, an AP2 domain DNA-binding protein transcription factor. AP2-G is the master 
regulator of sexual commitment32, 33 and is a transcriptional activator for early 
gametocytogenesis genes34. Once fully mature, gametocytes are believed to remain 
dormant in G0 phase of the cell cycle inside erythrocytes until uptake by a mosquito35. 
Both male and female gametocytes are required to be taken up by a mosquito to 
generate the next parasite progeny in the vector stages. 
 
Following uptake of male and female gametocytes into a female mosquito, by means of 
blood meal, the mature gametocytes escape from their erythrocytes and form gametes. 
Inside the midgut of the mosquito, both gametocytes round up with the male gametocyte 
undergoing three rounds of rapid replication to form 8 motile microgametes which leave 
the erythrocyte and adhere to neighbouring erythrocytes in an observable process called 
exflagellation36. Differentiation into gametes is caused by two environmental triggers: a 
drop in temperature37 and mosquito derived xanthurenic acid38, 39. Microgametes go in 
search for a female macrogamete, to initiate fertilisation, with fusion of plasma 
membranes and nuclear fusion to form a tetraploid, or diploid zygote40. The zygote 
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transforms into a motile ookinete, which traverses the midgut epithelium and embeds 
itself between the basement epithelium and basal lamina to form an oocyst41. Following 
successful embedding, mitotic division occurs40 and sporozoites are formed within 
syncytial lobes of the oocyst called sporoblasts42 in a process called sporogony. Rupture 
of the oocysts release sporozoites into the haemocoel of the mosquito either through 
sporozoites actively escaping the oocyst membrane43 or the action of a protease44. Once 
in the haemocoel, the sporozoites travel via haemolymph circulation and attach and 
invade salivary glands to further mature45. The host mosquito now harbours infectious 
sporozoites ready to be released during probing and salivation, prior to blood feeding, 
thus restarting the Plasmodium life cycle. 
 
THE PRE-ERYTHROCYTIC STAGES OF MALARIA 
The development of an efficacious vaccine against malaria is still a long way away, 
though major advances in technology and techniques have allowed more information to 
be derived from the host-parasite interactions of the parasite at its different life stages 
and the immune responses that are induced. Alongside advances in vaccine 
development, there is now increased understanding of how to best induce appropriate 
immune responses to provide protection against parasite development in these stages. 
Focusing on the pre-erythrocytic stages, I will review the biological and immunological 
processes that occur at these stages, derived from murine and human studies and 
highlight recent advances in these fields. Creating a vaccine against the pre-erythrocytic 
stage is attractive because elimination of the parasite at an early time point following 
sporozoite injection by mosquito and prior to fulminant blood stage infection would 
prevent all malarial pathology associated with the erythrocytic stage and also prevent 
further transmission of the parasite. 
 
Previously, the pre-erythrocytic stages of Plasmodium infection were considered a 
singular process. However, given the changes in parasite form and migration through 
multiple locations in the vertebrate host, we, amongst others, have seen it pertinent to 
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reconsider these stages in terms of these differences. While sporozoites and EEFs are 
perpetually interlinked, classical immunology would suggest that sporozoite and EEFs 
would be dealt with quite differently. Considerations of the environment in which the 
parasite is found will also likely have an impact on the immune responses that are 
induced. 
 
HOST-PARASITE INTERACTIONS 
Entry and exit from the skin 
Sporozoites are injected intradermally into the skin of the host, by mosquito bite, where 
they search for a blood vessel in order to travel to the liver. Experimentally, only around 
100 sporozoites are injected into the skin by a single infected mosquito, though inoculum 
dose and ability of infected mosquitoes to inject sporozoites varies46, with around 1-2.5 
sporozoites per second released from the proboscis47, 48. There is recent evidence from 
human and mouse studies that mosquitoes with high numbers of sporozoites in the 
salivary gland post feeding are more likely to have transmitted the parasite49. New 
advances with the engineering of enamel coated glass pipettes may allow more 
physiological injection of sporozoites intradermally for intravital imaging rather than that 
previously executed using metal needles50. 
 
Sporozoites move in the skin and liver by gliding on the extracellular substrate using the 
surface Thrombospondin Related Anonymous Protein (TRAP) that connects to a 
submembrane actin-myosin motor, which propels the parasite forward51. TRAP 
originates in the microneme organelles at the apical end of the sporozoite52, which also 
release other proteins important for adhesion and motility53. In humans, thev-subunit 
of integrins, with a preference for v3 integrins, are the direct host receptors for P. 
falciparum TRAP54. Sporozoites glide at an average speed of 1-2m/s55 but show an 
increasingly constrained motility at the inoculation site. The peak of sporozoite motile 
and dispersal activity occurs in the first 15 minutes, with more sporozoites exhibiting a 
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circling rather than meandering behaviour as time progresses15. Sporozoites face a 
tripartite fate once deposited in the skin14, 55 with ~60% parasites remaining in the skin 
(sporozoites start to be killed off after 3 hours in the dermis14) and the other sporozoites 
either successfully enter the bloodstream via a blood vessel (25%) or enter a lymphatic 
vessel (15%)55. The sporozoite uses gliding motility and cell traversal to move between 
different cells including fibroblasts and leukocytes to reach a vessel56 with traversal 
through endothelial cells to finally reach the lumen of the vessel. Several proteins that 
have important roles in gliding and cell traversal have been investigated for role in 
sporozoite exit from the skin. TRAP is essential for gliding57, 58; the proteins Sporozoite 
microneme Protein Essential for Cell Traversal (SPECT) and Perforin-Like Protein 1 
(PLP1) are important for cell traversal of phagocytes, to avoid clearance and prevent 
infection of cells in the skin which the parasite is not destined for59. Also, TRAP-Like 
Protein (TLP) and Phospholipase (PL) both may have a role in sporozoite traversal in 
the dermis as parasite liver loads are significantly lower in mice receiving intradermal 
injections of murine infective P. berghei PbTLP– 60 or PbPL knock-out61 (KO) parasites 
compared to wild-type (WT) parasites. Invasion of blood vessels seems to be aided by 
some structural tropism, with a preference for blood vessels with a similar curvature to 
the sporozoite60 that strengthens the argument that sporozoites are guided to blood 
vessels more by physical characteristics than a reliance of chemotactic signals61. 
 
Entering the lymphatics is considered a dead end for the parasite62 in terms of 
development as sporozoites become trapped in the proximal draining lymph node where 
they mostly associate or are taken up by CD11c+ dendritic cells (DCs) and while EEFs 
do form in endothelial cells, they do not reach full development akin to intra-hepatocyte 
development55. Interestingly, EEF development has also been shown to occur at the 
inoculation site in the skin63, 64. Up to 10% of sporozoite remaining in the skin can develop 
into EEFs, which are comparable to those seen in the hepatocytes, but with a reduced 
susceptibility to primaquine63, 64. However, the ability to induce a blood stage infection in 
vivo could not be demonstrated63, 64. Only one study could induce parasitaemia, by 
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intravenous injection of skin derived P. berghei merozoites, in naïve mice63. In fact, P. 
berghei has also been found growing in immunoprivileged hair follicles63 although the 
possibility that they could represent a dormant reservoir has not been further investigated 
and it is not known how this may translate to human Plasmodia. However, sporozoites 
that lack the N-terminus of Circumsporozoite Protein (CSP),  that masks the C-terminal 
Type I Thrombospondin Repeat (TSR) motif to prevent invasion of hepatocytes until the 
right time, cannot leave the skin but subsequently develop and induce a blood stage 
infection in situ, indicating a key role for CSP conformation in maintaining the sporozoite 
in a migratory state65. CSP is the major surface protein of the sporozoite, attached to the 
parasite plasma membrane (PPM) by a C-terminal glycosylphosphatidylinositol anchor66. 
It is a conserved protein across Plasmodia species with conserved N-terminal and C-
terminal regions flanking a central species-specific repeat section67. CSP is necessary 
for sporozoite development and hepatocyte targeting68 and is constantly shed from the 
sporozoite during gliding motility69. 
 
Seeking a hepatocyte 
Once sporozoites have traversed the endothelia of dermal blood vessels and entered 
the bloodstream, the destination they seek is the hepatocytes of the liver. Development 
in hepatocytes in mammals is an obligatory step in the Plasmodia life cycle and 
sporozoites are passively transported to the liver sinusoid in a matter of minutes70. The 
liver sinusoid is the open pore capillary network of the liver which perfuses the 
parenchyma plates of hepatocytes made up of Liver Sinusoid Endothelial Cells (LSECs), 
whose fenestrations allows passage of small molecules across their cytoplasm into the 
perisinusoidal space of Disse which separates the vessel from the hepatocytes71. The 
sinusoid also contains Kupffer cells (KCs), vascular resident macrophages, found in the 
lumen, and stellate cells, in the space of Disse, which secrete Heparan Sulphated 
Proteoglycans (HSPGs). Sporozoites passing through the liver in the blood are 
essentially stalled in the sinusoid and associate with the lumen by interaction between 
the parasite surface CSP with HSPGs72 that protrude through the LSEC fenestrations, 
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like a signal indicating that the sporozoite has reached the liver73. Sporozoites need to 
traverse the sinusoid to arrive at the hepatocytes. Sporozoites can cross the endothelium 
in a number of ways. They can traverse KCs16, 74, 75, LSECs16 or migrate between 
LSECs16 with the vast majority of entry events being traversal related through KCs16. Cell 
traversal seems to act two-fold, as the quickest way to get across the sinusoid to the 
hepatocytes and as a mechanism to avoid phagocytosis by KCs16. Traversal of KCs has 
been proposed to occur by interaction of glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) on the sporozoite surface with CD68, a transmembrane glycoprotein, 
expressed on cells of the macrophage lineage, with interference of this interaction 
conferring protection from sporozoite challenge76. 
 
The CSP-HSPG interaction as well as acting as the pathway marker is also believed to 
be the driver of shifting sporozoites into an invasive phenotype77. The sporozoites exhibit 
cell traversal as a normal phenotype, however when they come into contact with the 
uniquely high level of sulphation on HSPGs as seen in the liver, parasite calcium 
dependent protein kinase 6 (CDPK6) is activated77 that leads to N-terminal CSP 
cleavage by a cysteine protease78, which in turn exposes the TSR C-terminal fragment65. 
This exposure of the TSR is the indicator of an invasive phenotype. However, it is unclear 
when sporozoites switch to invasive phenotype, which could occur in the sinusoid lumen, 
later in the space of Disse or in the parenchyma. Switching to invasion appears not to be 
a binary process, with several signals likely required to execute a fully invasive 
phenotype79 and thus sporozoites are seen to continue to exhibit cell traversal, passing 
through several hepatocytes before ‘choosing’ a hepatocyte to invade and develop in17. 
It has been shown that sporozoites traverse hepatocytes using transient vacuoles, which 
they can escape from before leaving the cell through the action of PLP118, though 
whether this is the case in other cell types it is not known. SPECT and PLP1 have been 
shown to be essential for human hepatocyte traversal of P. falciparum and that traversal 
is important for invasion for human hepatocytes in humanised mice in vivo80. A further 
traversal related protein, LIMP (referring to the sporozoite phenotype when the protein 
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is epitope tagged), has been characterised with KO parasites limp showing a severe 
reduction in gliding and adhesion to hepatocytes, a complete inability to traverse 
hepatocytes and a vastly reduced ability to invade hepatocytes81. 
 
The trigger for the unmasking of the TSR of CSP and the exact interactions that the TSR 
has with the hepatocyte to initiate invasion are not known. Using experimental genetics, 
several proteins have been found to have critical and major roles in invasion, but the 
actual series of events that occur during invasion have not been completely realised, in 
contrast to the extensive knowledge of events occurring during erythrocyte invasion of 
merozoites28. Sporozoite invasion of hepatocytes has been shown to be influenced by 
cGMP and Ca2+ signalling with an essential and important role for cGMP-dependent 
protein kinase (PKG) and calcium-dependent protein kinase 4 (CDPK4) respectively, 
with invasion affected by the enzymes limiting sporozoite motility82. TRAP binds to 
HSPGs through its extracellular domain and binds the actin-myosin motor through its 
cytoplasmic domain83 using aldolase as a bridge84, 85. P52 and P36 are members of the 
6-cys protein family and are likely interlinked in their invasive roles. 6-cys proteins contain 
one or multiple s48/45 domains, a conserved protein fold containing 6-cysteines which 
can form disulphide bridges86. Proteins containing these domains have been found on 
the surface of gametes, sporozoites and merozoites with many having adhesion related 
functions86. Deletions or disruptions of P52 and/or P36 genes in P. berghei87, 88, P. yoelii89 
and P. falciparum88, 90 have been shown to result in inabilities to invade or subsequent 
disruption in PVM and EEF development. CD81 and SR-BI are hepatocyte membrane 
proteins required for invasion but in P. berghei, P. yoelii and P. falciparum, the different 
species have differing usage of the receptors to mediate invasion with P36 mediating 
these interactions91. Invasion results with the movement of the parasite through a moving 
junction involving actin remodelling92 and invagination of the hepatocyte. A number of 
rhoptry proteins have been shown to be important in the formation of the moving 
junction93, 94, though the roles of rhoptry proteins in sporozoite invasion have been less 
well understood in comparison to their role in merozoite invasion28. During invasion, 
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TRAP also provides the traction for the parasite to move against and as such is 
translocated to the posterior end of the parasite where it is then cleaved to release the 
bond with HSPG58.  
 
Thus, the parasite has successfully invaded and now resides in a parasitophorous 
vacuole (PV) encapsulated by a parasitophorous vacuole membrane (PVM) of host cell 
origin, essentially evading detection inside the cell and destruction through the 
endosomal-lysosomal pathway. The next stage begins with the parasite changing from 
an invasive phenotype, by clearing its micronemes95, to a replicative and metabolically 
active phenotype. Upon invasion, the sporozoite localises proximal to the hepatocyte 
nucleus and endoplasmic reticulum19. The sporozoite undergoes cytoskeleton 
remodelling starting with a hump proximal to its nucleus. The inner membrane complex 
(IMC) breaks down, the micronemes and contents are released into the PV and the 
parasite rounds up, containing only the organelles it requires for biosynthesis96. 
 
Development inside a hepatocyte 
In the hepatocyte, the parasite remodels the PVM with parasite-derived proteins to allow 
it to complete EEF development97. Many proteins associate with the PVM providing 
different functions to ensure survival. Although the parasite is metabolically capable, the 
acquisition of host factors and metabolites surely aids its development. Only two sets of 
molecules have been formally shown to have host-PVM interactions and these are with 
respect to host factor acquisition. Both Exported Protein 1 (EXP1) and Upregulated In 
Sporozoites gene 3 (UIS3) protein are expressed early on in EEF development45, 98 and 
have been shown to recruit Apolipoprotein H (ApoH)99 and Liver Fatty Acid Binding 
Protein 1 (FABP1)100  respectively which are proposed to be crucial for EEF 
development. UIS3 is essential for development101, and while an EXP1 knock-out could 
not be generated, deletion of the C-terminal fragment of EXP1 that interacts with ApoH 
significantly reduced liver parasite burden99. Acquisition of other metabolites from the 
host including lipids102-104, glucose105, arginine106, biotin107 and metal ions108-110 have also 
31 
 
been shown to promote EEF development. Of the parasite expressed membrane 
transporters109-111 described, with two being described as required for liver stage 
infection110, 111, all have been identified in the PPM and until recently none have been 
characterised at the PVM. Aquaporin-3 has been shown to locate to the PVM and its 
absence significantly reduces EEF development but whether a disruption in transport of 
water and glycerol in Plasmodium causes this defect has yet to be determined112.  It has 
been noted that molecules up to 855Da can pass through the PVM19  but how larger 
molecules make it through remains a mystery. Several publications have pointed to 
methods relating to vesicular transport involving the endocytic113, 114 and autophagy115 
pathways as additional methods for acquisition of nutrients from the host, possibly 
through the use of the tubovesicular network of the parasite116. Parasite-derived 
subversion of the autophagy machinery has also been described117, perhaps ensuring 
the parasite can benefit fully from the nutrition autophagy could supply. 
 
Other parasite-derived proteins have also been shown to have an association with the 
PVM at various stages in EEF development, however their functions remain a mystery 
despite absences in these proteins leading to impaired or completely ablated EEF 
development97. The early expressed PVM protein encoded by Upregulated in Infectious 
Sporozoites gene 4 (UIS4) 45 is crucial for EEF development118 and like UIS3, is highly 
transcribed in the sporozoite119 presumably to allow quick remodelling of the PVM, with 
translational repression preventing UIS4 protein expression until the sporozoite 
formatively invades a hepatocyte120. Liver-specific proteins 1 and 2 (LISP1 and LISP2) 
have peaks of expression later in EEF development121, 122. LISP1 KO parasites, Lisp1, 
have an impaired ability to rupture the PVM121 and LISP2 have also been shown to 
translocate into the hepatocyte cytosol and nucleus where they are proposed to modify 
the host environment for the benefit of the parasite122. Recently, Sporozoite surface 
Protein Essential for Liver stage Development (SPELD), as the name suggests, is a 
protein expressed in sporozoites and early stage EEFs and is required for early EEF 
development123. SPELD localises at the PVM at 17 hours but not later123. pbspeld KO 
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parasites arrest with a very significant impairment in development and no merozoites are 
formed when mice receive infectious mosquito bites123. Regarding the disposal of waste 
products from the EEF, there is no clear evidence for how the parasite manages this 
while remaining hidden from the host with no description of a food vacuole as described 
in blood stage parasites124. Nonetheless, a potential iron detoxification mechanism has 
been proposed, as Plasmodium express an orthologue of a plant vacuolar iron 
transporter (VIT) which transports Fe2+ ions. VIT has been shown to be important for 
parasite EEF and blood stage (BS) growth125. 
 
The process of DNA replication and division of the parasite begins around 20 hours after 
invasion of the hepatocyte126. It involves schizogony, an obscure variation of mitosis to 
that exhibited normally in eukaryotes. The nucleus undergoes division and replication 
13-14 times to generate a syncytium, a multinucleated schizont containing tens of 
thousands of nuclei127. At the same time, the apicoplast and mitochondria form 
intertwined branched structures, appearing to remain singular organelles and do not 
associate with the nuclei128. Entering the cytomere stage after nuclear division has been 
completed; the PPM invaginates and leads to the partitioning of the cytoplasm, nuclei 
associate with the plasma membrane with close proximity to the apicoplast, and the 
mitochondria clump in the centre. In a synchronous fashion, the apicoplast divides, 
followed by the mitochondria and the invagination of the PPM ultimately results in 
cytokinesis and daughter merozoite formation. The RNA-binding protein PlasMei2 has 
been shown to be a critical factor in late schizogony129. P. yoelii plasmei2– KO parasites 
exhibit incorrect DNA segregation and organelle maturation with no cytomere formation 
and a failure in merozoites formation129. Autophagy (ATG)-related protein 8, ATG8, an 
ubiquitin-like protein associated with autophagosome formation130, has also been 
implicated in apicoplast maintenance, in addition to microneme dissolution after invasion 
and merozoite differentiation95. With relevance to hypnozoite forming Plasmodia, the 
hypnozoite EEFs of P. vivax in human liver-chimeric mice do not undergo schizogony 
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but stay as dormant trophozoites8, though the processes involved in preventing 
schizogony or later re-activation of hypnozoites are not known. 
 
Egress of merozoites out of the hepatocyte is the next step in the journey. The release 
of merozoites and the death of the host hepatocyte is very much interlinked, to ensure 
the parasite evades destruction by hepatocyte-driven and immune system-driven 
responses for the greatest possible time and reach the blood with the minimum of fuss. 
Egress again involves the parasite using the host cell for its own benefit, before killing it 
and leaving little trace for the immune system131. First the PVM is broken down inside 
the hepatocyte which is mediated by phospholipase (PL)132. LISP1 is also important for 
PVM rupture121, however it has no functional protease domain and its mechanism of 
action has yet to be formally shown: it may act as a receptor or upstream molecule for 
PL or other protease action. The release of merozoites into the hepatocyte cytoplasm is 
closely followed by the disintegration of the host mitochondria essentially preventing the 
cell from producing ATP131.Upon PVM rupture, the actin cytoskeleton of the hepatocyte 
dissociates from the plasma membrane with a concomitant modulation of membrane 
content possibly caused by a disruption in protein biosynthesis20. This actin-membrane 
disruption leads to detachment of the hepatocyte from the parenchyma. The dissociated 
hepatocyte, with the parasites inside, passes through the sinusoid, squeezing through 
the gaps between LSECs, whereby it comes into contact with the shear forces in the 
blood vessel which cause merosomes (pockets of membrane containing merozoites) to 
bud off from the hepatocyte20. These merosomes have then been shown, in rodent 
models, to release the merozoites in the pulmonary capillaries of the lung133, presumably 
to enhance erythrocyte infection. Over time, the membrane of what remains of the 
hepatocyte, after most of the parasites have been released, loses phosphatidylserine 
asymmetry and membrane integrity131 which signals to phagocytes to engulf the remains. 
The wrapping of the merozoites inside a hepatocyte derived membrane also mediates 
extra protection against KCs, who would recognise merozoites as foreign, and the 
removal of major histocompatibility complex (MHC) class I molecules from the merosome 
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prevents recognition by T cells131. All in all, the parasite has a very elegant and co-
ordinated approach to entry, development and egress out of hepatocytes to ensure full 
development and survival. 
 
IMMUNE RESPONSES TO THE PRE-ERYTHROCYTIC STAGES 
There is limited data for naturally acquired immunity against the pre-erythrocytic stages 
of Plasmodium infection, with contributions from antibodies and T-cells134 but ultimately 
never the acquisition of sterile protection. A number of factors contribute to this lack of 
protective immunity including the size and site of sporozoite inoculum, the tolerogenicity 
of the liver, protection of the EEF by PVM and immunosuppressive nature of the blood 
stages135. Thus, it is imperative to understand the immune responses that are induced 
by the parasite in order to be able to enhance them through vaccination and induce, 
develop and sustain sterile protection. While clinically these stages may appear silent, 
immune responses are most definitely being induced, with the parasite simultaneously 
trying to avoid them. Through experimentation, mainly using mouse models, the immune 
responses occurring during the pre-erythrocytic stages, particularly those that can induce 
protection, are being established. With this knowledge, the next generations of malaria 
vaccines can be developed to enhance immune responses and subvert parasite immune 
evasion.  
  
Innate immune response evasion and exploitation 
The first induction of host immunological responses occurs as soon as the mosquito 
probes the skin looking for a blood vessel to feed from. The saliva of the mosquito has 
immunomodulatory properties136 and probing contributes to Damage-Associated 
Molecular Patterns (DAMPs) and presumably Pathogen-Associated Molecular Patterns 
(PAMPs), although no sporozoite PAMPs have been discovered yet137. Mast cells have 
also been shown to be recruited upon probing by mosquitos138. Mast cell degranulation 
and release of histamine increases extravasation of fluid in blood vessels139, which the 
sporozoites may exploit in their search for a dermal blood vessel. This increase in 
35 
 
vascular permeability also leads to influx of leukocytes138, including neutrophils and 
resident myeloid cells first, followed by the recruitment of monocytes at the inoculation 
site and proximal draining lymph node140. The skin stage is possibly the most overlooked 
part of the pre-erythrocytic stages of malaria. The longest time that the parasite is 
exposed and extracellular in the vertebrate host is when sporozoites are deposited in the 
skin, so this would be a great avenue for targeting70. 
 
Upon entering the liver, Plasmodium elicits further responses from the innate immune 
system with the secretion of Type I and II interferons (IFNs) by hepatocytes. Also 
produced in response to Plasmodium blood stages141, in vivo type I IFN release by 
hepatocytes infected with P. berghei142 or P. yoelii143 results in recruitment of leukocytes 
to the liver by signalling through the cytosolic receptor melanoma differentiation-
associated protein 5 (MDA5). This suggests host sensing of parasite RNA with further 
signalling through mitochondrial antiviral signalling protein (MAVS) and transcription 
factors Interferon-Regulatory Factors 3 (IRF3) and IRF7142, 143. While this release of Type 
I IFN does not peak until the final stages of EEF development in mouse models and thus 
subsequently does not affect EEF development upon primary infection, their release has 
been shown to recruit Natural Killer (NK) T cells which have been shown to be crucial in 
combating subsequent infections through IFN- production143. The role of Type I IFNs 
following sensing of hepatic parasites in human infection and the subsequent 
downstream responses remain to be determined. 
 
Parasite antigen presentation and T cell priming 
Early on, CD8+ T cells were shown in mouse models to be the critical leukocyte for pre-
erythrocytic driven protection following vaccination with radiation attenuated sporozoites 
(RAS)144 with a correlation between CD8+ T cells and protection later observed in 
humans vaccine studies145, 146. The role of CD4+ T cells in pre-erythrocytic immunity is 
less clear. In mouse models their role seems to be dependent on mouse strain, vaccine 
strategy and parasite used147. In humans, different vaccination strategies indicate 
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conflicting correlations between CD4+ T cells and protection145, 146, 148. The process of 
pre-erythrocytic parasite antigen processing and presentation and T cell priming is poorly 
understood. Vertebrate hosts are exposed to sporozoite antigens as sporozoites migrate 
and traverse cells or through cross-presentation following sporozoite degradation by 
phagocytosis. Exposure to liver stage antigens occurs following arrested development 
of the EEF or following phagocytosis of the dead infected hepatocyte after the 
merosomes have been released149. 
 
Sporozoites antigens are presented by cells in the liver as well as in the draining lymph 
nodes (dLNs). Despite entering the lymphatics and reaching a developmental dead end, 
the sporozoite plays a crucial role in priming the immune system against sporozoite 
antigens. In the skin dLN, migratory sporozoites have been shown to prime protective P. 
yoelii CSP-specific CD8+ T cells150, with P. berghei CSP-specific CD8+ T cells being 
primed by dLN–resident CD8+ DCs151. While data suggests that the skin dLN is the 
major site for priming of CD8+ T cells specific for sporozoite antigens following natural 
intradermal inoculation of sporozoites150, dermal inoculation of live attenuated 
sporozoites induces weaker CD8+ T cell responses than intravenous inoculation152. 
Previously this was thought to be a result of a reduced number of parasites reaching the 
liver but it now seems that inoculation and prolonged exposure in the skin induces more 
regulatory adaptive immune responses with a development preference for IL-10 
producing B and T cells, though the reason for this and the interactions in the skin that 
induce this dampening of immune responses in liver and skin dLNs is not known. In 
addition to the dLN, intravenous injection of RAS leads to priming of CD8+ T cells by 
CD8+ DCs in the spleen153. 
 
Antigen presentation and CD8+ T cell priming in the liver is equally poorly understood. 
LSECs, KCs, DCs and hepatocytes in the liver can all present antigen with differing 
degrees of efficiency which most often lead to tolerance in the liver, however immune 
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responses can be induced. The liver is inherently a tolerogenic organ given the large 
amount of blood and lymph that flows through it, containing food breakdown products 
and microbial antigens from the gastrointestinal tract and systemic blood circulation. A 
continuous production of IL-10 in the liver maintains this tolerogenic environment154, 
though in the case of infection, the switch can be made. IFN production can lead to an 
upregulation of major histocompatibility complex (MHC) class I and II presentation 
although how tolerogenic signals are overcome is not known with the likely involvement 
of many factors making the process very complex155.  
 
LSECs are likely heavily exposed to sporozoite surface antigens including CSP, which 
can translocate into the cytosol following cell contact156, or antigens can be cross-
presented by LSECs acting as antigen presenting cells (APCs) to activate naïve CD8+157 
and CD4+ T cells158. However, most entry events by sporozoites seeking the hepatic 
parenchyma occur with an involvement with KCs16. Traversal would lead to release of 
sporozoite antigens in the KC cytoplasm, which has been shown for CSP in vitro74. 
However, it is unknown what the role of KCs is in relation to immunity and antigen 
presentation. CSP has shown to have a ribotoxic effect on macrophages159 and there is 
in vitro evidence that KCs do not survive sporozoite traversal and undergo apoptosis160. 
This would limit the capacity of KCs as APCs. However, in vivo responses of KCs 
following challenge of naïve and RAS-immunised mice are vastly different. Upon 
challenge, immunised mice induced an upregulation of antigen presentation with an 
increase in MHC class I (MHC-I) molecules, costimulatory molecules and IL-12 
expression on KCs161. The mechanism of RAS inducing this activation of KCs is not 
known, but it seems to mediate the transition of the liver from a tolerogenic to a more 
inflammatory environment. Inflammation in other systems has also been shown to 
abrogate tolerance induction by KCs162. This suggests that KCs do not have a definitive 
role as APCs in the context of malaria, but activation of KCs (by an unknown mechanism) 
leads to increased capacity for phagocytosis by KCs in immunised individuals. Other 
data suggests a similar notion that sporozoites use their cell traversal capabilities to be 
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able to avoid KCs to successfully infect the liver, otherwise they would be rapidly 
phagocytosed16. Further research is required to fully determine the roles of LSECs and 
KCs in parasite antigen presentation in the liver and their capacity to prime and recall 
effector T cell responses, rather than induce tolerance163, 164. 
 
Hepatic DCs are immature at resting state154. The exact mechanisms of recruitment 
and/or priming of DCs associated with Plasmodium liver infection is poorly understood. 
Hepatic DCs are located in the periportal and pericentral regions154 and draining lymph 
nodes165. Protective immunity induced in a P. berghei model presented an association 
with CD8+ DC accumulation in the liver after RAS immunisation166, 167. This recruitment 
and movement of DCs to the liver takes time. There are several options that might occur 
to activate CD8+ T cells in the liver. These DCs may travel back to the portal regions and 
draining lymph nodes to present antigen and activate CD8+ T cells, or directly present 
and activate CD8+ T cells in the liver sinusoid. The fact that large numbers of CD8+ T 
cells are required for protection168 indicates that the elimination of infected hepatocytes 
is an inefficient process which likely requires large numbers of DCs for optimal antigen 
presentation and CD8+ T cell activation149. More work is required to determine where 
and how hepatic DCs sample and present parasite antigens and the mechanism by 
which CD8+ T cells are activated and act upon infected hepatocytes. Given the priming 
seen in the skin dLNs, it also been proposed that liver dLNs could be most likely site for 
priming of CD8+ T cells against liver stage and blood stage antigens149. Hepatic DCs 
have also been shown to be able to present antigens after phagocytosing dead infected 
hepatocytes (following merosome release or EEF arrest)169 but whether these migrate to 
the dLNs is unknown170. 
 
Parasite development in hepatocytes (in addition to EEF development in the skin) is the 
only time EEF antigens are expressed so hepatocytes are a crucial cell type for 
presentation of these antigens as well as signalling their infected status. While antigen 
presentation on hepatocytes usually results in tolerisation170, hepatocytes have been 
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shown to successfully prime naïve CSP-specific CD8+ T cells171 and convert 
systemically primed effector CD8+ T cells to become liver-resident memory cells172. 
Parasite-derived peptides have been shown to reach the cytosol of the hepatocyte, with 
loading of MHC-I molecules occurring in an endosomal-independent TAP-dependent 
manner173, 174. Using bone chimeras, it has also been determined that the elimination of 
hepatocytes occurs in an antigen dependent manner150, 173, 175. While the repertoire of 
proteins expressed by the EEF is vast, only a few proteins have been shown to induce 
antigen-specific CD8+ T cell driven responses that protect against sporozoite infection. 
That being said, these include sporozoite surface proteins176, 177, proteins involved in 
traversal178, EEF proteins179 and PVM associated proteins180. This illustrates the range 
of proteins that can potentially be presented by hepatocytes and induce protective 
responses. Protective CD8+ T cell responses can also be induced using a parasite that 
expresses SIINFEKL from ovalbumin in the context of heat shock protein 70 (HSP70), 
indicating cytosolic parasite antigen can also be presented on hepatocytes173. 
 
Effector functions of CD8+ T cells 
As mentioned before, a key role for CD8+ T cells in protective immunity was determined 
early on144 with CD8+  T cell depletion abrogating protection144, 181. However now it has 
also been shown that for long lasting complete protection, a threshold of parasite-specific 
memory CD8+ T cells are required which is postulated to be 100-1000 times greater than 
that needed for protection against viral or bacterial pathogens182. The reason for this is 
not fully understood but it is generally accepted that very few sporozoites reach the liver, 
which is a massive organ and given the short duration of EEF development in mice (2 
days), this means that a very large CD8+ T cell compartment would be required to find 
and kill all the infected hepatocytes. It has also been found, however, that fewer parasites 
also lead to reduced CD8+ T cell responses, presumably because it is harder to initiate 
proliferation and a large response if the target is so small183. Thus a fine balance 
connects the number of inoculated sporozoites and memory CD8+ T cells to drive an 
optimum response which will result in the killing of all infected hepatocytes and sterile 
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protection183. Naïve CD8+ T cells take several days to become fully activated, proliferate 
and gain effector function. Proliferation of adoptively transferred naïve CSP-specific 
transgenic CD8+ T cells could only be detected in the spleen after 2 days following 
immunisation with P. yoelii RAS184. While induction of IFN- production in transferred 
naïve CD8+ T cells was rapidly observable after 24 hours following antigen exposure 
with RAS, only mice harbouring activated effector CD8+ T cells at the time of challenge 
could kill infected hepatocytes184. Mice harbouring naïve CD8+ T cells at challenge did 
not induce significant levels of killing presumably because all EEFs had developed and 
merozoites had been released before the CD8+ T cells could be activated, proliferate 
and exercise their effector functions184. This stands in contrast to memory CD8+ T cells 
which can produce IFN- within 4 hours after reactivation150. In humans, the role of naïve 
CD8+ T cells may be different given the extended development of the EEF (~7 days 
depending on the species of Plasmodium). Immunisation with viral vectors against P. 
falciparum TRAP185 indicated that fewer IFN- producing CD8+ T cells were required for 
protection in humans compared to that required in mice. Still CD8+ T cells are estimated 
to be looking for one infected hepatocyte out of 106 in mice and one out of 109 in humans 
which is quite the race against time with a single infected hepatocyte able to propagate 
a blood stage infection186. 
 
Following clearance of infections, a subset of effector CD8+ T cells differentiate into 
memory T cells: either central memory (TCM) or effector memory T cells (TEM)187. Central 
memory T cells have shown to have a limited role in providing protection against 
sporozoite infection188 with the majority of parasite-specific T cells in the liver following 
RAS immunisation exhibiting a TEM phenotype189. Recently tissue resident memory (TRM) 
CD8+ T cells have also been described as being crucial for protection of RAS immunised 
mice from sporozoite challenge172. Tissue resident T cells are a non-circulating 
population of memory T cells found in all non-lymphoid tissues with a distinct phenotype 
to TCM and TEM, expressing CD69190 and low levels of KLRG1172 and are retained in the 
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liver by their expression of CXCR6191. They have been shown to patrol the sinusoid192 
and targeting CD8+ T cells to the liver using a systemic prime and liver trap immunisation 
protects immunised mice from sporozoite challenge172. This immunisation strategy could 
be a great tool for the generation of new malaria vaccines to improve killing of EEFs in 
the liver. 
  
As previously mentioned, infected hepatocytes are required to express and present 
parasite specific peptides on MHC molecules to be eliminated by the cognate CD8+ T 
cell150, 173, 175. It has been shown that antigen-specific173, 193 and non-specific CD8+ T 
cells193 cluster around EEFs. Through using antigenically different parasites it has also 
been shown that there is a lack of bystander effect in EEF elimination by CD8+ T cells194. 
The mechanism for elimination of EEFs by CD8+ T cells has been heavily researched; 
however, the exact mechanism is still to be determined. It is clear from mouse studies 
that depending on the strain of mouse and species of Plasmodium used, that the effector 
CD8+ T cell mechanisms differ147, 195. Effector molecules investigated include cytokines, 
cytotoxic proteins and death receptors. However, there is contention over whether 
cytotoxic granules can be released onto hepatocytes by CD8+ T cells given that 
significant contact between CD8+ T cell and target is normally required.  
 
It has been suggested that contact-dependent killing can occur in vitro with the release 
of perforin196 however; there is little in vivo evidence of contact dependent mechanisms 
for EEF elimination. Intravital imaging in mice has demonstrated that antigen-specific 
CD8+ T cells cluster around EEFs but contact between lymphocyte and hepatocyte was 
not conclusively demonstrated173, 193. Another study showed that parasite-specific CD8+ 
T cells are immobilised in the liver but no contact is made with EEFs192. Adoptively 
transferred CD8+ T cells have been shown to exhibit slow velocity192, 193 and 
immobilisation in the liver for at least 3 days following transfer192, which may be due to 
differing anatomical locations and microenvironmental changes altering local T cell 
differentiation149 or a slowing to survey presenting hepatocytes in an antigen-specific 
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manner197. Thus, the lack of contact with EEFs but an observed reduction in EEFs 
following adoptive transfer of parasite-specific CD8+ T cells192, 193 heavily suggests a role 
for soluble factors and contact independent mechanisms i.e. not the release of cytotoxic 
granules. In fact, using perforin–/– or granzyme B–/– KO mice or mice homozygous for Fas 
ligand (FasL) mutations indicated that these factors were dispensable for protecting RAS 
or viral vector immunised mice challenged with sporozoites147, 198, 199.In addition, where 
clustering was seen, multiple EEF death phenotypes were observed193 and protection 
could be maintained by adoptively transferring CD8+ T cells lacking the ability to produce 
IFN- and/or perforin173 which indicates that multiple mechanisms are involved in 
protection. It has been found that T cells can monitor hepatocytes using trans-endothelial 
hepatocyte-lymphocyte interactions (TEHLIs) that stretch through the fenestrations of 
the LSECs avoiding the need for extravasation across the sinusoid200. However, given 
the division between lymphocyte and hepatocyte and the lack of evidence for 
extravasation in vivo, it is unlikely that sufficient contact is made by TEHLI to form a 
functional immunological synapse and allow cytotoxic granule release201. Thus, it has 
been proposed that CD8+ T cells in the liver use TEHLIs to survey hepatocytes, and 
when a cognate interaction has been made, the minimal contact of the TEHLI forms a 
stimulatory synapse that is sufficient to allow cytokines to be released and act on the 
infected hepatocytes149, 202. 
 
IFN- is generally considered the central mediator of protection against EEFs203. 
Recombinant IFN- was first shown to inhibit murine and human Plasmodia EEF 
development in vitro204-206. Then in vivo, systemic blockage of IFN- was shown to inhibit 
EEF development in immunised mice that were normally protected against sporozoite 
challenge144. The first CD8+ T cell response that definitively demonstrated that antigen-
specific protection based on IFN- secretion was identified from a CD8+ T cell clone 
specific for an epitope from CSP with cross-specificity for P. berghei and P. yoelii207. IFN-
 from CD8+ T cells has been shown to function by activating the L-arginine-dependent 
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inducible production of nitric oxide synthase pathway, which was shown to be crucial for 
protection in RAS immunised mice208. IFN- production induces increased production of 
inducible nitric oxide synthase (iNOS), the enzyme that converts L-arginine to L-citrulline 
and nitric oxide. Nitric oxide then acts on several metabolic pathways by reaction with 
iron centres, formation of reactive oxygen species and nitrosation of nucleophilic 
centres209 which are toxic to the EEF208. iNOS can act to inhibit EEF development192 or 
kill the parasite in the hepatocyte completely208. This will likely depend on the 
concentration of CD8+ T cells and IFN- in the local area surrounding the EEF149. Long 
lasting protection, in mice immunised with P. berghei RAS or infectious sporozoites 
under drug prophylaxis, correlates with sustained IFN- responses from hepatic memory 
CD8+ T cells210. 
 
However, as mentioned before, multiple soluble effector molecules may act on infected 
hepatocytes as IFN- independent protection has been reported147, 195. It is becoming 
clear in mouse models that levels of protection are dependent on murine host strain and 
Plasmodium species. Comparing two commonly used mouse strains, C57BL/6 mice 
require more immunisations to induce a greater antigen-specific memory CD8+ T cell 
response and afford protection than in  BALB/c and protection against P. berghei is more 
easily achieved than against P. yoelii168. Using mice that express the same MHC alleles, 
differences in protection have shown to be due to the murine genetic background211. In 
terms of effector molecules, blockage of IFN- in P. yoelii challenged RAS immunised 
B10.D2 mice had no effect on protection and only a partial effect in CD-1 mice147. P. 
yoelii or P. berghei challenge of IFN-–/– BALB/c mice, immunised by prime-boost (DCs 
and recombinant Listeria monocytogenes) to induce CSP-specific CD8+ T cell 
responses, showed a 35% and 50% reduction in protection respectively in the absence 
of IFN-195. This incomplete abolition of protection indicates that other effector molecules 
can mediate protection. In the same study, neutralisation of TNF- reduced protection 
against P. berghei challenge by 40% and P. yoelii challenge by 85%195. Depletion of 
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perforin had no effect on protecting mice from P. berghei infection but reduced protection 
by 50% when mice were challenged with P. yoelii195. The role of perforin has not been 
fully determined as some models show correlation with protection while others indicate 
a dispensability for protection. It is particularly interesting that there is a correlation in 
RAS vaccinated human volunteers between perforin producing CD8+ T cells and 
protection145. Further work will be required to determine the role of perforin given that 
immunological synapses between T cells and hepatocytes have yet to be described in 
vivo. But this shows that, in addition to IFN-, other cytokines can have a role in protecting 
against sporozoite infection, indicating that CD8+ T cell mediated protection occurs in a 
multi-faceted manner. Consequently, in addition to a requirement for CD8+ T cells above 
a certain threshold, the ability of these cells to produce IFN- and other cytokines, 
alternatively or in concert, seems to define whether a host can be robustly protected from 
sporozoite infection.  
 
Antibodies against Plasmodium sporozoites 
Anti-sporozoite antibodies are induced by individuals living in malaria endemic areas, 
however antibody titres against sporozoite antigens are lower than those against blood 
stage antigens212. This is probably due to the much shorter time that the sporozoite is 
visible to the immune system, compared to merozoites. Passive transfer of IgG from 
immune adults was shown to reduce parasitaemia in children213, and more recently 
administering monoclonal antibodies from individuals naturally exposed to P. falciparum 
has been shown to reduce parasite liver development in liver-chimeric humanised mice 
following P. falciparum challenge214. Using RAS, the first sporozoite-specific antibodies 
determined were those against CSP215, the major sporozoite surface protein, with 
transfer of monoclonal antibodies shown to protect mice from sporozoite challenge216. 
This finding inspired the development of a CSP-based vaccine217 which would then lead 
to the development of RTS,S/AS01, the most advanced malaria vaccine to date. There 
is an association between titres of anti-CSP antibodies and vaccine efficacy in RTS,S 
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trials218. Thus while antibodies have been shown to immobilise sporozoites in the skin219, 
it is likely that a very high titre of anti-sporozoite antibodies would be required to prevent 
all sporozoites from leaving the skin and prevent sporozoites infecting hepatocytes if they 
manage to exit the dermis unscathed. Antibodies against other parasite antigens have 
also been identified with titres for TRAP and LSA-1 correlating with reduced incidence of 
clinical malaria in P. falciparum naturally exposed Kenyan children220. While antibodies 
clearly play a role in reducing Plasmodium sporozoite infections (and particularly acting 
against blood stage infection), complete protection from sporozoite challenge can be 
achieved in B-cell depleted mice221, indicating that they are not the major player in 
providing protection against pre-erythrocytic immunity. 
 
PRE-ERYTHROCYTIC STAGE VACCINES 
Over the last 50 years, malaria vaccines have been gathering momentum. Despite the 
reduction in malaria incidence seen over the last couple of decades, elimination of 
malaria is highly unlikely without the advent, introduction and deployment of an 
efficacious vaccine. There have been major breakthroughs and movements in malaria 
vaccine generation however, it has become apparent that the complexity of Plasmodium 
compared to other pathogens such as viruses is slowing down vaccine development in 
terms of time from inception to successful, deployed vaccine. 
 
The initial inklings that a malaria vaccine was possible, came from two major findings. 
Firstly, in endemic settings, individuals that are constantly exposed to infectious 
mosquito bites and malaria infection develop immunity against the disease over time222. 
While it is extremely rare, and thus probably undocumented, that individuals develop 
sterile immunity against parasites, asymptomatic malaria infections are very common. 
This development of immunity has been associated with age though the immunological 
basis has yet to be fully unravelled222. The other finding resulting in actual sterile 
protection, which spearheaded the malaria vaccine movement was the use of radiation 
treated sporozoites as an experimental vaccine. Multiple immunisations with sporozoites 
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attenuated by radiation, leading to random DNA damage, were first shown to protect 
mice223 and then humans224, 225 and non-human primates226 from infectious non-
irradiated sporozoite challenge in a stage227 and species228 specific manner. These 
findings show that the immune system develops following exposure to parasite antigens 
and upon reinfection these responses can be recalled to slow parasite replication in the 
blood or impact parasite development in the liver. In this way, a vaccine could be 
developed to prime and enhance the immune system to fight Plasmodium parasites. 
Here I focus on the development of pre-erythrocytic vaccines. 
 
With the discovery that radiation-attenuated sporozoite (RAS) vaccination induces sterile 
protection, this should have been the end of malaria. However, the technicalities behind 
production of a RAS vaccine stymied its introduction. Challenges include dissection of 
salivary gland sporozoites from mosquitoes by hand (to date no automated machine 
exists) followed by purification, the exposure of sporozoites to a standardised level of 
radiation (too much will make sporozoites nonviable and non-immunogenic, too little and 
breakthrough blood stage infections could occur) and a suitable method of 
cryopreservation and transport to site, followed by appropriate storage.  
While RAS was established as the ‘gold standard’ vaccine against pre-erythrocytic 
malaria, research became more focused on generating a subunit vaccine, akin to more 
traditional vaccines, which would probably be less onerous to manufacture under 
regulations. 
 
Pre-erythrocytic subunit vaccines 
Subunit vaccines to date targeting the pre-erythrocytic stages have been designed to 
induce antibody responses against the sporozoite or induce T cell responses against the 
EEFs. RTS,S/AS01 is the most advanced P. falciparum malaria vaccine which is 
currently seeking approval for licensure. RTS,S is based on the central repeat region 
and C-terminal region of P. falciparum CSP, which contains B cell and T cell epitopes 
respectively, conjugated to hepatitis B virus surface antigen (HBsAg). The latest 
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longitudinal results come from a large multi-site Phase III trial in Africa, conducted with 
children (5-17 months) and young infants (6-12 weeks) who received three doses of 
RTS,S (or control rabies or meningococcal serogroup C conjugate vaccines - C3C), one 
month apart, with an RTS,S booster (R3R) or a control boost (R3C - control boost was 
meningococcal serogroup C conjugate vaccine) at month 20229. Assessing the number 
of clinical malaria cases compared to control groups, vaccine efficacy of RTS,S/AS01 to 
prevent episodes of clinical malaria in children over 48 months was 36.3% in the R3R 
group and 28.3% in the R3C group. In young infants, over 38 months, vaccine efficacy 
was 25.9% in the R3R group and 18.3% in the R3C group229. The trial detailed a gradual 
waning of vaccine efficacy as has been previous noted230, 231.  The booster dose in 
children provided incremental efficacy of 25.6% in the first 12 months following booster 
administration which drops to 16.2% by the study end 27 months later. In infants, 
incremental efficacy of the booster dose was 22.3% after 12 months and 17.5% after 18 
months229. The efficacy of RTS,S/AS01 against severe malaria was much less 
pronounced than that preventing clinical episodes. In vaccinated children, RTS,S/AS01 
induced anti-CSP antibody titres and anti-CSP CD4+ T cell responses, which have been 
proposed to correlate with protection232, 233. Thus RTS,S/AS01 induces modest vaccine 
efficacy with value gained from an additional booster dose. However there is concern 
over cases of meningitis and febrile convulsions following administration of RTS,S/AS01 
which has yet to be explained229. In addition, it has been noted that children who received 
RTS,S/AS01 experienced more malaria episodes, than those in the control group, 
several years after vaccination possibly because while the vaccine provided immunity 
against sporozoites, the children had a delay in developing blood stage immunity234. It is 
unclear whether additional boosters every year or so will benefit. This notion, as well as 
safety, are being considered as RTS,S/AS01 is further analysed before it can be 
approved to be rolled out. With antibody titres likely to be the mode of action of 
RTS,S/AS01, additional steps are being taken in earlier stage clinical trials to improve 
antibody titres and thus protection by altering the dose regimen235 or P. falciparum CSP 
composition in the vaccine236, 237. 
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Subunit vaccines against the liver stage of Plasmodium infection have tended towards 
the need to induce high numbers of parasite-specific CD8+ T cells which target infected 
hepatocytes. As previously mentioned, a numerical threshold of CD8+ T cells is required 
to protect mice182 from subsequent sporozoite challenge and therefore this requires the 
use of different vaccine platforms compared to those that are designed to induce high 
antibody titres. This has included the use of viral vectors to administer malaria antigens 
into the host238. While it is well accepted that boosting with subsequent immunisations 
improves a vaccine’s efficacy, it seems that using heterologous viral vectors encoding 
the same antigen improves efficacy better than homologous boosting239. So far, the most 
effective regimen for inducing high levels of human malaria antigen-specific CD8+ T cell 
is using AdCh63 prime followed by MVA boost encoding PfTRAP linked to a multi-
epitope string of other malaria epitopes (ME-TRAP)185, 238. This vaccine induces IFN- 
producing CD8+ T cells observable in peripheral blood which correlates with protection 
from sporozoite challenge in humans185. Research is ongoing to determine other 
antigens that are presented on hepatocytes, including antigen combinations, which could 
produce large viral vectored vaccine-induced CD8+ T cell responses. 
  
Whole sporozoite vaccines 
With the concept of using multiple antigens in a vaccine and the less than satisfactory 
vaccine efficacy imparted particularly by RTS,S/AS01, research has returned to whole 
sporozoite vaccines (WSVs). As mentioned before, WSVs in animals and humans have 
been shown to induce protective responses223-225 226. WSV benefit from the exposure of 
the host to many different parasite antigens, not just the one or two encoded in the 
subunit vaccine. There are four WSV strategies currently under investigation in humans 
and animal models240.  
 
Published in 2002, vaccination with RAS was shown to promote long lasting sterile 
immunity against challenge, when individuals were immunised with a thousands of bites 
from P. falciparum infected mosquitoes241. Extensive research into using RAS as a 
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vaccine outside of experimental medicine followed this result with the development of 
Sanaria Inc., a company that is able to produce, purify, attenuate and cryopreserve a 
metabolically active, non-replicating P. falciparum sporozoite vaccine (PfSPZ) in a 
standardised manner than meets all the regulatory requirements of the United States 
Food and Drug Administration242. With the intention of delivering a radiation attenuated 
whole sporozoite vaccine, they produced a vaccine that could induce complete sterile 
protection, through multiple high dose intravenous immunisations145. While intravenous 
injection may not seem the best method of administration, it has been shown that 
intradermal or subcutaneous injection of PfSPZ induced weaker immune responses and 
failed to protect from infectious mosquito bite challenge243. However, recently it has been 
shown that intradermal vaccination using a needle and a laser to locally damage blood 
vessels near the injection site is a better proxy for mosquito infection than traditional 
needle-administered intradermal inoculation as it mimics the damage induced by the 
mosquito proboscis244. While induction of immune responses with this method was vastly 
improved compared to traditional intradermal inoculation, CD8+ T cell responses did not 
completely match those induced by intravenous inoculation. Nonetheless, immunisation 
with purified P. yoelii RAS by this method was able to completely protect against 
sporozoite challenge equivocal to intravenous immunisation244. The authors suggest that 
technical developments in vaccine administration could permit PfSPZ to be administered 
intradermally, which is less effort than intravenous injection and would be more cost-
effective244, though whether the same results are replicated in humans has yet to be 
determined.  
 
Other whole sporozoite vaccines have entered clinical trials following on from advances 
in genetic manipulation of Plasmodia. Genetically attenuated parasites (GAPs) 
administered as sporozoites, were first developed in order to achieve parasites that 
arrest at a more precise time than occurring with irradiated sporozoites101. GAPs involve 
the knock-out (KO) of particular gene(s) that are crucial for liver stage development but 
do not affect other stages of the Plasmodia life cycle240. GAPs need to be safe attenuated 
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parasites (abrogating blood stage infection following sporozoite infection) but the 
parasite also needs to induce potent sterilising protective responses240. The first GAP to 
enter clinical testing in humans146 was a double KO of two proteins of the 6-cys family 
(P52 and P36) which are vital for EEF development87, 88, 91, 245. But, upon high bite 
exposure from infected mosquitoes, a breakthrough infection with p52-/p36- occurred146. 
However, further removing the sap1 (slarp) gene from the parasite lead to a fully 
attenuated GAP following mosquito bite246. These two GAPs target the early stages of 
EEF development, however a GAP lacking fabb/f247, a gene that encodes a protein 
involved in fatty acid synthesis, led to parasites that arrested later than early arresting 
RAS248. fabb/f− GAP gave long lasting sterile immunity against sporozoites challenge248 
as well as blood-stage challenge highlighting stage-transcending immunity248, 249. 
However, FabB/F is essential for P. falciparum to produce sporozoites and thus is not an 
option for human GAPs250. Nonetheless the generation of the GAP lisp2–/plasmei2–, a 
double KO in P. yoelii, showed very late liver arrest with no breakthrough infections and 
long lasting sterile immunity against infectious sporozoites with induction of liver resident 
memory CD8+ T cells251. With high conservation of these genes in human Plasmodia, 
the generation of a long lasting sterilely protecting human GAPs could be soon on the 
horizon. 
 
A further WSV strategy that has shown promise is the administration of infectious 
sporozoites concomitantly with anti-malarial drugs (ChemoProphylaxis and Sporozoites 
– CPS). Similar to GAPs, drug prophylaxis would ensure full EEF development and thus 
increased antigen exposure to the host immune system, with the premise of inducing 
broader action immune responses. Immunisation of sporozoites by mosquito bite252, 253 
or intravenous injection148 with chloroquine cover provided complete sterile protection. 
While efficacy against heterologous challenge was shown to be limited254, continual 
administration of chloroquine not appearing to be the most appropriate regimen 
considering chloroquine resistance in endemic settings and the potential regulatory 
issues of generating a live unattenuated parasite, the amount of sporozoites required for 
51 
 
CPS immunisation to achieve protection is 10-100-fold less than that required for RAS 
immunisations255. While subjects are exposed to transient low level parasitaemia during 
vaccination, immunity is targeted mainly against pre-erythrocytic antigens256, with the 
contribution of chloroquine to induce cross-stage protective immunity, as seen in animals 
studies257, 258, impossible to study in human vaccine studies where monitoring 
parasitaemia over time is not possible. 
 
Other drugs have been tested as alternatives to chloroquine for CPS. Mefloquine was 
shown in humans to give equivalent results to chloroquine following human trails 
receiving infectious P. falciparum mosquito bites259 in humans. In mice, primaquine260, 
pyrimethamine261, piperaquine262, artesunate263, azithromycin260, 264 and clindamycin260, 
264 have been tested and compared, with azithromycin inducing the best immunity and 
protection260. This suggests that full EEF development without the release of viable 
merozoites is most beneficial for protection, which corroborates data suggesting blood 
stage infections negatively impacts pre-erythrocytic immunity265.  
 
The least investigated WSV strategy has been using chemically attenuated parasites, 
where sporozoites266, 267 or blood stage merozoites268 are incubated with centamycin or 
Tafuramycin-A, Seco-cyclopropyl pyrrolo indole analogues, that are thought to 
irreversibly alkylate polyA rich DNA regions. In both stages of the life cycle, complete 
attenuation of growth occurs, and sterile immunity induced. While there are concerns 
over complete attenuation and the possibility of reversion and drug toxicity to hosts, 
safety and immunogenicity trials in humans using P. falciparum infected erythrocytes 
treated with Tafuramycin-A is underway to assess the viability of this strategy for 
vaccination269 which may then lead on to vaccination with sporozoites.  
 
Nonetheless, while many still deem the use of whole sporozoite vaccines, especially in 
malaria endemic areas, as unlikely, the use of RAS, GAPs and CPS has allowed many 
immunological determinants induced by these vaccines to be identified. Correlates of 
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protection have been achieved and the contribution of different arms of the immune 
system induced by these vaccines have been investigated, first in mice and then tested 
and translated into human vaccine studies. Despite few clinical studies, of which many 
were conducted in malaria-naïve cohorts, some assertions have been made to the 
responses induced by WSVs. 
 
CD8+ T cells are considered the major effector immune response eliciting sterile 
protection following WSV, with varying contributions from CD4+ T cells and antibodies270. 
In humans, studying the contribution of T cells is difficult as depletion studies and 
determining the presence of liver resident memory T cells is not possible. However, 
vaccination with RAS145 or p52-/p36- GAP146 induced parasite-specific IFN- producing 
CD8+ T cells detectable in peripheral blood in most subjects, with a dose dependent 
response145. In a CPS study using chloroquine, only 2/9 protected individuals had 
observable parasite-specific IFN- CD8+ T cells in peripheral blood148. This may be the 
result of the protective CD8+ T cells remaining trapped in the liver as has been shown in 
mouse models using a late arresting GAP251 and RAS immunised non-human 
primates243, though why RAS and GAP generally induce this peripheral blood correlate 
but not CPS is not known. Another CPS study found an association between Granzyme 
B expression on peripheral blood CD8+ T cells, following stimulation with P. falciparum 
infected erythrocytes, and protection, which may indicate the induction of protective 
responses to late-liver stage antigens271. 
  
The protective role of CD4+ T cells in pre-erythrocytic immunity after vaccination is less 
clear. Mouse models suggest the role is dependent on mouse strain, vaccine strategy 
and parasite used147. It has also been proposed that the role of CD4+ T cells in protection 
is dependent on timing of challenge in RAS270 and possibly other WSVs. In humans, 
intravenous vaccination with RAS induces CD4+ T cell response whose magnitude 
correlates with vaccine dose145. In addition, immunisation with p52-/p36- GAP146 and 
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sporozoites administered under chloroquine prophylaxis148, induced polyfunctional 
cytokine-producing memory CD4+ T cell responses. This correlated with pre-erythrocytic 
and erythrocytic protection in the CPS study148 but correlations to protection could not be 
determined when using a GAP146. A further association in a CPS study was found 
between protection and CD107a expression on peripheral blood CD4+ T cells, following 
stimulation with P. falciparum infected erythrocytes, which may again indicate responses 
to late-liver stage antigens271. 
 
The contribution of antibodies to protection is the least clear adaptive immune response. 
As mentioned before, anti-sporozoite antibody responses can be induced in mice using 
WSVs215, 216 however protection is also achievable upon depletion of B cells221. In human 
studies, vaccination with RAS induced high anti-CSP antibody titres, which correlated 
with immunisation dose, and higher titres were observed in protected individuals 
compared to non-protected individuals145. Results from CPS studies show that 
antibodies against CSP148, 252, 256, 272 and other proteins expressed in sporozoites and 
EEFs148, 272 were induced, but anti-CSP antibodies were deemed to be short-lived253 and 
no correlation was found between protection and antibody responses to any protein148. 
Immunisation with p52-/p36-146 and p52-/p36-/sap1-246 GAPs also elicited antibodies 
against CSP146, 246 and other sporozoite and EEF proteins246. It is clear that while 
antibodies induced by WSVs have significant functional activity in the ability to block 
sporozoite invasion in vitro145, 146, 148, 243, 273 and in chimeric mice274, they are probably not 
the main effector of the immune system targeting Plasmodium in the liver. The role of 
blood-stage reactive antibodies to protect against blood stage parasites following 
sporozoite vaccination has also not been fully determined. It is not determined in humans 
what level of exposure to blood stage parasites is required to confer protection, whether 
human late arresting GAPs could induce stage-transcending immunity249, 251 and the full 
impact of blood stage parasites on immunoregulatory mechanisms which may negatively 
impact other immune responses265.  
 
54 
 
Further insights into WSV-induced immunity will be achieved with the increasing number 
of clinical trials using RAS, GAPs and CPS. Through this, the differences in the strategies 
and (protective) immune responses induced can be delineated. It is also imperative to 
have more data from clinical trials in malaria endemic settings to determine correlates of 
protection. 
 
Overall, whole sporozoite vaccines have been very useful in informing how the immune 
system responds to malaria parasites and also how best to modulate immune responses 
to achieve protection against the pre-erythrocytic stages. Given the complexity of the 
parasite and natural immune responses, fast-forwarding natural acquired immunity is 
probably not the most appropriate method as sterile protection is never induced275. 
Instead, vaccines against pre-erythrocytic immunity should be more focused towards 
developing unnaturally high immune responses to induce sterile protection240.  
 
To improve existing vaccines, it is this unnatural immunity that needs to be maintained 
to sustain protection. In terms of targeting sporozoites, strong and durable titres of broad 
acting polyclonal antibodies are required to maximise inhibition of sporozoite traversal 
and invasion. A strong, broad acting antibody response would likely also favour a 
reduction in merozoites in the blood, however, the acquisition of sterile protection against 
blood stage parasites, and the role of blood stage parasites in dampening pre-
erythrocytic responses, has yet to be fully unravelled despite stage-transcending 
immunity being possible in mouse models with late arresting GAPs249, 251. The 
identification of new targets is also a high priority using the plethora of new genetic, 
transcriptomic and proteomic data sets and tools. 
 
To improve current CD8+ T cell inducing strategies, while it may be difficult to determine, 
assessing the ability of vaccines to induce Plasmodium specific-liver resident CD8+ T 
cells will be vital as a correlate for protection, as these cells have been shown to play a 
major role in protection and can be induced by vaccination172, 251, 276-278 in mice and non-
55 
 
human primates. Developing a vaccine to induce large numbers of potent liver resident 
CD8+ T cells as well as developing an assay to determine this induction will be crucial 
next stages in developing and testing efficacious pre-erythrocytic targeting malaria 
vaccines. Further identification of the targets of these protective responses will also aid 
the development of next generation T-cell targeting vaccines, particularly late expressed 
EEF antigens which have been shown to give superior immunity to earlier expressed 
EEF antigens248. 
 
Vaccines targeting the other stages of the Plasmodium life cycle also exist, based on 
inducing strong antibody responses against merozoites and sexual stages, to protect 
against blood stage infection and prevent transmission of the parasite to the mosquito255. 
The advent of an efficacious subunit vaccine could involve combining antigenic elements 
from all of the Plasmodium life cycle stages to achieve long-lasting, cross-stage immunity 
against malaria. 
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AIMS AND RESEARCH OBJECTIVES 
The importance of CD8+ T cells in conferring protection to the pre-erythrocytic stages of 
malaria is apparent, however few antigens have been described as being responsible 
for these immunological responses. More work has been carried out looking at the 
responses to sporozoite antigens, particularly CSP, with EEF antigens being very much 
a mystery in terms of induced CD8+ T cell responses and protective capability. 
Sporozoites are extracellular and thus antigens would be accessible to the immune 
system for presentation prior to hepatocyte invasion. Conversely, EEFs are hidden inside 
a hepatocyte and surrounded by a parasitophorous vacuole membrane, blocking access 
to the cytosol and antigen processing machinery. Given this, my working hypothesis was 
that sporozoite antigens are more immunogenic than EEF antigens, as they are more 
likely to be presented to CD8+ T cells. 
 
The overall aim of this PhD project was to determine the CD8+ T cell responses and 
subsequent protection induced by different antigens expressed in the pre-erythrocytic 
stages of Plasmodium infection with a focus on EEF antigens. 
 
My research objectives were to: 
 Compare a sporozoite surface and an EEF vacuolar membrane antigen and 
investigate the effect of spatial and temporal differences of pre-erythrocytic 
antigen expression on CD8+ T cell responses and their roles in vaccine-induced 
protection (Chapters 2 and 3). 
 Compare early and later expressed EEF antigens to investigate the effect of 
temporal expression of antigens expressed by EEFs on CD8+ T cell responses 
and vaccine-induced protection (Chapter 4). 
 Investigate CD8+ T cell responses and protection induced by the 
immunodominant CD8+ T cell epitope of sporozoite surface circumsporozoite 
protein (Chapter 5). 
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 Identify novel CD8+ T cell epitopes from pre-erythrocytic antigens, especially 
those expressed in the EEF, using bioinformatics tools and laboratory screening 
(Chapter 6). 
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ABSTRACT 
Vaccine discovery and development critically depends on predictive assays, which 
prioritise protective antigens. Immunogenicity is considered one important criterion for 
progression of candidate vaccines to further clinical evaluation, including phase I/ II trials. 
Here, we tested this assumption in an infection and vaccination model for malaria pre-
erythrocytic stages. We engineered Plasmodium berghei parasites that harbour a well-
characterised H-2-Kb epitope for stimulation of CD8+ T cells either as an antigen in the 
circumsporozoite protein (CSP), the surface coat protein of extracellular sporozoites or 
in the upregulated in sporozoites gene 4 (UIS4), a major protein associated with the 
parasitophorous vacuole membrane (PVM) that surrounds the intracellular exo-
erythrocytic forms (EEF). We show that the antigen origin results in profound differences 
in immunogenicity with a sporozoite antigen eliciting robust and superior antigen-specific 
CD8+ T cell responses, whilst an EEF antigen evokes poor responses. Despite their 
contrasting immunogenic properties, both sporozoite and EEF antigens gain access to 
antigen presentation pathways in hepatocytes. Recognition and targeting by vaccine-
induced, antigen-specific effector CD8+ T cells results in high levels of protection when 
targeting both antigens. Our study is the first demonstration that poor immunogenicity of 
EEF antigens does not preclude their susceptibility to antigen-specific CD8+ T cell killing. 
Our findings that antigen immunogenicity is an inadequate predictor of vaccine 
susceptibility have wide-ranging implications on antigen prioritisation for the design and 
testing of next-generation malaria vaccines. 
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 INTRODUCTION 
Malaria, caused by the apicomplexan parasites Plasmodium, is responsible for 
more than 200 million clinical cases and over 440,000 deaths annually worldwide1. Whilst 
current malaria control strategies have led to marked reduction in incidence rate, cases, 
and mortality for the past 16 years, a highly efficacious vaccine is likely essential to 
approach the ambitious World Health Organisation’s (WHO) vision of “a world free of 
malaria”. Targeting the malaria pre-erythrocytic stages, an obligatory and clinically silent 
phase of the parasite’s life cycle, is considered an ideal and attractive strategy for 
vaccination; inhibiting parasite infection of and development in hepatocytes results in 
preclusion of both disease-causing blood stages and transmissible sexual stages. Yet, 
despite intensive research for over 25 years, a highly efficacious pre-erythrocytic stage 
vaccine remains elusive2. An in-depth characterisation of how the complex biology of 
pre-erythrocytic stages influences the generation of protective immune responses is 
warranted to inform the design of future malaria vaccines.  
CD8+ T cells are crucial mediators of protective immunity to malaria pre-
erythrocytic stages3. Whilst often considered as a single phase of the parasite’s life cycle, 
the malaria pre-erythrocytic stage is comprised of two different parasite forms: (i) 
sporozoites, which are motile extracellular parasites that are delivered by infected 
mosquitoes to the mammalian host, and (ii) exo-erythrocytic forms (EEF; also known as 
liver stages), which are intracellular parasites resulting from the differentiation and 
growth of sporozoites inside a parasitophorous vacuole (PV) within hepatocytes4. How 
these two spatially different parasite forms and the ensuing temporal expression of 
parasite-derived antigens impact the magnitudes, kinetics and phenotypes of CD8+ T 
cell responses elicited following infection is poorly understood. Furthermore, the 
complexity within the pre-erythrocytic stages has fuelled a long-standing debate focused 
on the contributions of distinct sporozoite and EEF antigens in parasite-induced 
responses, and whether sporozoite or EEF proteins are better targets of vaccines.  
Our current understanding of CD8+ T cell responses to malaria pre-erythrocytic 
stages has been largely based on measuring responses to the H-2-Kd-restricted epitopes 
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of P. yoelii (Py)5 and P. berghei (Pb)6 circumsporozoite proteins (CSP), the major surface 
antigen of sporozoites. Many of these fundamental studies have focused on using 
infections with irradiated sporozoites, the gold-standard vaccine model for malaria. 
Infection with Py sporozoites elicits an expected T cell response typified by early 
activation and induction of effector CSP-specific CD8+ T cells followed by contraction 
and establishment of quantifiable memory populations7. CSP-specific CD8+ T cells are 
primed by dendritic cells that cross-present sporozoite antigens via the endosome-to-
cytosol pathway8. Yet, CSP is a unique antigen because it is expressed in both 
sporozoites and EEFs9. Whilst the expression of CSP mRNA ceases after sporozoite 
invasion, the protein on the parasite surface is stable and endures in EEFs during 
development in hepatocytes10. In vitro data indicate that primary hepatocytes process 
and present PbCSP-derived peptides to CD8+ T cells in a proteasome-dependent 
manner, involving export of antigen to the cytosol8. Taken together, these data imply that 
sporozoite antigens induce quantifiable CD8+ T cell responses after infection. Antigens 
that have similar expression to CSP, persisting to EEFs and with epitope determinants 
expressed on hepatocytes, are excellent targets of CD8+ T cell-based vaccines. 
The paucity of EEF-specific epitopes has hindered not only our ability to 
understand the immune responses that are evoked whilst the parasite is in the liver, but 
also their utility as targets of vaccination. Accordingly, the contribution of EEF-infected 
hepatocytes in the in vivo induction of CD8+ T cell responses is poorly understood. The 
liver is an organ where the primary activation of CD8+ T cells is generally biased towards 
the induction of tolerance11,12. Yet, studies in other model systems have demonstrated 
antigen-specific primary activation within the liver13. Another confounding issue with 
EEFs is their development in PVs with constrained access to the hepatocyte’s cytosol4. 
Nonetheless, if CD8+ T cells specific for EEF antigens are primed, do they expand and 
contract with distinct kinetics? Moreover, are EEF-specific epitopes efficiently generated 
for recognition and targeting by vaccine-induced CD8+ T cells? Answers to these 
questions will be key for antigen selection and design of future malaria vaccines. 
In this study, we compared the initiation and development of CD8+ T cell 
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responses – elicited following parasite infection – to CSP, a sporozoite antigen, and to 
upregulated in infective sporozoites gene 4 (UIS4), an EEF-specific vacuolar protein14. 
UIS4, a member of the early transcribed membrane protein (ETRAMP) family, is 
abundantly expressed in EEFs and associates with the PVM14.  Whilst UIS4 mRNA 
expression is present in sporozoites, translation is repressed until when EEFs develop10. 
To control for epitope specificity, we generated Pb transgenic parasites that incorporate 
the H-2-Kb epitope SIINFEKL, from ovalbumin, in either CSP or UIS4. We assessed the 
immunogenic properties of SIINFEKL expressed in the context of CSP and UIS4, 
defining immunogenicity as the ability of CSP and UIS4 to induce SIINFEKL-specific 
CD8+ T cell responses following immunisation with irradiated Pb transgenic sporozoites. 
We followed the kinetics of the CD8+ T cell response to each antigen and effector 
functions induced. Furthermore, we evaluated the capacity of vaccine-induced CD8+ T 
cells to target these parasites in a mouse challenge model. Our data shows disparate 
immunogenic properties between a sporozoite and an EEF vacuolar membrane antigen 
but equivalent susceptibility to vaccine-induced CD8+ T cells. 
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RESULTS 
Transgenic CSPSIINFKEL and UIS4SIINFEKL parasites display normal sporozoite motility 
and liver invasion 
We generated, by double homologous recombination, transgenic Pb parasites 
expressing the immunodominant H-2-Kb-restricted CD8+ T cell epitope of ovalbumin 
(SIINFEKL) in the context of the sporozoite surface antigen CSP or the EEF vacuolar 
membrane antigen UIS4 (Figure 1a, b). Constructs included the TgDHFR/TS positive 
selection cassette and incorporated SIINFEKL in the context of the gene open reading 
frame. For CSPSIINFEKL, SIINFEKL replaced SYIPSAEKI, the immunodominant H-2-Kd-
restricted CD8+ T cell epitope of CSP, which allowed for recognition in H-2-Kb-carrying 
C57BL/6 mice. For UIS4SIINFEKL, the SIINFEKL epitope was added to the immediate C-
terminus of the UIS4 protein. Appending the C-terminus was chosen because it had been 
shown in Toxoplasma gondii that the potency of the immunodominant epitope of GRA6 
was associated with its C-terminal location, which may have enhanced the presentation 
by parasite-infected cells15. Whilst undefined for UIS4 itself, it has been shown for several 
other ETRAMPs that the C-terminus faces the host cell cytoplasm16, which might 
enhance exposure to the MHC I machinery. 
The resulting parasites showed a phenotype comparable to WT parasites, with 
comparable midgut infectivity (Figure 1c), number of salivary gland sporozoites (Figure 
1d), functional sporozoite motility (Figure 1e) and normal invasive capacity and 
development inside hepatocytes (Figure 1f). Thus, the introduced mutations to generate 
CSPSIINFEKL and UIS4SIINFEKL parasites did not interfere with the completion of the life 
cycle, in either mosquito vector or mouse. All C57BL/6 mice that received 800 
sporozoites of either CSPSIINFKEL or UIS4SIINFEKL intravenously developed a patent blood 
stage infection by day 4, comparable to infection with WT sporozoites (data not shown). 
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Figure 1: Generation and characterisation of transgenic CSPSIINFEKL and UIS4SIINFEKL 
P. berghei lines 
Plasmodium berghei parasites expressing the CD8+ T cell epitope of ovalbumin, 
SIINFEKL, in the context of CSP or UIS4 were generated using double homologous 
recombination, combining drug-resistance selection (through incorporation of the dhfr/ts 
gene from Toxoplasma gondii) and cloning by limiting dilution to select for correctly 
recombined parasites. (a,b) Diagrams illustrate the reverse genetics strategy. (a) In 
CSPSIINFEKL SIINFEKL replaces the immunodominant CD8+ T cell epitope SYIPSAEK(I) 
of CSP. (b) In UIS4SIINFEKL SIINFEKL is adjoined to the carboxyl-terminus of the UIS4 
protein. Purified schizonts of WT P. berghei ANKA were transfected with linearized 
plasmid by electroporation as described17, and immediately injected intravenously in the 
tail vein of a mouse. The day after transfection, pyrimethamine (70 mg/l) was orally 
administered in the drinking water for selection of transgenic parasites. Transgenic 
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clones were generated in mice by in vivo cloning by limiting dilution. Correct integration 
of the constructs and purity of the transgenic lines was verified by diagnostic PCR using 
primer combinations specific for the unmodified CSP or UIS4 locus, and for the 5’ and 3’ 
recombination events as indicated by lines, arrows and expected fragment sizes. (c) 
Oocyst midgut infectivity of mosquitoes infected with WT, CSPSIINFEKL or UIS4SIINFEKL. The 
mean (±SD) of infected midguts was enumerated 10-14 days after infection (n= at least 
7 infections). (d) Salivary glands were isolated from WT, CSPSIINFEKL or UIS4SIINFEKL 
infected mosquitoes and mean sporozoite numbers (±SD) were enumerated between 
18-23 days after infection (n= at least 13 infections). (e) Sporozoite immunofluorescent 
antibody staining of WT, CSPSIINFEKL or UIS4SIINFEKL sporozoites after gliding on BSA-
coated glass slides. Shown are microscopic images of the respective sporozoites that 
were stained with anti-CSP (green), anti-UIS4 (red) and nuclear stain Hoechst 33342 
(blue). Scale bars, 10m. The numbers show mean percentage (±SD) of sporozoites 
with trails (n≥220 sporozoites viewed from two independent experiments). (f) 
Fluorescent-microscopic images of EEF-infected Huh7 hepatoma cells. 24 and 48 hours 
after infection with WT, CSPSIINFEKL or UIS4SIINFEKL sporozoites, the cells were fixed and 
stained with anti-UIS4 (red), anti-HSP70 (green) and the nuclear stain Hoechst (blue). 
Scale bars: 10µm. The numbers show mean numbers of intracellular parasites (±SD; n≥ 
200 EEFs viewed, from three independent experiments, and for WT from two 
independent experiments). 
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Peripheral blood CD8+ T cell responses and early proliferative capacity of splenic 
CD8+ T cells are superior if elicited by a sporozoite surface protein in contrast to 
a vacuolar membrane protein in the infected liver 
We first wanted to determine whether the generated transgenic parasites allow antigen-
specific responses to be tracked using SIINFEKL as a surrogate CD8+ T cell epitope for 
sporozoite surface and EEF vacuolar membrane antigens. To this end, we assessed the 
kinetics of the CD8+ T cell response following intravenous immunisation with CSPSIINFEKL 
or UIS4SIINFEKL sporozoites. To augment the CD8+ T cell response, mice were adoptively 
transferred with 2 x 106 OT-I cells expressing a SIINFEKL-specific TCR8, prior to 
receiving 10,000 -radiation attenuated WT, CSPSIINFEKL or UIS4SIINFEKL sporozoites. Prior 
work showed that -radiation attenuation of P. berghei sporozoites does not impact host 
cell invasion and UIS4 expression18. 
Peripheral blood was taken at days 4, 7, 14, 21, 42 and 88 after immunisation and CD8+ 
T cell responses were analysed after staining with H-2-Kb-SIINFEKL pentamers and for 
CD11a, a marker for antigen-experienced T cells19,20 (Figure 2a). A substantial 
proportion of Kb-SIINFEKL+ CD11a+ CD8+ T cells were observed in mice immunised 
with CSPSIINFEKL; the response was highest on day 4, reaching 5% of all antigen-
experienced CD8+ T cells, and declined steadily until day 21, when the response 
stabilised and remained unchanged for several weeks (Figure 2b). In marked contrast, 
UIS4SIINFEKL immunisation induced a poor CD8+ T cell response; the proportion of Kb-
SIINFEKL+ CD11a+ CD8+ T cells was only higher than the control groups at day 4 after 
immunisation, and the response remained within background levels for the duration of 
the experiment. Control groups included mice receiving OT-I cells only or in addition to 
WT sporozoites, which lack SIINFEKL sequences.  
The poor CD8+ T cell response induced by UIS4SIINFEKL sporozoites, as compared 
to CSPSIINFEKL, led us to characterise the early events in the proliferation and 
differentiation of these cells. Mice were adoptively transferred with CFSE-labelled OT-I 
cells and immunised with -radiation attenuated WT, CSPSIINFEKL or UIS4SIINFEKL 
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sporozoites. 5 days later, as shown by gating on CD8+ T cells (Figure 2c, g), 
immunisation with CSPSIINFEKL sporozoites recruited Kb-SIINFEKL+ CD8+ T cells to 
undergo massive proliferative activity, which was 6x larger than that observed with 
UIS4SIINFEKL sporozoites, in good agreement with the peripheral blood data described 
above (Figure 2b). Consistent with the activation of these cells, the proliferation of 
antigen-specific CD8+ T cells by both parasites was associated with the development of 
effector and effector-memory phenotypes as evidenced by upregulation of CD11a and 
CD49d, and downregulation of CD62L, respectively (Figure 2d-f). 
Taken together, these findings establish that immunisations with CSPSIINFEKL and 
UIS4SIINFEKL sporozoites permit antigen-specific responses to be tracked longitudinally in 
the peripheral blood. Importantly, we demonstrate that a sporozoite surface protein 
evokes a CD8+ T cell response of superior magnitude than an EEF vacuolar membrane 
protein following immunisation with malaria sporozoites. 
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Figure 2: Kinetics of CD8+ T cell responses induced by transgenic parasites.  
(a-b) C57BL/6 mice (n=3-5 per group) received 2x106 OT-I cells alone (diamonds) or 
were additionally immunised with 10,000 -radiation attenuated WT (triangles), 
CSPSIINFEKL (squares) or UIS4SIINFEKL (circles) sporozoites intravenously. (a) Flow 
cytometry plots show the gating strategy for identifying Kb-SIINFEKL+ CD11a+ CD8+ T 
cells. (b) Peripheral blood was obtained on days 4, 7, 14, 21, 42 and 88 after 
immunisation and stained for Kb-SIINFEKL+ CD11a+ CD8+ T cells. Line graph shows 
data pooled from two experiments (mean values ± SEM; *, p<0.05; **, p<0.01; ***, 
p<0.001; Welch’s t-test comparing CSPSIINFEKL and UIS4SIINFEKL). (c-g) C57BL/6 mice 
(n=4 per group), which received 2x106 CFSE-labelled OT-I splenocytes, were immunised 
with 10,000 -radiation attenuated WT, CSPSIINFEKL or UIS4SIINFEKL sporozoites 
intravenously. 5 days later, mice were sacrificed, spleens harvested and splenocytes 
assessed for (c) CFSE dilution and stained ex vivo (d-f) for effector CD8+ T cell surface 
markers. Shown are flow cytometry plots of Kb-SIINFEKL co-staining with markers of 
effector phenotypes: (d) CD11ahi, (e) CD62Llo, (f) CD49dhi and (g) the proliferation of 
CFSE-labelled antigen experienced Kb-SIINFEKL+ CD11a+ CD8+ T cells. 
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High magnitude splenic and hepatic CD8+ T cell responses to a sporozoite antigen  
Previous research has shown that CD8+ T cells are primed primarily in the spleen 
following intravenous immunisation with malaria sporozoites21 and that liver lymphocytes 
form a front-line defence against developing EEFs in hepatocytes22,23. Thus, we further 
analysed the development of CD8+ T cell responses in the spleens and livers of mice 
adoptively transferred with OT-I cells and intravenously immunised with WT, CSPSIINFEKL 
or UIS4SIINFEKL sporozoites. Consistent with our aforementioned results, surface staining 
of splenic and liver lymphocytes showed higher proportion and absolute numbers of Kb-
SIINFEKL+ CD11a+ CD8+ T cells at day 14 and day 42 following immunisation with 
CSPSIINFEKL compared to UIS4SIINFEKL sporozoites (Figure 3a-c). In addition to CD11a 
upregulation, the splenic and liver CD8+ T cells, elicited by both CSPSIINFEKL or 
UIS4SIINFEKL sporozoites, had effector and effector memory cell phenotypes (CD62L-, 
CD49d+ and CD44+) (Supplementary Figure 1). Although low, the numbers of antigen-
specific CD8+ T cells induced by UIS4SIINFEKL sporozoites were within the detection limits 
of the assay. 
To assess for effector functions, splenic and liver lymphocytes were stimulated 
ex vivo with the SIINFEKL peptide. Generally, higher numbers (proportion and absolute 
numbers) of IFN--secreting CD8+ T cells were observed at day 14 and day 42 following 
immunization with CSPSIINFEKL compared to UIS4SIINFEKL sporozoites (Figure 3d-f). In 
addition, these CD8+ T cells also expressed TNF and IL-2, suggesting some potential 
polyfunctionality (Supplementary Figure 2).  
Altogether, even though effector and effector memory CD8+ T cell responses can 
be detected against both sporozoite surface protein and EEF vacuolar membrane protein 
antigens following immunisation with malaria sporozoites, the two antigens show a 
striking difference in the magnitude of CD8+ T cell responses they induce. 
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Figure 3: Sporozoite surface antigen induces a higher CD8+ T cell response than 
EEF vacuolar membrane antigen in the spleen and liver. 
C57BL/6 mice (n=3-5 per group) received 2x106 OT-I cells alone or were additionally 
immunised with 10,000 -radiation attenuated WT, CSPSIINFEKL or UIS4SIINFEKL sporozoites 
intravenously. Spleens and livers were harvested either at day 14 or day 42. Proportions 
and numbers of (a-c) Kb-SIINFEKL+ CD8+ T cells were enumerated or (d-f) IFN--
secreting CD8+ T cells following restimulation ex vivo with SIINFEKL peptide were 
quantified. Flow cytometry plots show representative percentages of CD8+ T cells co-
stained with CD11a and (a) Kb-SIINFEKL or (d) IFN-. The upper panel of bar charts (b, 
e) show the percentage of co-stained CD8+ T cells and the lower panel (c, f) the absolute 
cell counts. Bar charts show mean values (±SEM) from one representative experiment 
of two experiments performed (*, p<0.05; **, p<0.01; ***, p<0.001; one-way ANOVA with 
Tukey’s multiple comparison test). 
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Quantification of endogenously produced antigen-specific CD8+ T cells following 
intravenous or intradermal parasite immunisation  
Previous work tracking responses to SIINFEKL-tagged proteins has used adoptively 
transferred cells from OT-I mice, with all T cells from these mice expressing T cell 
receptors specific to SIINFEKL8,24. We employed this robust approach by adoptively 
transferring a fixed amount of OT-I splenocytes in order to augment the response and 
allow visualisation (Figures 2 and 3). Next, we wanted to explore whether we can 
capture the endogenous Kb-SIINFEKL+ CD11a+ CD8+ T cell population, which is elicited 
by immunising with parasites without OT-I cell transfer. We performed ex vivo 
restimulation of lymphocytes with SIINFEKL peptide followed by flow cytometry and were 
able to clearly identify the endogenous population with a trend complementary to our 
earlier results (Figure 4a-c). Immunisation with CSPSIINFEKL sporozoites elicited a 
superior splenic and liver CD8+ T cell response than with UIS4SIINFEKL sporozoites. As 
expected, the proportion and absolute cell numbers were considerably lower than with 
adoptive transfer of OT-I cells, but this did not preclude the ability to visualise IFN--
secreting CD8+ T cells and capture the differences between the two groups.  
Under normal conditions of transmission, sporozoites are delivered into the host 
skin by mosquito bite. All preceding immunisation experiments were performed with 
parasites injected intravenously. As a proxy for the natural route of infection, whilst 
ensuring consistent quantities of parasites were inoculated, CSPSIINFEKL and UIS4SIINFEKL 
sporozoites were injected via the intradermal route into the ear pinnae. Under these 
conditions, CSP still induced a greater number of IFN--secreting SIINFEKL-specific 
CD8+ T cells following restimulation with SIINFEKL compared to UIS4, with a 
comparable magnitude as after intravenous injection (Figure 4d-f). Thus, these 
biologically and immunologically more appropriate data entirely recapitulate the strong 
immunogenicity of a sporozoite surface antigen compared to an EEF vacuolar 
membrane protein. 
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Figure 4: OT-I cells are not required to detect SIINFEKL-specific CD8+ T cell 
responses. 
C57BL/6 mice (n=3-6 per group) received 10,000 -radiation attenuated WT, CSPSIINFEKL 
or UIS4SIINFEKL sporozoites, either (a-c) intravenously or (d-f) intradermally. Additional 
control mice did not receive sporozoites. Spleens and livers were harvested either at day 
14 or day 42, and IFN--secreting lymphocytes following restimulation ex vivo with 
SIINFEKL peptide were quantified. Flow cytometry plots show representative 
percentages of CD8+ T cells co-stained with IFN- and CD11a (a, d). The upper panel 
of bar charts (b, e) show the percentage of CD11a+ IFN-+ CD8+ T cells and the lower 
panel (c, f) the absolute cell counts. (b-c) Bar charts show mean values (±SEM) from 
one representative experiment of two experiments performed (*, p<0.05; **, p<0.01; ***, 
p<0.001; one-way ANOVA with Tukey’s multiple comparison test). (e-f) Bar charts show 
mean values (±SEM) from one experiment performed (*, p<0.05; **, p<0.01; ***, p<0.001; 
one-way ANOVA with Tukey’s multiple comparison test). 
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Increasing the amount of EEF vacuolar membrane antigen does not impact on 
CD8+ T cell responses  
Both CSP and UIS4 are essential proteins expressed by the sporozoite and EEF 
respectively, and both proteins are important for survival and succession into the 
subsequent life stage and parasite form10,14,25. Previous studies have shown that the 
magnitude of the CD8+ T cell response to a sporozoite surface antigen depended on the 
amount of parasites used for immunisation26. Hence, poor immunogenicity of an EEF 
vacuolar membrane protein could be a result of the lower level of protein expression 
during parasite infection. It is possible to enhance CD8+ T cell responses by increasing 
the number of parasites used for immunisation26. Therefore, we immunised groups of 
mice with 8,000 CSPSIINFEKL, 8,000 UIS4SIINFEKL or 64,000 UIS4SIINFEKL sporozoites and 
compared the magnitude of the elicited antigen-specific responses. Strikingly, the CD8+ 
T cell response following 8x sporozoite immunisation dose with UIS4SIINFEKL did not 
increase proportionally and was not significantly higher than immunisation with a 1x dose 
(Figure 5a, b). This result suggests that, in the context of attenuated sporozoite 
immunisation, EEF vacuolar membrane antigens induce poor CD8+ cell responses and 
increasing antigen fails to substantially improve the magnitude of these CD8+ T cell 
responses.  
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Figure 5: Increasing antigen dose does not improve antigen-specific CD8+ T cell 
responses to an EEF vacuolar membrane protein. 
C57BL/6 mice (n=4 per group) received an intravenous dose of 8,000 -radiation 
attenuated CSPSIINFEKL or UIS4SIINFEKL sporozoites or 64,000 -radiation attenuated 
UIS4SIINFEKL sporozoites. Spleens and livers were harvested at day 12 and IFN--
secreting lymphocytes following restimulation ex vivo with SIINFEKL peptide were 
quantified. (a) Flow cytometry plots show representative CD8+ T cells co-stained with 
IFN- and CD11a. (b) The upper panel of bar charts show the percentage of CD11a+ 
IFN-+ CD8+ T cells and the lower panel the absolute cell counts. Bar charts show mean 
values (±SEM) from one representative experiment of two experiments performed (***, 
p<0.001; one-way ANOVA with Tukey’s multiple comparison test). 
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Immunogenicity of parasite antigens does not predict effector responses 
following vaccination 
Our findings thus far showed that sporozoite surface proteins appear more immunogenic 
than EEF vacuolar membrane proteins and raised an intriguing and important question; 
does immunogenicity predict susceptibility to vaccine-induced effector responses? To 
address this, we vaccinated mice, which had received OT-I cells, with a recombinant 
adenovirus expressing full-length ovalbumin27. This vaccination protocol resulted in 
frequencies of ~7.5% SIINFEKL-specific CD8+ T cells in peripheral blood (Figure 6a, b). 
Vaccinated mice were then challenged with CSPSIINFEKL or UIS4SIINFEKL sporozoites, and 
protection was assessed by two complementary assays; (i) determination of the 
reduction of parasite load in the liver (Figure 6c), and (ii) induction of sterile protection 
(Figure 6d). Vaccinated mice challenged with CSPSIINFEKL or UIS4SIINFEKL sporozoites 
showed a dramatic reduction in parasite load in the liver (Figure 6c) as compared to 
vaccinated mice challenged with WT parasites. Strikingly, there was no statistical 
difference in the protection observed when vaccinated mice were challenged with either 
CSPSIINFEKL or UIS4SIINFEKL sporozoites. Consistent with these findings, both groups of 
vaccinated mice challenged with either CSPSIINFEKL or UIS4SIINFEKL sporozoites exhibited 
sterile protection of comparable levels (Figure 6d). These findings indicate that spatial 
and temporal aspects of antigen expression may affect protein immunogenicity in the 
context of parasitic infection but not necessarily the same target’s susceptibility to 
antigen-specific CD8+ T cell killing. 
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Figure 6: Sporozoite surface and EEF vacuolar membrane antigens are presented 
to vaccine-induced CD8+ T cells for killing, leading to sterile protection.  
Mice received 1x108 ifu recombinant AdHu5 expressing whole ovalbumin (AdOVA) 
and/or 2x106 OT-I splenocytes. (a) Flow cytometry and (b) scatter plots represent CD8+ 
T cells derived from peripheral blood co-stained with IFN- and CD11a, following ex vivo 
restimulation with SIINFEKL. (c) Protective efficacy as measured by quantitative real-
time PCR. Groups of mice (n=3-11 per group) were vaccinated as described and 
challenged 19 days later with 10,000 WT, CSPSIINFEKL or UIS4SIINFEKL sporozoites. 42 
hours later livers were removed and parasite load was assessed by qPCR. Plots show 
the relative parasite load of mice in each condition (**, p<0.01; Mann-Whitney U test). 
(d) Proportion of sterile protection after immunization. Mice (n=8 per group) were 
vaccinated as described and were challenged with 1,000 WT, CSPSIINFEKL or UIS4SIINFEKL 
sporozoites. Data for a-d are from one representative experiment of two experiments 
performed with scatter plots showing median values + interquartile range. 
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DISCUSSION 
The malaria pre-erythrocytic stages have been a prime target for the 
development of a Pf vaccine for more than 35 years. Indeed, RTS,S/AS01, the most 
advanced malaria sub-unit vaccine candidate to date is based on CSP, the major surface 
protein of sporozoites28. Yet, final results of the Phase III trial showed that RTS,S/AS01 
offers only modest efficacy, which rapidly wanes over time29. Thus, there is an imperative 
need not only to widen the pursuit for new sub-unit vaccine candidates, but also to 
radically improve the antigen selection process. Antigens are generally prioritised based 
on a range of criteria, including their immunogenicity in the context of parasitic infection. 
We examined this notion in an infection and vaccination model for malaria pre-
erythrocytic stages.  
 The malaria pre-erythrocytic stages consist of two spatially-different parasite 
forms:  extracellular sporozoites and intracellular EEFs. The transformation of 
sporozoites into EEFs involves regulation at both transcriptional30 and translational31,32 
levels, resulting in both spatial and temporal expression of many antigens that are distinct 
for each parasite form33. Whilst our current understanding of immune responses to 
malaria pre-erythrocytic stages has focused on CSP, the lack of well-defined epitopes 
that are expressed only by EEFs has restrained fundamental studies investigating the 
contributions of EEF antigens in parasite-induced CD8+ T cell responses and their value 
as target of vaccines.  
In this study, we contrasted the development of CD8+ T cell responses induced 
by CSP and UIS4, two major proteins expressed by sporozoites and EEFs, respectively. 
We generated transgenic Pb parasites where SIINFEKL is expressed as part of either 
CSP or UIS4, allowing the presentation of the epitope at the same space and time as 
the respective protein. This approach is in contrast to a more common strategy of 
inserting the whole ORF of ovalbumin to be expressed as part of an Pb endogenous 
gene and then tracking the immune response elicited by this extraneous molecule24,34. 
Since CSP is expressed in both sporozoites and EEFs, the processing and presentation 
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of the SIINFEKL in CSPSIINFEKL occurs as soon as sporozoites are inoculated and are 
able to interact with dendritic cells, which present antigens via an endosome-to-cytosol 
pathway8. CSP also has direct access to the hepatocyte’s cytosol for processing and 
presentation of the CSP-derived epitope8.  However, since UIS4 is expressed only in the 
PVM of EEFs, processing and presentation of the epitope in UIS4SIINFEKL is restricted to 
just hepatocytes.  
Our results establish that following sporozoite-immunisation, a sporozoite surface 
protein induces superior CD8+ T cell responses – as measured both by pentamer 
staining and by IFN- secretion following peptide stimulation – than an EEF vacuolar 
membrane protein. Detailed kinetic and phenotypic analysis of the development of 
antigen-specific CD8+ T cells to both CSP and UIS4 revealed that the responses only 
differ in magnitude but not in durability, demonstrating the ability of both antigens to elicit 
effector and effector memory responses. There was no difference in our results whether 
sporozoites are delivered using the commonly used intravenous immunisation or the 
more physiological intradermal delivery. We also showed that increasing the number of 
UIS4SIINFEKL parasites used for immunisation did not augment CD8+ T cell responses, 
signifying that the poor immunogenicity of an EEF vacuolar membrane protein is not a 
due to the level of UIS4 expression during parasite infection. Our findings support the 
idea that EEF antigens have minimal contributions to the magnitude of immune 
responses following whole sporozoite immunisation, which corroborates with prior data 
showing that that hepatocytes are poor at priming T cell responses11,12. 
Regardless of their differing CD8+ T cell immunogenicities in the context of 
parasitic infection, we further demonstrated that both sporozoite and EEF antigens are 
effectively targeted by antigen-specific effector CD8+ T cells, which were generated by 
vaccination using priming and boosting with recombinant viruses expressing the epitope. 
Importantly, mice harbouring vaccine-induced, antigen-specific CD8+ T cells were 
comparably protected when challenged with either CSPSIINFEKL or UIS4SIINFEKL. These 
findings imply that both sporozoite and EEF antigens comparably access the antigen 
presentation pathways in hepatocytes leading to recognition of defined epitopes.  
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Our study is the first demonstration that poor natural immunogenicity, in this case 
of an EEF antigen, does not preclude antigen-specific CD8+ T cell killing. Our findings 
that antigen immunogenicity in this context is an inadequate predictor of vaccine efficacy 
have wide-ranging implications on antigen prioritisation for the design and testing of next 
generation malaria vaccines. To broaden the repertoire of liver-stage malaria vaccines, 
antigens secreted into the hepatocytes of either infected or traversed cells must be tested 
as these constitute promising targets of anti-malaria vaccines. Additionally, combining 
EEF antigens with CSP would be a favourable concept. 
While CSP and UIS4 only represent one antigen expressed in the sporozoite or 
EEF, they act as good surrogates for assessing CD8+ T cell responses to sporozoite 
and EEF antigens. Both antigens are highly abundant in their respective life stages, so 
should represent antigens that are likely to have significant access to the antigen 
presentation machinery compared to lesser expressed proteins. These antigens have 
also offered an insight into the effect of temporal and spatial factors of antigen expression 
on CD8+ T cell responses. Temporally, CSP protein is expressed early in the pre-
erythrocytic stages like other sporozoite antigens, while UIS4 protein is expressed later, 
following hepatocyte invasion, like all EEF-specific antigens. Spatially, CSP is expressed 
on the sporozoite surface as it travels through the skin and bloodstream in search of the 
liver and so other sporozoite antigens have similar niches, contacting many cells and 
increasing their propensity to be presented. UIS4 protein is expressed solely by the 
parasite in the hepatocyte and exported to the PVM, much like other EEF proteins. The 
close proximity of the PVM to the hepatocyte cytosol may also increase the likelihood of 
the protein being processed and presented, compared to a protein remaining inside the 
parasite plasma membrane. This is not to say that CSP or UIS4 are completely akin to 
all sporozoite or EEF antigens respectively. To fully resolve the spatiality effects of 
antigen expression on CD8+ T cell responses in the pre-erythrocytic stages of malaria, 
further antigens would need to be investigated. For instance, the differences between 
intracellular and extracellular sporozoite antigens, and intracellular EEF antigens and 
those exported to the PVM should be compared in their capability to induce CD8+ T cell 
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responses and be susceptible to vaccine-induced CD8+ T cells. The temporal effects of 
EEF antigen expression on CD8+ T cell responses have also been started to be probed 
to see if later expressed EEF antigens induce similar CD8+ T cell responses compared 
to those expressed earlier like UIS4 (Chapter 4: Gibbins et al., paper in preparation). 
A key direction for future research will be identifying the mechanisms by which 
EEF antigens elicit protection and finding new assays to easily distinguish good vaccine 
targets, namely those antigens that can protect (via susceptibility to vaccine-induced 
CD8+ T cells) rather than those that naturally induce strongly immunogenic responses. 
Ultimately, the molecular mechanisms of presentation of EEF antigens, those expressed 
in the PVM and within the parasite itself, onto the surface of infected hepatocytes 
remains to be fully understood. Determination of the processes involved in parasite 
antigen presentation in the pre-erythrocytic stages of malaria may elucidate links to 
protection and the identification of further antigens that could drive the development of 
an efficacious protective malaria vaccine. 
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METHODS 
Ethics and animal experimentation 
Animal procedures were performed in accordance with the German ‘Tierschutzgesetz in 
der Fassung vom 18. Mai 2006 (BGBl. I S. 1207)’ which implements the directive 2010/6 
3/EU from the European Union. Animal experiments at London School of Hygiene and 
Tropical Medicine were conducted under license from the United Kingdom Home Office 
under the Animals (Scientific Procedures) Act 1986. NMRI, CD-1, C57BL/6 and OT-I 
laboratory mouse strains were bred in house at LSHTM or purchased from Charles River 
Laboratories (Margate, UK or Sulzfeld, Germany). Female mice were used for 
experiments at the age of 6-8 weeks. 
 
Generation of transgenic parasites 
Transgenic P. berghei ANKA mutants CSPSIINFEKL and UIS4SIINFEKL were developed using 
double homologous recombination. In the CSPSIINFEKL mutant, the CSP gene is altered 
so the epitope SYIPSAEKI (residues 252-260) is replaced with the H-2b restricted Gallus 
gallus ovalbumin epitope SIINFEKL. In the UIS4SIINFEKL mutant, the SIINFEKL epitope is 
appended to the C-terminal end of the UIS4 protein. Clonal parasite lines were generated 
by limiting dilution. Details of plasmid design, including the primers used and the cloning 
of parasites can be found in Supplementary Experimental Procedures and 
Supplementary Table 1. 
 
Plasmodium berghei ANKA immunisation 
P. berghei wild type (WT; strain ANKA clone c15cy1 or clone 507) parasites and 
CSPSIINFEKL and UIS4SIINFEKL (clone c15cy1) parasites were maintained by continuous 
cycling between murine hosts (NMRI or CD-1) and Anopheles stephensi mosquitoes. 
Infected mosquitoes were kept in incubators (Panasonic and Mytron) at 80% humidity 
and 20°C. Sporozoites were isolated from salivary glands and -irradiated at 1.2 x 104 
cGy. Mice were immunised intravenously in the lateral tail vein or intradermally in the ear 
pinnae with 10,000 sporozoites, unless otherwise stated, and challenged with either 
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1,000 or 10,000 sporozoites injected intravenously. 
 
Indirect fluorescent antibody staining (IFA) of sporozoites 
Epoxy-covered 8-well glass slides were coated with 3% BSA-RPMI. 10,000 sporozoites 
were added per well in 3% BSA-RPMI and incubated for 45 minutes during which the 
shed surface proteins are deposited in the gliding motility process. Sporozoites and their 
trails were stained with a mouse anti-CSP35 primary antibody and a rabbit polyclonal anti-
PbUIS431 primary antibody and the respective fluorescently labelled secondary 
antibodies. Nuclei were stained with Hoechst 33342 and slides mounted with 
'Fluoromount-G' (Southern Biotech). Sporozoites and trails were analysed by fluorescent 
microscopy (Zeiss Axio Observer).  
 
In vitro infection of hepatoma cells and fluorescent staining 
In vitro EEF development was analysed in infected Huh7 hepatoma cells for 24 and 48 
hours. Triplicate Labtek (Permanox plastic - Nunc) wells were infected with 10,000 
transgenic CSPSIINFEKL or UIS4SIINFEKL parasites and duplicate wells were infected with 
10,000 WT parasites. Infected cells were analysed by fluorescence microscopy using a 
mouse anti-PbHSP7036 and a rabbit polyclonal anti-PbUIS431 primary antibody, the 
respective fluorescently labelled secondary antibodies and nuclear staining with Hoechst 
33342. Staining were analysed by fluorescent microscopy (Zeiss Axio Observer).  
 
Quantification of SIINFEKL-specific CD8+ T cell responses 
Spleens and livers were harvested from immunised or naïve mice and perfused with 
PBS. Lymphocytes were derived from spleens by passing through 40 or 70m cell 
strainers (Corning) and from livers by passing through 70m cell strainers (Corning). Red 
blood cells were lysed with PharmLyse (BD), and lymphocytes were resuspended in 
complete RPMI (cRPMI- RPMI + 10% FCS + 2% Penicillin-Streptomycin + 1% L-
glutamine (Gibco)). For cell counting, lymphocytes were diluted 40x with Trypan Blue 
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(ThermoFisher Scientific) and enumerated using a Neubauer ‘Improved’ 
haemocytometer (Biochrom). Alternatively, lymphocytes were counted using a 
MACSQuant flow cytometer (Miltenyi Biotec), using propidium iodide (PI) (Sigma Aldrich) 
or, in the case of hepatic lymphocytes, using CD45.2-Alexa647 (Biolegend) to distinguish 
between hepatocytes and lymphocytes, prior to PI administration and counting. 
Peripheral blood was acquired by tail vein puncture collected in Na+ heparin capillary 
tubes (Brand) and assayed in 96-well flat bottom plates (Corning). For CD8+ T cell 
stimulations, 2-3x106 splenocytes or 1-2x105 liver cells were incubated with SIINFEKL 
peptide (Peptides and Elephants, Henningsdorf) at a final concentration of 10g/ml in 
the presence of Brefeldin A (eBioScience). Cells were incubated at 37°C, 5% CO2 for 5-
6 hours, before incubation at 4°C overnight. For staining of cell surface markers and 
intracellular cytokines, cells were incubated for 1 hour at 4°C. Cells derived from the 
spleen or liver were fixed with 4% paraformaldehyde, and cells from peripheral blood 
were fixed with 1% paraformaldehyde between the extra- and intracellular staining steps. 
Data was acquired by flow cytometry using an LSRII or LSRFortessa (BD). Antibodies 
used for staining were as follows; BD: CD3 (500A2); eBioScience: CD8 (53-6.7), CD11a 
(M17/4), CD49d (R1-2), CD62L (MEL-14), CD44 (IM7), IFN- (XMG1.2), TNF- (MP6-
XT22) and IL-2 (JES6-5H4); ProImmune: H-2-Kb-SIINFEKL pentamers. 
 
CFSE labelling of OT-I cells 
Spleens from OT-I mice were lysed and cells washed twice in PBS without serum. 
Splenocytes resuspended at a density of 5x106 cells/ml in PBS had 1:5,000 CFSE 
(ThermoFisher Scientific) added and were incubated in the dark at room temperature, 
with gentle inversion for 4 minutes. The labelling reaction was quenched with cRPMI and 
cells washed twice in cRPMI. Cells were recounted and 2x106 cells were injected per 
mouse. 
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Vaccination with OVA expressing recombinant adenovirus 
To assess parasite liver load after vaccination with virus-expressed OVA, groups of 
C57BL/6 mice were immunised with recombinant human adenovirus serotype 5 (AdHu5) 
expressing full-length chicken ovalbumin (AdOVA)27. Each mouse received 1x108 
infective units (ifu) in a volume of 100µl administered intramuscularly (50µl into each 
thigh). At the same time vaccinated and control mice received OT-I splenocytes 
intravenously (2x106 cells/mouse). 19 days after vaccination, mice were challenged with 
10,000 WT, CSPSIINFEKL or UIS4SIINFEKL sporozoites administered intravenously. 42 hours 
after the challenge the livers were harvested and homogenised in TRIzol (ThermoFisher 
Scientific) for total RNA isolation. Afterwards, cDNA was generated using the 
RETROScript Kit (Ambion). Quantitative real-time PCR was performed using the 
StepOnePlus Real-Time PCR System and Power SYBR Green PCR Master Mix (Applied 
Biosystems). Relative liver parasite levels were quantified using the ΔΔCt method 
comparing levels of P. berghei 18S rRNA normalised to mouse GAPDH mRNA31. To 
assess sterile protection, AdHu5 OVA-vaccinated and control mice received 2x106 OT-I 
splenocytes one day prior to vaccination. 14 days after vaccination, all mice were 
challenged with 1,000 WT, CSPSIINFEKL or UIS4SIINFEKL sporozoites. Blood smears were 
taken from day 3-14 after challenge to determine the presence of blood stage parasites.  
 
Statistics 
Data were analysed using FlowJo version 9.5.3 (Tree Star Inc., Oregon, USA), Microsoft 
Excel and GraphPad Prism v7 (GraphPad Software Inc., CA, USA). We used Mann-
Whitney U test for analysing data from two groups that were not normally distributed, 
and Welch’s t-test or one-way ANOVA with Tukey’s multiple comparison test for normally 
distributed data. 
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SUPPLEMENTARY FIGURES 
 
Supplementary Figure 1: Sporozoite surface antigen induces a greater effector 
CD8+ T cell phenotype than EEF vacuolar membrane antigen. 
C57BL/6 mice (n=3-5 per group) received 2x106 OT-I cells alone or were additionally 
immunised with 10,000 -radiation attenuated WT, CSPSIINFEKL or UIS4SIINFEKL sporozoites 
intravenously. Spleens and livers were harvested either 14 or 42 days later, and 
proportions of CD8+ T cells expressing effector surface markers were quantified. Flow 
cytometry plots show representative percentages of CD8+ T cells co-staining Kb-
SIINFEKL and markers of effector phenotype (CD11ahi, CD49dhi, CD62Llo, CD44hi). 
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Supplementary Figure 2: Antigen experienced SIINFEKL-specific CD8+ T cells also 
produce TNF- and IL-2. 
C57BL/6 mice (n=3-5 per group) received 2x106 OT-I cells alone or were additionally 
immunised with 10,000 -radiation attenuated WT, CSPSIINFEKL or UIS4SIINFEKL sporozoites 
intravenously. Spleens and livers were harvested either 14 or 42 days after immunisation 
and lymphocytes restimulated ex vivo with SIINFEKL peptide at 10g/ml per well for 5-6 
hours. The upper panel of bar charts show the percentage of CD11a+ TNF- secreting 
CD8+ T cells, the bottom panel CD11a+ IL-2 secreting CD8+ T cells. This is a 
representation of one experiment from two experiments performed. Bar charts show 
mean values (±SEM) from representative experiments (*, p<0.05, **, p<0.01, ***, 
p<0.001; one-way ANOVA with Tukey’s multiple comparison test). 
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SUPPLEMENTARY EXPERIMENTAL PROCEDURES 
Generation of CSPSIINFEKL and UIS4SIINFEKL transgenic P. berghei parasite lines 
B3D-CSPSIINFEKL plasmid was assembled by successive cloning of three fragments, CSP-
C, CSP-B and CSP-A, obtained by PCR amplification from P. berghei ANKA genomic 
DNA followed by restriction enzyme digestion. These fragments correspond respectively 
to a 3’ homology region downstream of CSP (CSP-C, 0.7 kb), a fragment comprising the 
CSP ORF downstream of the SYIPSAEKI epitope followed by the CSP 3’ UTR (CSP-B, 
0.8 kb) and a fragment comprising a 5’ promoter region followed by the CSP modified 
ORF where the SYIPSAEK coding sequence has been replaced by a SIINFEKL coding 
sequence (CSP-A, 1.8 kb). The resulting B3D-CSPSIINFEKL plasmid, containing the 
Toxoplasma gondii dihydrofolate reductase/thymidylate synthase (TgDHFR/TS) 
pyrimethamine resistance cassette flanked by CSP-A and CSP-B on one side, and CSP-
C on the other, was linearized with NotI and SacII before transfection. Integration of the 
construct after double crossover homologous recombination results in replacement of 
the WT CSP gene by a modified copy containing the SIINFEKL coding sequence instead 
of the SYIPSAEKI coding sequence. The B3D-UIS4SIINFEKL plasmid was assembled by 
successive cloning of three fragments, UIS4-A, UIS4-B and UIS4-C, obtained by PCR 
amplification from P. berghei ANKA genomic DNA followed by restriction enzyme 
digestion. These fragments correspond respectively to a fragment comprising a 5’ 
upstream sequence followed by the UIS4 entire ORF fused in frame to the SIINFEKL 
coding sequence (UIS4-A, 1.2 kb), to the UIS4 3’ UTR sequence (UIS4-B, 0.6 kb) and 
to a 3’ homology region downstream of UIS4 (UIS4-C, 0.9 kb). The resulting B3D-
UIS4SIINFEKL plasmid, containing the TgDHFR/TS pyrimethamine resistance cassette 
flanked by UIS4-A and UIS4-B on one side, and UIS4-C on the other, was linearized with 
SacII and KpnI before transfection. Integration of the construct after double crossover 
homologous recombination results in replacement of the WT UIS4 gene by a modified 
copy containing the SIINFEKL coding sequence just upstream of a STOP codon. P. 
berghei CSPSIINFEKL and UIS4SIINFEKL parasites were generated by transfection of P. 
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berghei ANKA with linearized B3D-CSPSIINFEKL and B3D-UIS4SIINFEKL plasmids, 
respectively. Purified schizonts of WT P. berghei ANKA (clone c15cy1) were transfected 
with 5-10μg of linearized plasmid by electroporation using the AMAXA Nucleofector 
device (program U33), as described17, and immediately injected intravenously in the tail 
vein of a mouse. The day after transfection, pyrimethamine (70 mg/l) was administrated 
in the mouse drinking water, for selection of transgenic parasites. Transgenic clones 
were isolated after limiting dilution and injection into mice. Correct integration of the 
constructs and purity of the transgenic lines was verified by analytical PCR using primer 
combinations specific for the unmodified CSP or UIS4 locus, and for the 5’ and 3’ 
recombination events. All primers used in this study are indicated in Supplementary 
Table 1. 
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 Oligonucleotide  Sequence 5´ → 3´ 
Production of 
B3D-
CSPSIINFEKL 
construct 
CSP-A forward ATAAGAATGCGGCCGCATGGTTATATTTTGT
GCAATGCTAAAATGG 
CSP-A reverse CGGAATTCTAGTATCAGTTTTTCAAAGTTGA
TTATACTATCGTCATTATTATTATTTTTGTTA
TTG 
CSP-B forward GGACTAGTGAATTCGTTAAACAGATCAGGG
ATAGTATCACAGAGG 
CSP-B reverse CCGCAATTGTACAAAAAATATTTTCGACAAA
GGATAACG 
CSP-C forward CCCAAGCTTTGGGAATCTATTTTACAATATT
ATTTAAGGG 
CSP-C reverse CGGGGTACCCCGCGGTTATTGAAAAAGACA
CAAAATAGCTAG 
Production of 
B3D-
UIS4SIINFEKL 
construct 
UIS4-A forward TCCCCGCGGATAGCTATATTTTATGGTTGAT
CCTTTCC 
UIS4-A reverse GGACTAGTTTACAGTTTTTCAAAGTTGATTA
TACTTATGTATGGGCCGAATGATTTATTTTC
C 
UIS4-B forward GGACTAGTTTCATTATGAGTAGTGTAATTCA
GAAAGAG 
UIS4-B reverse CCGGAATTCTATGTAAAAAAGTTTGCATATA
CGGCTG 
UIS4-C forward CCCAAGCTTAGTGAAATATAAATATGAATGG
AAGCAGCC 
UIS4-C reverse CGGGGTACCAGCAGCTAATGTCAATATATT
TTATGCAC 
Genotyping of 
transgenic 
parasites 
TgDHFR forward CGCATTATATGAGTTCATTTTACACAATCC 
OVA reverse CTAGTTTACAGTTTTTCAAAGTTGATTATAC 
CSP WT forward TGTGAACTTTTCCTTATTTATTACGATTATG 
CSP test forward AATATGAGCACGCTTTTACTTTGTCCAGG 
CSP test reverse ACGAATCGAAATAAGTTACTATTCGTGCC 
UIS4 test forward TGGTTCTTAATATTATTTTGGATACATGC 
UIS4 test reverse CTCGTGTCCTTTGTAGTAAAAATAAACC 
Supplementary Table 1 – Primers used to generate and genotype CSPSIINFEKL and 
UIS4SIINFEKL transgenic parasites.  
Restriction sites in the primer sequences are underlined. 
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ABSTRACT 
 
Sporozoite antigens are the basis of many vaccines currently being tested against the 
pre-erythrocytic stages of malaria. Research focusing on liver stage antigens is lacking 
and their contribution to pre-erythrocytic immunity is less well understood. Whole 
sporozoite vaccination studies have shown that immunisation with late liver stage 
arresting parasites lead to improved protection against infectious sporozoite challenge. 
Nonetheless, few liver stage antigens have been discovered that can induce protection 
against sporozoite challenge. Previously our group had shown that UIS4, a 
parasitophorous vacuolar membrane (PVM) protein, expressed constitutively during 
liver stage development of the parasite, induces poor CD8+ T cell responses following 
immunisation with radiation attenuated P. berghei sporozoites. Given that radiation 
attenuated P. berghei sporozoites arrest early in their host hepatocytes, we employed 
an alternative sporozoite immunisation strategy in an effort to improve endogenous 
CD8+ T cell responses to UIS4. Here we employed azithromycin prophylaxis to ensure 
full liver stage development. However, we found that increasing the duration of 
expression of UIS4 in the liver stage parasite does not improve its cognate CD8+ T cell 
responses. Therefore, it is now important to define if late-expressing EEF antigens can 
contribute to protective CD8+ T cell responses against the pre-erythrocytic stages of 
malaria. 
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INTRODUCTION 
 
There is a far greater abundance of research delineating Plasmodium sporozoite 
antigens, the immune responses they induce and their potential for use in malaria pre-
erythrocytic vaccines compared to antigens expressed in the liver stage or exo-
erythrocytic forms (EEFs) of malaria infection. Early identification of pre-erythrocytic 
antigens focused on sporozoite antigens due to their high immunogenic capacity. 
Sporozoites are an extracellular form of the parasite, clearly visible to the immune 
system and have been found to induce strong antibody responses1. Experimentally, the 
generation of sporozoites from mosquitoes is also much easier than generating EEFs, 
which require a suitable hepatocyte tissue system2. However, to generate an 
efficacious pre-erythrocytic vaccine, it is imperative to investigate immune responses to 
the parasite as it resides in the liver. During this development in a hepatocyte, the 
parasite is stationary, thus fit for immune-mediated destruction, which would prevent 
the subsequent symptomatic and transmissible stages.  
 
Vaccination induced protection against the pre-erythrocytic stages of malaria was first 
shown to be possible in animals and humans using radiation attenuation sporozoites 
(RAS)3-5. RAS became the gold standard that all future malaria vaccines were 
compared to. Sterile protection induced by RAS has been shown to be mediated 
primarily by CD8+ T cells6, 7. Efficient recall of CD8+ T cell responses following 
presentation of parasite antigens on hepatocytes is crucial due to the short liver stage 
(in mice infected with Plasmodium berghei this is around 48-52 hours8), in order to kill 
all the developing EEFs. Despite the protection RAS can mediate, around 24 hours 
post immunisation with Plasmodium berghei RAS, parasites arrest their development in 
the hepatocyte as they reach the early schizont stage9, 10. In contrast, genetically 
attenuated parasites (GAPs) that arrest later in EEF development have been 
generated, with immunisation offering greater levels of sterile protection against pre-
erythrocytic infection compared to RAS or early-arresting GAPs11, 12. 
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In addition, another whole sporozoite vaccine approach involving administration of 
antibiotics as anti-malarial chemoprophylaxis can protect mice from challenge13. 
Antibiotics target the apicoplast of the parasite, which are a relict plastid-like organelle 
obtained by endosymbiosis. The apicoplast has lost its photosynthetic properties 
however it is still an essential organelle for the parasite, with antibiotic treated asexual 
forms of P. falciparum unable to develop inside red blood cells (RBCs) following 
reinvasion, and perpetuate the infection14, leading to a ‘delayed death’ phenotype. 
Apicoplasts in the progeny are unable to branch and segregate, unlike the nucleus14. 
Thus, where daughter merozoites do not contain a nucleus and an apicoplast, 
perpetuation of the infection is not possible. In the EEF, the action of antibiotics on the 
parasite is similar. EEF development appears to occur as normal, with clear 
schizogony of the nucleus. However, the antibiotics target the apicoplast, with a lack of 
branching occurring upon schizogony15, 16. The merosomes that are produced following 
P. berghei sporozoite infection of hepatoma cells treated with antibiotics in vitro contain 
non-viable merozoites, with these merozoites unable to infect mice when administered 
intravenously16. As in the RBC, antibiotics target the apicoplast of the EEFs in 
hepatocytes to prevent normal branching morphology during schizogony and daughter 
merozoites fail to be infectious and produce progeny because they fail to inherit an 
apicoplast16. 
 
Several antibiotics have been tested as prophylactic drugs concomitant with sporozoite 
immunisation and the greatest levels of sterile protection, following challenge, occurred 
when mice were immunised multiple times under azithromycin cover13. The level of 
protection was also greater compared to immunisation with chloroquine prophylaxis or 
RAS13 and mice receiving three immunising doses of sporozoites with azithromycin 
prophylaxis survived a second re-challenge 6 months after the first challenge16. In 
these investigations, azithromycin was given as three doses of 160mg/kg 
intraperitoneally13, 16, however in humans this can be given orally. Prevention of malaria 
by daily dosing with azithromycin has been shown to be effective in Kenya17 and 
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Indonesia18 indicating a generally safe, widely available antibiotic could be repurposed 
as a malaria prophylactic19. 
 
Molecular docking techniques have tried to identify the mode of action of azithromycin. 
There is evidence that point mutations in the apicoplast large subunit unit (LSU) rRNA 
gene and apicoplast-encoded ribosomal protein L4 (rpl4) gene confer azithromycin 
resistance in P. falciparum. With these mutations, azithromycin is unable to bind to L4, 
which complexes with L22 and the LSU rRNA at the nascent peptide exit tunnel20. This 
suggests that azithromycin blocks apicoplast development by inhibiting the apicoplast 
translation machinery, preventing new apicoplast-encoded polypeptides from being 
released from the ribosome. Using in silico docking software suggests this docking of 
azithromycin to apicoplast ribosomal proteins is organelle specific, as azithromycin 
does not dock in mitochondrial ribosomal proteins with the same affinity due to different 
side chains affecting the environment of the docking site21. 
 
As mentioned above, azithromycin allows full development of the EEF and merosome 
formation, which may be the reason for the increased sterile protection it induces. This 
increased protection may be achieved using the same mode of action as seen for late 
arresting GAPs12. It is hypothesised that upon extended EEF development, extended 
repertoires of antigens are expressed thus leading to a more diverse CD8+ T cell 
repertoire12. In addition to increased repertoires, the length of single antigen expression 
may also be increased. However, the CD8+ T cell responses induced by EEF proteins 
are currently not well defined.  
 
Previous research from our group has shown that CD8+ T cell responses to an EEF 
vacuolar membrane protein, UIS422, were weaker compared to those against 
circumsporozoite protein (CSP) when mice were immunised with P. berghei RAS. 
Nonetheless, both sporozoite and EEF antigen could robustly protect when used in a 
viral vaccination regimen (Chapter 2: Müller and Gibbins, paper in preparation). Both 
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antigens are abundantly expressed, with CSP constitutively present at the sporozoite 
surface and UIS4 constitutively present at the PVM following sporozoite invasion of a 
hepatocyte22, 23. Here we wanted to determine if the magnitude of antigen-specific 
CD8+ T cells responses to this EEF antigen could be improved by altering the method 
of parasite attenuation. In a side-by-side study, we compared CD8+ T cell responses 
following different immunisation strategies of C57BL/6 mice with P. berghei transgenic 
parasites expressing the reporter CD8+ T cell epitope SIINFEKL in the context of CSP 
or UIS4 (Chapter 2: Müller & Gibbins, paper in preparation). Mice were immunised 
either with RAS or sporozoites and azithromycin prophylaxis. Here we hypothesised 
that prolonged PVM protein expression would increase CD8+ T cell responses against 
EEF vacuolar membrane proteins. 
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MATERIALS AND METHODS 
 
Ethics and animal experimentation 
All animal work was conducted in accordance with the German Tierschutzgesetz in der 
Fassung von 18. Mai 2006 (BGB1. I S. 1207), which implements the Directive 
86/609/EEC from the European Union and the European Convention for the protection 
of vertebrate animals used for experimental and other scientific purposes. Animal 
experiments performed at London School of Hygiene and Tropical Medicine were 
conducted under licence from the United Kingdom Home Office under the Animals 
(Scientific Procedures) Act 1986. All protocols were approved by the ethics committee 
of the Max Planck Institute for Infection Biology and the Animal Welfare and Ethics 
Review Board of the London School of Hygiene and Tropical Medicine. NMRI, CD-1 
and C57BL/6 laboratory mouse strains were bred in house at LSHTM or purchased 
from Charles River Laboratories (Margate, UK or Sulzfeld, Germany). NMRI and CD-1 
were used for cycling of parasites between vertebrate and mosquito hosts. Female 
C57BL/6 mice were used for immunology experiments at age 6-8 weeks. 
 
Plasmodium berghei ANKA immunisation 
P. berghei CSPSIINFEKL and UIS4SIINFEKL (strain ANKA clone c15cy1) parasites (Chapter 
2: Müller and Gibbins, paper in preparation) were maintained by continuous cycling 
between murine hosts (NMRI or CD-1) and Anopheles stephensi mosquitoes. Infected 
mosquitoes were kept in incubators (Panasonic and Myrton) at 70-80% humidity and 
20°C. Sporozoites were isolated from salivary glands no earlier than 18 days after 
infection. Mice were immunised with 10,000 sporozoites intravenously in the lateral tail 
vein. Sporozoites were either -irradiated at 1.2 x 104 cGy or administered under 
prophylactic azithromycin drug cover. Azithromycin (Pfizer) was administered at a dose 
of 240 mg/kg intraperitoneally on the same day as immunisation and one day after16. 
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Quantification of SIINFEKL-specific CD8+ T cell responses 
Spleens and livers perfused with 5ml PBS were harvested from immunised and naive 
mice. Lymphocytes were filtered by passing the organs through 70m cell strainers 
(Corning). Red blood cells were lysed with PharmLyse (BD) and lymphocytes were 
resuspended in complete RPMI (cRPMI- RPMI + 10% FCS + 2% Penicillin-
Streptomycin + 1% L-glutamine (Gibco)). 
Cells were diluted 40x in Trypan Blue (ThermoFisher Scientific) and counted by 
microscopy using a Neubauer ‘Improved’ haemocytometer (Biochrom) or cells were 
counted using a MACSQuant flow cytometer (Miltenyi Biotec), using propidium iodide 
(PI) (Sigma Aldrich) and CD45.2-Alexa647 (Biolegend) to distinguish between 
hepatocytes and lymphocytes. 2-3x106 splenocytes or 0.5-1x106 liver cells were plated 
in flat bottom 96 well plates and incubated with peptides at final concentration 10g/ml 
in the presence of Brefeldin A (eBioScience). Peptides SIINFEKL, SALLNVDNL24 and 
VNYSFLYLF24 were synthesised and purchased from Peptides and Elephants. Cells 
were incubated at 37°C, 5% CO2 for 5-6 hours, before incubation at 4°C overnight. 
Cells were stained the following day for cell surface markers and intracellular IFN-. 
Cells were incubated for 1 hour at 4°C for cell surface marker staining first then 
intracellular staining. Between stainings cells were fixed with 4% paraformaldehyde 
and permeabilised using PermWash (BD). Data was acquired by flow cytometry using 
an LSRII or LSRFortessa (BD). Antibodies used for stainings were obtained from BD: 
CD3 (500A2) or eBioScience: CD8 (53-6.7), CD11a (M17/4), IFN- (XMG1.2). 
 
Statistics 
Data was analysed using FlowJo version 10.0.8 (Tree Star Inc., Oregon, USA), 
Microsoft Excel and GraphPad Prism v7 (GraphPad Software Inc., CA, USA). Statistics 
were calculated using one-way ANOVA with Tukey’s multiple comparison test. 
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RESULTS 
 
We first investigated the effect of different methods of sporozoite attenuation on the 
expansion of antigen-experienced CD8+ T cells, in the spleen and liver following 
immunisation, by flow cytometry. Previous work has shown that upregulation of CD11a 
and downregulation of CD8 is a durable and accurate phenotype for identifying 
infection or vaccine induced parasite-specific CD8 T cells25-27. We found that 
immunisation with RAS or those attenuated by azithromycin produced a similar 
proportion of CD11ahi CD8+ T cells, around 8% in the spleen and 30% in the liver, 2 
weeks after immunisation, determined post ex vivo stimulation with SIINFEKL peptide 
(Figure 1 and 2). This corroborates with previous work that shows both of these 
methods of attenuation induce comparable high levels of antigen-experienced cells in 
peripheral blood following immunisation13.  
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Figure 1 – Flow cytometry gating strategies 
The flow cytometry gating strategy used to assess the proportion of antigen-
experienced CD8+ T cells (CD11ahi CD8lo) and IFN- producing antigen-specific CD8+ 
T cells (IFN-+ CD11a+) in the (A) spleen and (B) liver. 
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Figure 2 – Similar levels of antigen-experienced CD8+ T cells are induced in mice 
immunised with irradiated and drug attenuated sporozoites 
Mice (n=3-5 per group) were immunised with CSPSIINFEKL or UIS4SIINFEKL RAS or 
sporozoites with azithromycin cover (AZ). Spleens and livers from immunised and 
naïve mice were harvested 14 days later. Lymphocytes were restimulated with 
SIINFEKL and stained for flow cytometry. The graphs show the (A) percentage and (B) 
absolute cell counts of CD11ahi CD8lo cells from the CD8+ T cell compartment in the 
spleen (left panel) and liver (right panel). Bar charts depict data pooled from three 
independently conducted experiments with mean values ± SEM shown. 
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We then compared antigen-specific CD8+ T cell responses by peptide ex vivo 
stimulation and found that the magnitude of responses to SIINFEKL in the context of 
UIS4 also did not change regardless of the attenuation method (Figure 3). The 
extension of UIS4 expression permitted by azithromycin administration did not alter the 
frequency and number of IFN- producing SIINFEKL-specific CD8+ T cells induced 
compared to when RAS were given. We also assessed the SIINFEKL-specific 
responses in the context of CSP expression and found the number of IFN- producing 
SIINFEKL-specific CD8+ T cell responses were significantly higher than those elicited 
against UIS4 as reported before (Chapter 2: Müller & Gibbins, prepared for 
publication). However, interestingly, SIINFEKL-specific CD8+ T cell responses in the 
spleen in the context of CSP are significantly lower when mice are immunised with 
sporozoites attenuated by azithromycin cover compared to RAS although this 
significance disappears when assaying liver infiltrating lymphocytes. Thus, we show 
that extending EEF development, and presumably vacuolar membrane antigen 
expression, does not amplify IFN- producing CD8+ T cell responses to EEF vacuolar 
membrane proteins constitutively expressed in the EEF. 
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Figure 3 – Extending the duration of EEF development during immunisation does 
not enhance CD8+ T cell responses to EEF vacuolar membrane proteins 
Mice (n=3-5) were immunised with CSPSIINFEKL or UIS4SIINFEKL RAS or sporozoites with 
azithromycin cover (AZ). Spleens and livers from immunised and naïve mice were 
harvested 14 days later. Lymphocytes were restimulated with SIINFEKL and stained 
for flow cytometry. The graphs show the (A) percentage and (B) absolute cell counts of 
CD8+ T cells co-expressing IFN- and CD11a in the spleen (left panel) and liver (right 
panel). Bar charts depict data pooled from three independently conducted experiments 
with mean values ± SEM shown (*, p<0.05; **, p<0.01; ***, p<0.001; one-way ANOVA 
with Tukey’s multiple comparison test). 
  
131 
 
To determine if the lack of effect of azithromycin on antigen-specific CD8+ T cell 
responses was specific to EEF antigens, we assessed endogenous CD8+ T cell 
responses to two sporozoites antigens, thrombospondin related anonymous protein 
(TRAP) and sporozoite-specific gene 20 (S20), that are not expressed during the liver 
stage. Following ex vivo restimulation with peptides corresponding to their CD8+ T cell 
epitopes24 we found that similar levels of CD8+ T cell responses were induced 
irrespective of attenuation method (Figure 4) with the only exceptions being a 
difference in absolute cell numbers of TRAP- and S20-specifc CD8+ T cell responses 
observed in the livers of mice receiving UIS4SIINFEKL parasites 
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Figure 4 – CD8+ T cell responses to sporozoite antigens are not affected by an 
extended EEF development 
Mice (n=3-5) were immunised with CSPSIINFEKL or UIS4SIINFEKL RAS or sporozoites with 
azithromycin cover (AZ). Spleens and livers from immunised and naïve mice were 
harvested 14 days later. Lymphocytes were restimulated with peptides corresponding 
to the immunogenic CD8+ T cell epitopes of TRAP protein (SALLNVDNL)24 (A,B) and 
S20 protein (VNYSFLYLF)24 (C,D) and stained for flow cytometry. The graphs show the 
(A,C) percentage and (B,D) absolute cell counts of CD8+ T cells co-expressing IFN- 
and CD11a in the spleen (left panel) and liver (right panel). Bar charts depict pooled 
data from three independently conducted experiments with mean values ± SEM (**, 
p<0.01; ***, p<0.001; one-way ANOVA with Tukey’s multiple comparison test). 
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DISCUSSION 
 
Azithromycin prophylaxis allows full EEF development of Plasmodium but inhibits 
apicoplast maturation and inheritance leading to non-infectious merozoites that fail to 
initiate erythrocytic infections16. Using azithromycin, we can immunise against antigens 
expressed throughout the pre-erythrocytic stages spanning from those antigens 
expressed by the sporozoite to those expressed very late on in the EEF prior to 
merozoite release into the blood. This would seem beneficial for increasing the pool of 
immunisation-induced CD8+ T cells that are specifically targeted against EEF antigens. 
Specifically looking at P. berghei UIS4, a PVM protein expressed constitutively in the 
liver following proper sporozoite invasion of a hepatocyte; azithromycin prophylaxis 
would allow UIS4 to continue to be expressed for the full 48-52 hours of EEF 
development in contrast to ~24 hours if RAS were used. Nonetheless, we show here 
that increasing the duration of UIS4 expression, facilitated by azithromycin, does not 
improve the magnitude of cognate CD8+ T cell responses against this vacuolar 
membrane protein. This is in concert with our previous finding that responses to UIS4 
could also not be improved by increasing the dose of sporozoites used for 
immunisation (Chapter 2: Müller & Gibbins, prepared for publication). In addition, 
similar levels of antigen-experienced CD8+ T cells are induced following immunisation 
with RAS or sporozoites under azithromycin prophylaxis as previously shown13. Similar 
levels of memory CD8+ T cells following sporozoite immunisation under chloroquine 
cover compared to RAS have also been identified28. This is surprising considering that 
immunisation with late-arresting GAPs induce the greatest protection from sporozoite 
challenge11, 12, thus a larger antigen-specific CD8+ T cell compartment would have 
been expected11 if EEF development was extended. Alas, while CD8+ T cells have 
been shown to be crucial for pre-erythrocytic protection, the acquisition of protection 
following immunisation with diversely attenuated parasites (RAS, GAPs or drug 
prophylaxis) are likely different, which means the correlates of protection following each 
immunisation are also probably distinct. Further research is required to deduce the 
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differences in responses induced by different parasite immunisation strategies and how 
they mediate protection. 
 
C57BL/6 mice immunised twice with P. berghei sporozoites under azithromycin cover 
have been shown to be better protected from sporozoite challenge than when they are 
immunised with RAS13. The authors also remark a non-significant but trending 
observation for better protection when assaying relative parasite load in the liver at 50 
hours post challenge compared to 42 hours. At 42 hours there is no difference in 
parasite load in the liver, whereas 8 hours later, a trend appears for a lower parasite 
load in liver when mice receive sporozoite immunisation under azithromycin cover 
rather than RAS immunisation. This suggests, in concert with sterile protection data 
that azithromycin induces protective CD8+ T cells that are specific for late-expressed 
EEF antigens, which act in the later stages of EEF development13. However, under 10 
days of chloroquine cover after both immunisations, parasite load in the liver was 
significantly higher than mice under azithromycin cover and sterile protection was 
comparable to RAS immunisation. This superior protection may be achieved because 
of increased immune responses to late expressed antigens on the non-invasive 
merozoite, which would never be presented using RAS or unlikely to be presented on 
the hepatocyte under chloroquine cover as merozoites do not arrest in the host 
hepatocyte but enter the bloodstream normally. We report similar results when 
assessing specific CD8+ T cell responses to mid-late expressed antigens LISP1 and 
LISP2 using the reporter epitope SIINFEKL as a proxy (Chapter 4: Gibbins et al., paper 
in preparation). Mice, vaccinated with adenovirus expressing ovalbumin, have high 
parasite loads in the liver compared to non-vaccinated controls at 40 hours post 
sporozoite challenge with parasites expressing SIINFEKL in the context of LISP1 or 
LISP2. However, when mice were followed for the onset of parasitaemia, 50% of mice 
exhibit sterile protection. This suggests that LISP1 and LISP2 induce CD8+ T cells that 
have some protective capability and may act very late following challenge, leading to 
the discrepancy between the parasite load in the liver data and sterile protection data 
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(Chapter 4: Gibbins et al, paper in preparation). Together, these data suggest that 
increasing the breadth of CD8+ T cell responses to include later expressed EEF 
antigens could lead to greater protection. Here we extended expression of UIS4 protein 
hypothesising that late expression of EEF antigens may still be important. However, 
extending EEF antigen expression via drug cover does not increase the number of 
cognate CD8+ T cell responses. More research is required to determine the kinetics of 
antigen-specific CD8+ T cell responses and other immune responses in the liver stage 
of malaria. Investigation into how to enhance liver stage responses to achieve 
protection and identification of antigens that are presented at this stage will be crucial 
in designing and developing new generation malaria vaccines. 
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ABSTRACT 
 
Understanding the liver stage of Plasmodium infection is important for the development 
of future vaccines, however research on effective immune responses in the liver is 
lacking. Only recently have the intricacies of parasite development in the liver and the 
interactions with the host begun to be fully determined. CD8+ T cells are known to be 
critical immune cells in targeting the parasite hidden inside hepatocytes, however the 
antigen specificity of these cells is only just starting to come to light. Using genetically 
attenuated parasites it has been found that vaccination with parasites that arrest in the 
late stages of parasite development in the hepatocyte induce a greater level of anti-
Plasmodium immunity and protection from sporozoite challenge. Using Plasmodium 
berghei parasites expressing a reporter epitope, we show that antigens expressed during 
mid-late liver stage development induce antigen-specific CD8+ T cell responses and 
offer partial protection against sporozoite challenge. With delayed antigen expression 
and presentation, but the ability to induce effective CD8+ T cell responses, this result 
emphasises the potential for including late liver stage antigens in new malaria vaccines. 
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INTRODUCTION 
 
Malaria is a global health burden affecting more than around 216 million cases per year, 
resulting in around 445,000 deaths, with 80% of global cases occurring in 14 countries 
in sub-Saharan Africa and India1. However, with the rise and spread of drug resistant 
parasites2, the road to elimination will be slow without the advent of efficacious vaccines.  
 
A vaccine that targets the pre-erythrocytic stages of malaria is favourable because it 
would target a natural bottleneck in the life cycle of Plasmodium. Only a few hundred 
sporozoites are injected into the skin by an infected female Anopheles mosquito3, gliding 
in the dermis4 in a random pattern until they reach a blood vessel5 where they travel to 
the liver, invade6 and undergo replication within an hepatocyte. Only 25% of this small 
inoculum of sporozoites successfully make it out of the skin into the bloodstream7. So, if 
the few sporozoites that find the liver could be killed en route or whilst developing in the 
liver, then subsequent blood stages, which lead to both symptoms and transmission, 
would be prevented. 
 
Vaccine research against the pre-erythrocytic stages of malaria to date, has broadly 
focused on sporozoite antigens. Two antigens in particular, circumsporozoite antigen 
(CSP) and thrombospondin-related anonymous protein (TRAP), were originally shown 
to induce strong immunological responses, in the form of anti-CSP antibody production8 
and anti-CSP CD4+ T cells9-11 or anti-TRAP CD8+ T cells12 following immunisation of 
humans with radiation attenuated sporozoites. This led to subunit vaccine development 
and thus CSP and TRAP remain the most described malaria vaccine candidates to date.  
 
RTS,S/AS01 is the most advanced malaria vaccine to date. RTS,S/AS01 is a subunit 
vaccine based on the major surface antigen of sporozoites, CSP, which offered modest 
protection against clinical episodes of Plasmodium falciparum malaria in a multi-site 
Phase III study in Africa, however efficacy waned over time13. Vaccine-induced 
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protection was correlated with the induction of high-titres of anti-CSP antibodies and 
CSP-specific CD4+ T cells14. A Phase IIb trial in Kenya showed promising 67% efficacy 
against P. falciparum malaria infection for a viral vectored prime-boost ME-TRAP vaccine 
(multiple epitope (ME) string containing T cell epitopes of other pre-erythrocytic antigens 
in addition to TRAP), however longevity of efficacy over time could not be determined 
due to the short follow-up period15. Furthermore, combining 3 doses of RTS,S/AS01B 
and the viral vectored ME-TRAP prime-boost regimen gave promising sterile efficacy 
against malaria infection following CHMI (Controlled Human Malaria Infection) 12 weeks 
after first vaccination and repeat CHMI 6 months later in a UK based Phase I/IIa study16. 
Therefore, vaccines based on sporozoite antigens are successful at protecting 
individuals from malaria in endemic regions. 
 
This focus on sporozoite surface antigens may be due to the perception that they are 
more accessible to the immune system than antigens expressed by liver stages or exo-
erythrocytic forms (EEFs) of the parasite hidden away within a hepatocyte. However 
recently we have demonstrated that by expressing the model epitope of ovalbumin, 
SIINFEKL, in the context of different P. berghei proteins, the temporal and spatial effects 
of pre-erythrocytic antigen expression on CD8+ T cell responses could be determined 
by proxy (Chapter 2: Müller and Gibbins, paper in preparation). Previously, we generated 
two transgenic parasites which express the reporter epitope in the context of sporozoite 
surface protein CSP or EEF parasitophorous vacuole membrane (PVM)-associated 
upregulated in infectious sporozoites gene 4 (UIS4)17. We showed that despite the 
greater immunogenic qualities (CD8+ T cell cytokine production and proliferative 
capacity) of sporozoite antigens compared to EEF vacuolar membrane antigens, both 
antigens were equally protective when mice were vaccinated prior to sporozoite 
challenge. This finding highlighted two concepts- poor natural antigen-specific CD8+ T 
cell responses don’t necessarily negate an antigen’s suitability as a vaccine candidate 
and that EEF antigens can be protective. Following on from this discovery, we wanted to 
know at what stage of EEF development can the parasite still be detected, and the 
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infected hepatocyte destroyed. We hypothesised that later expressed EEF antigens 
would not provide the same level of protection as those expressed constitutively. 
 
Here, our aim was to investigate CD8+ T cell responses and protection offered by 
proteins expressed later during EEF development. Given that development of 
Plasmodium berghei EEFs in mice only lasts for around 48-52 hours18 before the first 
merozoites are released into the bloodstream, we chose two mid-late expressed PVM 
associated proteins to compare against constitutively expressed UIS4. UIS4 protein is 
constitutively expressed upon development of parasite within a hepatocyte and localises 
to the PVM17, 19. In contrast, Liver Specific Protein 1 (LISP1)20 and Liver Specific Protein 
2 (LISP2)21 have similar mid-late EEF specific expression profiles, with mRNA and 
protein expression being absent during early EEF development and expression peaking 
at 48 hours in vitro and in vivo. LISP1 has been shown to be crucial for egress of 
merozoites from the PVM20, while LISP2 is carried to the PVM by secretory vesicles and 
subsequently transported to the cytoplasm and nucleus of hepatocyte where it is 
suggested that it plays a role in modifying the running of the cell for its own devices21. 
We generated transgenic parasites expressing SIINFEKL in the context of LISP1 or 
LISP2 and here we show the CD8+ T cell responses launched against these mid-late 
expressed EEF antigens and the partial protection against the pre-erythrocytic stages 
that they induce. 
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MATERIALS AND METHODS 
 
Ethics and animal experimentation 
Animal procedures were performed in accordance with the Directive 2010/63/EU from 
the European Parliament and Council ‘On the protection of animals used for scientific 
purposes’.  Animal experiments performed at London School of Hygiene and Tropical 
Medicine were conducted under license from the United Kingdom Home Office under the 
Animals (Scientific Procedures) Act 1986. Protocols were approved by the Charles 
Darwin Ethics Committee of the University Pierre et Marie Curie, Paris, France and the 
Animal Welfare and Ethics Review Board of the London School of Hygiene and Tropical 
Medicine. Swiss Webster mice were purchased from Janvier (Saint Berthevin, France) 
and used to generate the transgenic parasites. CD-1 mice were bred in house at LSHTM 
and used for cloning by limiting dilution and for cycling parasites between murine and 
mosquito hosts. C57BL/6 mice were purchased from Charles River Laboratories 
(Margate, UK). OT-I mice were purchased from Charles River Laboratories (L'Arbresles, 
France) or spleens were kindly donated by James Cruickshank at the Babraham 
Institute, Cambridge. Female mice were used for experiments at age 6-8 weeks. 
 
Parasites and mosquitoes 
Transgenic parasites pLISP1-UIS4SIINFEKL, pLISP2-UIS4SIINFEKL, LISP1SIINFEKL and 
LISP2SIINFEKL were generated in a Plasmodium berghei ANKA strain which expresses 
GFP at the dispensable p230p locus22. Wild type P. berghei (clone 507) was used in 
comparison which expresses GFP at the elongation factor 1 alpha (eef1a) locus. 
Additional P. berghei CSPSIINFEKL and UIS4SIINFEKL parasites that do not express GFP 
(Chapter 2: Müller and Gibbins, paper in preparation) were used for immunological 
comparisons. Anopheles stephensi mosquitoes were reared and infected with these P. 
berghei parasites. Infected mosquitoes were kept incubators (Panasonic) at 22°C and 
70% humidity. Infected mosquitoes were given a second naïve blood feed from 
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anaesthetised mice 7 days post infection23. Salivary gland sporozoites were dissected at 
least 21 days post infection. 
For immunological experiments, mice were immunised intravenously or intradermally 
once with 10,000 sporozoites concomitantly with azithromycin (Pfizer) given at a dose of 
240 mg/kg intraperitoneally on the same day as immunisation and one day after24. Viral 
vaccinated mice were challenged with 1,000 or 10,000 sporozoites intravenously for 
sterile protection and parasite load in the liver experiments respectively. 
 
Transgenic parasite generation 
pLISP1-UIS4SIINFEKL, pLISP2-UIS4SIINFEKL, LISP1SIINFEKL and  LISP2SIINFEKL parasites were 
generated using In-Fusion (Clontech) technology to generate plasmids for transfection 
based on generation of a common plasmid25 (MG1 - Figure 1). The similarities between 
the parasites include the addition of mCherry, SIINFEKL epitope and 3’ UTR from UIS4 
appended to the end of a designated protein. In the case of pLISP1-UIS4SIINFEKL and 
pLISP2-UIS4SIINFEKL (plasmids MG2b and MG2c respectively), the mCherry-SIINFEKL 
modification occurs at the C-terminus of an additional copy of the UIS4 protein. This 
modified ORF is under the promoter of LISP1 or LISP2, appearing downstream of the 
endogenous ORF at the UIS4 locus.  In the case of LISP1SIINFEKL (plasmid MG2e), the 
mCherry-SIINFEKL modification occurs at the C-terminus of the endogenous LISP1 
protein. In the case of LISP2SIINFEKL, the mCherry-SIINFEKL modification occurs at the 
C-terminus of the endogenous LISP2 protein. Plasmids were transfected into 
Plasmodium berghei ANKA expressing GFP at the dispensable p230p22 by 
electroporation of merozoites using Nucleofector buffer and an AMAXA Nucleofector26. 
Swiss Webster mice were immediately injected with electroporated merozoites 
intravenously. Transgenic clones were isolated after limiting dilution and injection into 
CD-1 mice. Details of plasmid design, primers, cloning and genotyping of parasites can 
be found in Supplementary Experimental Procedures and Supplementary Table 1.  
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In vitro infection of hepatoma cells and fluorescent staining 
In vitro liver EEF development was analysed in infected Huh7 hepatoma cells at 12, 24 
and 48 hours. Duplicate Labtek (Nunc) wells were infected with 10,000 P. berghei WT, 
pLISP1-UIS4SIINFEKL, pLISP2-UIS4SIINFEKL, LISP1SIINFEKL or LISP2SIINFEKL sporozoites. 
Cells were fixed with 4% paraformaldehyde and stained for analysis by fluorescence 
microscopy using polyclonal anti-PbUIS4 (SICGEN) or anti-DsRed/mCherry (Takara 
Bio) primary antibodies. Corresponding secondary antibodies conjugated to Alexa546 
were used and nuclear staining was visualised using DAPI before mounting with 
Vectashield (Vector Labs). The stainings were analysed using an Eclipse Ti-E inverted 
microscope (Nikon). 
 
Restimulation of splenic, liver infiltrating and peripheral blood lymphocytes 
Spleens and livers perfused with PBS were harvested from immunised and naïve mice. 
Peripheral blood was acquired by tail vein puncture collected in Na+ heparin capillary 
tubes (Brand) and assayed in 96-well flat bottom plates (Corning). Organs were 
homogenised using 70m cell strainers (Corning), hepatocytes removed using a Percoll 
(GE Healthcare) gradient, and red blood cells lysed using PharmLyse (BD). 
Lymphocytes were resuspended in complete RPMI (cRPMI- RPMI + 10% FCS + 2% 
Penicillin-Streptomycin + 1% L-glutamine (Gibco)). Cells were counted by microscopy 
following 40x dilution with Trypan Blue (ThermoFisher Scientific) on a Neubauer 
‘Improved’ haemocytometer (Biochrom). 2-3x106 splenocytes or 0.5-1x106 liver cells 
were incubated with SIINFEKL peptide (Peptides and Elephants) at final concentration 
of 10g/ml in the presence of Brefeldin A (eBioScience) and incubated for 5-6 hours at 
37°C and 5% CO2 before incubation at 4°C overnight. CD8+ T cells were stained for flow 
cytometry using CD3 (500A2), CD8 (53-6.7) and CD11a (M17/4) and intracellular 
cytokine markers IFN- (XMG1.2). Antibodies were obtained from BD (CD3 only) or 
eBioscience.  Spleen or liver cells were fixed using 4% paraformaldehyde and peripheral 
blood cells were fixed with 1% paraformaldehyde. Cells were permeabilised using 
151 
 
PermWash (BD). Data was acquired on an LSRII (BD). 
 
Vaccination with OVA expressing recombinant adenovirus for assessment of 
parasite load in the liver and sterile protection 
To assess parasite load in the liver and sterile protection, mice were vaccinated 
recombinant human adenovirus serotype 5 (AdHu5) expressing full-length chicken 
ovalbumin (AdOVA)27. Mice received 1x108 infective units (ifu) diluted in ice cold PBS 
with 100µl of the virus administered subcutaneously (50µl into each thigh). Vaccinated 
and control mice also received 2x106 OT-I splenocytes intravenously. 
 
Quantitative real time PCR to determine parasite load in the liver 
14 days after vaccination, vaccinated and control mice were challenged with 10,000 P. 
berghei ANKA sporozoites intravenously. 40hrs after the challenge, livers were 
harvested and homogenised in TRIzol (ThermoFisher Scientific) for total RNA isolation. 
Quantitative real-time PCR was performed using the 7500 Fast Real-Time PCR System 
and FastSYBR Green PCR Master Mix (Applied Biosystems). Relative liver parasite 
levels were quantified using the ΔΔCt method comparing levels of P. berghei 18S rRNA 
and normalised to levels of mouse GAPDH mRNA. Primers used can be found in 
Supplementary Table 1. 
 
Sterile protection 
14 days after vaccination, vaccinated and control mice were challenged with 1,000 P. 
berghei ANKA sporozoites intravenously. Parasitaemia in challenged mice was 
monitored by daily blood smears taken from day 3-14 after challenge, stained with 
Giemsa solution (VWR). 
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Statistics 
Data was analysed using FlowJo version 10.0.8. (Tree Star Inc., Oregon, USA), 
Microsoft Excel and GraphPad Prism v7 (GraphPad Software Inc., CA, USA). We 
calculated statistics between two groups using Mann-Whitney U test or Welch’s t-test for 
non-normally or normally distributed data, respectively, and one-way ANOVA with 
Tukey’s multiple comparison test for comparing more than two groups. 
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RESULTS 
 
Generation of LISP1SIINFEKL and LISP2SIINFEKL transgenic parasites 
We developed P. berghei parasites that express the reporter CD8+ T cell epitope of 
ovalbumin, SIINFEKL, in the context of LISP1 and LISP2 which are expressed at similar 
times in during EEF development, with mRNA transcripts and protein only detectable 
after 24 hours20, 21. Using the common plasmid MG1 (Figure 1) a similar strategy to that 
used to generate UIS4SIINFEKL (Chapter 2: Müller and Gibbins, paper in preparation) was 
employed. We modified the loci of LISP1 or LISP2 by appending the SIINFEKL epitope 
to the C-terminus of the LISP1 or LISP2 protein, as well as incorporating an mCherry tag 
prior to SIINFEKL. LISP1SIINFEKL (Figure 2A) and LISP2 SIINFEKL (Figure 2B) thus 
expressed one copy of LISP1 or LISP2 which was mCherry-SIINFEKL tagged, regulated 
by the endogenous promoter region although the 3’ UTR was from UIS4, not the gene 
specific 3’ UTR. This was because we generated two sets of parasites but used the 
common plasmid MG1 (Figure 1) to generate both. We generated in parallel, pLISP1-
UIS4SIINFEKL and pLISP2-UIS4SIINFEKL parasites that were modified at the UIS4 locus, so 
that an extra copy of UIS4, under the promoter of LISP1 or LISP2, was incorporated 
which would contain the mCherry-SIINFEKL tag (Figure 3A, B). These parasites were 
generated so that if the parasites LISP1SIINFEKL and LISP2SIINFEKL failed to express 
functional modified LISP1 or LISP2 tagged protein that did not associate with the PVM, 
a later expressed tagged UIS4 protein could be used to probe responses to a PVM 
protein that is expressed later than endogenous UIS4. The tagged UIS4 was placed 
under a separate 3’ UTR of UIS4. It was necessary to engineer the tagged version of 
UIS4 as regulatorily separate from the endogenous copy, because a single copy of UIS4 
strictly under the LISP1 or LISP2 promoter would prevent early EEF development. All 
four transgenic parasites were generated using the MG1 plasmid which contained a 
mCherry-SIINFEKL-UIS4 3’ UTR cassette (Figure 1), hence why LISP1SIINFEKL and 
LISP2SIINFEKL contain this unconventional 3’ UTR. 
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Figure 1 
Generation of mCherry-SIINFEKL-UIS4 3’ UTR containing plasmid 
All parasites were based on MG1 starting plasmid. Full details of plasmid construction 
are described in the Supplementary Experimental Procedures. The hDHFR cassette 
(blue) provided the drug selectable resistance gene against pyrimethamine allowing 
determination of parasites incorporating the plasmid.  MG1 was linearised by EcoRI 
(grey), with gene fragments for the other plasmids inserted here using In-Fusion 
(Clontech) technology. Ultimately, following insertion of gene fragments, genes would be 
appended 3’ by the mCherry-SIINFEKL-UIS4 3’ UTR sequences. Thus, following 
translation, proteins would be mCherry tagged (red) at the C-terminus followed by the 
SIINEKL CD8+ T cell target epitope (green). The 3’ UTR of UIS4 (purple) would be the 
3’ regulatory region functioning to signal the end of transcription, though transcription 
may not be under the promoter region of UIS4, depending on the parasite in question. 
The sequence of the T7 promoter (pink) present in the plasmid was used in conjunction 
with a sequence from hDHFR to genotype parasites and identify episome formation.  
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Transgenic parasites develop normally into sporozoites and EEFs with 
localisation of UIS4, LISP1 and LISP2 with the parasitophorous vacuole membrane 
Recombinant parasites that had integrated the plasmid, containing the human 
dihydrofolate reductase drug selectable marker gene (hDHFR), were selected for by 
treatment with pyrimethamine, followed by limiting dilution to isolate clones. Genotyping 
PCRs were performed using primers designed to determine the presence of WT 
parasites, 5’ and 3’ integration and the presence of episomes (LISP1SIINFEKL- Figure 2C; 
LISP2SIINFEKL- Figure 2D; pLISP1/2-UIS4SIINFEKL- Figure 3C). Primers were also required 
to determine the difference between pLISP1-UIS4SIINFEKL and pLISP2-UIS4SIINFEKL by 
amplifying the LISP1 or LISP2 promoters ahead of the UIS4-mCherry-SIINFEKL gene 
(Figure 3C). Clones for all four parasites were successfully acquired. 
 
Transmission to mosquitoes is an important attribute with genetically modified 
Plasmodium parasites. All parasites were successfully transmitted to Anopheles 
stephensi mosquitoes, with comparable numbers of salivary gland sporozoites to WT 
(LISP1/2SIINFEKL- Figure 2E; pLISP1/2-UIS4SIINFEKL- Figure 3D) except pLISP1-
UIS4SIINFEKL where the average load of sporozoites dissected from salivary glands was 
consistently and drastically lower than the other parasites. 
 
We infected Huh7 hepatoma cells with sporozoites to determine development of the 
transgenic parasites and also the subcellular localisation of LISP1 or LISP2 
(LISP1/2SIINFEKL- Figure 2F, G); pLISP1/2-UIS4SIINFEKL- Figure 3E, F). All parasites 
developed with sizes comparable to WT parasites. We used anti-mCherry antibodies as 
a proxy to stain for our tagged proteins. UIS4 but not LISP1 nor LISP2 showed 
localisation to the PVM at 12 hours. All three proteins could be visualised at the PVM 
after 24 hours with a similar localisation pattern to UIS4 in our WT parasites, which we 
stained with anti-UIS4 because these parasites do not express mCherry. This confirmed 
that expression of LISP1 and LISP2 protein does not occur in the first 12 hours after 
hepatocyte invasion whereas UIS4 protein is expressed very soon after invasion19. 
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Previously, weak LISP2 expression at 24 hours was described in parasites that express 
mCherry tagged LISP2 and visualised using mCherry antibodies as we have here20. 
Visualisation of LISP1 and LISP2 expression using LISP1 or LISP2 primary antibodies 
suggested that the protein was not visible until 36 or 24 hours respectively after 
invasion20, 21. These differences may be due to the increased sensitivity of the mCherry 
primary antibody. Nonetheless the proteins localise as reported previously20, 21 both at 
24 and 48 hours. In the same way we visualised expression of UIS4 under the promoters 
of LISP1 or LISP2 in pLISP1-UIS4SIINFEKL and pLISP1-UIS4SIINFEKL respectively with UIS4 
localised as seen for WT with similar levels of expression at 24 hours and 48 hours. 
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Figure 2 
Generation and characterisation of LISP1SIINFEKL and LISP2SIINFEKL parasites 
(A-B) The plasmids used to generate LISP1SIINFEKL and LISP2SIINFEKL parasites were 
based on MG1 starting plasmid (Figure 1) before In-Fusion (Clontech) technology was 
used to append short C-terminal regions of (A) LISP1 or (B) LISP2 ORFs before the 
mCherry-SIINFEKL sequences. Consequently, following correct integration at (C) LISP1 
or (D) LISP2 locus, endogenous (A) LISP1 and (B) LISP2 would now have mCherry-
SIINEFKL appended to the C-terminus. (C) LISP1SIINFEKL and (D) LISP2SIINFEKL Parasites 
were genotyped using PCR with specific primers to amplify regions to assess for the 
presence of WT parasites, 5’ and 3’ integration of the plasmid and episome formation. 
(E) The number of sporozoites dissected from salivary glands from mosquitos infected 
with WT, LISP1SIINFEKL or LISP2SIINFEKL transgenic parasites 18-27 days post infection 
from at least nine different infections per parasite. (F-G) EEF development of WT, 
LISP1SIINFEKL and LISP2SIINFEKL parasites in Huh7 hepatocytes in vitro at 12, 24 hours and 
48 hours. (F) EEFs were counted from a minimum of 2 wells with experiments performed 
2-3 times (G) Parasites expressing GFP (green) were also stained with anti-UIS4 or anti-
mCherry (red) and DAPI for nuclear staining (blue). Images show representative EEF 
development. Scale bars: 10m. (E, F) Bar charts show mean values (±SEM) with 
statistics calculated by Welch’s t-test (*, p<0.05). 
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Figure 3 
Generation and characterisation of pLISP1-UIS4SIINFEKL and pLISP2-UIS4SIINFEKL 
parasites 
(A-B) Plasmids used to generate pLISP1-UIS4SIINFEKL and pLISP2-UIS4SIINFEKL parasites 
were based on MG1 starting plasmid (Figure 1) before In-Fusion (Clontech) technology 
was used to add fragments containing UIS4 ORF and (A) LISP1 or (B) LISP2 promoter 
regions before the mCherry-SIINFEKL sequences. (C) Parasites were genotyped using 
PCR with specific primers to amplify regions to assess for the presence of WT parasites, 
5’ integration and episome formation, 3’ integration and to distinguish between the 
modified LISP1 and LISP2 promoters. (D) The number of sporozoites dissected from 
salivary glands from mosquitos infected with WT, pLISP1-UIS4SIINFEKL or pLISP2-
UIS4SIINFEKL parasites 18-27 days post infection from at least seven different infections 
per parasite. (E-F) EEF development of WT, LISP1SIINFEKL and LISP2SIINFEKL parasites in 
Huh7 hepatocytes in vitro at 24 hours and 48 hours. (E) EEFs were counted from a 
minimum of 2 wells with experiments performed 2-3 times. (F) Parasites expressing GFP 
(green) were also stained with anti-UIS4 or anti-mCherry (red) and DAPI for nuclear 
staining (blue). Images show representative EEF development. Scale bars: 10m. (D-
E) Bar charts show mean values ± SEM. 
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Early and mid-late EEF antigens induce similar CD8+ T cell responses 
We immunised mice once with parasites intravenously (Figure 4A-C) or intradermally 
(Figure 4D-F) under azithromycin prophylaxis. Azithromycin prophylaxis was used to 
ensure that parasites developed fully inside hepatocytes and that arrest did not affect 
the normal expression patterns of the LISP1 and LISP2 promoters prior to merozoite 
release. We restimulated splenocytes and liver infiltrating lymphocytes with SIINFEKL 
ex vivo to determine proportions and numbers of SIINFEKL-specific effector cell CD8+ 
T cells with the capacity to produce IFN-. We co-stained with CD11a, which has been 
shown to be a robust and reliable marker of antigen experienced CD8+ T cells28, 29. More 
akin to responses to UIS4SIINFEKL than CSPSIINFEKL, LISP1SIINFEKL and LISP2SIINFEKL induced 
a similar proportion and number of IFN- producing SIINFEKL-specific CD8+ T cells. 
pLISP1-UIS4SIINFEKL and pLISP2-UIS4SIINFEKL (Figure 4A-C) also have a similar 
immunogenic profile to UIS4SIINFEKL, LISP1SIINFEKL and LISP2SIINFEKL for inducing CD8+ T 
cells. pLISP1-UIS4SIINFEKL and pLISP2-UIS4SIINFEKL parasites were only used for 
assessing CD8+ T cell responses following intravenous immunisation and were not 
further investigated as LISP1SIINFEKL and LISP2SIINFEKL parasites express SIINFEKL in a 
more physiological context, with the native protein localising to the PVM as seen 
previously20, 21 despite our previous concern. Together these results suggest that early 
and mid-late EEF antigens are equally poor immunogens. 
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Figure 4 
Early and mid-late expressed EEF proteins induce low frequencies of antigen 
specific CD8+ T cell responses when sporozoites are administrated intravenously 
or intradermally 
(A-C) Mice (n=4-7 per group) were immunised intravenously once with 10,000 
CSPSIINFEKL, UIS4SIINFEKL, pLISP1-UIS4SIINFEKL, pLISP2-UIS4SIINFEKL, LISP1SIINFEKL or 
LISP2SIINFEKL sporozoites under azithromycin prophylaxis. Splenocytes and liver 
infiltrating lymphocytes from immunised or naïve mice (n=4) were restimulated with 
SIINFEKL 14 days post immunisation and co-stained with CD11a and IFN- and CD8+ 
T cell populations were enumerated by flow cytometry. (A) Flow cytometry gating 
strategy used. (B) The percentage of all CD8+ T cells co-expressing IFN- and CD11a. 
(C) The absolute cell counts of all CD8+ T cells co-expressing IFN- and CD11a. Data 
shown is from one representative experiment of two experiments performed. (D-F) Mice 
(n=6-7 per group) were immunised intradermally once with 10,000 CSPSIINFEKL, 
UIS4SIINFEKL, LISP1SIINFEKL or LISP2SIINFEKL sporozoites under azithromycin prophylaxis. 
Splenocytes and liver infiltrating lymphocytes from immunised or naïve mice (n=2) were 
restimulated with SIINFEKL 14 days post immunisation and co-stained with CD11a and 
IFN- and CD8+ T cell populations were enumerated by flow cytometry. (D) Flow 
cytometry gating strategy used. (E) The percentage of all CD8+ T cells co-expressing 
IFN- and CD11a. (F) The absolute cell counts of all CD8+ T cells co-expressing IFN- 
and CD11a. Data shown is from one experiment performed. (B,C,E,F) Bar charts show 
mean values (±SEM) with statistics calculated using one-way ANOVA with Tukey 
multiple comparisons post-test (*, p<0.05; **, p<0.01, ***, p<0.001). 
  
168 
 
Mid-late EEF antigens offer partial protection 
UIS4 was as poorly immunogenic as LISP1 and LISP2 at inducing CD8+ T cells 
responses which suggested that the CD8+ T cell response to an EEV PVM antigen is 
not improved by the duration for which the antigen is expressed. To assess the time 
scale within which an EEF antigen can be protective, we decided to determine if 
vaccination could show a protective role for LISP1 and LISP2, compared to that rendered 
by UIS4. Mice were vaccinated with adenovirus expressing full length ovalbumin and 
OT-I splenocytes which induced high levels of SIINFEKL-specific CD8+ T cells 
(Supplementary Figure 1) before mice were challenged 14 days later with our transgenic 
parasites. Vaccine efficacy was assessed by reduction in parasite load in the liver and 
sterile protection.  
Challenge with LISP1SIINFEKL and LISP2SIINFEKL resulted in around ~70% reduction in 
parasite load in the liver, however vaccinated mice had a reduction of >99% when 
challenged with CSPSIINFEKL and UIS4SIINFEKL (Figure 5A, B). These data would suggest 
that the mice challenged with LISP1SIINFEKL and LISP2SIINFEKL would not be sterilely 
protected. However, LISP1 and LISP2 induced around 50% sterile protection (Figure 
5C). Compared to the nearly 90% protection offered by CSPSIINFEKL and UIS4SIINFEKL, it 
contradicts the parasite load in the liver data as a two log difference in liver load would 
not normally lead to any mice being sterilely protected. Also, the onset of parasitaemia 
in challenged vaccinated mice that were not sterilely protected was delayed with some 
mice becoming visibly parasitaemic by blood smear, occurring up to four days later than 
those mice challenged with CSPSIINFEKL or UIS4SIINFEKL (Figure 5D).  
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Figure 5 
Despite the poor immunogenicity of mid-late EEF antigens, following vaccination 
they induce a reduction in parasite load in the liver and unlikely levels of sterile 
protection 
(A-D) Vaccinated mice received AdOVA and OT-I cells (n=5) and control mice received 
just OT-I cells (n=4). (A-B) Mice were challenged with 10,000 sporozoites two weeks 
after vaccination. (A) The relative parasite load in the liver for individual mice comparing 
the difference between the concentration of mouse GAPDH mRNA and P. berghei 18S 
rRNA. Data is from one representative experiment of two independent qPCR 
experiments performed. The mean + interquartile range is shown with statistics 
calculated by Mann Whitney U-test (*, p<0.05). (B) The average percentage reduction in 
parasite load in the liver of mice in the vaccinated group, compared with a normalised 0 
value for mice in the non-vaccinated group. Each data point is the average from each 
experiment. (C-D) Vaccinated (n=3-11) and control mice (n=2-7) were challenged with 
1,000 sporozoites. (C) The percentage of mice which did not become parasitaemic 
following challenge with sporozoites. (D) Kaplan-Meier curve showing the onset of 
parasitaemia in vaccinated (V) and control mice (NV) following challenge with WT 
(black), CSPSIINFEKL (red), UIS4SIINFEKL (blue), LISP1SIINFEKL (pink) or LISP2SIINFEKL (green). 
(C-D) Data are pooled from two experiments performed.  
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DISCUSSION 
 
Much research has emerged with a focus on improving the efficacy of current malaria 
vaccines in trials with further antigens. Many have come to the conclusion that, unlike a 
single protein subunit vaccine against a virus or bacteria, many antigens from different 
life stages of the parasite will be required to evoke long-lasting vaccine efficacy against 
Plasmodium30, 31. Here we have presented evidence that antigen specific CD8+ T cell 
responses induced by the mid-late EEF antigens LISP1 and LISP2 are as poor as those 
induced by constitutively expressed EEF antigens UIS4. However, following viral 
vaccination, LISP1 and LISP2 induce a small reduction in parasite load in the liver but 
around 50% sterile protection, highlighting their potential for use in next-generation 
malaria vaccines. 
 
Our previous work (Chapter 2: Müller and Gibbins, paper in preparation) had shown that 
UIS4, a PVM protein, can be as protective as CSP. Using a reporter epitope marker, 
CSP induced a larger frequency of antigen-specific CD8+ T cells than UIS4, however 
both proteins were successful in their ability to reduce parasite load in the liver following 
vaccination and challenge. This suggests that both proteins were presented on infected 
hepatocytes, inducing recognition by effector memory CD8+ T cells and the killing of the 
developing parasite inside the hepatocyte. CSP has been shown previously to be 
presented on infected hepatocytes to antigen-specific CD8+ T cells and be protective32, 
33, but the protective capability of EEF antigens has not been investigated. 
 
The liver stage infection in mice infected with Plasmodium berghei is relatively short with 
merozoite release starting 48-52 hours post infection18. CD8+ T cells have been shown 
to peak in cytolytic activity against peptide coated cells in culture between 20-24 hours34, 
35 and CD8+ T cells from Toxoplasma gondii immunised mice have been shown to lyse 
peptide labelled cells within 4 hours with a peak at 16 hours in vivo36. UIS4 protein 
translation in the liver is constant, starting soon after sporozoite invasion of the 
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hepatocyte up until merozoite release17, 19. Thus, the potential for recognition of UIS4 
protein presented on the hepatocyte surface can occur very soon after sporozoite 
invasion, with MHC being present on the cell surface of infected and uninfected 
hepatocytes from 3 hours with a large upregulation between 12 and 15 hours37. When 
vaccinated mice were challenged, which possessed a large proportion of antigen-
specific CD8+ T cells in the blood, UIS4-targeted responses reduced the parasite load 
in the liver by more than 99% despite UIS4 inducing a weak endogenous CD8+ T cell 
response following sporozoite immunisation. Thus, if a liver-PVM associated antigen 
expressed constitutively during EEF development can protect in a 48-hour window, what 
would happen if this period was shortened? Essentially at what point is the parasite still 
vulnerable to attack in the liver?  
 
LISP1 and LISP2 are highly expressed proteins that associate with the PVM but their 
expression profiles peak later than UIS4; nonetheless they are all required for effective 
EEF development. UIS4 is required for absolute development in the liver; without it, EEF 
development does not occur. LISP1 is associated with rupturing of the PVM; LISP1-KO 
merozoites inside the merosome are infective, but ten-fold less merozoites are released 
by the merosome due to an impairment with PVM lysis20. LISP2-KO parasites arrest as 
late merozoites which is proposed to be because LISP2 modulates a change in host 
hepatocyte environment, which is critical for merogony21. We show that expression of 
LISP1 and LISP2 is absent 12 hours after infection but appears at 24 hours and induce 
weak CD8+ T cell responses following sporozoite immunisation. However, the degree of 
partial sterile protection induced by LISP1 and LISP2, despite the poor CD8+ T cell 
responses they induce following sporozoite immunisation and the delay in their protein 
expression, highlights the importance and rapidity of CD8+ T cell mediated attack in the 
liver. Yet the discrepancy between the lack of reduction of parasite load in the liver, as 
determined by relative expression of P. berghei 18S rRNA, in vaccinated mice following 
sporozoite challenge and the apparent partial protection from blood stage parasitaemia 
remains to be explained. 
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18S rRNA is a very stable nucleic acid structure with a half-life of 3-7 days in cells grown  
in vitro38-40 and 5 days in vivo41 and there is >1000x greater concentration of 18S rRNA 
in sporozoites compared to their genomic coding rDNA42. It is the structural nucleic acid 
of the 40S small ribosomal subunit in eukaryotes and is often used as an internal control 
for reverse transcription PCR. Killing of the EEF leads to destruction of the parasite and 
hepatocyte proteins and nucleic acids. It has been shown that DNA from the genome of 
non-viable (freeze-thawed) Plasmodium chaubaudi AS merozoites is detectable in the 
host blood 24 hours after injection but not after 48 hours, suggesting non-viable parasite 
DNA in the blood is turned over between 24 and 48 hours43. Focusing on the liver; in 
mice receiving late arresting genetically attenuated P. yoelii parasites, arrested EEFs 
observed by microscopy start to lose their viability (as determined by PVM integrity) from 
36 hours, with the majority being compromised at 48 hours (when WT parasites are 
starting the process of merozoites egress)44. While EEF abundance in the liver was no 
different to WT at 44 hours prior to merozoite egress, no genetically attenuated EEFs 
could be observed after 60 hours, suggesting that the parasites had been removed from 
the system over this time44. These data suggest that dead or arrested parasites are 
quickly turned over in the host. With regard to 18S rRNA; following intravenous injection 
of P. yoelii sporozoites into the tail vein of mouse, subsequent blood spot samples from 
the tail were taken to show that parasite 18S rRNA from sporozoites does not persist in 
the blood following hepatocyte invasion42. It was shown that genomic 18S rDNA is 
constantly detectable at the site of inoculation42, 45 (but not a spatially different site)42, 
suggesting the qPCR was detecting locally deposited, residual parasite contamination42. 
However, 18S rRNA could not be detected in blood after 30 mins, indicating a more rapid 
turnover of rRNA compared to rDNA in the absence of the parasite42. In a plant system, 
victorin  toxin, produced by the plant fungus Cochliobolus victoriae, induces 
programmable cell death of Avena sativa (oats) which has characteristics of animal 
apoptosis46. Leaves incubated with victorin toxin suffered severe and then complete loss 
of leaf viability following four and then six hours incubation with the toxin46. A time-course 
of incubation with the toxin showed that specific cleavage and degradation of 18S rRNA 
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was observable from 2 hours and a reduction in intact 18S rRNA observable from 6 
hours46. This further shows that 18S rRNA is broken down following death of cells. While 
it is not fully understood how CD8+ T cells kill the parasite inside hepatocytes, these data 
do suggest that 18S rRNA is rapidly broken down following death or arrest of EEF 
parasites with turn over quicker than that of genomic DNA in non-viable parasites43. 
 
In our experiments, in vaccinated mice challenged with CSPSIINFEKL or UIS4SIINFEKL, 
antigen-specific responses are assumed to have removed the majority of EEFs over a 
period of 40 hours, as a significant reduction in parasite liver load was observed and that 
in a parallel experiment, most mice were sterilely protected. With complete removal of 
arrested EEFs from the liver observed over a 26 hour period44, it is possible that the 18S 
rRNA observed in those mice receiving LISP1SIINFEKL or LISP2SIINFEKL challenge did not 
reflect the level of EEF killing that was starting or about to start at 40 hours post-infection, 
the point at which livers were harvested.  LISP1 and LISP2 protein expression peaks in 
the final stages of EEF development, which may ensure the final stages of merozoite 
development and release occur correctly20, 21 but we do not observe protein expression 
in the first 12 hours. With a 12-hour delay in protein expression compared to CSP and 
UIS4, the critical period of killing of infected hepatocytes induced by LISP1 and LISP2 
may not have yet happened by 40 hours. The minimal reduction in parasite load in the 
liver we report would not normally have yielded sterilely protected mice. By performing 
qPCR at 40 hours, we cannot determine parasite prevalence of LISP1SIINFEKL and 
LISP2SIINFEKL parasites in the last 8-12 hours of the liver stage before merozoite release, 
with killing possibly affected by the minimum 12-hour delay in antigen presentation and 
recognition. We suggest there is a level of killing occurring in this timeframe which is 
sufficient to provide some mice with sterile protection. The delay in patency, as shown 
here in the Kaplan-Meier curves, also suggests that LISP1SIINFEKL and LISP2SIINFEKL 
merozoites are reduced in number as a result of induced immune responses. To 
investigate this stage, it would be pertinent to take liver sections from vaccinated and 
non-vaccinated mice that have been challenged to look for parasite viability and 
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morphology at various time points to determine when different parasites are being killed 
and determine the cause of delayed patency in non-protected vaccinated mice. 
 
Additionally, while the percentage of antigen experienced, IFN- producing SIINFEKL-
specific CD8+ T cells in the blood following vaccination averaged around 8% of all CD8+ 
T cells, within the liver this may be a different story. Tissue-resident memory CD8+ T 
cells have been described in the sinusoid of the liver in RAS-immunised and vaccinated 
mice exhibiting a patrolling phenotype which function in parasite surveillance47. The 
authors show that with a vaccination method using PbT-I cells, from a T cell receptor 
transgenic mouse which produce CD8+ T cells specific for a malaria antigen expressed 
in the sporozoite and the blood stages48, a large TRM population in the liver can be 
induced and mice are protected from challenge with sporozoites one month later. They 
also show that inducing TRM CD8+ T cells through a liver centric vaccination strategy 
using hepatocyte targeting viruses can achieve better protection from challenge than 
using radiation-attenuated sporozoites. It would be interesting to investigate the 
differences in TRM expression molecules on our SIINFEKL-specific CD8+ T cells induced 
by different liver antigens to determine if antigen expression timing affected the liver 
residence of CD8+ T cells and if this correlated with protection. The expression of MHC 
class I molecules has also been shown to be reduced following very late EEF 
development37, so it would be interesting to know if merozoite proteins would still be 
protective, given their late expression and down-regulation of MHC class I molecules. 
 
Historically, the liver stage has not been investigated as much as the blood stage for 
instance, possibly because of the complexity of the models used and the curious 
tolerogenic nature of the liver environment. However, antigens and epitopes are starting 
to be identified against this stage of the parasite life cycle. Recently Speake et al. 
identified six novel antigens that, when given as DNA vaccines prior to challenge with 
sporozoites, induced a reduction in parasite load in the liver49. One of these genes 
included LISP1, which when combined with a CSP DNA vaccine further reduced parasite 
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load in the liver. This corroborates our data to highlight the importance of LISP1. Later, 
Pichugin et al. went on to identify a novel CD8+ T cell epitope in a Plasmodium berghei 
“Middle domain of eukaryotic initiation factor 4G(MIF4G)-like-protein” EEF protein50, 
which had previously been identified in the DNA vaccine study49. Murphy et al. also 
identified that an epitope presented by BALB/c mice from L3 60S ribosomal protein from 
Plasmodium yoelii (PY05881/PY17X_0513000) expressed throughout the liver stage 
and blood stages, which induced strong CD8+ T cell responses but did not ultimately 
protect mice on its own51. Speake et al. suggest that those antigens expressed 
throughout and with increasing magnitude in the EEF are those that show greater 
protection49. This has been echoed in genetically attenuated parasite studies, where 
parasites that arrest later during EEF development induce the most protection following 
challenge44, 52. It has also been suggested that fewer doses of sporozoites are required 
to protect mice when immunised with chloroquine prophylaxis because of the extended 
potential repertoire of antigen expressed53. We concur with our data here and previously 
(Chapter 3: Gibbins et al., paper in preparation) showing that longer antigen expression 
in EEF does not increase the number of antigen-specific CD8+ T cells and that greater 
protection is likely achieved through generation of a wide repertoire of CD8+ T cells. We 
also propose that while viral vaccination can induce large numbers of antigen-specific 
CD8+ T cells, there must be sufficient time for the antigen to be presented and 
recognised by its cognate CD8+ T cell for parasite destruction to occur. This would 
explain why LISP1 and LISP2 are not as protective as UIS4, as LISP1 and LISP2 have 
at least a 12-hour delay in protein expression in the EEF and thus their potentiality for 
presentation is delayed. 
 
Nonetheless. we have shown that mid-late expressed EEF antigens are presented to the 
immune system and can induce killing of infected hepatocytes in a CD8+ T cell 
dependent manner. This further enhances the argument that more research should be 
conducted on determining the role of EEF antigens in the induction of pre-eyrthrocytic 
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stage immunity and be considered for development in next generation malaria vaccines, 
most likely in combination with other pre-erythrocytic antigens. 
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SUPPLEMENTARY INFORMATION 
 
SUPPLEMENTARY EXPERIMENTAL PROCEDURES 
Transgenic parasite generation 
The common plasmid MG1 was generated from a starting plasmid (OS-DHFR-mCherry) 
containing a T7 promoter, Toxoplasma gondii dihydrofolate reductase/thymidylate 
synthase (TgDHFR/TS) pyrimethamine resistance cassette and mCherry cassette. The 
mCherry cassette was released by excision using restriction enzymes EcoRI and SacII 
and the vector backbone was purified. MG1 was generated from this backbone by 
adjoining two fragments called mChOVA and OVAutr using In-Fusion technology. 
mChOVA was generated by amplifying the mCherry region of the OS-DHFR-mCherry 
plasmid and incorporating SIINFEKL coding sequence at the 3’ end. OVAutr was 
generating by amplifying the 3’ UTR of UIS4 from Plasmodium berghei WT genomic DNA 
and appending the SIINFEKL encoding region to the 5’ end of the fragment. In-Fusion 
(Clontech) technology works such that fragments are designed to have 15 base 
overhangs so that in the presence of In-Fusion Enzyme, DNA fragments with 
complementary 15mer overhangs are fused together and fused into the linearised vector 
backbone. To generate MG1, the two fragments would then have complementary 
regions in the SIINFEKL coding region and with the 5’ and 3’ region of the restricted 
plasmid. MG1 was then ready to be modified further by incorporated more fragments 5’ 
to the mCherry coding sequence which following transfection of parasites would lead to 
the mCherry-SIINFEKL-UIS4 3’ UTR being incorporated to the 3’ end of the ORF of the 
gene of interest. XL10 competent E. coli were transformed with MG1 and plasmid 
amplified and retrieved by miniprep and plasmid verified by sequencing. 
Additional fragments were generated by designing primers to amplify LISP1 and LISP2 
promoters and ORFs for UIS4, LISP1 and LISP2 following PCR of Plasmodium berghei 
WT genomic DNA.  
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Generation of MG2b-pLISP1-UIS4SIINFEKL, MG2c-pLISP2-UIS4SIINFEKL, MG2e-
LISP1SIINFEKL and MG2f-LISP2SIINFEKL plasmids was achieved by digestion of MG1 with 
EcoRI and In-Fusion with gene specific promoter and ORF DNA fragments. 
For MG2b-pLISP1-UIS4SIINFEKL, fragments consisting of the promoter of LISP1 (L1prom) 
and UIS4 ORF (U4orf) were fused into MG1. For MG2c-pLISP2-UIS4SIINFEKL, fragments 
consisting of the promoter of LISP2 (L2prom) and UIS4 ORF (U4orf) were fused into 
MG1. For MG2e-LISP1SIINFEKL, two overlapping fragments corresponding to a 3’ region 
and end of the LISP1 ORF (L1Aorf and L1Borf) were fused into MG1.  For MG2f-
LISP2SIINFEKL, two fragments corresponding to a 3’ region and end of the LISP2 ORF 
(L2Aorf and L2Borf) were fused into MG1. In this way, when the corresponding plasmid 
is incorporated into the genome at the UIS4 locus by single cross-over homologous 
recombination, MG2b-pLISP1-UIS4SIINFEKL and MG2c-pLISP2-UIS4SIINFEKL will result in 
an extra UIS4 gene being inserted which was appended by the mCherry-SIINFEKL-UIS4 
3’ UTR cassette. For MG2e-LISP1SIINFEKL and MG2f-LISP2SIINFEKL, following single cross-
over homologous recombination at the LISP1 or LISP2 locus respectively, the 
endogenous gene would now be appended by the mCherry-SIINFEKL-UIS4 3’ UTR 
cassette.  
Following miniprep and verification by sequencing, plasmids were transfected into 
Plasmodium berghei ANKA expressing GFP at the dispensable p230p22 by 
electroporation of merozoites using Nucleofector buffer and an AMAXA Nucleofector26. 
Briefly, Plasmodium berghei blood stage parasites were generated in Swiss Webster 
mice and blood taken late in the day by cardiac puncture when parasitaemia was around 
5%. Red blood cells were incubated in RPMI with 20% FCS overnight at 36.5°C with 
shaking at 70 rpm to slow the asexual cycle and allow for isolation of viable, mature, 
synchronised schizonts the following morning. Nycodenz was used to isolate the 
schizonts by density gradient centrifugation. Isolated schizonts were resuspended in 
Nucleofector buffer and DNA plasmid to rupture the RBCs and release merozoites. 
Merozoites were electroporated with the plasmid using AMAXA Nucleofector (program 
U33) and Swiss Webster mice were injected with electroporated merozoites 
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intravenously. Mice were provided with pyrimethamine (7g/ml) in drinking water the day 
after injection. Mice were monitored and were bled by cardiac puncture when their 
parasitaemia was at 1.5%. Genomic DNA was extracted using PureLink Genomic DNA 
Kits (Invitrogen) and primers were designed to genotype the parasites, assessing for the 
presence of WT and recombinant parasites, 5’ and 3’ integration of the plasmid and 
presence of episomes. Upon appearance of recombinant populations with the correct 
integration of the plasmid, transgenic clones were generated by limiting dilution into CD-
1 mice. Clones were verified by genotyping PCR (FastStart Taq, Roche). PCR products 
were run on 1.2% agarose gels with SybrSafe (ThermoFisher Scientific) intercalatant. 
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SUPPLEMENTARY FIGURES 
 
Supplementary Figure 1 
Vaccination with AdOVA and OT-I cells 
(A) Flow cytometry panel used to assess (B) the magnitude of SIINFEKL-specific CD8+ 
T cells in the blood of non-vaccinated and vaccinated mice following restimulation with 
SIINFEKL peptide. Scatter plot shows mean ±SEM. 
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Supplementary Table 1 
Table of primers for plasmid generation, parasite genotyping and parasite load in 
the liver qPCR 
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CHAPTER 5 
 
The importance of the immunodominant CD8+ T cell epitope of Plasmodium 
circumsporozoite protein in parasite- and vaccine-induced protection 
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ABSTRACT 
The circumsporozoite protein (CSP), the surface coat of sporozoites, has been at the 
forefront in malaria pre-erythrocytic stage vaccine development for the last 30 years. 
CSP has been shown to induce robust CD8+ T cell responses that are capable of 
eliminating the developing parasites in hepatocytes resulting in protective immunity. In 
this study, we characterised the importance of SYIPSAEKI, the immunodominant CSP-
derived epitope of Plasmodium berghei in both sporozoite- and vaccine-induced 
protection in murine infection models. In BALB/c mice, where SYIPSAEKI is efficiently 
presented in the context of the major histocompatibility complex class I (MHC-I) molecule 
H-2-Kd, we establish that epitope-specific CD8+ T cell responses contribute to parasite 
killing following sporozoite immunisation. Yet, sterile protection is achieved in the 
absence of this epitope confirming that other antigens are crucial for parasite-induced 
protective immunity. Moreover, we demonstrate that SYIPSAEKI-specific CD8+ T cell 
responses elicited by viral-vectored CSP-expressing vaccines effectively target parasites 
in hepatocytes and the resulting sterile protection strictly relies on the expression of 
SYIPSAEKI. We further show that in C57BL/6 mice, which expresses an irrelevant MHC-
I and therefore unable to express the immunodominant epitope, CSP-based vaccines do 
not confer protection. These findings further demonstrate the importance of CSP in 
protection against malaria pre-erythrocytic stages and that a significant proportion of the 
protection against the parasite is mediated by CD8+ T cells that are specific for the 
immunodominant epitope of this sporozoite surface protein. 
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INTRODUCTION 
Malaria is caused by a protozoan parasite of the genus Plasmodium and remains a major 
global health challenge in tropical and subtropical countries(1). A vaccine that reduces 
the burden of disease and prevents malaria transmission remains an ultimate goal for 
malaria elimination programmes. As a gold standard in malaria vaccination, multiple 
immunisations of -radiation-attenuated Plasmodium sporozoites (RAS) can completely 
protect against sporozoite challenge(2-4). This parasite-induced protection targets the 
developing exo-erythrocytic forms in the liver and completely abrogates blood stage 
infection. Antibodies and T cells have been implicated as important mechanisms of 
protection(5). In murine infection models, CD8+ T cells are the prime mediators of 
protective immunity(6, 7).  
 
The circumsporozoite protein (CSP), the major surface coat protein of the malaria 
sporozoite, has been at the head of vaccination studies for more than 30 years – being 
the basis of RTS,S/AS01, the most progressed malaria vaccine candidate to date(8). 
Immunisation of BALB/c mice with Plasmodium berghei (Pb) or P. yoelii (Py) RAS 
evokes immunodominant major histocompatibility complex class I (MHC-I) H-2-Kd-
restricted CD8+ T cell responses against distinct CSP epitopes: SYIPSAEKI for Pb(9) 
and SYVPSAEQI for Py(10). Indeed, the measurement of responses to these epitopes 
have become the standard in fundamental immunological studies in BALB/c mice. 
Furthermore, numerous vaccination studies involving different viral-vectored CSP- or 
CSP epitope-expressing vaccines – used alone or in combination as part of prime-boost 
regimens – have corroborated that CSP is a highly protective antigen in the BALB/c 
infection model(11-17). In these studies, elevated levels of either SYIPSAEKI- or 
SYVPSAEQI-specific CD8+ T cell responses correlated with protection.  
 
Several studies have interrogated the immunological relevance of whole CSP in parasite-
induced protection. These studies emanated from observations that in naturally exposed 
humans, T cell responses to CSP are scarce(18). Moreover, multiple immunisations are 
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required to elicit CD8+ T cell-dependent protective immunity in various mouse strains, 
particularly where no other CSP-derived CD8+ T cell epitopes have been identified(19). 
In PyCSP-transgenic BALB/c mice which are tolerant to PyCSP, complete protection can 
be achieved by Py RAS immunisation(20). In good agreement, BALB/c mice immunised 
with Pb WT parasites were completely protected when challenged with transgenic 
parasites where the endogenous CSP has been swapped with the P. falciparum 
CSP(21). Taken together, these studies indicate that immune responses to CSP are 
dispensable for protection, and that other antigens are important to elicit protective 
immunity. 
 
In this study, we extend previous work by dissecting the relevance of a single CSP-
derived immunodominant epitope in parasite- and vaccine-induced protection in BALB/c 
mice, by utilising transgenic Pb parasites lacking SYIPSAEKI for immunisation and 
challenge experiments. In addition, we highlight the level of protection achieved by CSP-
based vaccines, in mice expressing the relevant (BALB/c) [or irrelevant (C57BL/6)] MHC-
I that is needed to present a single CSP-derived immunodominant epitope. 
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RESULTS AND DISCUSSION 
Sporozoite-induced SYIPSAEKI-specific CD8+ T cell responses contribute to 
parasite killing but are dispensable for the development of sterile immunity. First, 
we interrogated the role that SYIPSAEKI, the H-2-Kd-restricted immunodominant epitope 
of PbCSP, plays in protective immunity induced after sporozoite immunisation. For this 
purpose, PbCSPSIINFEKL RAS, where the SYPSAEKI sequence has been replaced with 
SIINFEKL (the H-2-Kb-restricted epitope of ovalbumin), were used to immunise H-2-Kd-
expressing BALB/c mice. There are no other reported H-2-Kd-restricted PbCSP epitopes. 
As shown in Figure 1A, PbCSPSIINFEKL RAS parasites elicited no SYIPSAEKI-specific 
CD8+ T cell responses in BALB/c mice, whilst these parasites evoke robust SIINFEKL-
specific responses in H-2-Kb-expressing C57BL/6 mice (Chapter 2: Müller and Gibbins 
et al., paper in preparation).  
 
To ascertain whether SYIPSAEKI contributes to parasite-induced protection, BALB/c 
mice were immunised once with either PbWT or PbCSPSIINFEKL RAS. 14 days later, 
immunised mice were challenged with PbWT sporozoites and protection was determined 
by measuring the parasite loads in the liver 40 hours later. As shown in Figure 1B, a 
significant reduction in parasite load – up to 4-log difference as compared to naïve 
challenge mice – was observed in mice immunised with PbWT RAS and challenged with 
PbWT parasites. In contrast, protection was reduced in mice immunised with 
PbCSPSIINFEKL RAS (Figure 1B). We observed similar results following two immunisations 
(data not shown) indicating that a substantial degree of protection in PbWT RAS-
immunised mice, measured by reduction in parasite load in the liver over two orders of 
magnitude, can be attributed to SYIPSAEKI-specific CD8+ T cell responses. These 
results highlight the notion that within PbCSP, the SYIPSAEKI epitope has a critical and 
immunodominant contribution to protecting BALB/c mice after one or two immunisations 
with RAS. 
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However, at least three immunisations with RAS are required to induce sterile protection. 
To establish whether the development of sterile immunity is dependent on SYIPSAEKI-
specific CD8+ T cell responses, BALB/c mice were immunised thrice with PbCSPSIINFEKL 
RAS one week apart; 14 days after the last immunisation, mice were challenged with 
PbWT sporozoites. As shown in Figure 1C, all mice were protected from blood stage 
infection compared to the naïve controls.  
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FIGURE 1 
SYIPSAEKI is dispensable for RAS immunisation but predominates protection with fewer 
immunisations. (A) BALB/c mice (n=2-3) were immunised once with 104 PbWT or 
PbCSPSIINFEKL RAS. Spleens were removed after two weeks. Splenocytes from the mice 
were pooled and restimulated with SYIPSAEKI peptide. IFN- production was assessed 
by ICS and flow cytometry. Each point represents the result from one well, with data 
pooled from two independent experiments. The results of this experiment were 
additionally confirmed using another transgenic parasite also lacking the SYIPSAEKI 
epitope of CSP (unpublished and data not shown). 
(B) Groups of BALB/c mice were immunised once with 1.5x104 PbWT RAS (n=9) or 
PbCSPSIINFEKL RAS (n=3). Immunised mice and BALB/c naïve controls (n=10) were 
challenged with 104 PbWT parasites two weeks after the last immunisation. Livers were 
harvested 40 hours post-challenge and relative liver parasite levels were quantified using 
the ΔΔCt method comparing levels of P. berghei 18S rRNA and levels of mouse GAPDH 
mRNA. Median values + interquartile ranges are shown with statistics calculated using 
the Mann-Whitney U-test (*, p<0.05; **, p<0.01; ***, p<0.001). 
(C) BALB/c mice (n=12) were thrice immunised with 104 PbCSPSIINFEKL RAS with 
immunisations one week apart. Immunised mice and BALB/c naïve controls (n=11) were 
challenged with 5x103 PbWT parasites 16 days after the last immunisation. Blood smears 
were taken on day 3-14 days after challenge. Smears were stained with Giemsa and 
parasitaemia was assessed by microscopy. Data shown is pooled from two independent 
experiments. 
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Prime-boost vaccination with CSP-expressing viruses induces strong anti-CSP 
antibody and CD8+ T cell responses but SYIPSAEKI is the key mediator of 
protection. Next, we probed the requirement for SYIPSAEKI presentation in protection 
elicited by viral-vectored CSP-expressing vaccines administered in a prime-boost 
regimen. Priming with adenovirus (Ad) carrying a foreign antigen and boosting with 
orthopoxvirus modified vaccinia Ankara (MVA) expressing the same antigen has 
consistently been shown to induce strong CD8+ T cell responses capable of inducing 
high levels of efficacy against intracellular pathogens including malaria pre-erythrocytic 
stages(14, 17). 
 
Chimpanzee adenovirus serotype 63 (AdCh63) and MVA vaccines expressing PbCSP 
were used to vaccinate BALB/c mice with a two-week resting period between priming 
and boosting (Figure 2A). Two weeks after boosting, whole blood was collected and was 
restimulated ex vivo with SYIPSAEKI peptide. The frequencies of IFN- secreting CD8+ 
T cells were enumerated by flow cytometry (Figure 2B) and as shown in Figure 2C, Ad-
MVA PbCSP-vaccinated mice elicited ~12% SYIPSAEKI-specific circulating CD8+ T 
cells. Serum samples were also collected from the vaccinated animals and were used in 
an immunofluorescence assay against air-dried Pb sporozoites. As shown in Figure 2D, 
Ad-MVA PbCSP-vaccinated BALB/c mice induced strong anti-CSP antibody tires (1:104). 
These data indicate that Ad-MVA PbCSP vaccination elicit both high frequencies of 
SYPSAEKI-specific CD8+ T cells and high titres of CSP-specific antibodies. It is probable 
that the vaccination regimen induced CD8+ T cell and antibody responses to other 
unidentified CD8+ T cell epitopes of CSP.   
 
Two weeks after boosting, Ad-MVA PbCSP-vaccinated mice were challenged with 
PbWT or PbCSPSIINFEKL parasites. Protection was assessed by two complementary 
assays; (i) determination of the reduction of parasite load in the liver and (ii) induction of 
sterile protection. As shown in Figure 2E, parasite load in the liver of Ad-MVA PbCSP-
vaccinated mice was not significantly different to non-vaccinated mice when challenged 
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with PbCSPSIINFEKL sporozoites in contrast to challenge with PbWT sporozoites. As 
shown in Figure 2F, vaccinated mice challenged with PbCSPSIINFEKL sporozoites were 
patent for parasitaemia by day 5, whereas vaccinated mice challenged with PbWT 
sporozoites remained completely protected. These results denote that vaccine-induced 
effector SYIPSEAKI-specific CD8+ T responses efficiently target parasites expressing 
the cognate epitope. Parasites lacking the SYIPSAEKI epitope are not eliminated despite 
high levels of CSP-specific antibodies evoked by vaccination. 
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FIGURE 2 
Prime-boost vaccination with CSP expressing viruses induces strong anti-CSP antibody 
and CD8+ T cell responses but SYIPSAEKI-specific CD8+ T cell responses are 
absolutely required for protection. (A) BALB/c mice were vaccinated with AdCh63 and 
MVA vaccines expressing the mammalian codon-optimised fragment of PbCSP and 
challenged with 104 PbWT or PbCSPSIINFEKL sporozoites as shown. (B) The flow 
cytometry gating strategy used to determine proportions of IFN-+ CD11a+ CD8+ T cells. 
(C) Blood drawn from the tail from naïve (n=9) and vaccinated mice (n=10) two weeks 
after boost and restimulated with SYIPSAEKI and stained for CD8, CD11a surface 
markers, and IFN- by ICS. (D) Serum from naïve (n=11) and vaccinated mice (n=12) 
was isolated two weeks after boost and CSP specific antibody titres were measured by 
immunofluorescent antibody assay. (E) Livers from vaccinated mice challenged with 
PbWT (n=6) or PbCSPSIINFEKL sporozoites (n=5) and non-vaccinated mice challenged 
with PbWT (n=5) or PbCSPSIINFEKL sporozoites (n=5) were harvested 42 hours post-
challenge and relative liver parasite levels were quantified using the ΔΔCt method 
comparing levels of P. berghei 18S rRNA and levels of mouse GAPDH mRNA. (F) 
Groups of vaccinated and non-vaccinated mice (n=6) were challenged with 5x103 PbWT 
or PbCSPSIINFEKL sporozoites. Vaccinated mice challenged with PbWT (triangles) or 
PbCSPSIINFEKL (squares) and non-vaccinated mice challenged with PbWT (inverted 
triangles) or PbCSPSIINFEKL (diamonds) had daily tail smears taken from day 3-14 post 
challenge. Slides were stained with Giemsa and parasitaemia was assessed by 
microscopy. (C-E) Each data point represents one mouse with median values + 
interquartile ranges with statistics calculated using the Mann-Whitney test (*, p<0.05; ***, 
p<0.001). 
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CSP-based vaccines do not elicit sterile immunity in C57BL/6 mice. To further 
investigate the requirement of SYIPSAEKI as the necessary protective epitope of CSP, 
mice unable to present this epitope were vaccinated with Ad and MVA expressing 
PbCSP with an interval of 2 weeks between vaccines, followed by challenge with either 
PbWT or PbCSPSIINFEKL parasites (Figure 3A). C57BL/6 mice were used because 
SYIPSAEKI is an H-2-Kd restricted epitope, an MHC-I allele which they do not express. 
Thus, SYIPSAEKI would fail to be presented by infected hepatocytes. As before, blood 
and serum were derived 2 weeks after boost (Figure 3C,D). As expected, no 
SYIPSAEKI-specific CD8+ T cells were observed in Ad-MVA PbCSP-vaccinated 
C57BL/6 mice (Figure 3C), but strong anti-CSP antibody tires (1:104) were elicited 
(Figure 3D). As shown in Figure 3E, Ad-MVA CSP-vaccinated C57BL/6 mice challenged 
with either PbWT or PbCSPSIINFEKL parasites had comparable parasite load in the liver 
(Figure 3E) and no mice from any groups were sterilely protected (data not shown).  
203 
 
  
204 
 
FIGURE 3 
Prime-boost vaccination with CSP expressing viruses does not protect C57BL/6 mice, 
irrespective of induced antibody titres. (A) C57BL/6 mice were vaccinated with AdCh63 
and MVA vaccines expressing the mammalian codon-optimised fragment of PbCSP and 
challenged with 104 PbWT or PbCSPSIINFEKL sporozoites as shown. (B) The flow 
cytometry gating strategy used to determine proportions of IFN-+ CD11a+ CD8+ T cells. 
(C) Blood drawn from the tail from naïve (n=10) and vaccinated mice (n=10) two weeks 
after boost was restimulated with SYIPSAEKI and stained for CD8, CD11a surface 
markers, and IFN- by ICS. (D) Serum from naïve (n=6) and vaccinated mice (n=9) was 
isolated two weeks after boost and CSP specific antibody titres were measured by 
immunofluorescent antibody assay. (E) Livers from groups of 5 mice per condition were 
harvested 42 hours post-challenge and relative liver parasite levels were quantified using 
the ΔΔCt method comparing levels of P. berghei 18S rRNA and levels of mouse GAPDH 
mRNA. (C-E). Each data point represents one mouse with median values + interquartile 
ranges shown with statistics calculated using the Mann-Whiney test (***p<0.001). 
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Our data further support the notion that CSP is an immunodominant antigen following 
RAS immunisations in BALB/c mice(20). In addition, a single epitope, SYIPSAEKI is the 
immunodominant CD8+ T cell epitope of CSP and is responsible for the antigen’s 
protective capacity against parasites in the liver. Following RAS immunisation, CD8+ T 
cell responses to SYIPSAEKI contribute to the reduction in parasite load in the liver 
following sporozoite challenge because when RAS-immunised mice are challenged with 
PbCSPSIINFEKL, transgenic parasites lacking SYIPSAEKI, reduced anti-Plasmodium 
activity in the liver is observed. Nonetheless, complete protection is achievable in the 
absence of SYIPSAEKI-specific CD8+ T cell responses, demonstrating that responses 
to other epitopes contribute to parasite-killing. It is conceivable that these epitopes are 
encoded by the hundreds of other Plasmodium genes expressed in malaria pre-
erythrocytic stages.  
 
Our findings also emphasise the importance of SYIPSAEKI-specific CD8+ T cell 
responses for promoting protective immunity when using CSP-based vaccines in BALB/c 
mice. These vaccines are aimed at generating high levels of epitope-specific CD8+ T 
cells but rely on the expression of relevant MHC-I in the vaccinated host and the 
presence of the cognate epitope in the parasite used for challenge. Notably, despite high 
levels of antibodies elicited following Ad-MVA PbCSP vaccination, sterile protection was 
not achieved following challenge of C57BL/6 mice, which cannot present SYIPSAEKI, 
nor when challenging BALB/c or C57BL/6 mice with a parasite lacking SYIPSAEKI.  
 
These results have significance for the development of next generation malaria vaccines. 
We have demonstrated the significance of a single epitope of CSP in mediating 
protective CD8+ T cell responses while also recapitulating that protection can be 
achieved in the absence of responses to CSP(20, 21). In BALB/c mice, SYIPSAEKI-
specific CD8+ T cell responses offered protection, however, to achieve complete sterile 
protection: either multiple sporozoite immunisations or viral vaccines, which induced 
large populations of SYIPSAEKI-specific CD8+ T cells, were required. Multiple 
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immunisations likely induced a wide range of immune responses and multiple high-dose 
immunisations with RAS in humans has been shown to induce dose-dependent anti-
sporozoite CD8+ T cell responses in addition to dose dependent anti-sporozoite antibody 
and CD4+ T cell responses(4). In line with this, our findings lead us to suggest that future 
pre-erythrocytic malaria vaccine research should not only focus on inducing strong CD8+ 
T cell responses against one or a few antigens but should try to target a broad array of 
antigens to offer the best protection possible. The identification of novel antigens and 
epitopes that contribute to protection will aid this development. While RTS,S, the leading 
subunit malaria vaccine based on CSP, seems to offer some protection against P. 
falciparum re-infection(8) probably by the action of anti-sporozoite antibodies(22-24), 
peripheral blood CD8+ T cell responses were not identified to provide a role following 
sporozoite challenge. Similar findings from whole sporozoite vaccination challenge 
studies(4, 25, 26) show protected individuals exhibit variable peripheral blood CD8+ T 
cell responses, which may indicate that the protective CD8+ T cells are restricted to the 
liver. With evidence from mouse(27, 28) and non-human primates(29) studies indicating 
an association between liver-resident CD8+ T cells and protection, the generation of 
vaccines that can induce efficacious liver resident CD8+T cell populations that target the 
parasite in the liver would likely also be advantageous. Whilst it will probably be difficult 
to directly assess these responses in humans, a population of liver-resident CD8+ T cells 
with broad antigen specificities will surely be pivotal in contributing to protection against 
malaria. 
  
207 
 
MATERIALS AND METHODS 
Ethics and animal experimentation. Animal procedures were performed in accordance 
with the German ‘Tierschutzgesetz in der Fassung vom 18. Mai 2006 (BGBl. I S. 1207)’ 
which implements the directive 2010/6 3/EU from the European Union. Animal 
experiments at London School of Hygiene and Tropical Medicine were conducted under 
license from the United Kingdom Home Office under the Animals (Scientific Procedures) 
Act 1986. CD-1 mice were bred in-house at LSHTM while NMRI, C57BL/6 and BALB/c 
laboratory mouse strains were purchased from either Charles River Laboratories 
(Margate, UK or Sulzfeld, Germany) or Janvier (Saint Berthevin, France). Female mice 
of 6-8 weeks of age were used in the experiments. 
 
Plasmodium parasites and immunisation. The transgenic P. berghei ANKA 
CSPSIINFEKL (PbCSPSIINFEKL) parasite was generated with the immunodominant CSP 
CD8+ T cell epitope SYIPSAEKI (252-260aa) being replaced with the H-2-b restricted 
Gallus gallus ovalbumin CD8+ T cell epitope SIINFEKL (258-265aa) via double 
homologous recombination (Chapter 2: Müller and Gibbins et al., paper in preparation). 
Wild-type Plasmodium berghei ANKA (clone c115cy1) (PbWT) and PbCSPSIINFEKL were 
maintained by continuous cycling between murine hosts (NMRI or CD-1) and Anopheles 
stephensi mosquitos. Infected mosquitos were kept in incubators (Panasonic and 
Mytron) at 80% humidity and 20°C temperature. Sporozoites were isolated from the 
salivary glands and attenuated by -irradiation at 1.2x104cGy. Mice were immunised with 
104 sporozoites administered intravenously with multiple doses given 1 week apart 
unless otherwise stated. For challenge infections, 5x103 or 104 live sporozoites were 
administered intravenously to assess sterile protection and parasite load in the liver 
respectively.  
 
Viral-vectored CSP-expressing vaccines. AdCh63 and MVA vaccines expressing the 
mammalian codon-optimised fragment of PbCSP were constructed and propagated 
based on previously published viral vectors(30, 31). The viral vectors were administered 
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intramuscularly in endotoxin-free PBS at a concentration of 105 viral particles for 
AdPbCSP to prime and 106 viral particles MVAPbCSP to boost. 
 
Immunofluorescent antibody assay. 104 sporozoites were spotted onto glass slides 
with marked rings (Medco), dried at room temperature and stored at -20°C. Thawed 
slides were fixed in acetone, dried and rehydrated with PBS before incubation in 10% 
FCS supplemented DMEM (Gibco) for 1 hour at 37°C in a humid chamber. Serum at 
concentrations 1:103, 1:3.3x103, 1:104, 1:3.3x104, 1:105 (and additionally 1:3.3x105 and 
1:106 for C57BL/6 serum) were added to the ring wells and incubated for 1 hour at 37°C 
in a humid chamber. Slides were washed and stained with a mouse  anti-CSP(32) 
primary antibody and a respective fluorescently labelled secondary antibody. Nuclei 
were stained with DAPI or DRAQ5 before a further 1-hour humid incubation. Slides were 
washed and mounted with 'Fluoromount-G' (Southern Biotech) and analysed by 
fluorescent microscopy (Zeiss Axio Observer).  
 
Quantification of SYIPSAEKI-specific CD8+ T cell responses. Spleens were 
harvested and lymphocytes were derived by passing spleens through 40m cell strainers 
(Corning). Peripheral blood was drawn from the tail vein and collected in Na+ heparin 
capillary tubes (Brand) and assayed in 96-well flat bottom plates (Corning). Red blood 
cells were lysed using PharmLyse (BD) and lymphocytes were resuspended in 10% 
FCS, 2% Penicillin-Streptomycin and 1% L-glutamine supplemented RPMI 1640 (Gibco). 
Splenocytes were counted using a 40x dilution with Trypan Blue (ThermoFisher 
Scientific) and a Neubauer ‘Improved’ haemocytometer (Biochrom). 2x106 splenocytes 
and the lysed blood samples were prepared in 96 well plates and incubated with a final 
concentration of 10g/ml of SYIPSAEKI peptide in in the presence of Brefeldin A 
(eBioScience) for 5-6 hours at 37°C and 5% CO2. For staining of cell surface markers 
and intracellular cytokines, cells were incubated for 1 hour at 4°C for each staining. Cells 
were stained for CD8 (53-6.7) and CD11a (M17/4) (eBioscience). Splenic cells were 
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fixed with 4% paraformaldehyde and peripheral blood cells were fixed with 1% 
paraformaldehyde before staining for IFN- (XMG1.2) (eBioscience). Data was acquired 
by flow cytometry using an LSRFortessa or LSRII (BD) and analysed using Flowjo9.5.2 
(Tree Star, Inc.). 
 
Quantification of parasite load in the liver. Livers were harvested 40-42 hours after 
sporozoite challenge and total RNA was extracted following homogenisation using 
TRIzol (ThermoFisher Scientific). cDNA was generated using the RETROScript Kit 
(Ambion). Quantitative real-time PCR was performed using the StepOnePlus Real-Time 
PCR System and Power SYBR Green PCR Master Mix (Applied Biosystems). Relative 
liver parasite levels were quantified using the ΔΔCt method comparing levels of P. 
berghei 18S rRNA using specific primers and normalised to levels of mouse GAPDH 
mRNA(33).  
 
Assessment of parasitaemia. Sterile protection was assessed by daily blood smears, 
taken from mice 3-14 days post sporozoite challenge, stained with Giemsa's stain 
improved solution (VWR) to determine the presence of blood stage parasites. 
 
Statistical analysis. Statistical analysis was performed using GraphPad Prism v7 
(GraphPad Software, Inc.). Statistics were calculated using the Mann-Whiney U test. 
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ABSTRACT 
CD8+ T cells are known to be important immune cells in providing protection against the 
liver stage of malaria. However, the identity of the parasite proteins which induce 
protective CD8+ T cells remain largely unknown. Using bioinformatics neural networks, 
which predict peptides that bind strongly to MHC class I molecules, we have identified 
novel CD8+ T cell epitopes that induce strong IFN- responses against proteins 
expressed in the sporozoite and liver stages following sporozoite immunisation of mice 
under azithromycin prophylaxis. Feature analysis of these derivative proteins also 
highlights a link between secreted or cell surface proteins and immunogenicity of 
antigens expressed in the pre-erythrocytic stages of malaria. A quarter of the induced 
CD8+ T cell response were found to express an antigen-experienced phenotype 
following immunisation and up to 20% of these cells produced IFN- following 
restimulation with pools of peptides. We propose that the majority of antigens that induce 
CD8+ T cell responses against the pre-erythrocytic stages of malaria still remain 
unknown. 
  
219 
 
INTRODUCTION 
Malaria is a formidable, yet ancient, disease which continues to burden the human 
population1. Today it still causes significant morbidity and mortality, with around 216 
million cases per year, resulting in around 445,000 fatalities, with the vast majority of 
death occurring in sub-Saharan Africa2. 
 
Efforts to identify efficacious vaccine targets against malaria have been ongoing for many 
years. First isolated from murine infective Plasmodium berghei in the early 1980s, 
circumsporozoite protein (CSP)3-5, became the basis of the most advanced malaria 
vaccine candidate to date, RTS,S/AS01, inspired by the discovery that anti-CSP 
monoclonal antibodies could protect mice from sporozoite challenge4, 6. RTS,S/AS01 is 
a sub-unit vaccine based on the central repeat and C-terminal regions of CSP conjugated 
with hepatitis B virus surface antigen. In a multisite Phase III trial in Africa, RTS,S/AS01 
showed an efficacy of preventing clinical malaria episodes of 28.3% in children and 
18.3% in infants following a 3 dose immunisation, which increases to 36.3% and 25.9% 
respectively following a booster dose, 18 months after the last dose7. However, vaccine 
efficacy of RTS,S/AS01 wanes over time and does not realise a long lasting and robust 
effect. Thus, the hunt continues to find better vaccine targets and develop a more 
efficacious vaccine; a key requirement for malaria eradication. 
 
An alternative vaccination approach showed that rodents8, primates9 and humans10, 11 
can be protected from infectious sporozoite following multiple immunisation with 
irradiated sporozoites. This protection was shown to be mediated by CD8+ T cells, which 
have been shown to have an essential role in combating liver stage infection in mice12-14 
and primates15. However, only a handful of targets of these CD8+ T cells have been 
identified. 
 
A vaccine that targets the pre-erythrocytic stages of malaria is an attractive prospect 
because only around 100 sporozoites are injected into the skin by an infected mosquito16 
220 
 
and not all of these reach the liver17, 18 and develop into liver stage exo-erythrocytic forms 
(EEFs). Blocking this narrow bottleneck in the parasite life cycle has the potential to 
prevent the subsequent blood stages which cause all the symptoms associated with 
malarial disease. 
 
Using reverse immunological approaches, we set out to identify novel immunogenic 
CD8+ T cell epitopes against the pre-erythrocytic stages of malaria using MHC class I-
peptide binding prediction algorithms. These algorithms seek to predict the affinity with 
which peptides bind strongly to MHC binding grooves using experimental binding data. 
It has been shown that peptides predicted to bind strongly to MHC class I (MHC-I) 
molecules induce strong T cell responses following interaction with the cognate T cell 
receptor19. Using this general idea, 178 novel immunogenic Yersinia pestis CD8+ T cell 
epitopes20 and 10 immunogenic Trypanosoma cruzi CD8+ T cell epitopes21 have been 
identified recently. In this work, we attempted to achieve a similar feat with Plasmodium. 
Previously in our group, Hafalla et al. were able to identify two highly immunogenic CD8+ 
T cell epitopes by predicting CD8+ T cell epitopes from salivary gland sporozoite and 
liver stage datasets, genome wide surveying and previously described antigenic P. 
falciparum proteins22. Here, we used a similar approach focusing on more recent and 
extensive proteomic and transcriptomic sporozoite and liver stage expression studies23-
27. 
 
Additionally, the “rules” on what makes an epitope/ antigen immunogenic and potentially 
protective in a disease setting are not well defined, hindering the rapid discovery of new 
vaccines. Here we sought to address this and provide supplementary information that 
could further improve bioinformatics prediction algorithms while further informing 
immunological fields to immunogenic antigens, vital for vaccine developments. Looking 
at different pathogens, some protein features have been proposed to induce strong 
CD8+ T cell responses. Characteristics such as antigen secretion28 and position within 
a protein29 have been suggested to be responsible for enhanced CD8+ T cell responses. 
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We performed a feature analysis on the proteins in our dataset, determining a wide range 
of predicted features and characteristics, to look for the enrichment of features that 
correlated with immunogenicity. Given the paucity of CD8+ T cell epitopes from pre-
erythrocytic antigens we also assessed how much of the antigen repertoire of the effector 
CD8+ T cell population we could account for using peptide pools from our screens. 
 
Using the notoriously hard to protect Plasmodium berghei-C57BL/6 model, we report 
herein novel CD8+ T cell epitopes against the pre-erythrocytic stages of malaria and 
discuss the idea of features affecting the immunogenicity of antigens.  
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MATERIALS AND METHODS 
Ethics and animal experimentation 
Animal procedures were performed either at the Max Planck Institute of Infection Biology, 
Berlin or the London School of Hygiene and Tropical Medicine. Procedures were carried 
out following the approval by the institutional ethics review boards. Procedures were 
carried out in accordance with the German ‘Tierschutzgesetz in der Fassung vom 18. 
Mai 2006 (BGBl. I S. 1207)’, or under license from the United Kingdom Home Office 
under the Animals (Scientific Procedures) Act 1986 both which implement the directive 
86/609/EEC from the European Union and the European Convention for the protection 
of vertebrate animals used for experimental and other scientific purposes. Female 
C57BL/6 mice and NMRI were purchased from Charles River (Sulzfeld, Germany or 
Margate, UK) and CD-1 mice were bred in-house at LSHTM. 
 
Parasites 
Plasmodium berghei ANKA (clone 507) parasites were continuously cycled between CD-
1 or NMRI mice and Anopheles stephensi mosquitoes. Adult mosquitos were kept in 
incubators (Panasonic) at 20°C and 70-80% humidity. Sporozoites were dissected from 
salivary glands no earlier than 18 days after infection. Mice were immunised 
intravenously with 10,000 sporozoites concomitantly with azithromycin (Pfizer) given at 
a dose of 240 mg/kg intraperitoneally on the same day as immunisation and one day 
after30. Mice were immunised with sporozoites twice with immunisations one week apart 
unless stated otherwise. 
 
CD8+ T cell epitope prediction and feature analysis 
The dataset of genes expressed in the sporozoite and liver stages was culminated from 
published suppression subtractive hybridisation experiments23, 24, mass spectrometric 
data25-27, published27 and unpublished microarray data (Olivier Silvie, personal 
communication). Genes derived from experiments using P. yoelii and P. falciparum were 
converted to P. berghei orthologous genes and protein sequences were downloaded 
223 
 
using PlasmoDB31. Sequences were ran through NetMHCpan32, 33 and NetMHCcons34 
prediction software to predict peptides with strong binding affinity to MHC class I (MHC-
I) molecules H-2-Db and H-2-Kb, the alleles expressed by C57BL/6 mice, using IC50 
values and %Rank scores as guides35. 586 peptides were chosen and synthesised by 
Mimotopes (Melbourne, Australia) at batch ‘as synthesised’ purity for first-pass screening 
(purity range 4.89-98.6%, mean 62.95%, median 66.62%) and 95 peptides were 
resynthesised at greater purity (range 69-99%, mean 90.7%, median 94%). When 
performing NetMHCcons predictions, amino acids N at position P1 of the peptide and C 
at position P2 were mutated to V and S, respectively. This correction was required to 
address the lack of experimental data with the NC configuration, which we proposed may 
overly penalise candidate epitopes starting with the dipeptide NC. The models, servers 
and algorithms employed for feature analysis are listed in Table 1. 
 
Splenocyte isolation and peptide restimulation 
Spleens were harvested 14 days after the last immunisation. Splenocytes were isolated 
using a 70m cell strainer (Falcon) and red blood cells lysed using PharmLyse (BD). 
2x106 splenocytes in complete RPMI (10% FCS, 2% Penicillin-Streptomycin, 1% L-
glutamine (Gibco)) were restimulated with a final peptide concentration of 10g/ml unless 
otherwise stated. We assessed the immunogenicity of novel predicted peptides against 
a panel of 10 published peptides36 (TRAP130-138 – SALLNVDNL22; S20318-326 – 
VNYSFLYLF22, GAP5040-48 – SQLLNAKYL37; RPA1227-234 – EIYIFTNI38; RFC1651-658 – 
LLPHFSIL38; *LSG119-126 – LSGRYNDL38; RNR402-409 – WGDEFEKL38; ApiAP21898-1905 – 
YYYDYDKI38; BLN592-599 – IITDFENL39; *NCY397-404 – NCYDFNNI40). Cells were 
incubated in the presence of 0.6g Brefeldin A for 5-6 hours at 37°C, 5% CO2. Cells were 
stained the following day with extracellular stains for CD3 (clone 500A2) (BD); CD8 
(clone 53-6.7) and CD11a (M17/4) (eBioscience), and intracellular stain for IFN- (clone 
XMG1.2) (eBioscience). Cells were fixed using 4% paraformaldehyde. Flow cytometric 
analysis of samples was acquired using an LSRII or LSRFortessa (BD). 
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Data and statistical analysis 
Flow cytometric data was analysed using FlowJo version 9.5.3 (Tree Star Inc., Oregon, 
USA). Finite mixture model calculations were performed using Stata 15 (StataCorp). 
Graphs were produced in GraphPad Prism version 7 (GraphPad Software Inc., CA, 
USA). Statistical analysis for the feature analysis and boosting was performed using R 
(Foundation for Statistical Computing, Vienna, Austria). Statistics in the feature analysis 
were calculated assessed by a 10,000 resample comparison with significance 
considered as a p-value of <0.05. Statistics for boosted responses was determined by 
empirical Bayes t-test41 with Benjamini-Hochberg adjustment to control for false 
discovery rate below 5%42. 
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RESULTS 
Novel CD8+ T cell epitopes to P. berghei pre-erythrocytic antigens can be 
identified purely through their MHC-peptide binding affinity 
Our study focused on the sporozoite and liver stage forms of Plasmodium and we used 
several published and unpublished proteomic and transcriptomic expression datasets of 
these life stages to identify new CD8+ T cell epitopes. These included mass 
spectrometric datasets of P. yoelii26 and P. falciparum25, 26 salivary gland sporozoite 
proteomes and P. yoelii liver stage proteomes27. Genes were also chosen from a 
comprehensive microarray experiment assessing multiple stages of pre-erythrocytic 
infection in P. yoelii27, an unpublished microarray experiment comparing WT and slarp 
KO transgenic P. berghei sporozoites (Olivier Silvie, personal communication), as well 
as suppression subtractive hybridisation experiments comparing P. yoelii salivary gland 
sporozoites and merozoites23 and P. berghei oocyst sporozoites versus salivary gland 
sporozoites24. Our experimental model used P. berghei, a rodent infective species of 
Plasmodium, thus all the genes were transformed using PlasmoDB31 to generate a 
degenerate list of P. berghei sporozoite and liver stage specific genes. 
 
Our approach involved immunisation of C57BL/6 mice, the most difficult mouse strain to 
protect from P. berghei infection43, which present antigen to CD8+ T cells in the context 
of H-2-b MHC-I molecules. Thus the subsequent set of 2976 P. berghei antigens were 
run through MHC-I epitope prediction servers NetMHCpan32, 33 and NetMHCcons34, 
returning peptides with predicted binding affinities to H-2-Db and H-2-Kb molecules 
(Figure 1). We chose peptides that were predicted to bind strongly to H-2-Db and H-2-Kb 
molecules as well as peptides with a lower predicted affinity to test the doctrine that 
peptides that bind strongly to MHC-I molecules are more likely to be immunogenic than 
those that do not19. We chose predicted strong binders according to their IC50 values 
and %Rank scores35. IC50 values are a measure of predicted affinity of the peptide to 
the MHC-I molecule in the form of a dissociation concentration at which half of a 
reference peptide would be displaced by the predicted peptide. %Rank score returns a 
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% rank of the predicted peptide to a set of 200,000 random natural peptides35, indicating 
the relative binding strength of the predicted peptide compared to many others 
associating with the same MHC-I molecule. Thus, we chose strong binders with IC50 
values of less than 50nM and a %Rank score of 0.05 or lower. This corroborates with 
published CD8+ T cell epitopes against malaria, for example the epitopes from 
sporozoite antigens thrombospondin related anonymous protein (TRAP130-138) and 
sporozoite-specific gene 20 (S20318-326) induce strong CD8+ T cell responses in 
sporozoite immunised mice22 with low IC50 values of 3.58nM and 4.88nM respectively, 
and a %Rank scores of 0.01. In contrast, the *NCY397-404 peptide also induces strong 
CD8+ T cell responses  in sporozoite immunised mice36, 40; however, the  IC50 value and 
%Rank score are much poorer than one would expect (IC50: 3786.74nM, %Rank 
score:9). We hypothesize this discrepancy may be due to the paucity of peptides 
containing cysteine at position 2 in the training sets of NetMHCcons, thus preventing the 
algorithm to incorporate this preference. Given this, predictions for candidate epitopes 
starting with the dipeptide NC were repeated by replacing these residues with the more 
favoured V at P1 and S at P2. When our protein dataset was re-assessed, the top 
predicted strong binders with an original NC in position 1 and 2 (n=20) or C in position 2 
(n=34) were also chosen for synthesis. 
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Figure 1 – Flow chart for CD8+ T cell epitope discovery 
Genes upregulated in the sporozoite and liver stages of P. berghei, P. yoelii and P. 
falciparum were retrieved and converted into P. berghei through PlasmoDB. From the 
2976 genes, 586 novel peptides were selected for batch synthesis based on a number 
of parameters. Using NetMHCpan in the first instance we chose peptides that were 
predicted to bind strongly to H-2-Db and H-2-Kb molecules with an IC50 affinity of under 
22nM and a %Rank score of 0.05 or below (n=349) and additionally, 54 weaker binding 
peptides with affinity IC50 values ranging from 22.381-388.44, but always a %Rank 
score of 0.5 or below. We later used NetMHCcons for prediction of MHC-I epitopes, 
choosing peptides with an affinity of under 22nM and a %Rank score of 0.05 or below 
(n=98) and additionally, 30 weaker binding peptides with predicted IC50 values ranging 
from 23.05-531.38, also with a %Rank score of 0.5 or below. Additionally, with reference 
to the previously shown immunogenic *NCY397-404 peptide36, 40, which during the project 
returned a very high IC50 value and %Rank score, NetMHCcons predictions were 
repeated to consider NC in positions 1 and 2 as not so deleterious for binding by mutating 
for a more favourable amino acid binding motif, VS. When our dataset was re-assessed 
by the modified algorithm, the top predicted strong binders with NC in position 1 and 2 
(n=20) or C in position 2 (n=34) were also chosen for synthesis. From 586 synthesised 
peptides, 43 peptides induced IFN- responses above a cut-off calculated by finite 
mixture model based on mean + 3 S.D. of the negative population. These 43 peptides 
and an extra 52 peptides from throughout the remaining responding peptides were 
chosen for synthesis at higher purity. 9 peptides induced IFN- responses above a cut-
off calculated by assessing responses to the irrelevant peptide SIINFEKL, derived from 
Gallus gallus ovalbumin. 
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Thus, 586 novel peptides from 403 P. berghei proteins, were synthesised and tested. 
Peptides were synthesised for first pass screening and used for ex vivo restimulation of 
splenocytes from mice twice immunised with P. berghei sporozoites under azithromycin 
cover. Azithromycin was used to achieve the greatest repertoire of antigen expression 
by liver stage parasite in the liver30, without induction of a blood stage infection, to aid 
identification of novel liver stage epitopes. Antigen experienced CD8+ T cells, expressing 
the surrogate marker CD11a44, were assessed for IFN- production by intracellular 
cytokine staining and flow cytometry (Figure 2A,B). A finite mixture model (FMM) was 
used to determine which peptides induced positive responses and should be 
resynthesised at a higher purity. We used an FMM to separate all the 586 peptides into 
a positive and a negative population based on the IFN- responses they induced. 
Following this, a cut-off was derived, consisting of the mean + 3 S.D. of the negative 
population. This led to 43 novel peptides rising above this cut-off (Figure 2C and 
Appendix 1). These peptides we were sure were true positives based on the initial 
peptide screens. Given that the difference in response of the lowest positive peptides (of 
the 43 above the cut-off) and those in the negative population was quite small (Figure 
2B), we wanted to ensure against false negative assignment. An additional 52 novel 
peptides were carried forward, drawing peptides at random from throughout the list of 
negative hits below the cut off, to be re-synthesised and re-tested. Choosing at least the 
same number of peptides from below the cut-off as positive peptides would also allow 
us to demonstrate that our experimental strategy of peptide restimulation was reliable 
and could identify responsive CD8+ T cell epitopes effectively.  
 
During re-screening, the capacity of these 95 novel peptides to stimulate their cognate 
CD8+ T cells to produce IFN- was assessed by comparison with a series of positive 
controls: CD8+ T cell epitopes from published papers. Previously, only 5 papers had 
been published which identified 10 novel CD8+ T cell epitopes from P. berghei with a H-
2-b MHC-I allele restriction22, 37-40. Only 2 of these epitopes were identified in the pre-
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erythrocytic stage (from sporozoites22), while the remainder were discovered in the blood 
stages37-40, 45. However, we show in a recent paper that 4 of the epitopes identified from 
blood stage studies, also have cross-stage reactivity with pre-erythrocytic stages36, in 
corroboration with evidence of cross-stage reactivity against the *NCY397-404 epitope40. 
From 95 novel peptides, we identified nine peptides that report consistent production of 
IFN- from antigen specific CD8+ T cells, above background responses using a cut-off 
based on the response to an irrelevant H-2-Kb restricted peptide, SIINFEKL (Figure 2D 
and Appendix 1). Interestingly the highest responding epitope is a refinement of the 
S20318-326 epitope22. Originally published as a 9mer, the 8mer epitope we describe here 
lacks a phenylalanine at the C-terminus but induces a higher response than the 9mer. 3 
further completely novel epitopes also give convincing comparable responses to those 
induced by the published GAP5040-4837, RPA1227-23438 and S20318-32622 peptides (Figure 
2E). Our data suggests that azithromycin may have aided our identification of novel 
epitopes from proteins expressed in the liver stage, as six out of the nine highest 
responders are from proteins expressed during the liver stages27. Additionally, we 
reiterate that trained algorithms, which predict peptides that will bind strongly to MHC-I 
molecules, are a successful and useful tool in identifying novel CD8+ T cell epitopes. 
 
We also assessed the responses to our novel epitopes, following a single sporozoite 
immunisation to see if responses were boostable. At an individual level, seven novel 
epitopes and three published peptides induced higher IFN production from CD8+ T cells 
following a second immunisation, though none survived Benjamini-Hochberg adjustment 
for false discovery (Figure 3). 
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Figure 2 – Novel peptide restimulation of splenocytes from mice immunised with 
sporozoites under azithromycin prophylaxis 
Mice (n=3-6) were immunised twice with P. berghei ANKA sporozoites under 
azithromycin prophylaxis. Splenocytes were harvested 14 days after the last 
immunisation and pooled. 2x106 pooled splenocytes were restimulated with peptides at 
a final concentration of 10g/ml in the presence of Brefeldin A for 5-6 hours. Splenocytes 
were stained for assessment by flow cytometry to identify CD8+ T cells expressing IFN-
 and CD11a as a marker of antigen experience. (A) Flow cytometry gating strategy used 
to gate CD8+ T cells. (B) The magnitude of responses induced by 586 novel peptides 
synthesised at batch (as synthesised) purity level in terms of percentage of IFN-+ 
CD11a+ CD8+ T cells. The dashed line shows the cut-off derived by finite mixture model 
calculation (mean + 3 S.D. of negative population). Each peptide was assayed in at least 
two separate experiments. (C) The 42 peptides that induced responses above the cut-
off. (D) The magnitude of responses induced by 95 novel peptides (black bars) and 
published peptides (red bars) synthesised at a purity of >70% batch. The dashed line 
shows a cut-off defined by using an irrelevant peptide (mean + 3 S.D. of responses 
induced by SIINFEKL). Results shown are mean results ± SEM for each peptide with 
each peptide assayed in at least two separate experiments. (E) The top nine novel 
peptides (black bars) and top six published peptides (red bars) that induced responses 
above the cut-off (as shown in D). 
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Figure 3 – CD8+ T cell responses to novel epitopes are not significantly boosted 
by a secondary homologous immunisation 
Mice (n=3-6) were immunised once (light grey bars) or twice (dark grey bars) with P. 
berghei ANKA sporozoites under azithromycin prophylaxis. 2x106 pooled splenocytes 
harvested 14 days after the last immunisation and restimulated with 18 high responding 
novel peptides and 5 high responding published peptides at a final concentration of 
10g/ml in the presence of Brefeldin A for 5-6 hours. Splenocytes were stained for 
assessment by flow cytometry to identify the magnitude of CD8+ T cell responses 
through expression of IFN- and CD11a as a marker of antigen experience as before. 
Results shown are mean results ± SEM for each peptide pooled from at least two 
experiments. P-values are from unadjusted empirical Bayes t-test41; with Benjamini-
Hochberg42  false discovery (5%) no q-values were statistically significant (*, <0.05).  
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What makes a peptide immunogenic? 
To help define the hallmarks of immunogenic CD8+ T cell epitopes, we performed a 
feature analysis comparing the proteins containing immunogenic epitopes with the 
remainder of the dataset. 14 different derivative proteins, within which our 15 highest 
responding epitopes (nine novel and six published) can be found, made up the 
immunogenic dataset. The features of these 14 proteins were compared to 10,000 
groups of 14 proteins selected at random from the remaining 2,857 proteins in the data 
set. The 105 largest proteins (sizes above 4500aa) were excluded from analysis as some 
of the prediction software programs introduce errors when sizes exceed this threshold. 
We assessed for a variety of structural features, functions, subcellular locations and 
biophysical properties (Table 1). 
 
From this analysis, some features were enriched in our positive cohort (Table 2) and 
some were depleted (Table 3). Most strikingly, both secretory pathway and signal 
peptide, and cell envelope and transmembrane helix features appeared enriched, 
identified by independent prediction methods. This gives power and confidence to the 
prediction software results and corroborates previous suggestions for associations 
between secreted proteins, from intracellular non-viral pathogens28, and enhanced CD8+ 
T cell responses. However, other theories that had been proposed to improve 
immunogenicity of CD8+ T cell epitopes were not reflected in this study. In the context 
of P. berghei, we did not find a correlation to the position of immunogenic peptides within 
a protein and the magnitude of their response as previously described in Toxoplasma 
gondii29.  
We were also unable to find a correlation between antigen expression, using data from 
PlasmoDB31, and immunogenicity. 
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Prediction tool Classification Feature 
 
 
 
 
 
 
 
 
 
 
 
 
 
ProtFun-2.246, 47  
 
 
 
 
 
 
 
 
 
 
 
Functional category 
Amino acid biosynthesis 
Biosynthesis of cofactors 
Cell envelope 
Cellular processes 
Central intermediary 
metabolism 
Energy metabolism 
Fatty acid metabolism 
Purines and pyrimidines 
Regulatory functions 
Replication and 
transcription 
Translation 
Transport and binding 
Enzyme/non-enzyme 
Enzyme 
Non-enzyme 
Enzyme class 
Oxidoreductase (EC 1) 
Transferase (EC 2) 
Hydrolase (EC 3) 
Isomerase (EC 4) 
Ligase (EC 5) 
Lyase (EC 6) 
 
 
Gene Ontology category 
 
Signal transducer 
Receptor 
Hormone 
Structural protein 
237 
 
 
 
 
 
 
 
ProtFun-2.246, 47 
 
 
 
 
 
Gene Ontology category 
Transporter 
Ion channel 
Voltage-gated ion channel 
Cation channel 
Transcription 
Transcription regulation 
Stress response 
Immune response 
Growth factor 
Metal ion transport 
TargetP-1.148, 49 Sub-cellular location 
Secretory pathway 
Mitochondrial location 
Other location 
TMHMM-2.050 
Transmembrane helices in 
proteins 
Transmembrane helix 
IUPred51 Disorder 
Long disorder 
Short disorder 
PlasmoDB31 Expression data Expression 
In-house script Hydrophobicity Hydrophobicity 
SignalP-4.152 Signal peptide and cleavage sites Signal peptide 
In-house script Molecular weight Molecular weight 
In-house script Isoelectric point Isoelectric point 
NetMHCpan-2.832 MHC binders density SIR score 
 
Table 1 – Prediction of protein features  
The prediction methods used to determine the enrichment and depletion of features in 
proteins that contain immunogenic CD8+ T cell epitopes. 
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Table 2 – The enrichment of features in immunogenic proteins 
Features enriched in those 14 proteins harbouring the highest immunogenic epitopes 
from Figure 2E (9 novel peptides and 6 published peptides) compared to 10,000 random 
sets of 14 proteins from the remaining 2857 proteins in the dataset, including those 
containing peptides below the cut-off in Figure 2E. 
 
 
 
Table 3 - The depletion of features in immunogenic proteins 
(A) Features depleted in those 14 proteins harbouring the highest immunogenic epitopes 
from Figure 2E (9 novel peptides and 6 published peptides) compared to 10,000 random 
sets of 14 proteins from the remaining 2857 proteins in the dataset, including those 
containing peptides below the cut-off in Figure 2E. 
  
Enriched features 
p-value 
Classification Feature 
Functional category 
Cell envelope 0.0042 
Transport and binding 0.0082 
Sub-cellular location Secretory pathway 0.0193 
Signal peptide and cleavage sites Signal peptide 0.0160 
Transmembrane helices in proteins Transmembrane helix 0.0474 
Depleted features 
p-value 
Classification Feature 
Functional category 
Cellular processes 0.0369 
Replication and transcription 0.0424 
Gene Ontology category 
Voltage-gated ion channel 0.0241 
Immune response 0.0306 
Disorder Short disorder 0.0398 
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Accounting for more of the functional CD8+ T cell response 
It has been noted that the majority of epitopes that make up the CD8+ T cell repertoire 
specific to Plasmodium, as well as other arms of the adaptive immune system, have yet 
to be discovered. Doll et al showed that 15% of the antigen-experienced (CD11ahi) CD8+ 
T cell population induced after a single immunisation with radiation attenuated 
sporozoites produce IFN- with specificity for just four epitopes, determined by summing 
the four individual peptide restimulation responses together53. We asked, is it possible to 
account for more IFN- producing effector CD8+ T cells by restimulating with pooled 
peptides? Using this approach, we investigated whether we could account for antigen-
specificity in a greater proportion of antigen-experienced CD8+ T cells induced following 
immunisation by restimulating with pools of peptides from our screens.,  
 
We restimulated with a pool of 17 novel epitopes, 7 published peptides and a combined 
pool of 24 peptides. The 17 novel epitopes were chosen for pooling based on their high 
immunogenicity across several experiments in comparison to the irrelevant H-2-Kb 
restricted peptide, SIINFEKL. The 7 published peptides included the 6 highest 
responding published peptides used as controls in this study: TRAP130-138, S20318-326, 
GAP5040-48, RPA1227-234, BLN592-599, *NCY397-404 as well as the novel S20 8mer peptide 
identified in this study. A pool of 24 peptides combined these two groups. Splenocytes 
were restimulated with pools of a final concentration of 2g/ml/peptide, in addition to 
restimulation with individual peptides at the same final concentration of 2g/ml. 
 
Compared to around 4% in naïve mice, around 25% of the total splenic CD8+ T cell 
population from mice immunised twice with sporozoites with azithromycin prophylaxis, 
exhibited a CD11ahi phenotype (Figure 4A-C). Comparing the responses to individual 
peptides, pooling the 7 published peptides restimulated around 20% of this compartment 
to produce IFN-, up from a maximum of nearly 4% IFN- production following 
restimulation with just VNYSFLYL (Figure 4B and 4D). Simply added, the combined 
240 
 
response to these 7 peptides should have been 30%. Pooling the 17 novel epitopes did 
not massively increase the proportion of IFN-+ producing cells accountable compared 
to individual peptide restimulation. When splenocytes were restimulated with the 24 
peptide pool, the proportion of cells producing IFN- was reduced (~16%) compared to 
that seen when restimulating with the 7 published peptide pool. Simply added, the 
combined response to these 24 peptides should have been 35%.The same trend can be 
seen when the proportion of IFN-+ CD11a+ cells from the total CD8+ T cell population 
is gated for (Figure 4E and 4F) While, we have assigned antigen-specificity to a  greater 
proportion of the sporozoite immunisation induced CD8+ T cell response than previously 
noted53, our methodology suggests there may be a ceiling to the maximum proportion of 
IFN- producing cells that can be visualised using this approach. By pooling peptides in 
this system, we may be underestimating the proportion of antigen-specific CD8+ T cells 
that can be determined compared to simplistically summing individual responses. 
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Figure 4 – Restimulating splenocytes with a pool of peptides can increase the 
production of IFN- by CD8+ T cells and allow more of the total CD11ahi CD8+ T 
cell response to be accounted for 
Mice were immunised twice with P. berghei ANKA sporozoites under azithromycin 
prophylaxis (n=3-4). 2x106 splenocytes harvested 14 days after the last immunisation 
were restimulated with a pool of 7 high responding published peptides (hi pub 7), 17 high 
responding novel peptides (novel 17) or a combined pool of 24 peptides (novel + hi pub 
7) from both novel and published groups. Each peptide within the pool was at a final 
concentration of 2g/ml. Restimulation with individual peptides was also at a 
concentration of 2g/ml. (A) Flow cytometric example of the proportion of CD11ahi CD8 
T cells from naive mice splenocytes compared with (B) splenocytes from immunised 
mice and the proportion of IFN- producing CD8+ T cells from this population when 
restimulated with VNYSFLYL. (C, D) The left hand panel of the graphs show the 
proportion of (C) CD11ahi CD8+ T cells  and (D) IFN- producing CD11ahi CD8+ T cells 
induced by individual peptide restimulation, with the right hand panel of the graphs 
showing the proportions of the same groups of cells following pooled peptide 
restimulation. (E) Flow cytometric example of the proportion of IFN-+ CD11a+ cells 
gated from total CD8+ T cells. (F) The left hand panel of the graph show the proportion 
of IFN-+ CD11a+ cells gated from CD8+ T cells induced by individual peptide 
restimulation and the right hand panel of the graphs shows the proportions of the same 
groups of cells following peptide pool restimulation. (C, D, F) Individual wells stimulated 
with individual peptides (left panel) or pooled peptides (right panel) are shown as single 
points as well as mean result. This figure shows results from one representative 
experiment from three independent experiments.  
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DISCUSSION 
In our study, we have identified nine novel immunogenic CD8+ T cell epitopes, against 
pre-erythrocytic P. berghei proteins, using MHC-I epitope prediction methods. Using 
rodent models only epitopes from three sporozoite stage antigens (in P. berghei22, 54 and 
P. yoelii55) and two liver stage antigens (in P. yoelii56 and very recently in P. berghei57) 
have previously been published. Additionally several other CD8+ T cell epitopes had 
been discovered in the blood stage37-40, with some being found to have cross-stage 
reactivity in the pre-erythrocytic stages36, 40. Four of the novel epitopes give responses 
stronger than the recently published S20318-326 epitope22 and GAP5040-48 epitope37. The 
epitope with the highest IFN- response, even greater than our controls, was a 
refinement of that same S20318-326 epitope22, with a loss of a phenylalanine from the C-
terminus likely allowing more favourable binding to the H-2-Kb MHC-I molecule58, 59 which 
may have improved responses. All nine epitopes had an IC50 binding affinity of less than 
50nM and a %Rank score of 0.15 or lower, which strengthens the notion that strong 
binding peptide-MHC interactions produce strong immunogenic responses19-21. This 
further highlights the value of the epitope prediction software used33, 34 as effective 
methods of identifying novel CD8+ T cell epitopes. Most pertinently, all nine antigens, 
which harbour the novel epitopes discovered here, have orthologous genes in nearly all 
the five human infective species of Plasmodium highlighting their relevance in human 
malaria vaccine research. 
 
In parallel, within our workflow, we also looked into the anomalous immunogenic 
*NCY397-404 peptide. In our initial screenings, we found that this peptide gave a very high 
IC50 value and %Rank score, suggesting it binds much more weakly than other epitopes 
we had predicted. However, in the initial paper it was discovered in, this peptide gave 
strong immunogenic responses against the blood stages of P. berghei infection40 and 
exhibits cross-stage reactivity with sporozoites36, 40. Given the lack of experimental data 
containing asparagine in position 1 and cysteine in position 2 for MHC-I restricted 
peptides, NetMHCcons may be biased towards considering these configurations as 
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deleterious. To address this bias, modified versions of the NC peptides were introduced 
to predict binding affinity, mutating asparagine to valine and cysteine to serine in 
positions 1 and 2 respectively. High scoring mutants were selected and their original 
versions synthesised and assayed for immunogenicity as before. Nonetheless, we were 
unable to enrich our panel of high responding peptides with NC or C2 peptides. It may 
not be a true anomaly as six of the other nine published epitopes also exhibit high affinity 
scores38, 39, which would have excluded them from our selection criteria of an IC50 of 
below 50nM and/or %Rank of below 0.5. However, as we progressed in this project the 
predicted scores for these peptides decreased as the algorithms were retrained with 
more data from more diverse datasets. Nonetheless, the predicted scores for these 
peptides remain higher than we would expect for an immunogenic peptide which 
suggests that this may be a Plasmodium specific phenomenon, particularly for cross-
stage reactive peptides.  
 
With this in mind, could there be a defining feature of the derivative proteins from which 
these epitopes arise, which induce such strong CD8+ T cell responses? It became 
apparent that signal peptides and transmembrane regions were enriched in the positive 
cohort, further suggesting that secreted proteins are associated with increased antigen 
presentation and CD8+ T cell responses as previously proposed28 and corroborating with 
results from tumour vaccination studies60, 61 for an association between transmembrane 
domains and heightened CD8+ T cell responses. For peptides to be loaded onto MHC-I 
molecules, it is generally considered that antigens must be exposed to the cytosol to be 
processed by the proteasome. Thus, in the context of malaria liver stages, it is feasible 
that a parasite protein could be directed away by a signal peptide, transported across 
the parasitophorous vacuole membrane (PVM) and into the cytosol of the hepatocyte to 
be presented on an infected hepatocyte. Equally, if the protein were associated with the 
PVM, a portion of the transmembrane region would be exposed to the hepatocyte 
cytoplasm, providing an avenue for degradation by the proteasome. However, as can be 
seen by the large number of negative results compared to our comparatively small 
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immunogenic cohort, the strength of the suggestions we can make is limited by the size 
of the dataset. 
 
Nonetheless, processing of pre-erythrocytic proteins is likely very complicated and the 
role of signal peptides, transmembrane domains and cell envelope association in relation 
to immunogenicity has not fully been realised, with their presence unlikely to be an 
absolute property that will result in immunogenic peptides. The mechanism for 
presentation of Plasmodium pre-erythrocytic antigens on infected hepatocytes has still 
yet to be fully characterised. Equally, we have not determined here whether non-
responding peptides are not being presented on the surface of infected hepatocytes 
following MHC loading or if the derivative proteins fail to reach the cytosol and MHC 
loading machinery in the first instance. Cockburn et al. elegantly showed that CSP must 
arrive to the hepatocyte cytosol, and like dendritic cells, TAP1 is required for peptides to 
be loaded onto MHC molecules62. However, they also show that CSP does not have to 
arrive in the cytosol as a result of its PEXEL motif, a Plasmodium specific export signal 
discovered in blood stages63, 64, nor does it traffic in an endosome-cytosol translocation 
manner as was shown to be possible for presentation on dendritic cells62. While this 
suggests a role for secretion in antigen presentation, more work is required to assess 
how peptides from antigens in the liver stages are presented and how this relates to 
CD8+ T cell responses. Are antigens from certain subcellular locations in the parasite 
more favourably presented? This will be important for focused vaccine target discovery 
to find protective antigens. It has already been shown in Toxoplasma gondii that targeting 
proteins with immunogenic epitopes to dense granules (facilitating increased protein 
secretion into the parasitophorous vacuole increases the protective cognate CD8+ T cell 
response65. It has also been shown that signal peptide regions from M. tuberculosis 
proteins contain a greater abundance of epitopes making them more inherently 
immunogenic66, but we have not tested this concept in the context of P. berghei. 
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Another notion that has been shown in Toxoplasma gondii is that making a subdominant 
CD8+ T cell epitope more C-terminal enhances immunodominance. Feliu et al. showed 
that the presence of the HF10 epitope from the immunodominant GRA6 protein at the 
C-terminus of the protein was critical for its protective qualities29. Furthermore, 
appending the subdominant SM9 epitope from GRA4 at this same C-terminal position in 
GRA6 increased processing, presentation and ultimately protection. They hypothesise 
this may be due to GRA6 being a vacuolar protein with the C-terminus exposed to the 
cytosol29. Whilst we find an association for cell membrane and transmembrane regions, 
we however find no correlation with the position of an epitope in the protein and the IFN-
 response it induces in the context of Plasmodium. Equally, given the lack of annotation 
for many Plasmodium genes and proteins we cannot further strengthen arguments that 
vacuolar or vacuolar membrane protein are more immunogenic.  
 
The expression data we have used to identify whether a protein is expressed in the 
sporozoite, liver stage or both is sparse compared to that available for blood stages of 
Plasmodium. While it may be difficult to draw correlations between immunogenicity and 
specific life stages, we report that there seems to be no correlation between the level of 
proteins expressed in the pre-erythrocytic stages and immunogenicity. This, however 
agrees with previous reports using other systems that also fail to find a correlation 
between antigen expression levels and CD8+ T cell responses67, (Chapter 2: Müller and 
Gibbins et al, paper in preparation). 
 
Part of this study included trying to account for the total IFN- producing compartment of 
the CD8+ T cell population induced in response to Plasmodium berghei sporozoite 
immunisation. Multiple immunisations of C57BL/6 mice with attenuated sporozoites can 
protect them from subsequent challenge8 in a CD8+ T cell manner14 however the entire 
epitope repertoire with which CD8+ T cells respond to Plasmodium is not known. Hence, 
we attempted to account for an increased proportion of CD8+ T cells capable of 
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producing IFN- by pooling our novel epitopes with previously published epitopes. 
Around a quarter of the total CD8+ T cell population exhibit a CD11ahi antigen-
experienced phenotype following a double homologous immunisation with sporozoites 
attenuated by azithromycin prophylaxis. We were able to account for 20% of the IFN- 
producing CD8+ T cells of the CD11ahi compartment by restimulating with 6 published 
peptides and the novel S20 8mer VNYSFLYL. The proportion of cells producing IFN- 
was not increased when we combined 17 novel epitopes into this pool, in fact the 
proportion decreased. This may be because there are not enough antigen presenting 
cells in the system, with competition for presentation of peptides and a potential 
dominance for certain epitopes. Nonetheless, we have been able to show that an 
increased proportion of Plasmodium berghei antigen-specific CD8+ T cells producing 
IFN- can be accounted for by pooling peptides, in excess of that shown previously even 
without considering the strong responses to CSP53. With more antigen presenting cells 
in the assay, such as a dendritic cell line capable of superior antigen presentation to 
splenic cells, this may prove a useful method to determine the full repertoire of antigens 
that induce CD8+ T cell responses following sporozoite immunisation. 
 
Despite the obvious benefit that immunogenic CD8+ T cell epitopes can give as read 
outs of correlates of protection, the importance of antigen immunogenicity may be 
overstated, misleading the efforts to characterise vaccine candidates. We showed 
recently, that SIINFEKL expressed as part of the UIS4 protein, a vacuolar membrane 
protein expressed soon after sporozoites invasion of hepatocytes68, 69, is poorly 
immunogenic compared to SIINFEKL expressed in the context of sporozoite surface 
protein CSP. Despite this, when mice vaccinated with adenovirus expressing ovalbumin 
are challenged with sporozoites expressing SIINFEKL in the context of CSP or UIS4, 
both mice are protected with lower parasite liver loads and comparable high levels of 
sterile protection (Chapter 2: Müller & Gibbins et al, paper in preparation). 
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Thus, continued identification of Plasmodium antigens expressed in the pre-erythrocytic 
stages and dissection of the immune responses they induce is required to further inform 
vaccine research and aid development of an efficacious vaccine against malaria. 
  
249 
 
ACKNOWLEDGEMENTS 
We would like to acknowledge Katja Müller for her technical assistance and Kai 
Matuschewski for permission to perform the initial screens in his laboratory. We would 
like to thank Will Stone for guidance on running the statistical analysis used to compare 
boosted responses. We would like to thank Ernest Diez-Benavente and Marta Campillo 
Poveda for their critical reading of the manuscript. 
JCRH was funded by grants from The Royal Society (University Research Fellowship 
UF0762736/UF120026 and Project Grant RG130034) and the National Centre for the 
Replacement, Refinement & Reduction of Animals in Research (Project Grant 
NC/L000601/1) This project was also part funded by Royal Society International 
Exchange Grants IE131078 and IE14111. The funders had no role in study design, data 
collection and analysis, decision to publish, or preparation of the manuscript. 
  
250 
 
ADDENDUM TO CHAPTER 6: Identification of non-CSP targets of CD8+ T cell 
responses to malaria pre-erythrocytic stages in a BALB/c model 
 
INTRODUCTION 
CSP-specific responses have been the standard in measuring cellular responses to 
malaria pre-erythrocytic stages in fundamental immunological studies in mice. The 
responses to the immunodominant CD8+ T cell epitope of P. berghei CSP (Chapter 5: 
Gibbins et al., paper in preparation) have been widely assessed using BALB/c mice as 
a model. This is because, in contrast to C57BL/6 that cannot present the SYIPSAEKI 
epitope due to its MHC restriction, BALB/c mice can present SYIPSAEKI on MHC class 
I H-2-Kd molecules. Here we attempted to uncover CD8+ T cell epitopes from non-CSP 
pre-erythrocytic antigens from P. berghei and P. yoelii, presented in the same mouse 
model where CD8+ T cell responses to SYIPSAEKI are immunodominant. We used an 
MHC-I prediction algorithm 70, 71 to identify potential epitopes from published and 
unpublished P. berghei and P. yoelii sporozoite and liver stage transcriptomic and 
proteomic data sets 23, 24, 72, 73 and ex vivo restimulation of splenocytes from immunised 
mice to screen the candidate epitopes. 
 
RESULTS AND DISCUSSION 
Identification of a novel epitope that induces reproducible CD8+ T cell responses 
and exhibits Plasmodium cross-species reactivity. Using ex vivo peptide 
restimulation of splenocytes from P. berghei RAS immunised mice, ICS and flow 
cytometry (Figure 4A), we identified a novel CD8+ T cell epitope exhibiting subdominant 
IFN- responses above the cut-off (Figure 4B). This epitope, LYIKSINNI, also exhibited 
cross-reactivity between species with consistent stimulation of IFN- production from 
CD8+ T cells when mice were immunised with PbWT or PyWT under azithromycin 
prophylaxis30 (Figure 4C). Immunisation with RAS and sporozoites under azithromycin 
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prophylaxis have been shown to give comparable proportions of antigen experienced 
CD8+ T cells74, (Chapter 3: Gibbins et al., paper in preparation). Our novel epitope, 
LYIKSINNI, derives from the S14 protein, originally identified in P. yoelii 23 
(PY17X_0608400 aa286-294) with total epitope sequence equivalence to P. berghei 
PBANKA_0605900 (aa247-255). At present this protein is a conserved uncharacterised 
antigen expressed in the sporozoite23, 26 and liver stage27 with an unknown function. Our 
results independently confirm IFN- production by S14-specific CD8+ T cells, which have 
recently been shown to be induced in BALB/c mice following multiple immunisations with 
a DNA vaccine based on P. yoelii S14 (PY17X_0608400)75. DNA vaccination with P. 
yoelii S14 led to a reduction in parasite load in the liver when mice were challenged with 
P. yoelii, with the protection only partially reliant on CD8+ T cells75. Additionally, the S14 
epitope showed stronger responses compared to another recently published liver-stage 
antigen, ribosomal protein L3 epitope, discovered in P. yoelii 56 (Figure 4C)  though we 
were unable to replicate the strong responses recorded by the authors using ELiSPOT56 
in our assay. In addition, our novel epitope induces responses in mice immunised with 
PbCSPSIINFEKL (Figure 4C) in the absence of CSP responses. Comparable CD8+ T cell 
responses to S14 presented here can also be seen when mice are immunised with one 
RAS inoculum of PbWT or PbCSPSIINFEKL or two RAS immunisations with PbWT, 
PbCSPSIINFEKL or another transgenic parasite also lacking the SYIPSAEKI epitope of CSP 
(unpublished and data not shown). 
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FIGURE 5 
Identification of a novel non-CSP CD8+ T cell epitope. (A) The flow cytometry gating 
strategy used to determine proportions of IFN-+ CD11a+ CD8+ T cells from splenocytes 
from immunised mice. (B) BALB/c mice (n=4) were twice immunised with PbWT RAS. 
Spleens were harvested and pooled splenocytes restimulated with a panel of 144 
predicted CD8+ T cell epitope peptides. The bar chart shows the magnitude of the 
responses to the top 20 most responsive peptides, in terms of percentage of IFN-+ 
CD11a+ CD8+ T cells. CSP: SYIPSAEKI; S14: LYIKSINNI. The cut-off is mean + 3 S.D. 
calculated by a finite mixture model. The data is representative of three separate 
experiments. (C) BALB/c mice (n=3-5) were immunised twice with PbWT (black bars), 
PyWT (grey bars) or PbCSPSIINFEKL sporozoites (white bars) under azithromycin cover. 
Spleens were harvested and pooled splenocytes were restimulated with SYIPSAEKI 
from PbCSP54, SYVPSAEQI from PyCSP55, LYIKSINNI from S14 and GYKSGMSHI from 
L356. Data shown is the mean ± SEM from four separate experiments (only one result 
shown for PbCSPSIINFEKL). 
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This highlights the identification of a subdominant CD8+ T cell response in a mouse 
model, where the majority of the response seen is against CSP (Figure 5B-C). These 
results also highlight the use of transgenic parasites which lack the immunodominant 
epitope of CSP we describe in this paper. While CSPSIINFEKL, which lacks the 
immunodominant epitope of CSP, has helped confirm the validity of the novel S14 
epitope, the immunodominant nature of CSP in this mouse model, may be precluding 
the ability to identify further epitopes as the response to S14 was not increased in the 
absence of SYIPSAEKI presentation. The profile of CD8+ T cell responses observed 
from BALB/c mice certainly contrast with the profile of responses to novel CD8+ T cell 
epitopes assayed using C57BL/6 mice (Chapter 6: Gibbins et al., paper in preparation). 
It is possible that the CD8+ T cell response to SYIPSAEKI is swamping the CD8+ T cell 
response to other antigens. Alternatively, the host genetics of these two mice may play 
a role in the epitopes that are presented. The use of an appropriate animal models and 
discovery strategies are crucial to finding more targets against the Plasmodium parasite, 
to best inform vaccine research and push development towards an efficacious malaria 
vaccine. 
 
ADDITIONAL MATERIALS AND METHODS 
Mosquitoes were infected with PbWT, PbCSPSIINFEKL and P. yoelii XNL (PyWT) parasites 
and kept in 80% humidity incubators (Panasonic) at 20°C (Pb) or 26°C (Py). Proteins 
and genes shown to be upregulated in the pre-erythrocytic stages of malaria from 
published P. berghei and P. yoelii sporozoite and liver stage transcriptomic and 
proteomic datasets 23, 24, 27, 72, 73, orthologs of LSA-131, 76 and unpublished data (Alyssa 
Ingmundson, personal communication) were used to identify novel CD8+ T cell epitopes 
with sequences acquired from PlasmoDB31. 9-mer peptide sequences with a H-2-Kd and 
H-2-Ld MHC-I restriction were predicted in silico using NetMHC70 and IEDB71. 144 
peptides with strong predicted binding were synthesised and purchased from Peptides 
and Elephants (Potsdam, Germany). For peptide screening, mice were immunised twice 
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intravenously with 104 PbWT RAS, two weeks apart. For comparing CD8+ T cell 
responses between P. berghei and P. yoelii immunised mice, 104 sporozoites were 
administered intravenously twice (two weeks apart) with azithromycin (Pfizer) given at a 
dose of 240 mg/kg intraperitoneally on the same day as immunisation and another dose 
the day after immunisation30. Two weeks after the last immunisation, spleens were 
harvested from immunised mice and 2-4x106 splenocytes were restimulated with 
peptides and assayed for flow cytometry as before.  
  
256 
 
REFERENCES 
1. Carter, R. and K.N. Mendis, Evolutionary and historical aspects of the burden of 
malaria. Clin Microbiol Rev, 2002. 15(4): p. 564-94. 
2. WHO, World Malaria Report 2017 2017, World Health Organisation: Geneva, 
Switzerland. 
3. Yoshida, N., et al., Hybridoma produces protective antibodies directed against the 
sporozoite stage of malaria parasite. Science, 1980. 207(4426): p. 71-3. 
4. Potocnjak, P., et al., Monovalent fragments (Fab) of monoclonal antibodies to a 
sporozoite surface antigen (Pb44) protect mice against malarial infection. J Exp Med, 
1980. 151(6): p. 1504-13. 
5. Yoshida, N., et al., Biosynthesis of Pb44, the protective antigen of sporozoites of 
Plasmodium berghei. J Exp Med, 1981. 154(4): p. 1225-36. 
6. Vanderberg, J.P., Reflections on early malaria vaccine studies, the first successful 
human malaria vaccination, and beyond. Vaccine, 2009. 27(1): p. 2-9. 
7. Rts, S.C.T.P., Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a 
booster dose in infants and children in Africa: final results of a phase 3, individually 
randomised, controlled trial. Lancet, 2015. 386(9988): p. 31-45. 
8. Nussenzweig, R.S., et al., Protective immunity produced by the injection of x-irradiated 
sporozoites of plasmodium berghei. Nature, 1967. 216(5111): p. 160-2. 
9. Gwadz, R.W., et al., Preliminary studies on vaccination of rhesus monkeys with 
irradiated sporozoites of Plasmodium knowlesi and characterization of surface 
antigens of these parasites. Bull World Health Organ, 1979. 57 Suppl 1: p. 165-73. 
10. Clyde, D.F., et al., Immunization of man against sporozite-induced falciparum malaria. 
Am J Med Sci, 1973. 266(3): p. 169-77. 
11. Rieckmann, K.H., et al., Letter: Sporozoite induced immunity in man against an 
Ethiopian strain of Plasmodium falciparum. Trans R Soc Trop Med Hyg, 1974. 68(3): p. 
258-9. 
12. Schofield, L., et al., Gamma interferon, CD8+ T cells and antibodies required for 
immunity to malaria sporozoites. Nature, 1987. 330(6149): p. 664-6. 
13. Weiss, W.R., et al., CD8+ T cells (cytotoxic/suppressors) are required for protection in 
mice immunized with malaria sporozoites. Proc Natl Acad Sci U S A, 1988. 85(2): p. 
573-6. 
14. Doolan, D.L. and S.L. Hoffman, The complexity of protective immunity against liver-
stage malaria. J Immunol, 2000. 165(3): p. 1453-62. 
15. Weiss, W.R. and C.G. Jiang, Protective CD8+ T lymphocytes in primates immunized with 
malaria sporozoites. PLoS One, 2012. 7(2): p. e31247. 
16. Medica, D.L. and P. Sinnis, Quantitative dynamics of Plasmodium yoelii sporozoite 
transmission by infected anopheline mosquitoes. Infect Immun, 2005. 73(7): p. 4363-9. 
17. Yamauchi, L.M., et al., Plasmodium sporozoites trickle out of the injection site. Cell 
Microbiol, 2007. 9(5): p. 1215-22. 
18. Amino, R., et al., Quantitative imaging of Plasmodium transmission from mosquito to 
mammal. Nat Med, 2006. 12(2): p. 220-4. 
19. Sette, A., et al., The relationship between class I binding affinity and immunogenicity of 
potential cytotoxic T cell epitopes. J Immunol, 1994. 153(12): p. 5586-92. 
20. Zvi, A., et al., Novel CTL epitopes identified through a Y. pestis proteome-wide analysis 
in the search for vaccine candidates against plague. Vaccine, 2017. 35(44): p. 5995-
6006. 
21. Teh-Poot, C., et al., From genome screening to creation of vaccine against 
Trypanosoma cruzi by use of immunoinformatics. J Infect Dis, 2015. 211(2): p. 258-66. 
22. Hafalla, J.C., et al., Identification of targets of CD8(+) T cell responses to malaria liver 
stages by genome-wide epitope profiling. PLoS Pathog, 2013. 9(5): p. e1003303. 
257 
 
23. Kaiser, K., et al., Differential transcriptome profiling identifies Plasmodium genes 
encoding pre-erythrocytic stage-specific proteins. Mol Microbiol, 2004. 51(5): p. 1221-
32. 
24. Matuschewski, K., et al., Infectivity-associated changes in the transcriptional repertoire 
of the malaria parasite sporozoite stage. J Biol Chem, 2002. 277(44): p. 41948-53. 
25. Lasonder, E., et al., Proteomic profiling of Plasmodium sporozoite maturation identifies 
new proteins essential for parasite development and infectivity. PLoS Pathog, 2008. 
4(10): p. e1000195. 
26. Lindner, S.E., et al., Total and putative surface proteomics of malaria parasite salivary 
gland sporozoites. Mol Cell Proteomics, 2013. 12(5): p. 1127-43. 
27. Tarun, A.S., et al., A combined transcriptome and proteome survey of malaria parasite 
liver stages. Proc Natl Acad Sci U S A, 2008. 105(1): p. 305-10. 
28. Blanchard, N. and N. Shastri, Topological journey of parasite-derived antigens for 
presentation by MHC class I molecules. Trends Immunol, 2010. 31(11): p. 414-21. 
29. Feliu, V., et al., Location of the CD8 T cell epitope within the antigenic precursor 
determines immunogenicity and protection against the Toxoplasma gondii parasite. 
PLoS Pathog, 2013. 9(6): p. e1003449. 
30. Friesen, J., et al., Natural immunization against malaria: causal prophylaxis with 
antibiotics. Sci Transl Med, 2010. 2(40): p. 40ra49. 
31. Aurrecoechea, C., et al., PlasmoDB: a functional genomic database for malaria 
parasites. Nucleic Acids Res, 2009. 37(Database issue): p. D539-43. 
32. Hoof, I., et al., NetMHCpan, a method for MHC class I binding prediction beyond 
humans. Immunogenetics, 2009. 61(1): p. 1-13. 
33. Nielsen, M. and M. Andreatta, NetMHCpan-3.0; improved prediction of binding to MHC 
class I molecules integrating information from multiple receptor and peptide length 
datasets. Genome Med, 2016. 8(1): p. 33. 
34. Karosiene, E., et al., NetMHCcons: a consensus method for the major histocompatibility 
complex class I predictions. Immunogenetics, 2012. 64(3): p. 177-86. 
35. Lund, O., et al., Bioinformatics identification of antigenic peptide: predicting the 
specificity of major MHC class I and II pathway players. Methods Mol Biol, 2013. 960: 
p. 247-260. 
36. Muller, K., et al., Evidence of cross-stage CD8+ T cell epitopes in malaria pre-
erythrocytic and blood stage infections. Parasite Immunol, 2017. 
37. Howland, S.W., et al., Brain microvessel cross-presentation is a hallmark of 
experimental cerebral malaria. EMBO Mol Med, 2013. 5(7): p. 916-31. 
38. Lau, L.S., et al., Blood-stage Plasmodium berghei infection generates a potent, specific 
CD8+ T-cell response despite residence largely in cells lacking MHC I processing 
machinery. J Infect Dis, 2011. 204(12): p. 1989-96. 
39. Poh, C.M., et al., Damage to the blood-brain barrier during experimental cerebral 
malaria results from synergistic effects of CD8+ T cells with different specificities. Infect 
Immun, 2014. 82(11): p. 4854-64. 
40. Lau, L.S., et al., CD8+ T cells from a novel T cell receptor transgenic mouse induce liver-
stage immunity that can be boosted by blood-stage infection in rodent malaria. PLoS 
Pathog, 2014. 10(5): p. e1004135. 
41. Smyth, G.K., Linear models and empirical bayes methods for assessing differential 
expression in microarray experiments. Stat Appl Genet Mol Biol, 2004. 3: p. Article3. 
42. Benjamini, Y. and Y. Hochberg, Controlling the False Discovery Rate - a Practical and 
Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B-
Methodological, 1995. 57(1): p. 289-300. 
43. Jaffe, R.I., G.H. Lowell, and D.M. Gordon, Differences in susceptibility among mouse 
strains to infection with Plasmodium berghei (ANKA clone) sporozoites and its 
relationship to protection by gamma-irradiated sporozoites. Am J Trop Med Hyg, 1990. 
42(4): p. 309-13. 
258 
 
44. Rai, D., et al., Tracking the total CD8 T cell response to infection reveals substantial 
discordance in magnitude and kinetics between inbred and outbred hosts. J Immunol, 
2009. 183(12): p. 7672-81. 
45. Agnandji, S.T., et al., Evaluation of the safety and immunogenicity of the RTS,S/AS01E 
malaria candidate vaccine when integrated in the expanded program of immunization. 
J Infect Dis, 2010. 202(7): p. 1076-87. 
46. Jensen, L.J., et al., Prediction of human protein function from post-translational 
modifications and localization features. J Mol Biol, 2002. 319(5): p. 1257-65. 
47. Jensen, L.J., et al., Prediction of human protein function according to Gene Ontology 
categories. Bioinformatics, 2003. 19(5): p. 635-42. 
48. Emanuelsson, O., et al., Predicting subcellular localization of proteins based on their N-
terminal amino acid sequence. J Mol Biol, 2000. 300(4): p. 1005-16. 
49. Nielsen, H., et al., Identification of prokaryotic and eukaryotic signal peptides and 
prediction of their cleavage sites. Protein Eng, 1997. 10(1): p. 1-6. 
50. Sonnhammer, E.L., G. von Heijne, and A. Krogh, A hidden Markov model for predicting 
transmembrane helices in protein sequences. Proc Int Conf Intell Syst Mol Biol, 1998. 6: 
p. 175-82. 
51. Dosztanyi, Z., et al., IUPred: web server for the prediction of intrinsically unstructured 
regions of proteins based on estimated energy content. Bioinformatics, 2005. 21(16): p. 
3433-4. 
52. Petersen, T.N., et al., SignalP 4.0: discriminating signal peptides from transmembrane 
regions. Nat Methods, 2011. 8(10): p. 785-6. 
53. Doll, K.L., et al., Discriminating Protective from Nonprotective Plasmodium-Specific 
CD8+ T Cell Responses. J Immunol, 2016. 196(10): p. 4253-62. 
54. Romero, P., et al., Cloned cytotoxic T cells recognize an epitope in the circumsporozoite 
protein and protect against malaria. Nature, 1989. 341(6240): p. 323-6. 
55. Weiss, W.R., et al., Cytotoxic T cells recognize a peptide from the circumsporozoite 
protein on malaria-infected hepatocytes. J Exp Med, 1990. 171(3): p. 763-73. 
56. Murphy, S.C., et al., A T-cell response to a liver-stage Plasmodium antigen is not 
boosted by repeated sporozoite immunizations. Proc Natl Acad Sci U S A, 2013. 
110(15): p. 6055-60. 
57. Pichugin, A., et al., Identification of a Novel CD8 T Cell Epitope Derived from 
Plasmodium berghei Protective Liver-Stage Antigen. Front Immunol, 2018. 9: p. 91. 
58. Deres, K., et al., Preferred size of peptides that bind to H-2 Kb is sequence dependent. 
Eur J Immunol, 1992. 22(6): p. 1603-8. 
59. DeVette, C.I., et al., NetH2pan: A Computational Tool to Guide MHC peptide prediction 
on Murine Tumors. Cancer Immunol Res, 2018. 
60. Paster, W., et al., Structural elements of a protein antigen determine immunogenicity 
of the embedded MHC class I-restricted T cell epitope. J Immunol, 2002. 169(6): p. 
2937-46. 
61. Tran, L., et al., The immunogenicity of the tumor-associated antigen alpha-fetoprotein 
is enhanced by a fusion with a transmembrane domain. J Biomed Biotechnol, 2012. 
2012: p. 878657. 
62. Cockburn, I.A., et al., Dendritic cells and hepatocytes use distinct pathways to process 
protective antigen from plasmodium in vivo. PLoS Pathog, 2011. 7(3): p. e1001318. 
63. Marti, M., et al., Targeting malaria virulence and remodeling proteins to the host 
erythrocyte. Science, 2004. 306(5703): p. 1930-3. 
64. Hiller, N.L., et al., A host-targeting signal in virulence proteins reveals a secretome in 
malarial infection. Science, 2004. 306(5703): p. 1934-7. 
65. Grover, H.S., et al., Impact of regulated secretion on antiparasitic CD8 T cell responses. 
Cell Rep, 2014. 7(5): p. 1716-1728. 
259 
 
66. Kovjazin, R., et al., Signal peptides and trans-membrane regions are broadly 
immunogenic and have high CD8+ T cell epitope densities: Implications for vaccine 
development. Mol Immunol, 2011. 48(8): p. 1009-18. 
67. Croft, N.P., et al., Kinetics of antigen expression and epitope presentation during virus 
infection. PLoS Pathog, 2013. 9(1): p. e1003129. 
68. Mueller, A.K., et al., Plasmodium liver stage developmental arrest by depletion of a 
protein at the parasite-host interface. Proc Natl Acad Sci U S A, 2005. 102(8): p. 3022-7. 
69. Silvie, O., et al., Post-transcriptional silencing of UIS4 in Plasmodium berghei 
sporozoites is important for host switch. Mol Microbiol, 2014. 91(6): p. 1200-13. 
70. Lundegaard, C., et al., NetMHC-3.0: accurate web accessible predictions of human, 
mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res, 
2008. 36(Web Server issue): p. W509-12. 
71. Vita, R., et al., The immune epitope database (IEDB) 3.0. Nucleic Acids Res, 2015. 
43(Database issue): p. D405-12. 
72. Rosinski-Chupin, I., et al., Serial Analysis of Gene Expression in Plasmodium berghei 
salivary gland sporozoites. BMC Genomics, 2007. 8: p. 466. 
73. Wang, Q., et al., Transcriptome of axenic liver stages of Plasmodium yoelii. Mol 
Biochem Parasitol, 2004. 137(1): p. 161-8. 
74. Friesen, J. and K. Matuschewski, Comparative efficacy of pre-erythrocytic whole 
organism vaccine strategies against the malaria parasite. Vaccine, 2011. 29(40): p. 
7002-8. 
75. Speake, C., et al., Identification of Novel Pre-Erythrocytic Malaria Antigen Candidates 
for Combination Vaccines with Circumsporozoite Protein. PLoS One, 2016. 11(7): p. 
e0159449. 
76. Guerin-Marchand, C., et al., A liver-stage-specific antigen of Plasmodium falciparum 
characterized by gene cloning. Nature, 1987. 329(6135): p. 164-7. 
 
260 
 
 
 
CHAPTER 7 
 
Discussion  
261 
 
DISCUSSION 
 
SUMMARY OF FINDINGS 
The data presented in this thesis has furthered our understanding of the CD8+ T cell 
immune responses that are induced against the pre-erythrocytic stages of malaria, 
unveiling antigen-specific and protective responses, with particular focus on antigens 
expressed in the EEF. I have shown that an EEF vacuolar membrane protein, UIS4, can 
protect mice from challenge, following vaccination, despite the low magnitude of antigen-
specific CD8+ T cell responses induced following RAS immunisation (Chapter 2). The 
protection induced is comparable to that targeted against the major sporozoite surface 
protein, CSP, which has been extensively investigated over the years, in part due to its 
high immunogenicity. This shows that poorly immunogenic antigens do not necessarily 
make poor vaccine targets. Additionally, I showed that attenuation of sporozoites using 
radiation or azithromycin drug prophylaxis did not affect CD8+ T cell responses seen 
against UIS4 (Chapter 3). Extending the expression of UIS4 prior to arrest did not 
enhance antigen-specific CD8+ T cell responses. To further probe responses to EEF 
antigens, I showed that mid-late expressed EEF antigens could offer some protection, 
following vaccination, despite no observable antigen expression in the first 12 hours of 
EEF development, and induction of low CD8+ T cell responses following sporozoite 
immunisation (Chapter 4). This, in conjunction with Chapter 2, highlights the potentiality 
for use of EEF antigens in pre-erythrocytic vaccines, where, if a large proportion of 
antigen-specific CD8+ T cells could be induced, then a degree of protection can be 
achieved. Furthermore, with reference to the protection offered by CSP, I have 
demonstrated that a single CD8+ T cell epitope of CSP is crucial for this protection 
(Chapter 5). Despite this, in the absence of this epitope, multiple immunisations with a 
parasite lacking this CSP epitope can provide complete sterile protection indicating that 
other antigens contribute to the induction of immune responses. From this, I have 
established novel pre-erythrocytic antigens that induce CD8+ T cell responses following 
sporozoite immunisation (Chapter 5 and 6). They were discovered in the context of two 
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different mouse models, BALB/c and C57BL/6, which, can or cannot, also present the 
immunodominant epitope of CSP respectively. Using bioinformatics analysis to predict 
epitopes, I have identified a novel CD8+ T cell epitope presented in BALB/c mice 
(Chapter 5) and nine CD8+ T cell epitopes presented in C57BL/6 mice (Chapter 6). 
These will be useful in providing readouts of immunisation status in addition to the small 
number of currently known CD8+ T cell epitopes, with a forward view to assessing their 
role in protection.  
 
POTENTIAL FUTURE RESEARCH 
Further probing of CD8+ T cell responses to EEF antigens  
Shifts in Plasmodium gene expression lead to a distinct repertoire of antigens being 
expressed only during intra-hepatocyte development1. Infected hepatocytes have also 
been shown to be eliminated in a cognate manner; only parasite specific peptides 
presented on infected hepatocytes by host MHC molecules2-4 will be destroyed by the 
corresponding CD8+ T cells. In the context of UIS4, LISP1 and LISP2, I have shown that 
CD8+ T cell responses to EEF antigens following sporozoite immunisation are poor. The 
identification of EEF targets has been slow, possibly due to their low immunogenicity. 
However, we provide a proof of principle that despite their poor CD8+ T cell 
immunogenicity, EEF antigens can elicit protection, following vaccination and the 
induction of a large population of antigen-specific CD8+ T cells. This suggests that the 
induction of protective responses against EEF antigens is no different to that against 
CSP- a ‘numbers game’. It has been shown that induction of a memory anti-CSP CD8+ 
T cell response, above a threshold of 1% of total peripheral blood lymphocytes, provides 
long-term protection to mice against sporozoite challenge5. The reason for the poor 
immunogenicity of EEF antigens may revolve around the fact that EEF antigens are only 
presented on hepatocytes, which have been shown to be poor at priming T cell 
responses in the tolerogenic liver environment6, 7. In contrast, sporozoite surface antigen 
CSP is presented on hepatocytes as well on dendritic cells in the skin draining lymph 
nodes, an immune site responsible for CD8+ T cell priming2. 
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Nonetheless, as effective presentation can occur, what remains to be determined is the 
mechanism for EEF antigen processing and presentation on MHC class I molecules. 
Cockburn et al showed that peptides from CSP are presented in different pathways 
depending on whether presentation occurs on dendritic cells or hepatocytes8. Cockburn 
et al also showed that presentation on hepatocytes occurs with CSP epitopes bring 
loaded onto MHC molecules in an endosomal independent, TAP dependent manner; 
which indicates that the protein must have made it to the hepatocyte cytosol and been 
processed by the proteasome8. In addition, parasites expressing ovalbumin, containing 
a PEXEL motif and localising at the PVM, has been shown to be presented better than 
cytosolic residing ovalbumin indicating a link between export signals and presentation9. 
The presentation of endogenous EEF proteins, associated and not associated with the 
PVM remains to be fully determined, including the mechanisms used for protein 
translocation across the PVM into the cytosol. By resolving these mechanisms, we will 
have a better understanding of the processes involved in the presentation of different 
parasite antigens, which may uncover subsets of antigens that are preferentially 
presented but, given the tolerogenic nature of the liver, manage to subvert cellular 
immune responses. If this was the case, as shown in Chapters 2 and 4, then large 
population of antigen-specific CD8+ T cells could be induced by vaccination to eliminate 
developing EEFs, with a combination of antigens likely to be necessary to achieve sterile 
protection. It is important to remember also that the development of human Plasmodium 
in the liver is longer than that of rodent Plasmodium and so the induction and contribution 
of different immune responses will likely be different. In addition, the presentation of 
proteins in humans will vary depending on MHC allele genotype, which will have an 
obvious effect on vaccine efficacy. 
 
Research into the mode of parasite killing in the liver has also gained momentum, with 
the rise of intravital imaging and more advanced microscopy techniques. Several groups 
have visualised CD8+ T cells clustering around infected hepatocytes3, 10, with IFN- 
generally considered the central mediator of protection11 though other effector molecules 
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may act in concert12, 13. With respect to the results I have presented in Chapter 4, one 
consideration that remains to be resolved is that following vaccination, upon challenge, 
LISP1 and LISP2 induce a minimal reduction in parasite liver load, yet half of vaccinated 
mice in a parallel experiment go on to develop sterile protection. As discussed in the 
chapter, this suggests that the critical window of killing may occur in the final hours of 
EEF development, possibly because of the delayed activation of memory antigen-
specific CD8+ T cells. The delay in parasitaemia in those mice that are not protected 
also suggests that there is considerable killing of EEFs, but there may just not be enough 
time to kill all the infected hepatocytes. This may be overcome by inducing even greater 
numbers of antigen-specific CD8+ T cells. Nonetheless, visualisation of EEF killing inside 
the livers of sporozoite challenged vaccinated mice, at several time points up to 
merozoite release, would be pertinent to fully determine the time at which antigen 
presentation on infected hepatocytes must occur for sufficient memory CD8+ T cells to 
be activated and protect. The later protein expression is turned on in the parasite, the 
later the protein could possibly be processed in the hepatocyte cytosol, leading to later 
MHC-peptide presentation and signalling to CD8+ T cells to mount a liver-wide response. 
In addition, it would be useful to generate a parasite from the same parent line as 
LISP1SIINFEKL and LISP2SIINFEKL; which expresses mCherry and SIINFEKL tagged UIS4 
for better comparison of the degree of killing targeted against UIS4, LISP1 and LISP2 as 
UIS4SIINFEKL described in Chapter 2 does not express GFP. By intravital imaging, targeted 
EEFs were shown to exhibit blebbing and a loss of GFP signal10 with parasite death 
occurring after around four hours of interaction with CD8+ T cells10. Generating a timeline 
of EEF killing in response to early and later expressed EEF antigens could probably also 
be determined from stained liver slices from challenged vaccinated mice. However, using 
intravital imaging would reduce the number of mice required, whilst providing 
opportunities for more advanced in vivo analysis of Plasmodium infection.  
 
Intravital microscopy has not been completely developed in humans yet14, but if possible, 
ethical considerations for assessing EEF development in human challenge studies would 
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still need to be resolved. Yet developments in chimeric mouse models have started to 
allow the determination of the immune responses that occur during P. falciparum 
infection15. In terms of assessing the immune responses to P. falciparum in the liver, 
chimeric mice engrafted with human hepatocytes16, 17 or hepatocytes and erythrocytes18 
have been shown to allow complete P. falciparum EEF development. Chimeric mouse 
models, which have an engrafted human immune system19, 20, have allowed 
physiologically relevant antibody and CD8+ T cell responses to P. falciparum CSP to be 
determined when mice were infected with rodent P. berghei which had its orthologous 
CSP partially or fully replaced with P. falciparum CSP20, 21. Whilst a humanised mouse 
model which contains both human immune system and liver tissues exists22, the 
contribution of mouse immune cells of the myeloid lineage cannot be discounted as they 
are not fully replaced in this model15. Alas, with contribution from hepatic dendritic cells23, 
24 and type I IFN effects on myeloid cells25 during Plasmodium infection, a single one-
stop-shop chimeric mouse that can fully capture representative human immune 
responses to P. falciparum in the liver has yet to be developed but would certainly be of 
benefit. 
 
Further CD8+ T cell epitope discovery 
The identification of novel CD8+ T cell epitopes seems to be skewed by host MHC class 
I (MHC-I) restriction. Two bioinformatics analyses were performed, predicting P. berghei 
peptides presented in two different mouse strains. The addendum of Chapter 5 predicted 
and assayed peptides with H-2-d restriction as encoded by BALB/c mice, while Chapter 
6 predicted and assessed peptides with H-2-b restriction as encoded in C57BL/6 mice. 
Only one novel epitope was discovered with an MHC-I H-2-d restriction, while nine novel 
epitopes were discovered with an MHC-I H-2-b restriction. While the size of the datasets 
varied in terms of peptides assayed experimentally (144 vs 586), the profile of responses 
induced by P. berghei epitopes with a H-2-d restriction compared to MHC-I H-2-b 
restriction was striking. In BALB/c mice, there is a large response to the immunodominant 
epitope of CSP, with only a few, much weaker responses to other antigens seen. In 
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C57BL/6 mice, CD8+ T cell responses to the immunodominant epitope of CSP cannot 
be determined due to its H-2-b genotype. In contrast, CD8+ T cell responses observed 
in C57BL/6 do not exhibit such an obvious immunodominance against one epitope. It 
would be interesting to know if this immunodominance is purely directed by the MHC-I 
molecules BALB/c express or whether host genetics play a role in anti-Plasmodium 
CD8+ T cell responses. To test this, responses in mice with a C57BL/6 background but 
H-2-d haplotype could be assessed. If a difference in the protection mediated by 
SYIPSAEKI-specific CD8+ T cells is observed, then this suggests that host factors 
besides MHC haplotype affect immune responses against Plasmodium infection. It has 
been noted that different mice exhibit different protective immune responses following 
sporozoite immunisation12 and that the effector mechanisms employed by memory CD8+ 
T cells differs depending on the parasite species and background strains of the 
immunised mice13. In addition, host genetic factors relating to susceptibility to liver 
infection, have been characterised though quantitative trait loci studies using different 
mouse strains26, 27. Host cell factors such as heme oxygenase28, 29, SR-BI28, 30 and CD8131 
have also been proposed to be involved in resistance of mice to Plasmodium liver 
infection. Nonetheless more research is required to deconvolute how host genetic factors 
contribute to resistance and immunity to Plasmodium infection32. 
 
With respect to identifying more EEF-specific CD8+ T cell responses, moving forward an 
alternative approach may be required. In principle we have shown that with UIS4, LISP1 
and LISP2, poorly immunogenic antigens can offer protective immunity if the antigen is 
presented and the cognate CD8 T cell response is large enough. However, not using 
immunogenicity as an indicator for protective capability does not make it easier to identify 
potentially protective EEF antigens. In fact, our analysis of the protein features contained 
in the derivative proteins that contain the most highly immunogenic peptides did not 
return any striking results (Chapter 6). Apart from an enrichment for signal peptide 
regions and transmembrane structures, suggesting secreted and surface bound proteins 
are more immunogenic, we could not deduce any significant characteristic that made a 
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pre-erythrocytic Plasmodium protein particularly good at expanding antigen-specific 
CD8+ T cells following processing and presentation. 
 
As we were concerned with identifying novel CD8+ T cell epitopes that could be used as 
an indicator of immunised state with the forward view to identifying systemic correlates 
of protection in murine and human infections, we focused on identifying those antigens 
and epitopes that induced large expansions of CD8+ T cells. However, it has been shown 
that liver tissue-resident CD8+ T cells (TRM) are crucial cells for mediating protection from 
sporozoite challenge33-37. Whilst, screening of peptides by ex vivo restimulation of liver 
infiltrating lymphocytes would have reduced the number of peptides that could have been 
tested, it may have identified prominent antigen-specific CD8+ T cell populations in the 
liver. An alternative approach to CD8+ T cell epitope discovery thus could involve the 
isolation of CD8+ T cells from livers of immunised mice, particularly those that exhibit 
protection from sporozoite challenge. Dissociation of peptides from MHC molecules 
presented on CD8+ TRM cells may shed some light on those antigens that can induce 
effective intra-hepatic CD8+ T cell responses. Generation of transgenic parasites, 
including chimeric rodent parasites expressing human Plasmodium proteins38 for testing 
in human immune system engrafted mice as seen already20, 21, would allow the degree 
of protection that these proteins can induce to be assessed. This information would be 
useful in informing subunit vaccine design to develop vaccines that can improve these 
populations of CD8+ T cells.   
 
 
IMPACT ON ERADICATION OF MALARIA 
The research I have presented here has clear implications for the development of next 
generation malaria vaccines. The majority of P. falciparum subunit malaria vaccines, that 
are currently in clinical trials target sporozoite antigens39 with only one vaccine targeting 
EEF antigens, liver stage antigen 1(LSA1) and liver stage associated protein 2 
(LSAP2)40. This may be due to the relative ease of characterising responses to 
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sporozoite antigens, as they are not restricted to presentation on hepatocytes, which we 
know exhibit poor T cell priming, likely not aided by the tolerogenic nature of the liver6, 7. 
In addition, the amount of transcriptomic and proteomic data available detailing the 
genetic expression repertoire during EEF development is poor compared to other stages 
of the life cycle1, 41-43. Thus, this has resulted in a distinct lack of data detailing antigen-
specific immune responses targeting the EEF compared to those targeting the sporozoite 
or blood stages. However, data is starting to accumulate to determine expression 
differences between replicating EEFs and dormant hypnozoites in P vivax and other 
relapsing malarias44-47, with the dawn of in vivo and in vitro systems48 which may herald 
the onset of more human Plasmodium EEF expression datasets. Yet, here I have 
presented data that indicates that EEF antigens can offer protection against the pre-
erythrocytic stages of malaria and that poor immunogenicity does not necessarily negate 
an antigen from being a poor vaccine target.   
 
Vaccines that induce antigen-specific antibodies have been shown to protect individuals 
against many diseases49 and the vast majority of vaccines currently licensed, mediate 
protection by inducing high titres of pathogen-specific antibody titres50. More recently, it 
has now been shown that memory CD8+ T cells above a certain threshold can protect 
against the pre-erythrocytic stages of malaria5, 51. Research has now started to focus on 
the development of vaccines that induce strong cellular immune responses52 as the 
induction of effective memory CD8+ T cell responses will be a crucial arm in next 
generation malaria vaccines. The notion of hepatic CD8+ TRM cells and protection is also 
really gaining traction with many papers released since the original indication showing 
that they are crucial for protection against sporozoite challenge in animal models33-37. 
While not investigated here, memory CD8+ T cell responses and protection against all 
new antigens should be considered in the context of these cells53. In addition, 
development of vaccines that induce hepatic CD8+ TRM responses by liver centric 
vaccination regime33, 37 are a very exciting, promising concept in the onward movement 
to generating a truly efficacious human malaria vaccine. 
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APPENDIX 1 
 
Inventory of novel H-2-b restricted CD8+ T cell epitopes and 
supplementary information 
VNYSFLYL PBANKA_1429200 conserved Plasmodium protein, unknown function 0.3725 0.795625
NCYDFNNI PBANKA_0714500 conserved Plasmodium protein, unknown function 0.67625
SALLNVDNL PBANKA_1349800 thrombospondin-related anonymous protein 0.57436
IITDFENL PBANKA_1137000 bergheilysin 0.370833333
VNYSFLYLF PBANKA_1429200 conserved Plasmodium protein, unknown function 0.212555556
1 FSIFNEFEI 0.046333333 0.16025
EIYIFTNI PBANKA_0416600 replication protein A1, small fragment 0.157
2 YSLANMIDTI 0.0625 0.140625
3 ISPDFYNNL 0.053 0.138125
SQLLNAKYL PBANKA_0819000 glideosome-associated protein 50, putative 0.121923077
4 ITFHWYPSYL 0.053 0.111625
5 YAYYNTYVL 0.0655 0.1085
6 VNYDFTYINLL 0.089 0.098375
7 YALKNVSYL 0.0805 0.0925
8 YSFLNVDNI 0.1 0.090205
9 TSMSNNIYI 0.1255 0.067375
10 FALNNFNYF 0.10525 0.06625
11 FAIYNLNNL 0.06875 0.066125
12 FSISNMDDF 0.14 0.060625
13 FSLTNNEVFL 0.11275 0.0475
14 STVSNYDVI 0.06425 0.04475
15 YALSNISAI 0.10275 0.044
16 VSYYFEYL 0.037 0.0425
17 YIIMNWTTI 0.0415 0.0415
18 DNYNFVGL 0.017 0.03975
19 VAYAFEII 0.022 0.03775
20 MAYVNSKYI 0.041 0.03307125
21 NSINNLDFI 0.10925 0.0325
22 YMHTNIYTI 0.13675 0.032
23 ANYFHFFQNYL 0.049 0.03183125
24 SNYSYIYFVFL 0.039 0.03025
25 IVYVFLHI 0.024 0.029
26 FAASNFNLDLL 0.1015 0.0275
27 VSFNYNNL 0.02 0.0270025
28 ISYSYYYL 0.021165 0.026
29 FAIYNLNNLSM 0.0735 0.0238775
30 RSIINNVAL 0.096 0.02275
31 IILYFFQL 0.024 0.0225
32 VAYKYYTYL 0.047 0.022
33 VSYDYYLAL 0.029 0.021805
34 MSFMNLKYLLL 0.03275 0.02075
35 SSYIFSIL 0.00952 0.0205
36 FIYFKYNYL 0.0405 0.01975
37 QNYYSFTNL 0.015 0.01975
Novel 
Peptide 
number
High purity 
restimulation % 
IFN-g+ CD11a+ / 
total CD8+ T 
cells
Peptide sequence
Novel peptides 
carried forward 
from batch 
purity -> high 
purity 
(black=top43, 
grey=other52)
Published 
control 
peptides
Top 
NetMHCpan 
peptides 
<22nM and 
<0.05 Rank %
NetMHCpan 
other 
peptides 
22.381-
388.44nM 
but always 
%Rank of 0.5 
or below 
Top 
NetMHCcons 
NC and C2
Top 
NetMHCcons 
peptides 
<22nM and 
<0.05 Rank %
NetMHCcons 
other peptides 
23.05nM-
531.38nM but 
always %Rank 
of 0.5 or below
Gene ID Protein
Batch purity 
restimulation 
% IFN-g+ 
CD11a+ / total 
CD8+ T cells
VNYSFLYL
NCYDFNNI
SALLNVDNL
IITDFENL
VNYSFLYLF
1 FSIFNEFEI
EIYIFTNI
2 YSLANMIDTI
3 ISPDFYNNL
SQLLNAKYL
4 ITFHWYPSYL
5 YAYYNTYVL
6 VNYDFTYINLL
7 YALKNVSYL
8 YSFLNVDNI
9 TSMSNNIYI
10 FALNNFNYF
11 FAIYNLNNL
12 FSISNMDDF
13 FSLTNNEVFL
14 STVSNYDVI
15 YALSNISAI
16 VSYYFEYL
17 YIIMNWTTI
18 DNYNFVGL
19 VAYAFEII
20 MAYVNSKYI
21 NSINNLDFI
22 YMHTNIYTI
23 ANYFHFFQNYL
24 SNYSYIYFVFL
25 IVYVFLHI
26 FAASNFNLDLL
27 VSFNYNNL
28 ISYSYYYL
29 FAIYNLNNLSM
30 RSIINNVAL
31 IILYFFQL
32 VAYKYYTYL
33 VSYDYYLAL
34 MSFMNLKYLLL
35 SSYIFSIL
36 FIYFKYNYL
37 QNYYSFTNL
Novel 
Peptide 
number
Peptide sequence
+/- +/- +/- +/- +/-
no 0 583 8 317 54.37393 Kb 0.854 4.88 0.01 Kb 0.9211 2.3472 0.0044 - + + + +
no 1 745 8 396 53.15436 Kb 0.238 3786.7 9 Kb 0.3864 764.103 1.4628 - - - - -
yes 1 606 9 129 21.28713 Db 0.882 3.58 0.01 Db 0.8572 4.6876 0.0043 - + + + +
no 0 1149 8 591 51.43603 Kb 0.531 159.89 0.8 Kb 0.5658 109.749 0.2824 + + + + -
no 0 583 9 317 54.37393 Kb 0.746 15.53 0.03 Kb 0.7121 22.5433 0.0548 - + + + +
no 3 4291 9 2850 66.41808 Db 0.821 6.97 0.01 Db 0.8256 6.602 0.0053 - - - - -
no 0 486 8 198 40.74074 Kb 0.568 107.14 0.4 Kb 0.6389 49.7716 0.1214 + + + + +
no 0 348 10 210 60.34483 Db 0.828 6.47 0.01 Db 0.8284 6.4043 0.0052 - - - - -
yes 0 1406 9 1121 79.72973 Kb 0.766 12.51 0.03 Kb 0.8378 5.7846 0.009 + - + - -
yes 2 395 9 39 9.873418 Db 0.704 24.47 0.05 Db 0.6878 29.3083 0.0094 + + + + +
yes 2 1349 10 627 46.47887 Kb 0.711 22.93 0.05 Kb 0.7652 12.6835 0.0256 + - - - +
yes 2 246 9 233 94.71545 Db 0.849 5.15 0.01 Db 0.841 5.586 0.0048 - - - - -
no 11 500 11 455 91 Kb 0.654 42.25 0.15 Kb 0.6943 27.3265 0.0695 + + + - +
no 0 1524 9 795 52.16535 Db 0.913 2.58 0.01 Db 0.8942 3.1415 0.0032 - - - - -
no 4 3245 9 448 13.80586 Db 0.871 4.06 0.01 Db 0.846 5.2896 0.0046 - - - - +
yes 0 721 9 65 9.015257 Db 0.815 7.4 0.01 Db 0.8033 8.3973 0.0059 - - + + -
no 0 656 9 56 8.536585 Db 0.77 12.04 0.03 Db 0.7757 11.3217 0.0068 - + - - +
yes 2 1349 9 1037 76.87176 Db 0.807 8.03 0.01 Db 0.8065 8.1158 0.0058 + - - - +
no 0 971 9 815 83.93409 Db 0.774 11.6 0.03 Db 0.6421 48.0466 0.013 - + - - +
no 8 4154 10 3491 84.03948 Db 0.784 10.41 0.03 Db 0.6982 26.1897 0.0091 + - - - +
no 0 950 9 923 97.15789 Db 0.83 6.29 0.01 Db 0.7974 8.9549 0.0061 + + - - +
no 0 441 9 184 41.72336 Db 0.914 2.54 0.01 Db 0.8694 4.1067 0.0039 + - - - -
yes 11 1245 8 1199 96.30522 Kb 0.852 4.96 0.01 Kb 0.9226 2.3096 0.0043 - - - - +
no 6 2724 9 882 32.37885 Db 0.857 4.72 0.01 Db 0.8024 8.4835 0.006 - - - - -
no 0 192 8 50 26.04167 Kb 0.624 58.45 0.2 Kb 0.5833 90.7555 0.2347 + + + - +
no 0 194 8 82 42.26804 Kb 0.668 36.12 0.1 Kb 0.7365 17.3072 0.0381 + + + + +
yes 0 1406 9 1010 71.83499 Db 0.714 22.19 0.05 Db 0.7217 20.3183 0.0084 + - + - -
no 1 865 9 676 78.15029 Db 0.869 4.13 0.01 Db 0.8411 5.5782 0.0048 + - - - -
yes 0 721 9 295 40.9154 Db 0.875 3.85 0.01 Db 0.7794 10.8791 0.0067 - - + + -
no 4 4204 11 3921 93.26832 Kb 0.73 18.67 0.05 Kb 0.7097 23.1316 0.0563 - + - - +
no 0 147 11 33 22.44898 Kb 0.677 32.77 0.1 Kb 0.7119 22.5826 0.0549 - - - - -
yes 1 2096 8 11 0.524809 Kb 0.752 14.55 0.03 Kb 0.8092 7.8778 0.0122 - - - - +
no 0 5176 11 3749 72.43045 Db 0.656 41.12 0.07 Db 0.5839 90.2414 0.0265 + + - - +
no 0 2966 8 422 14.22792 Kb 0.826 6.57 0.01 Kb 0.9185 2.4149 0.0045 - - - - +
no 0 1203 8 746 62.01164 Kb 0.875 3.85 0.01 Kb 0.937 1.9772 0.0035 - - - - -
yes 2 1349 11 1037 76.87176 Db 0.733 17.97 0.05 Db 0.6473 45.4509 0.0124 + - - - +
no 0 993 9 865 87.10977 Db 0.772 11.72 0.03 Db 0.7356 17.4782 0.008 + + + + -
yes 0 1796 8 1788 99.55457 Kb 0.726 19.39 0.05 Kb 0.7591 13.5475 0.0279 - + - - +
no 0 1285 9 407 31.67315 Kb 0.872 3.99 0.01 Kb 0.9314 2.0996 0.0038 - - - - -
no 0 486 9 475 97.73663 Kb 0.863 4.43 0.01 Kb 0.919 2.4011 0.0045 - - - - -
yes 0 3254 11 1671 51.35218 Kb 0.625 57.51 0.2 Kb 0.5717 102.973 0.2662 + - - - -
no 9 736 8 464 63.04348 Kb 0.835 5.99 0.01 Kb 0.9057 2.7727 0.0052 - + + - +
yes 1 1096 9 494 45.07299 Kb 0.785 10.24 0.01 Kb 0.7347 17.6521 0.0389 - - - - -
yes 0 1864 9 419 22.47854 Kb 0.723 20.03 0.05 Kb 0.7922 9.4727 0.0163 - + + + +
MHC allele 
restriction
1-
log50k
nM
%Rank 
score
MHC allele 
restriction
1-
log50k
nM
%Rank 
score
orthologs of P. yoelii
NetMHCcons 1.1 data NetMHCpan 4.0 data
No. of 
transmembrane 
domains 
predicted
Protein 
length 
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VNYSFLYL
NCYDFNNI
SALLNVDNL
IITDFENL
VNYSFLYLF
1 FSIFNEFEI
EIYIFTNI
2 YSLANMIDTI
3 ISPDFYNNL
SQLLNAKYL
4 ITFHWYPSYL
5 YAYYNTYVL
6 VNYDFTYINLL
7 YALKNVSYL
8 YSFLNVDNI
9 TSMSNNIYI
10 FALNNFNYF
11 FAIYNLNNL
12 FSISNMDDF
13 FSLTNNEVFL
14 STVSNYDVI
15 YALSNISAI
16 VSYYFEYL
17 YIIMNWTTI
18 DNYNFVGL
19 VAYAFEII
20 MAYVNSKYI
21 NSINNLDFI
22 YMHTNIYTI
23 ANYFHFFQNYL
24 SNYSYIYFVFL
25 IVYVFLHI
26 FAASNFNLDLL
27 VSFNYNNL
28 ISYSYYYL
29 FAIYNLNNLSM
30 RSIINNVAL
31 IILYFFQL
32 VAYKYYTYL
33 VSYDYYLAL
34 MSFMNLKYLLL
35 SSYIFSIL
36 FIYFKYNYL
37 QNYYSFTNL
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- - - - - -
+ - - + - -
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- - - - - -
- - - - - -
- + - - - -
- - - - + -
- + - - - -
- - - - - -
- - - - + +
+ - - - - -
- - - - - -
- + - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
+ - + - - -
- - - - - -
- + - - - -
- - - - - -
- - - - - -
- - - - + +
- + - - - -
- + - - - +
- - - - - -
- - - - - -
- - - - - -
- - - - - +
- - - - - -
- - - - - -
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Gene ID Protein
Batch purity 
restimulation 
% IFN-g+ 
CD11a+ / total 
CD8+ T cells
38 VNYFLHSGHL 0.033 0.01957
39 ASFHNQTYI 0.1035 0.019
40 VSYFYFLDL 0.0825 0.0183075
41 TNYAHYLSI 0.025 0.01769
42 LSLVNETTI 0.076666667 0.0173725
43 FKNMNILEL 0.026 0.01725
44 YALMNDNNSVL 0.1525 0.017
LSGRYNDL PBANKA_1337300 conserved Plasmodium protein, unknown function 0.016828
45 KSMSNGSFL 0.0675 0.0165
46 LSYNNTLDYF 0.014 0.0159225
47 YAIKKKDEI 0.00715 0.01578
48 ICFEHYQLF 0.065 0.0155
49 SSISQNEIVI 0.00978 0.0155
50 IVYRFRKL 0.01 0.01525
51 FAINNNEHL 0.151 0.0151775
52 FSSCNDTLEL 0.012 0.0149575
53 ISFAGFNAL 0.036 0.01481
54 ASLENVETI 0.13525 0.0146675
55 HAHANYAFL 0.0745 0.01425
56 KTMNFYGM 0.015 0.01425
57 NSVNNINYI 0.021 0.0142325
YYYDYDKI PBANKA_0521700 transcription factor with AP2 domain(s), putative 0.014082
58 VCIYYFDLL 0.019 0.0139175
WGDEFEKL PBANKA_0611600 ribonucleoside-diphosphate reductase large subunit, putative 0.013147
59 KNYFHFFNM 0.01879 0.01308
60 YSLNNTHVL 0.1035 0.013
61 STFLYYLL 0.02 0.01279
62 YAYRNGLYF 0.1085 0.0127725
63 RTFYYFHGLL 0.031 0.0127225
64 NCYIYNYV 0.035 0.01256
65 YALRNFTLF 0.14425 0.01256
66 FSLINHSVI 0.019 0.01212
67 IAVLNSLYL 0.09275 0.0117975
68 ITYLNSINI 0.00733 0.0117675
69 AAINNIEFV 0.1095 0.0115325
70 AAVNNLFTI 0.081 0.01148
LLPHFSIL PBANKA_0316000 replication factor C subunit 1, putative 0.011395
71 VGMRHLNL 0.016 0.0111075
72 VSYFYFLDLL 0.0505 0.0110425
73 YAVRNTRYL 0.019 0.01075
74 YALFNGNLI 0.12825 0.010235
75 YNMFYYTIL 0.02 0.0097425
76 STYSFMSL 0.0316 0.00962
77 YAIGNNDIAL 0.1495 0.00947
VNYSFLYL
Novel 
Peptide 
number
Peptide sequence
38 FLHSGHL
39 ASFHNQTYI
40 VSYFYFLDL
41 TNYAHYLSI
42 LSLVNETTI
43 FKNMNILEL
44 YALMNDNNSVL
LSGRYNDL
45 KSMSNGSFL
46 LSYNNTLDYF
47 YAIKKKDEI
48 ICFEHYQLF
49 SSISQNEIVI
50 IVYRFRKL
51 FAINNNEHL
52 FSSCNDTLEL
53 ISFAGFNAL
54 ASLENVETI
55 HAHANYAFL
56 KTMNFYGM
57 NSVNNINYI
YYYDYDKI
58 VCIYYFDLL
WGDEFEKL
59 KNYFHFFNM
60 YSLNNTHVL
61 STFLYYLL
62 YAYRNGLYF
63 RTFYYFHGLL
64 NCYIYNYV
65 YALRNFTLF
66 FSLINHSVI
67 IAVLNSLYL
68 ITYLNSINI
69 AAINNIEFV
70 AAVNNLFTI
LLPHFSIL
71 VGMRHLNL
72 VSYFYFLDLL
73 YAVRNTRYL
74 YALFNGNLI
75 YNMFYYTIL
76 STYSFMSL
77 YAIGNNDIAL
+/- +/- +/- +/- +/-
MHC allele 
restriction
1-
log50k
nM
%Rank 
score
MHC allele 
restriction
1-
log50k
nM
%Rank 
score
orthologs of P. yoelii
NetMHCcons 1.1 data NetMHCpan 4.0 data
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Expression data
orthologs of P. falciparum
Percentile 
of protein
Signal 
peptide 
predicted 
yes 0 668 10 369 55.23952 Kb 0.707 23.81 0.05 Kb 0.7319 18.1791 0.0404 + + + + +
yes 0 2997 9 1060 35.3687 Db 0.824 6.71 0.01 Db 0.7936 9.3281 0.0062 + + - - +
no 2 7480 9 2002 26.76471 Kb 0.818 7.2 0.01 Kb 0.8928 3.1888 0.0059 - + - - +
yes 2 1671 9 315 18.85099 Kb 0.716 21.6 0.05 Kb 0.8283 6.41 0.0095 - - - - +
no 0 1757 9 1720 97.89414 Db 0.855 4.83 0.01 Db 0.7878 9.9291 0.0064 + - - - -
no 0 255 9 70 27.45098 Db 0.429 482.07 0.4 Db 0.3628 987.103 0.2364 - + - - -
no 2 2599 11 1783 68.60331 Db 0.657 40.9 0.07 Db 0.7014 25.311 0.009 - - - - +
yes 1 329 8 118 35.86626 Kb 0.333 1369.5 4 Kb 0.3226 1524.09 2.5409 - + - - -
no 0 5309 9 4271 80.4483 Db 0.782 10.52 0.03 Db 0.7949 9.1969 0.0062 + + - - +
no 0 174 10 149 85.63218 Db 0.425 500.68 0.4 Db 0.3977 676.649 0.1709 - + - - -
no 0 194 9 177 91.23711 Db 0.488 255.99 0.25 Db 0.5549 123.457 0.035 + + + + +
no 0 3183 9 1805 56.70751 Kb 0.639 49.43 0.17 Kb 0.6407 48.7704 0.1196 + + - - +
no 0 104 10 12 11.53846 Db 0.495 234.76 0.2 Db 0.5955 79.5671 0.0234 + + + + +
no 9 543 8 175 32.22836 Kb 0.83 6.33 0.01 Kb 0.898 3.0161 0.0056 - + - - +
no 0 1613 9 434 26.90639 Db 0.807 8.07 0.01 Db 0.8087 7.9231 0.0058 + - - - -
no 0 130 10 11 8.461538 Db 0.424 508.87 0.4 Db 0.4073 609.8 0.1534 + + + + +
yes 0 473 9 254 53.69979 Kb 0.695 27.26 0.07 Kb 0.7839 10.3658 0.0193 + + - - +
yes 0 554 9 195 35.19856 Db 0.889 3.32 0.01 Db 0.8595 4.5711 0.0042 - - - - -
yes 0 1303 9 156 11.97237 Db 0.845 5.38 0.01 Db 0.7825 10.525 0.0066 + + - - +
no 0 288 8 71 24.65278 Kb 0.614 65.13 0.25 Kb 0.7061 24.0399 0.0586 + + + + +
yes 4 1785 9 687 38.48739 Db 0.722 20.24 0.05 Db 0.7233 19.9651 0.0083 - - - - +
no 0 2775 8 1956 70.48649 Kb 0.264 2858.2 7 Kb 0.3161 1634.72 2.7053 - + + + +
no 3 4291 9 1096 25.54183 Kb 0.603 73.76 0.3 Kb 0.6025 73.7649 0.187 - - - - -
no 0 847 8 401 47.34357 Kb 0.145 10471 32 Kb 0.1564 9206.28 12.8923 + - - - +
no 2 1585 9 935 58.99054 Kb 0.781 10.69 0.01 Kb 0.8497 5.0865 0.0083 - - - - -
no 0 2225 9 1829 82.20225 Db 0.831 6.26 0.01 Db 0.8156 7.3513 0.0056 - + - - +
no 2 957 8 549 57.36677 Kb 0.83 6.33 0.01 Kb 0.8686 4.1441 0.0073 - - - - -
yes 2 991 9 171 17.2553 Db 0.744 16.04 0.05 Db 0.7612 13.243 0.0072 + - + + -
yes 2 1349 10 832 61.67532 Kb 0.676 33.12 0.1 Kb 0.7185 21.0266 0.0507 + - - - +
no 2 1530 8 115 7.51634 Kb 0.311 1718.9 5 Kb 0.3701 911.712 1.6804 - + - - -
no 11 1935 9 1497 77.36434 Db 0.842 5.53 0.01 Db 0.7852 10.2158 0.0065 + - - - -
no 0 7263 9 3236 44.55459 Db 0.879 3.68 0.01 Db 0.8487 5.1418 0.0046 - - - - +
no 0 4287 9 3519 82.08537 Db 0.808 7.94 0.01 Db 0.7972 8.9735 0.0061 - - + - -
no 0 261 9 229 87.73946 Db 0.477 288.34 0.25 Db 0.409 598.77 0.1503 + - - - -
no 0 1149 9 479 41.68842 Db 0.867 4.24 0.01 Db 0.8333 6.0707 0.005 + + + + -
no 12 491 9 88 17.92261 Db 0.85 5.07 0.01 Db 0.8294 6.335 0.0051 + + + - +
no 0 861 8 650 75.49361 Kb 0.386 771.82 3 Kb 0.4523 374.756 0.8159 - + - - +
no 0 148 8 55 37.16216 Kb 0.684 30.38 0.07 Kb 0.7246 19.6741 0.0461 + + + + +
no 2 7480 10 2002 26.76471 Kb 0.76 13.35 0.03 Kb 0.786 10.1258 0.0185 - + - - +
yes 1 2096 9 1326 63.26336 Db 0.839 5.71 0.01 Db 0.8206 6.9694 0.0054 - - - - +
yes 0 604 9 100 16.55629 Db 0.85 5.07 0.01 Db 0.8469 5.2433 0.0046 + + - - +
yes 1 2096 9 898 42.84351 Kb 0.721 20.47 0.05 Kb 0.7958 9.1127 0.0151 - - - - +
yes 2 175 8 91 52 Kb 0.855 4.8 0.01 Kb 0.9077 2.7136 0.0051 - - - - +
no 0 8895 10 448 5.036537 Db 0.746 15.61 0.05 Db 0.6766 33.0909 0.0098 - + - - +
VNYSFLYL
Novel 
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number
Peptide sequence
38 FLHSGHL
39 ASFHNQTYI
40 VSYFYFLDL
41 TNYAHYLSI
42 LSLVNETTI
43 FKNMNILEL
44 YALMNDNNSVL
LSGRYNDL
45 KSMSNGSFL
46 LSYNNTLDYF
47 YAIKKKDEI
48 ICFEHYQLF
49 SSISQNEIVI
50 IVYRFRKL
51 FAINNNEHL
52 FSSCNDTLEL
53 ISFAGFNAL
54 ASLENVETI
55 HAHANYAFL
56 KTMNFYGM
57 NSVNNINYI
YYYDYDKI
58 VCIYYFDLL
WGDEFEKL
59 KNYFHFFNM
60 YSLNNTHVL
61 STFLYYLL
62 YAYRNGLYF
63 RTFYYFHGLL
64 NCYIYNYV
65 YALRNFTLF
66 FSLINHSVI
67 IAVLNSLYL
68 ITYLNSINI
69 AAINNIEFV
70 AAVNNLFTI
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72 VSYFYFLDLL
73 YAVRNTRYL
74 YALFNGNLI
75 YNMFYYTIL
76 STYSFMSL
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downregulated in 
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downregulated in 
SLARP KO) Silvie, 
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+/- +/- +/- +/- +/- +/-
P. berghei origin
MicroarrayMicroarray SSH
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- - - - - -
- + - - - -
- - - - - +
- - - - - -
- - - - - -
- + - - - -
+ - - - - -
- - - - - -
- - - - - -
- - - - - +
- + - - - -
- - - - - -
- + - - - -
- - - - - -
- - - - - -
+ - - - - -
- + - - - -
- + - - - -
- - - - - -
- + - - - -
- - - - - -
- - - - - -
- - - - + +
- + - - - -
- + - - - -
- - - - - +
- - - - - +
- - - - - -
- - - - - -
+ + - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
+ + - - - -
- + - - - -
- - - - - -
- + - - - -
- - - - - +
- - - - - -
- - - - - -
- - - - - -
- - - - - +
- - - - - +
Novel 
Peptide 
number
High purity 
restimulation % 
IFN-g+ CD11a+ / 
total CD8+ T 
cells
Peptide sequence
Novel peptides 
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Gene ID Protein
Batch purity 
restimulation 
% IFN-g+ 
CD11a+ / total 
CD8+ T cells
78 NCLNYYPL 0.017 0.0090075
79 RIYNFYHKL 0.032 0.0090025
80 NCYKYMLL 0.011 0.0089375
81 VSMYFTMHI 0.033 0.0087525
82 NCYDYGTL 0.022 0.0086875
83 FAHKNNVPI 0.0775 0.00829
84 INYNFYSM 0.0385 0.00733
85 SNFKYSFV 0.015 0.00733
86 NSIKNVLPI 0.088666667 0.007205
87 HSMENVDTM 0.035 0.007155
88 ISYYLYINL 0.042 0.0070475
89 ISFNCFLSTL 0.0335 0.0067025
90 VVIKFLQYM 0.019 0.006655
91 ISYLFHYIHF 0.036 0.0065
92 YSYKYYNYF 0.03925 0.0063025
93 SSYSYSNPL 0.012 0.00551
94 NCFYFKNV 0.01 0.0032725
EIYIFTNI (batch purity) PBANKA_0416600 replication protein A1, small fragment 0.27
NCYDFNNI (batch purity) PBANKA_0714500 conserved Plasmodium protein, unknown function 0.16
SQLLNAKYL (batch purity) PBANKA_0819000 glideosome-associated protein 50, putative 0.0945
LSGRYNDL (batch purity) PBANKA_1337300 conserved Plasmodium protein, unknown function 0.0895
WGDEFEKL (batch purity) PBANKA_0611600 ribonucleoside-diphosphate reductase large subunit, putative 0.089
LLPHFSIL (batch purity) PBANKA_0316000 replication factor C subunit 1, putative 0.0655
YYYDYDKI (batch purity) PBANKA_0521700 transcription factor with AP2 domain(s), putative 0.061
95 HSYPYYTNL 0.042
96 YSLSNRLQL 0.041
97 KSIQNMNCTEI 0.041
98 YSYNRFLTI 0.039
99 YIYRFFRSL 0.0385
100 VTYENLDPL 0.0375
101 SIFNFIYLL 0.037095
102 VSYLKHFAMEM 0.0365
103 ISFLHYYKL 0.036
104 IAYYFMFL 0.035
105 ISFYMFYHKM 0.035
106 HSFCRYILL 0.035
107 FTYLYYYYYL 0.035
108 VVYFFIMPV 0.034
109 FSIANVVYV 0.0335
110 MSWANNTTFL 0.0335
111 INYKFFKSI 0.032
112 NCIEFYEL 0.031
113 VCYKYMPLI 0.031
114 INYEYYNL 0.03
VNYSFLYL
Novel 
Peptide 
number
Peptide sequence
78 NCLNYYP
79 RIYNFYHKL
80 NCYKYMLL
81 VSMYFTMHI
82 NCYDYGTL
83 FAHKNNVPI
84 INYNFYSM
85 SNFKYSFV
86 NSIKNVLPI
87 HSMENVDTM
88 ISYYLYINL
89 ISFNCFLSTL
90 VVIKFLQYM
91 ISYLFHYIHF
92 YSYKYYNYF
93 SSYSYSNPL
94 NCFYFKNV
EIYIFTNI (batch purity)
NCYDFNNI (batch purity)
SQLLNAKYL (batch purity)
LSGRYNDL (batch purity)
WGDEFEKL (batch purity)
LLPHFSIL (batch purity)
YYYDYDKI (batch purity)
95 HSYPYYTNL
96 YSLSNRLQL
97 KSIQNMNCTEI
98 YSYNRFLTI
99 YIYRFFRSL
100 VTYENLDPL
101 SIFNFIYLL
102 VSYLKHFAMEM
103 ISFLHYYKL
104 IAYYFMFL
105 ISFYMFYHKM
106 HSFCRYILL
107 FTYLYYYYYL
108 VVYFFIMPV
109 FSIANVVYV
110 MSWANNTTFL
111 INYKFFKSI
112 NCIEFYEL
113 VCYKYMPLI
114 INYEYYNL
+/- +/- +/- +/- +/-
MHC allele 
restriction
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score
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score
orthologs of P. yoelii
NetMHCcons 1.1 data NetMHCpan 4.0 data
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Expression data
orthologs of P. falciparum
Percentile 
of protein
Signal 
peptide 
predicted 
no 0 347 8 72 20.74928 Kb 0.367 942.86 3 Kb 0.3645 968.567 1.7654 - + - - +
no 2 2042 9 1367 66.94417 Kb 0.773 11.66 0.03 Kb 0.8555 4.7742 0.008 - + - - +
no 14 1881 8 1612 85.6991 Kb 0.503 216.47 0.8 Kb 0.5582 119.159 0.3035 - - - - +
yes 1 1296 9 1094 84.41358 Kb 0.733 17.97 0.05 Kb 0.787 10.0168 0.0181 + - - - +
no 0 583 8 416 71.35506 Kb 0.34 1262.8 4 Kb 0.429 482.323 0.9797 - + + + +
no 0 5176 9 5025 97.08269 Db 0.891 3.27 0.01 Db 0.8486 5.1477 0.0046 + + - - +
no 3 1115 8 1012 90.76233 Kb 0.833 6.12 0.01 Kb 0.8875 3.3793 0.0062 - - - - -
no 0 288 8 243 84.375 Kb 0.71 23.05 0.05 Kb 0.8209 6.9417 0.0099 + + + + +
no 0 5176 9 412 7.959815 Db 0.845 5.38 0.01 Db 0.8102 7.795 0.0057 + + - - +
no 0 946 9 885 93.5518 Db 0.88 3.66 0.01 Db 0.867 4.2184 0.004 - - - - -
no 5 1461 9 155 10.60917 Kb 0.808 7.94 0.01 Kb 0.8837 3.5207 0.0064 - + - - +
no 2 1407 10 804 57.14286 Kb 0.658 40.46 0.12 Kb 0.7903 9.6689 0.017 - - - - -
no 0 130 9 32 24.61538 Kb 0.682 31.04 0.1 Kb 0.721 20.463 0.049 + - + + +
yes 1 599 10 569 94.99165 Kb 0.702 25.14 0.07 Kb 0.6946 27.2438 0.0692 - + + - +
no 0 380 9 318 83.68421 Kb 0.759 13.57 0.03 Kb 0.7979 8.9018 0.0146 - - - - -
no 0 233 9 39 16.7382 Kb 0.834 6.03 0.01 Kb 0.8552 4.7934 0.008 - - - - -
no 0 1113 8 763 68.55346 Kb 0.268 2737.1 7 Kb 0.3731 883.014 1.6428 - + - - +
no 0 486 8 198 40.74074 Kb 0.568 107.14 0.4 Kb 0.6389 49.7716 0.1214 + + + + +
no 1 745 8 396 53.15436 Kb 0.238 3786.7 9 Kb 0.3864 764.103 1.4628 - - - - -
yes 2 395 9 39 9.873418 Db 0.704 24.47 0.05 Db 0.6878 29.3083 0.0094 + + + + +
yes 1 329 8 118 35.86626 Kb 0.333 1369.5 4 Kb 0.3226 1524.09 2.5409 - + - - -
no 0 847 8 401 47.34357 Kb 0.145 10471 32 Kb 0.1564 9206.28 12.8923 + - - - +
no 0 861 8 650 75.49361 Kb 0.386 771.82 3 Kb 0.4523 374.756 0.8159 - + - - +
no 0 2775 8 1956 70.48649 Kb 0.264 2858.2 7 Kb 0.3161 1634.72 2.7053 - + + + +
no 13 2715 9 1655 60.95764 Kb 0.792 9.49 0.01 Kb 0.8997 2.9593 0.0056 - - + - -
no 0 367 9 249 67.84741 Db 0.815 7.44 0.01 Db 0.7648 12.7404 0.0071 - + - - +
no 0 3018 11 1987 65.8383 Db 0.653 42.71 0.07 Db 0.5719 102.679 0.0302 - - - - -
no 6 2724 9 2053 75.36711 Kb 0.78 10.87 0.01 Kb 0.7778 11.0693 0.0213 - - - - -
no 0 1155 9 182 15.75758 Kb 0.79 9.65 0.01 Kb 0.8812 3.6165 0.0066 + + - - -
no 1 366 9 224 61.20219 Db 0.75 14.87 0.05 Db 0.7369 17.2266 0.0079 - + + + +
yes 0 1218 9 118 9.688013 Kb 0.728 19.08 0.05 Kb 0.7615 13.2062 0.027 + - + + +
no 0 778 11 537 69.02314 Kb 0.639 49.43 0.17 Kb 0.6321 53.542 0.1321 - + - - +
no 0 1360 9 704 51.76471 Kb 0.795 9.19 0.01 Kb 0.8978 3.0219 0.0057 + - - - +
no 1 151 8 142 94.03974 Kb 0.827 6.54 0.01 Kb 0.8968 3.0556 0.0057 + - - - +
no 11 1935 10 359 18.55297 Kb 0.685 30.05 0.07 Kb 0.8144 7.4507 0.0111 + - - - -
no 0 1090 9 159 14.58716 Kb 0.74 16.57 0.05 Kb 0.721 20.475 0.049 - - - - +
yes 10 2361 10 2068 87.59 Kb 0.686 29.73 0.07 Kb 0.6247 58.0379 0.149 - - - - -
yes 1 1296 9 1174 90.58642 Kb 0.762 13.13 0.03 Kb 0.7299 18.5857 0.042 + - - - +
no 0 566 9 4 0.706714 Db 0.878 3.74 0.01 Db 0.8372 5.8204 0.0049 + - - - -
no 0 513 10 481 93.76218 Db 0.687 29.56 0.07 Db 0.5471 134.311 0.0372 + + - - +
yes 1 2096 9 2062 98.37786 Kb 0.729 18.77 0.05 Kb 0.8822 3.5774 0.0065 - - - - +
no 0 439 8 394 89.74943 Kb 0.274 2579 7 Kb 0.3385 1283.42 2.212 + + - - +
yes 1 185 9 142 76.75676 Kb 0.584 90.6 0.4 Kb 0.6201 60.9461 0.1564 + + - - +
no 0 7263 8 5736 78.97563 Kb 0.845 5.38 0.01 Kb 0.9141 2.5318 0.0048 - - - - +
VNYSFLYL
Novel 
Peptide 
number
Peptide sequence
78 NCLNYYP
79 RIYNFYHKL
80 NCYKYMLL
81 VSMYFTMHI
82 NCYDYGTL
83 FAHKNNVPI
84 INYNFYSM
85 SNFKYSFV
86 NSIKNVLPI
87 HSMENVDTM
88 ISYYLYINL
89 ISFNCFLSTL
90 VVIKFLQYM
91 ISYLFHYIHF
92 YSYKYYNYF
93 SSYSYSNPL
94 NCFYFKNV
EIYIFTNI (batch purity)
NCYDFNNI (batch purity)
SQLLNAKYL (batch purity)
LSGRYNDL (batch purity)
WGDEFEKL (batch purity)
LLPHFSIL (batch purity)
YYYDYDKI (batch purity)
95 HSYPYYTNL
96 YSLSNRLQL
97 KSIQNMNCTEI
98 YSYNRFLTI
99 YIYRFFRSL
100 VTYENLDPL
101 SIFNFIYLL
102 VSYLKHFAMEM
103 ISFLHYYKL
104 IAYYFMFL
105 ISFYMFYHKM
106 HSFCRYILL
107 FTYLYYYYYL
108 VVYFFIMPV
109 FSIANVVYV
110 MSWANNTTFL
111 INYKFFKSI
112 NCIEFYEL
113 VCYKYMPLI
114 INYEYYNL
TARUN 
2008 spz
Tarun 
2008 
EEF
UIS genes 
Matuschewski 
2002 (oocyst spz v 
sg spz)
S genes Kaiser 
2004 (sg spz v 
merozoites)
DSK hi (highly 
downregulated in 
SLARP KO) Silvie, 
unpublished
DSK lo (lowly 
downregulated in 
SLARP KO) Silvie, 
unpublished
+/- +/- +/- +/- +/- +/-
P. berghei origin
MicroarrayMicroarray SSH
Expression data
orthologs of P. yoelii
- - - - - -
- - - - - +
- - - - - -
- - - - - -
- - - + - -
- - - - - -
- - - - - +
- + - - - -
- - - - - -
+ - - - - -
- - - - - +
- - - - - +
- + - - - -
- - - - - -
- + - - - -
+ - - - - -
- - - - - -
- - - - + -
- - - - - -
- - - - - -
- - - - - -
- + - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
+ - - - - -
+ - + - - -
- - - - - +
+ - - - - -
- - - - - -
- - - - - -
- - - - - -
- + - - - -
- - - - - -
- - + - - -
- - - - - +
- - - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
- + - - - -
- - - - - -
Novel 
Peptide 
number
High purity 
restimulation % 
IFN-g+ CD11a+ / 
total CD8+ T 
cells
Peptide sequence
Novel peptides 
carried forward 
from batch 
purity -> high 
purity 
(black=top43, 
grey=other52)
Published 
control 
peptides
Top 
NetMHCpan 
peptides 
<22nM and 
<0.05 Rank %
NetMHCpan 
other 
peptides 
22.381-
388.44nM 
but always 
%Rank of 0.5 
or below 
Top 
NetMHCcons 
NC and C2
Top 
NetMHCcons 
peptides 
<22nM and 
<0.05 Rank %
NetMHCcons 
other peptides 
23.05nM-
531.38nM but 
always %Rank 
of 0.5 or below
Gene ID Protein
Batch purity 
restimulation 
% IFN-g+ 
CD11a+ / total 
CD8+ T cells
115 KNYYFTLSL 0.03
116 YSFFMYNEM 0.03
117 SCFYRMQML 0.029
118 YSYSYFINF 0.029
119 YAFYFWFFALL 0.029
120 SAINNCLI 0.0285
121 SSYIFILL 0.028
122 NCINFLLL 0.028
123 NCMSFYHI 0.028
124 MSILNEYNI 0.028
125 VSPFYHAL 0.028
126 WGYGFKYYPL 0.028
127 SSYKKFILLL 0.028
128 KSIINYNTI 0.027
129 FAYFNFEEI 0.027
130 YMHMNLSPL 0.027
131 ICYFFFYNI 0.027
132 SVYFSFRNL 0.027
133 RSFNFILL 0.027
134 ISFYRYFIM 0.027
135 TSLRNGNTL 0.027
136 IMYEFLLYGL 0.027
137 MSYPFFPLLL 0.0265
138 FALINFIAL 0.026
139 INYNFNSL 0.026
140 VSYRYREL 0.026
141 ITFFYRNGL 0.026
142 VNYHFSNYMNF 0.026
143 AAILNHTNI 0.0255
144 YSLNNANINIL 0.0255
145 YTYRYTPL 0.0255
146 ISFCFQAL 0.025
147 YSFFFMHL 0.025
148 CCYEYYCSL 0.025
149 NCFHLINL 0.025
150 IIYLFRETNL 0.025
151 VNYTYLCSIEL 0.025
152 INYNKYIHLL 0.02458
153 SNYAYFTIL 0.0245
154 AQYSNNFDYL 0.0245
155 SMINNDIPL 0.02449
156 ILYSFYNYL 0.024
157 SSILNNELI 0.024
158 VMYLFGRL 0.024
VNYSFLYL
Novel 
Peptide 
number
Peptide sequence
115 K Y TLSL
116 YSFFMYNEM
117 SCFYRMQML
118 YSYSYFINF
119 YAFYFWFFALL
120 SAINNCLI
121 SSYIFILL
122 NCINFLLL
123 NCMSFYHI
124 MSILNEYNI
125 VSPFYHAL
126 WGYGFKYYPL
127 SSYKKFILLL
128 KSIINYNTI
129 FAYFNFEEI
130 YMHMNLSPL
131 ICYFFFYNI
132 SVYFSFRNL
133 RSFNFILL
134 ISFYRYFIM
135 TSLRNGNTL
136 IMYEFLLYGL
137 MSYPFFPLLL
138 FALINFIAL
139 INYNFNSL
140 VSYRYREL
141 ITFFYRNGL
142 VNYHFSNYMNF
143 AAILNHTNI
144 YSLNNANINIL
145 YTYRYTPL
146 ISFCFQAL
147 YSFFFMHL
148 CCYEYYCSL
149 NCFHLINL
150 IIYLFRETNL
151 VNYTYLCSIEL
152 INYNKYIHLL
153 SNYAYFTIL
154 AQYSNNFDYL
155 SMINNDIPL
156 ILYSFYNYL
157 SSILNNELI
158 VMYLFGRL
+/- +/- +/- +/- +/-
MHC allele 
restriction
1-
log50k
nM
%Rank 
score
MHC allele 
restriction
1-
log50k
nM
%Rank 
score
orthologs of P. yoelii
NetMHCcons 1.1 data NetMHCpan 4.0 data
No. of 
transmembrane 
domains 
predicted
Protein 
length 
Peptide 
length
Peptide 
start 
position
TARUN 2008 
EEF Mass 
Spec (LS40-
50h)
LINDNER 
2013 Spz 
Mass Spec
LASONDER 
2008 spz Mass 
Spec
LASONDER 
2008 Spz (only 
day 18-22) 
Mass Spec
LINDNER 
2013 Spz 
Mass Spec
Expression data
orthologs of P. falciparum
Percentile 
of protein
Signal 
peptide 
predicted 
yes 10 2361 9 2145 90.85133 Kb 0.758 13.64 0.03 Kb 0.8403 5.6278 0.0088 - - - - -
yes 1 2081 9 1043 50.12013 Kb 0.718 21.14 0.05 Kb 0.6962 26.7536 0.0676 - + + + +
no 0 1474 9 446 30.2578 Kb 0.588 86.76 0.3 Kb 0.5514 128.178 0.3236 + - - - -
yes 2 896 9 259 28.90625 Kb 0.762 13.2 0.03 Kb 0.7932 9.3706 0.016 - + + - +
no 4 611 11 266 43.53519 Kb 0.698 26.39 0.07 Kb 0.6034 73.062 0.1851 - + - - +
yes 0 3254 8 539 16.56423 Db 0.399 666.93 0.5 Db 0.449 388.441 0.1045 + - - - -
no 6 705 8 529 75.03546 Kb 0.828 6.47 0.01 Kb 0.8744 3.8914 0.007 - + - - +
no 0 1471 8 988 67.16519 Kb 0.277 2496.6 7 Kb 0.3316 1382.3 2.3504 - - - - +
no 0 228 8 200 87.7193 Kb 0.211 5099 15 Kb 0.3277 1443.1 2.4307 - - - - -
yes 2 1671 9 860 51.46619 Db 0.743 16.13 0.05 Db 0.7429 16.1554 0.0078 - - - - +
yes 2 1671 8 578 34.59007 Kb 0.759 13.57 0.03 Kb 0.8224 6.834 0.0098 - - - - +
yes 1 1192 10 659 55.28523 Kb 0.663 38.12 0.12 Kb 0.645 46.564 0.1154 + + - - +
no 0 5309 10 1102 20.7572 Kb 0.742 16.39 0.03 Kb 0.7168 21.4241 0.0518 + + - - +
no 0 5249 9 3330 63.44066 Db 0.854 4.88 0.01 Db 0.8345 5.9952 0.005 + - - - -
no 0 511 9 191 37.37769 Db 0.877 3.8 0.01 Db 0.8558 4.7581 0.0043 - - - - +
no 8 1272 9 1190 93.55346 Db 0.883 3.53 0.01 Db 0.8267 6.5242 0.0052 - - - - +
yes 11 732 9 681 93.03279 Kb 0.577 97.73 0.4 Kb 0.6893 28.8443 0.0732 - - + + -
yes 1 3204 9 1326 41.38577 Kb 0.728 18.87 0.05 Kb 0.8347 5.9831 0.0092 - - + + -
yes 0 824 8 133 16.14078 Kb 0.785 10.18 0.01 Kb 0.8282 6.4175 0.0095 - + - - +
no 4 3053 9 1107 36.25942 Kb 0.789 9.81 0.01 Kb 0.8136 7.5126 0.0112 - + - - +
yes 0 477 9 33 6.918239 Db 0.777 11.17 0.03 Db 0.7632 12.9621 0.0071 + - - - -
yes 0 562 10 476 84.69751 Kb 0.738 17.12 0.05 Kb 0.6791 32.2151 0.0806 - + - - +
no 0 4287 10 3924 91.53254 Kb 0.758 13.79 0.03 Kb 0.8018 8.5334 0.0138 - - + - -
no 2 190 9 143 75.26316 Db 0.881 3.62 0.01 Db 0.8083 7.9614 0.0058 - + - - +
no 4 3350 8 2661 79.43284 Kb 0.834 6.03 0.01 Kb 0.9018 2.8923 0.0054 - + - - +
no 4 1504 8 971 64.56117 Kb 0.837 5.8 0.01 Kb 0.9083 2.696 0.0051 + - - - -
no 2 2091 9 1831 87.56576 Kb 0.749 15.12 0.03 Kb 0.8193 7.0627 0.01 - - - - -
yes 1 2081 11 811 38.97165 Kb 0.639 49.7 0.17 Kb 0.6704 35.3906 0.089 - + + + +
no 4 4204 9 2090 49.71456 Db 0.865 4.33 0.01 Db 0.8136 7.5134 0.0056 - + - - +
yes 0 1478 11 489 33.08525 Db 0.627 56.89 0.1 Db 0.6103 67.798 0.02 - - - - +
no 10 452 8 83 18.36283 Kb 0.846 5.29 0.01 Kb 0.9014 2.9059 0.0055 - + - - -
no 8 411 8 198 48.17518 Kb 0.842 5.53 0.01 Kb 0.906 2.7647 0.0052 - + + - +
no 0 1653 8 946 57.22928 Kb 0.824 6.71 0.01 Kb 0.8964 3.069 0.0057 - + - - +
no 0 277 9 154 55.59567 Kb 0.637 50.78 0.17 Kb 0.6921 27.9884 0.0712 - - - - -
no 2 7126 8 2543 35.68622 Kb 0.265 2858.2 7 Kb 0.3237 1505.51 2.5121 - - - - +
no 13 585 10 472 80.68376 Kb 0.645 46.32 0.15 Kb 0.7392 16.8036 0.0368 - + + - +
yes 0 1218 11 972 79.80296 Kb 0.635 51.89 0.17 Kb 0.6976 26.3685 0.0662 + - + + +
no 0 5249 10 3477 66.24119 Kb 0.707 23.81 0.05 Kb 0.7852 10.2132 0.0188 + - - - -
yes 0 1354 9 691 51.03397 Kb 0.82 7.05 0.01 Kb 0.9054 2.7834 0.0052 + + - - +
yes 0 999 10 122 12.21221 Db 0.681 31.38 0.07 Db 0.6399 49.2067 0.0133 - + + + +
no 0 1766 9 4 0.226501 Db 0.809 7.9 0.01 Db 0.7709 11.933 0.0069 - - - - -
no 0 1310 9 906 69.16031 Kb 0.83 6.29 0.01 Kb 0.865 4.3095 0.0075 - - - - -
yes 0 764 9 297 38.87435 Db 0.865 4.29 0.01 Db 0.8373 5.8119 0.0049 - - - - +
no 12 735 8 372 50.61224 Kb 0.834 6.03 0.01 Kb 0.8954 3.1013 0.0058 - + - - +
VNYSFLYL
Novel 
Peptide 
number
Peptide sequence
115 K Y TLSL
116 YSFFMYNEM
117 SCFYRMQML
118 YSYSYFINF
119 YAFYFWFFALL
120 SAINNCLI
121 SSYIFILL
122 NCINFLLL
123 NCMSFYHI
124 MSILNEYNI
125 VSPFYHAL
126 WGYGFKYYPL
127 SSYKKFILLL
128 KSIINYNTI
129 FAYFNFEEI
130 YMHMNLSPL
131 ICYFFFYNI
132 SVYFSFRNL
133 RSFNFILL
134 ISFYRYFIM
135 TSLRNGNTL
136 IMYEFLLYGL
137 MSYPFFPLLL
138 FALINFIAL
139 INYNFNSL
140 VSYRYREL
141 ITFFYRNGL
142 VNYHFSNYMNF
143 AAILNHTNI
144 YSLNNANINIL
145 YTYRYTPL
146 ISFCFQAL
147 YSFFFMHL
148 CCYEYYCSL
149 NCFHLINL
150 IIYLFRETNL
151 VNYTYLCSIEL
152 INYNKYIHLL
153 SNYAYFTIL
154 AQYSNNFDYL
155 SMINNDIPL
156 ILYSFYNYL
157 SSILNNELI
158 VMYLFGRL
TARUN 
2008 spz
Tarun 
2008 
EEF
UIS genes 
Matuschewski 
2002 (oocyst spz v 
sg spz)
S genes Kaiser 
2004 (sg spz v 
merozoites)
DSK hi (highly 
downregulated in 
SLARP KO) Silvie, 
unpublished
DSK lo (lowly 
downregulated in 
SLARP KO) Silvie, 
unpublished
+/- +/- +/- +/- +/- +/-
P. berghei origin
MicroarrayMicroarray SSH
Expression data
orthologs of P. yoelii
- - - - - +
- - - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
+ - - - - -
+ + - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
- + - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - +
- - - - - -
- + - - - -
- - - - - -
- - - + - -
- - - - - -
- - - - - -
+ - - - - -
- - - - - +
- - - - - -
- - - - - -
- - - - - -
- - - - - -
+ - - + - -
- - - - - +
- + - - - -
- - - - - -
- + - - - -
159 VVYRHFATL 0.024 no 0 157 9 62 39.4904459 Kb 0.857 4.67 0.01
160 YALSNGVNI 0.024 no 1 602 9 355 58.9700997 Db 0.885 3.45 0.01
161 VCYDYLYSL 0.024 no 0 2453 9 1920 78.2715043 Kb 0.633 52.74 0.17
162 AAFRNIKSI 0.024 no 0 194 9 150 77.3195876 Db 0.506 209.55 0.2
163 KTYPFFSNI 0.024 yes 0 2150 9 1952 90.7906977 Kb 0.728 18.87 0.05
164 VSYARHFL 0.024 yes 1 2081 8 1291 62.037482 Kb 0.729 18.77 0.05
165 ISYRHYSL 0.023 yes 7 628 8 328 52.2292994 Kb 0.851 5.01 0.01
166 KSLQNVDYI 0.023 no 0 647 9 33 5.10046368 Db 0.883 3.55 0.01
167 MIYYFQSL 0.023 no 2 1765 8 1446 81.9263456 Kb 0.823 6.79 0.01
168 SIYSYSYL 0.023 no 0 651 8 617 94.7772657 Kb 0.834 6.06 0.01
169 YSIMNINEI 0.023 no 0 1221 9 101 8.27190827 Db 0.917 2.47 0.01
170 KCISFFNTL 0.023 no 0 584 9 571 97.7739726 Kb 0.612 66.56 0.25
171 NCFNFNYI 0.023 no 2 1030 8 194 18.8349515 Kb 0.24 3705.68 9
172 NCIKYIKL 0.023 no 3 871 8 146 16.7623421 Kb 0.247 3435.38 9
173 INFSYNNM 0.023 yes 4 1785 8 1218 68.2352941 Kb 0.773 11.66 0.03
174 YSTWNLSFI 0.023 yes 1 1230 9 674 54.796748 Db 0.774 11.6 0.03
175 KAFDRHCNL 0.023 no 0 101 9 46 45.5445545 Kb 0.608 69.5 0.25
176 RCLKNNYTL 0.023 no 0 192 9 120 62.5 Db 0.42 531.38 0.4
177 VGYIFYNRL 0.023 yes 0 256 9 222 86.71875 Kb 0.841 5.62 0.01
178 FSYYKFSSL 0.023 no 0 1737 9 1140 65.6303972 Kb 0.829 6.4 0.01
179 TMLKFYNML 0.023 yes 1 633 9 536 84.6761453 Kb 0.778 10.99 0.01
180 SSMINNDIPL 0.023 no 0 1766 10 3 0.16987542 Db 0.776 11.29 0.03
181 YQLKNLETPI 0.023 yes 0 1406 10 571 40.6116643 Db 0.756 14.09 0.05
182 SNYYNHYFFL 0.023 yes 1 1192 10 701 58.8087248 Kb 0.714 22.19 0.05
183 MVYKKYIGL 0.0225 no 0 778 9 635 81.6195373 Kb 0.79 9.65 0.01
184 SVLSFFYKPL 0.0225 yes 0 2775 10 158 5.69369369 Kb 0.621 60.71 0.25
185 ISYTFLTM 0.022 no 2 177 8 163 92.0903955 Kb 0.832 6.19 0.01
186 RAIQNASTI 0.022 no 0 1331 9 178 13.3734035 Db 0.891 3.27 0.01
187 NCYVNLNL 0.022 no 2 2599 8 2430 93.497499 Kb 0.235 3911.67 9
188 TCFYYFILL 0.022 no 2 1618 9 300 18.5414091 Kb 0.653 42.71 0.15
189 SNYIFNFL 0.022 yes 2 1671 8 1522 91.0831837 Kb 0.805 8.2 0.01
190 KMFVNLSGFI 0.022 no 0 258 10 210 81.3953488 Db 0.507 207.3 0.2
191 MSYPFFPL 0.022 no 0 4287 8 3924 91.5325402 Kb 0.87 4.08 0.01
192 LNYYFYQEI 0.022 yes 3 1149 9 1085 94.4299391 Kb 0.768 12.24 0.03
193 CSMENSTYI 0.022 no 2 2017 9 514 25.4833912 Db 0.841 5.62 0.01
194 SSISFLSSL 0.022 yes 0 654 9 633 96.7889908 Kb 0.763 12.99 0.03
195 ISYKYKNYM 0.022 yes 0 1796 9 81 4.51002227 Kb 0.76 13.42 0.03
196 YTYPYYNLI 0.022 yes 8 5371 9 3996 74.3995532 Kb 0.732 18.17 0.05
197 IMVPFFSIM 0.022 no 13 585 9 121 72.8915663 Kb 0.736 17.49 0.05
198 VSYARHFLF 0.022 yes 1 2081 9 1291 62.037482 Kb 0.787 10.02 0.01
199 ISYFKYQPPV 0.022 yes 2 713 10 83 11.6409537 Kb 0.725 19.6 0.05
200 VNYFNQNLL 0.022 yes 0 1109 9 854 77.006312 Kb 0.734 17.88 0.05
201 FMYSRKLKL 0.022 yes 1 3204 9 1984 61.9225968 Kb 0.692 28.01 0.07
Batch purity 
restimulation % 
IFN-g+ CD11a+ / 
total CD8+ T cells
MHC allele 
restriction
1-log50k nM
%Rank 
score
NetMHCcons 1.1 data
Novel 
Peptide 
number
Percentile of 
protein
Top NetMHCcons 
peptides <22nM 
and <0.05 Rank %
NetMHCcons 
other peptides 
23.05nM-
531.38nM but 
always %Rank 
of 0.5 or below
Peptide sequence
Top 
NetMHCpan 
peptides 
<22nM and 
<0.05 Rank %
NetMHCpan 
other 
peptides 
22.381-
388.44nM 
but always 
%Rank of 0.5 
or below 
Top 
NetMHCcons 
NC and C2
Signal 
peptide 
predicted 
No. of 
transmembrane 
domains 
predicted
Protein 
length 
Peptide 
length
Peptide 
start 
position
159 VVYRHFATL
160 YALSNGVNI
161 VCYDYLYSL
162 AAFRNIKSI
163 KTYPFFSNI
164 VSYARHFL
165 ISYRHYSL
166 KSLQNVDYI
167 MIYYFQSL
168 SIYSYSYL
169 YSIMNINEI
170 KCISFFNTL
171 NCFNFNYI
172 NCIKYIKL
173 INFSYNNM
174 YSTWNLSFI
175 KAFDRHCNL
176 RCLKNNYTL
177 VGYIFYNRL
178 FSYYKFSSL
179 TMLKFYNML
180 SSMINNDIPL
181 YQLKNLETPI
182 SNYYNHYFFL
183 MVYKKYIGL
184 SVLSFFYKPL
185 ISYTFLTM
186 RAIQNASTI
187 NCYVNLNL
188 TCFYYFILL
189 SNYIFNFL
190 KMFVNLSGFI
191 MSYPFFPL
192 LNYYFYQEI
193 CSMENSTYI
194 SSISFLSSL
195 ISYKYKNYM
196 YTYPYYNLI
197 IMVPFFSIM
198 VSYARHFLF
199 ISYFKYQPPV
200 VNYFNQNLL
201 FMYSRKLKL
Novel 
Peptide 
number
Peptide sequence
TARUN 
2008 spz
Tarun 
2008 
EEF
UIS genes 
Matuschewski 
2002 (oocyst spz v 
sg spz)
S genes 
Kaiser 2004 
(sg spz v 
merozoites)
DSK hi (highly 
downregulated in 
SLARP KO) 
Silvie, 
unpublished
DSK lo (lowly 
downregulated in 
SLARP KO) Silvie, 
unpublished
+/- +/- +/- +/- +/- +/- +/- +/- +/- +/- +/-
Kb 0.9077 2.7156 0.0051 - - - - + - + - - - -
Db 0.8413 5.5693 0.0048 - - - - - + - - - - -
Kb 0.7114 22.7002 0.0552 - + - - + - - - - - -
Db 0.6274 56.3182 0.0147 + + + + + - + - - - -
Kb 0.8556 4.7694 0.008 - + - - - - - - - - -
Kb 0.7846 10.285 0.019 - + + + + - - - - - -
Kb 0.9048 2.8009 0.0053 - - - - + - - - - - -
Db 0.8693 4.1111 0.0039 - - - - - - - - - - -
Kb 0.877 3.7855 0.0068 - - - - + - - - - - -
Kb 0.8895 3.3052 0.0061 - + - - + - - - - - +
Db 0.8976 3.0276 0.0031 - - - - + - - - - - -
Kb 0.6478 45.1686 0.1127 - - - - - - + - - - -
Kb 0.3705 908.1188 1.6757 - - - - + - - - - - -
Kb 0.287 2241.1646 3.5287 - + - - + - - - - - -
Kb 0.8695 4.1031 0.0072 - - - - + - - - - - -
Db 0.7163 21.5292 0.0086 - + - - + + - - - - -
Kb 0.7044 24.4841 0.0596 + + - - + - + - - - -
Db 0.4655 324.8614 0.0891 + + + - + - - - - - -
Kb 0.9212 2.3465 0.0044 - + - - + - + - - - -
Kb 0.8398 5.6598 0.0089 + - - - - - - - - - -
Kb 0.7839 10.3599 0.0192 - + + + + - + - - - -
Db 0.7688 12.196 0.007 - - - - - - - - - - +
Db 0.7513 14.7429 0.0075 + - + - - - - - - - -
Kb 0.745 15.7899 0.034 + + - - + - - - - - -
Kb 0.7895 9.757 0.0173 - + - - + - - - - - -
Kb 0.6918 28.0645 0.0714 - + - - - - - - - - -
Kb 0.8838 3.5167 0.0064 - - - - - - + - - - -
Db 0.8624 4.4333 0.0042 - - - - + - - - - - -
Kb 0.2696 2704.5781 4.1452 - - - - + + - - - - -
Kb 0.6237 58.6502 0.1509 - + - - + - - - - - -
Kb 0.8775 3.7634 0.0068 - - - - + - - - - - -
Db 0.5454 136.8296 0.0377 + - - - - - - - - - -
Kb 0.9114 2.6074 0.0049 - - + - - - - - - - -
Kb 0.8545 4.8261 0.0081 + - - - - - - - - - -
Db 0.8429 5.4727 0.0047 + + - - - - - - - - -
Kb 0.8177 7.1895 0.0104 - + - - + - - - - - -
Kb 0.8102 7.796 0.012 - + - - + + - - - - -
Kb 0.7879 9.9237 0.0178 - - + - + + - - - - -
Kb 0.7561 14.0025 0.029 - + + - + - - - - - -
Kb 0.7464 15.5473 0.0334 - + + + + - - - - - -
Kb 0.7167 21.4353 0.0519 - - + - - - - - - - -
Kb 0.6949 27.1484 0.0689 - - - - - - - - - - +
Kb 0.5764 97.8019 0.2532 - - + + - - - - - - -
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202 VNYLYSNL 0.0215 no 0 920 8 582 63.2608696 Kb 0.861 4.48 0.01
203 IMYTYYFFTSL 0.021495 no 7 288 11 203 70.4861111 Kb 0.695 27.11 0.07
204 LTYNYYHPL 0.021006667 no 0 257 9 8 3.11284047 Kb 0.829 6.36 0.01
205 HAINNIDEI 0.021 no 0 1240 9 459 37.016129 Db 0.865 4.29 0.01
206 TALRNYATL 0.021 no 0 278 9 142 51.0791367 Db 0.889 3.31 0.01
207 YSILNDIFL 0.021 no 0 1485 9 883 59.4612795 Db 0.876 3.83 0.01
208 FCIYRYNNL 0.021 no 4 1504 9 28 1.86170213 Kb 0.581 93.59 0.4
209 LCFTFFPIL 0.021 no 6 755 9 736 97.4834437 Kb 0.555 123.32 0.5
210 VCFFCFTSL 0.021 yes 0 649 9 522 80.431433 Kb 0.607 70.64 0.25
211 GSISFLDYI 0.021 no 0 255 9 211 82.745098 Db 0.467 321.29 0.25
212 SIIIRHNEL 0.021 no 0 288 9 151 52.4305556 Kb 0.581 93.08 0.4
213 VIFMIVFL 0.021 no 2 101 8 51 50.4950495 Kb 0.574 100.41 0.4
214 KIYAFYNNL 0.021 no 4 2077 9 282 13.5772749 Kb 0.818 7.2 0.01
215 INYNYYDML 0.021 no 0 525 9 390 74.2857143 Kb 0.82 7.01 0.01
216 VSYIRYYCSL 0.021 no 0 142 10 110 77.4647887 Kb 0.746 15.7 0.03
217 YSLSNNEYYL 0.021 no 0 5317 10 2243 42.1854429 Db 0.843 5.47 0.01
218 YSIENAVGI 0.021 yes 2 887 9 497 56.0315671 Db 0.766 12.51 0.03
219 YLYNYFYKPL 0.021 yes 0 1272 10 1133 89.072327 Kb 0.61 68.01 0.25
220 YSYKYYNYFKL 0.021 no 0 380 11 318 83.6842105 Kb 0.669 35.92 0.1
221 SLYNYFFNLL 0.020865 no 0 3018 10 1805 59.8078197 Kb 0.717 21.49 0.05
222 FNFLFSNPM 0.0205 yes 1 341 9 320 93.8416422 Kb 0.755 14.17 0.03
223 VTYNFSKL 0.02 no 4 3472 8 1548 44.5852535 Kb 0.837 5.83 0.01
224 ICYSKYIGI 0.02 no 0 849 9 91 10.7184923 Kb 0.594 81.31 0.3
225 RCFKFFTFL 0.02 no 0 1228 9 1187 96.6612378 Kb 0.571 104.28 0.4
226 IAYAKFNDF 0.02 yes 0 1122 9 783 69.7860963 Kb 0.72 20.69 0.05
227 VSLININEV 0.02 yes 1 2081 9 1099 52.8111485 Db 0.733 17.97 0.05
228 YGILNLNNM 0.02 yes 1 1296 9 1021 78.7808642 Db 0.773 11.6 0.03
229 NALQNKASVV 0.02 no 0 255 10 88 34.5098039 Db 0.461 340.99 0.25
230 TMVIMTSTM 0.02 no 2 101 9 81 80.1980198 Db 0.453 371.82 0.3
231 VGMRHLNLL 0.02 no 0 148 9 55 37.1621622 Kb 0.671 34.96 0.1
232 YNISNDQVL 0.02 no 0 288 9 222 77.0833333 Db 0.59 84.45 0.12
233 IAILNNFEYI 0.02 no 0 5317 10 181 3.40417529 Db 0.843 5.44 0.01
234 YTIINDNEI 0.02 yes 0 1030 9 664 64.4660194 Db 0.76 13.35 0.03
235 YNYSFFYLYL 0.02 no 0 871 10 198 22.7324914 Kb 0.76 13.35 0.03
236 VIFTFYHILL 0.02 no 13 585 10 202 34.5299145 Kb 0.679 32.06 0.1
237 FGSQNYDTI 0.02 yes 1 2731 9 2023 74.0754302 Db 0.758 13.64 0.03
238 VSFVRILLL 0.0195 no 11 500 9 441 88.2 Kb 0.782 10.63 0.01
239 MMYLYNRL 0.019 no 0 3018 8 2024 67.064281 Kb 0.823 6.82 0.01
240 SMYYFSGL 0.019 no 0 489 8 44 8.99795501 Kb 0.85 5.07 0.01
241 ICYKRTSSL 0.019 yes 1 381 9 21 5.51181102 Kb 0.573 101.5 0.4
242 LCIEYFANL 0.019 no 0 1240 9 934 75.3225806 Kb 0.568 107.72 0.4
243 NCYNYANV 0.019 yes 0 2997 8 487 16.2495829 Kb 0.437 442.1 2
244 YCFHYFALM 0.019 no 1 1051 9 8 0.76117983 Kb 0.648 45.09 0.15
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Kb 0.9379 1.9576 0.0034 - - - - - - - - - + -
Kb 0.8173 7.2186 0.0104 - - + + + - + - - - -
Kb 0.8999 2.9544 0.0055 + + - - + - + - - - -
Db 0.8351 5.9576 0.005 - - - - + - - - - - -
Db 0.8254 6.6131 0.0053 - + - - + - - - - - -
Db 0.8429 5.4719 0.0047 - - - - + - - - - - -
Kb 0.5216 177.0402 0.4201 + - - - - - - - - - -
Kb 0.6516 43.3848 0.109 - + - - + - - - - - -
Kb 0.672 34.7588 0.0874 - - + - - - - - - - -
Db 0.5271 166.7706 0.0436 - + - - - - + - - - -
Kb 0.5155 189.1068 0.4493 + + + + + - + - - - -
Kb 0.5508 129.0767 0.3255 - + - - - - - - - - -
Kb 0.8881 3.3566 0.0062 - + - - + - - - - - -
Kb 0.8858 3.4422 0.0063 - + - - + - - - - - -
Kb 0.8618 4.4605 0.0076 - - - - - - + - - - -
Db 0.7605 13.3528 0.0072 - + + - - - - - - - -
Db 0.753 14.4809 0.0075 - + + - + - - - - - -
Kb 0.6418 48.1887 0.1185 + + - - + - - - - - -
Kb 0.728 18.9723 0.0435 - - - - - - + - - - -
Kb 0.7122 22.5106 0.0547 - - - - - + - - - - -
Kb 0.7396 16.7381 0.0366 + + + + + - + - - - -
Kb 0.9104 2.636 0.005 - - - - - - - - - - +
Kb 0.608 69.4875 0.1753 - + - - + - - - - - -
Kb 0.7104 22.9627 0.0559 - + - - + - - - - - -
Kb 0.676 33.3157 0.0836 + - + - - - - - - - -
Db 0.7345 17.6785 0.008 - + + + + - - - - - -
Db 0.7695 12.1048 0.007 + - - - + - - - - - -
Db 0.3624 991.2014 0.2372 - + - - - - + - - - -
Db 0.4056 621.2883 0.1565 - + - - - - - - - - -
Kb 0.6509 43.6749 0.1096 + + + + + - + - - - -
Db 0.6012 74.7904 0.0221 + + + + + - + - - - -
Db 0.7922 9.4699 0.0063 - + + - - - - - - - -
Db 0.7805 10.7546 0.0066 - + - - - - - - - - -
Kb 0.775 11.4078 0.0222 - + - - - - - - - - -
Kb 0.7467 15.5043 0.0332 - + + - + - - - - - -
Db 0.7127 22.3809 0.0087 - + - - - - - - - - -
Kb 0.7761 11.276 0.0219 + + + - + - - - - - -
Kb 0.8691 4.1212 0.0072 - - - - - + - - - - -
Kb 0.8971 3.0443 0.0057 - - - - + - - - - - -
Kb 0.6038 72.7031 0.1842 - - - - + - + - - - -
Kb 0.7308 18.4047 0.0413 - - - - + - - - - - -
Kb 0.4647 327.5546 0.7298 + + - - + - + - - - -
Kb 0.6693 35.795 0.09 - + - - - + + + - - -
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245 IIIRHNEL 0.019 no 0 288 8 152 52.7777778 Kb 0.601 74.57 0.3
246 NALQNKASV 0.019 no 0 255 9 88 34.5098039 Db 0.586 88.66 0.12
247 KSYSYFSGL 0.019 no 0 812 9 430 52.955665 Kb 0.847 5.24 0.01
248 RSFFYYRL 0.019 yes 0 2997 8 2896 96.6299633 Kb 0.806 8.11 0.01
249 YTYPYYNL 0.019 yes 8 5371 8 3996 74.3995532 Kb 0.818 7.16 0.01
250 SSIINSITL 0.019 no 0 367 9 168 45.7765668 Db 0.867 4.24 0.01
251 STYLYWLYL 0.019 no 0 2623 9 1876 71.521159 Kb 0.781 10.69 0.01
252 SSYTHYISKL 0.019 no 3 646 10 469 72.6006192 Kb 0.725 19.7 0.05
253 ASINNTAFV 0.019 no 1 689 9 594 86.2119013 Db 0.816 7.36 0.01
254 FTLINIPYI 0.019 yes 10 2361 9 2191 92.7996612 Db 0.756 13.94 0.05
255 VSFMYSRKLKL 0.019 yes 1 3204 11 1982 61.8601748 Kb 0.633 53.32 0.17
256 YSYLYLPL 0.01869 no 10 376 8 98 26.0638298 Kb 0.843 5.47 0.01
257 TSISNDNVIYI 0.01867 yes 0 506 11 326 64.4268775 Db 0.646 46.07 0.07
258 IVYTHFYNL 0.0185 yes 1 1296 9 429 33.1018519 Kb 0.81 7.77 0.01
259 ITYYYKNL 0.018 no 0 647 8 495 76.5069552 Kb 0.823 6.79 0.01
260 SIYFFMAL 0.018 no 0 1194 8 453 37.9396985 Kb 0.828 6.47 0.01
261 YSFLNPNYI 0.018 no 3 1429 9 31 2.1693492 Db 0.875 3.89 0.01
262 ICYEFQQEL 0.018 no 0 2704 9 2563 94.785503 Kb 0.606 71.02 0.25
263 TCYLFFGGF 0.018 yes 4 262 9 237 90.4580153 Kb 0.609 68.38 0.25
264 IIYFFSKI 0.018 yes 0 1796 8 1705 94.9331849 Kb 0.75 14.87 0.03
265 ISILNDTFL 0.018 yes 2 1671 9 795 47.5763016 Db 0.853 4.91 0.01
266 YSFNFHNTF 0.018 yes 4 1785 9 521 29.1876751 Kb 0.742 16.22 0.03
267 VSFYHFSNL 0.018 no 0 3439 9 1342 39.0229718 Kb 0.863 4.38 0.01
268 VNYRHLSIL 0.018 no 0 2310 9 1856 80.3463203 Kb 0.788 9.91 0.01
269 YNYKFFLL 0.018 yes 4 277 8 150 54.1516245 Kb 0.813 7.56 0.01
270 SIFNFIYL 0.018 yes 0 1218 8 118 9.68801314 Kb 0.791 9.54 0.01
271 YMFKNINPCYL 0.018 yes 0 824 11 500 60.6796117 Db 0.685 30.05 0.07
272 SSYYYYDNM 0.017895 no 0 824 9 753 91.3834951 Kb 0.823 6.79 0.01
273 NSIFNFIYL 0.0175 yes 0 1218 9 117 9.60591133 Db 0.78 10.81 0.03
274 SGYNNFTYL 0.0175 yes 10 2361 9 2063 87.3782296 Db 0.73 18.67 0.05
275 INFYFSML 0.017 no 0 943 8 754 79.9575822 Kb 0.851 5.04 0.01
276 ISYRHYSLL 0.017 yes 7 628 9 328 52.2292994 Kb 0.881 3.6 0.01
277 SSLSNFNYL 0.017 no 0 3796 9 278 7.32349842 Db 0.875 3.85 0.01
278 YSFYFYTFL 0.017 no 1 1563 9 236 15.0991683 Kb 0.831 6.22 0.01
279 NCLNYSKL 0.017 no 0 349 8 325 93.1232092 Kb 0.232 4062.65 10
280 NCYHYFFHL 0.017 no 0 6471 9 3756 58.043579 Kb 0.577 97.73 0.4
281 SCYKYNNLL 0.017 no 0 1650 9 116 7.03030303 Kb 0.592 82.64 0.3
282 SVYDFYFNL 0.017 no 2 7480 9 1340 17.9144385 Kb 0.844 5.41 0.01
283 FSLKNLNTM 0.017 no 0 1519 9 1261 83.0151415 Db 0.862 4.45 0.01
284 IIFDHFMNM 0.017 no 0 607 9 248 40.8566722 Kb 0.78 10.87 0.01
285 FSFNFLNNL 0.017 yes 8 5371 9 1679 31.2604729 Kb 0.782 10.52 0.01
286 VSYLKHFAM 0.017 no 0 778 9 537 69.0231362 Kb 0.777 11.17 0.01
287 TAHLNDHYI 0.017 yes 1 472 9 310 65.6779661 Db 0.816 7.32 0.01
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246 NALQNKASV
247 KSYSYFSGL
248 RSFFYYRL
249 YTYPYYNL
250 SSIINSITL
251 STYLYWLYL
252 SSYTHYISKL
253 ASINNTAFV
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259 ITYYYKNL
260 SIYFFMAL
261 YSFLNPNYI
262 ICYEFQQEL
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269 YNYKFFLL
270 SIFNFIYL
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285 FSFNFLNNL
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Kb 0.5877 86.6073 0.2232 + + + + + - + - - - -
Db 0.5356 152.1599 0.0405 - + - - - - + - - - -
Kb 0.9065 2.7494 0.0052 - + - - - - - - - - -
Kb 0.8916 3.2321 0.006 + + - - + - + - - - -
Kb 0.8729 3.957 0.007 - - + - + + - - - - -
Db 0.8463 5.2739 0.0046 - + - - + - + - - - -
Kb 0.7966 9.0283 0.0149 + + - - + + - - - - -
Kb 0.7845 10.2937 0.019 - + + + + - + - - - -
Db 0.7541 14.3099 0.0074 - - - - - - + - - - +
Db 0.7385 16.9284 0.0079 - - - - - - - - - - +
Kb 0.6685 36.1093 0.091 - - + + - - - - - - -
Kb 0.893 3.1827 0.0059 - - - - + - + - - - -
Db 0.5971 78.2277 0.023 + + + - + - - - - - -
Kb 0.8936 3.1626 0.0059 + - - - + - - - - - -
Kb 0.9127 2.5716 0.0048 - - - - - - - - - - -
Kb 0.8691 4.122 0.0072 - + - - + - - - - - -
Db 0.8768 3.7904 0.0037 - - - - + - - - - - -
Kb 0.6772 32.8682 0.0824 - + - - + - - - - - -
Kb 0.5963 78.9018 0.2003 + + - - - - + - - - -
Kb 0.8538 4.8627 0.0081 - + - - + + - - - - -
Db 0.8062 8.1379 0.0058 - - - - + - - - - - -
Kb 0.7053 24.2505 0.0591 - - - - + - - - - - -
Kb 0.932 2.0877 0.0038 - + - - + - - - - - -
Kb 0.8427 5.4872 0.0087 - + - - + - - - - - -
Kb 0.8416 5.5501 0.0088 - + - - + - - - - - -
Kb 0.8371 5.8298 0.009 + - + + + - - - - - -
Db 0.6573 40.7577 0.0113 - + - - + - - - - - -
Kb 0.8775 3.7637 0.0068 - - - - - - - - - - +
Db 0.7615 13.2012 0.0072 + - + + + - - - - - -
Db 0.7471 15.4323 0.0076 - - - - - - - - - - +
Kb 0.9277 2.1861 0.004 - - - - + - - - - - -
Kb 0.9237 2.2824 0.0042 - - - - + - - - - - -
Db 0.873 3.9497 0.0038 - - - - + - - - - - -
Kb 0.8784 3.7267 0.0067 - - - - + - - - - - -
Kb 0.2666 2792.7485 4.266 - - - - + - + - - - +
Kb 0.6713 35.0227 0.0881 - - + - - - - - - - +
Kb 0.5878 86.5034 0.2229 - - + + - - - - - - -
Kb 0.8987 2.9922 0.0056 - + - - + - - - - - +
Db 0.8406 5.609 0.0048 - + - - + - - - - - -
Kb 0.8321 6.148 0.0093 - + - - - - - - - - -
Kb 0.8247 6.6636 0.0097 - - + - + + - - - - -
Kb 0.7857 10.1572 0.0186 - + - - + - - - - - -
Db 0.7776 11.0946 0.0067 - + + + + - - - - - -
288 SQYHRFLKL 0.017 no 0 1246 9 650 52.1669342
289 VMYYTYEL 0.017 yes 1 3204 8 498 15.5430712
290 YGATNYDEM 0.017 yes 8 5371 9 3019 56.209272
291 ITILNYLPL 0.017 yes 0 1030 9 304 29.5145631
292 SVLWFFYKPL 0.017 yes 0 2773 10 158 5.69780022
293 VAYSHEYIGHM 0.017 yes 0 1272 11 1243 97.7201258
294 SNYAYFTILNL 0.016605 yes 0 1354 11 691 51.0339734
295 SSYLSYYLLPL 0.0165 yes 2 395 11 231 58.4810127
296 FSYSCHKYLLL 0.0165 yes 1 1791 11 845 47.1803462
297 INYLFGTL 0.016 no 2 2004 8 1126 56.1876248
298 SAVLNFTIL 0.016 no 6 230 9 201 87.3913043
299 SSLSFGNYI 0.016 no 0 91 9 24 26.3736264
300 INFSYFYSL 0.016 no 0 2038 9 833 40.8734053
301 VTYQMYYSRL 0.016 yes 0 248 10 210 84.6774194
302 SSFFFFSKF 0.016 no 11 948 9 425 44.8312236
303 YSFIRFSIL 0.016 no 0 3439 9 942 27.3916836
304 VIYKKFILL 0.016 no 0 2775 9 1374 49.5135135
305 YSFAKKYNYL 0.016 yes 0 335 10 299 89.2537313
306 FSPRNYFEI 0.0155 no 8 4154 9 2168 52.1906596
307 SGISNFFFI 0.01517 no 0 742 9 286 38.5444744
308 FAYNKYAPL 0.015 no 9 1936 9 422 21.7975207
309 MAMLNGFTL 0.015 no 0 438 9 4 0.91324201
310 TSYFFFPFL 0.015 yes 3 1058 9 886 83.7429112
311 LCLRYYALL 0.015 no 3 2151 9 383 17.8056718
312 SCYLFISLI 0.015 no 6 951 9 350 36.8033649
313 VNPFYHYL 0.015 yes 1 2081 8 1737 83.4694858
314 VNVHFYINL 0.015 yes 2 429 9 353 82.2843823
315 INYSFSIFL 0.015 yes 1 720 9 698 96.9444444
316 YSMSNYEDI 0.015 no 0 1828 9 10 0.54704595
317 VNYINFNYL 0.015 no 0 697 9 225 32.2812052
318 FNIYNLDFI 0.015 yes 0 2150 9 728 33.8604651
319 LSYTRFNNF 0.015 no 0 855 9 590 69.005848
320 STYFFRSIPL 0.015 yes 16 1292 10 870 67.3374613
321 SSYFNCAPI 0.015 no 0 1057 9 522 49.385052
322 SMFFYLSFNL 0.015 yes 0 2150 10 1580 73.4883721
323 YSYKYFYNFIL 0.015 yes 0 1796 11 211 11.7483296
324 VVMNFYFLL 0.01468 no 0 1155 9 34 2.94372294
irrelevant negative peptide (SIINFEKL) 0.01468
325 RSFFYYRLL 0.01465 yes 0 2997 9 2896 96.6299633
326 LNYIRYNML 0.01462 no 0 1069 9 1044 97.6613658
327 ISYLNYLNL 0.01457 no 0 441 9 199 45.1247166
328 YSYQNVNTM 0.014545 no 16 988 9 28 2.8340081
329 YTYYFFTSL 0.0145 no 7 288 9 205 71.1805556
330 STYYYSML 0.014 no 0 426 8 359 84.2723005
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288 SQYHRFLKL
289 VMYYTYEL
290 YGATNYDEM
291 ITILNYLPL
292 SVLWFFYKPL
293 VAYSHEYIGHM
294 SNYAYFTILNL
295 SSYLSYYLLPL
296 FSYSCHKYLLL
297 INYLFGTL
298 SAVLNFTIL
299 SSLSFGNYI
300 INFSYFYSL
301 VTYQMYYSRL
302 SSFFFFSKF
303 YSFIRFSIL
304 VIYKKFILL
305 YSFAKKYNYL
306 FSPRNYFEI
307 SGISNFFFI
308 FAYNKYAPL
309 MAMLNGFTL
310 TSYFFFPFL
311 LCLRYYALL
312 SCYLFISLI
313 VNPFYHYL
314 VNVHFYINL
315 INYSFSIFL
316 YSMSNYEDI
317 VNYINFNYL
318 FNIYNLDFI
319 LSYTRFNNF
320 STYFFRSIPL
321 SSYFNCAPI
322 SMFFYLSFNL
323 YSYKYFYNFIL
324 VVMNFYFLL
irrelevant negative peptide (SIINFEKL)
325 RSFFYYRLL
326 LNYIRYNML
327 ISYLNYLNL
328 YSYQNVNTM
329 YTYYFFTSL
330 STYYYSML
Novel 
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number
Peptide sequence
TARUN 
2008 spz
Tarun 2008 
EEF
+/- +/- +/- +/- +/- +/- +/-
Kb 0.756 14.09 0.03 Kb 0.7662 12.5458 0.0252 + + + + + - -
Kb 0.687 29.56 0.07 Kb 0.7616 13.1841 0.0269 - - + + - - -
Db 0.802 8.47 0.03 Db 0.7419 16.3306 0.0078 - - + - + + -
Db 0.775 11.41 0.03 Db 0.7213 20.4 0.0084 - + - - - - -
Kb 0.599 76.2 0.3 Kb 0.6916 28.1152 0.0715 - + - - - - -
Kb 0.606 71.02 0.25 Kb 0.6039 72.6403 0.184 + + - - + - -
Kb 0.668 36.31 0.1 Kb 0.8295 6.3243 0.0094 + + - - + - -
Kb 0.633 52.74 0.17 Kb 0.7 25.6876 0.0638 + + + + + - -
Kb 0.591 83.99 0.3 Kb 0.5404 144.409 0.3564 + - - - + - -
Kb 0.833 6.12 0.01 Kb 0.914 2.5364 0.0048 + + - - + - -
Db 0.866 4.29 0.01 Db 0.8265 6.5339 0.0052 - - - - + - -
Db 0.461 340.99 0.25 Db 0.487 257.467 0.0673 - - - - + - -
Kb 0.802 8.52 0.01 Kb 0.907 2.7351 0.0051 - + - - + - -
Kb 0.685 30.21 0.07 Kb 0.8584 4.6299 0.0078 - + + + - - -
Kb 0.796 9.04 0.01 Kb 0.8279 6.4396 0.0095 - + - - - - -
Kb 0.776 11.35 0.01 Kb 0.8059 8.1645 0.0129 - + - - + - -
Kb 0.792 9.49 0.01 Kb 0.8058 8.1774 0.0129 - + + + + - -
Kb 0.595 80 0.3 Kb 0.6087 69.0043 0.1742 + - + - - - -
Db 0.837 5.83 0.01 Db 0.7631 12.9736 0.0071 + - - - + - -
Db 0.844 5.41 0.01 Db 0.8438 5.4172 0.0047 + - - - - - -
Kb 0.85 5.07 0.01 Kb 0.8417 5.5457 0.0088 - - - - + - -
Db 0.868 4.17 0.01 Db 0.8755 3.8457 0.0038 - - - - + - -
Kb 0.831 6.26 0.01 Kb 0.8971 3.043 0.0057 - - - - - + -
Kb 0.596 79.14 0.3 Kb 0.6616 38.8957 0.099 - + - - + - -
Kb 0.557 120.03 0.5 Kb 0.5682 106.856 0.2756 - + - - + - -
Kb 0.736 17.49 0.05 Kb 0.7967 9.0203 0.0149 - + + + + - -
Kb 0.786 10.07 0.01 Kb 0.8703 4.0673 0.0072 - - + - - - -
Kb 0.796 9.09 0.01 Kb 0.863 4.4023 0.0076 - + + - + - -
Db 0.883 3.55 0.01 Db 0.8535 4.8784 0.0044 - + - - + - -
Kb 0.797 8.94 0.01 Kb 0.8284 6.4057 0.0095 - + - - + - -
Db 0.774 11.6 0.03 Db 0.7868 10.046 0.0064 - + - - - - -
Kb 0.774 11.53 0.03 Kb 0.7517 14.6821 0.0308 - + - - + - -
Kb 0.755 14.17 0.03 Kb 0.7367 17.271 0.038 - + - - + - -
Db 0.76 13.42 0.03 Db 0.7352 17.6 0.008 - + - - + - -
Kb 0.698 26.39 0.07 Kb 0.7237 19.8754 0.0468 - + - - - - -
Kb 0.631 53.9 0.2 Kb 0.7186 21.0134 0.0507 - + - - + + -
Kb 0.801 8.61 0.01 Kb 0.8091 7.8923 0.0122 + + - - - - -
Kb 0.796 9.09 0.01 Kb 0.8802 3.6565 0.0066 + + - - + - +
Kb 0.801 8.57 0.01 Kb 0.8212 6.9238 0.0099 + + - - + - -
Kb 0.777 11.17 0.01 Kb 0.8721 3.9901 0.0071 + - - - - - -
Db 0.837 5.8 0.01 Db 0.8333 6.0702 0.005 + + - - + - -
Kb 0.833 6.09 0.01 Kb 0.8841 3.5032 0.0064 - - + + + - +
Kb 0.853 4.93 0.01 Kb 0.8983 3.0057 0.0056 - + - - + - -
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288 SQYHRFLKL
289 VMYYTYEL
290 YGATNYDEM
291 ITILNYLPL
292 SVLWFFYKPL
293 VAYSHEYIGHM
294 SNYAYFTILNL
295 SSYLSYYLLPL
296 FSYSCHKYLLL
297 INYLFGTL
298 SAVLNFTIL
299 SSLSFGNYI
300 INFSYFYSL
301 VTYQMYYSRL
302 SSFFFFSKF
303 YSFIRFSIL
304 VIYKKFILL
305 YSFAKKYNYL
306 FSPRNYFEI
307 SGISNFFFI
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309 MAMLNGFTL
310 TSYFFFPFL
311 LCLRYYALL
312 SCYLFISLI
313 VNPFYHYL
314 VNVHFYINL
315 INYSFSIFL
316 YSMSNYEDI
317 VNYINFNYL
318 FNIYNLDFI
319 LSYTRFNNF
320 STYFFRSIPL
321 SSYFNCAPI
322 SMFFYLSFNL
323 YSYKYFYNFIL
324 VVMNFYFLL
irrelevant negative peptide (SIINFEKL)
325 RSFFYYRLL
326 LNYIRYNML
327 ISYLNYLNL
328 YSYQNVNTM
329 YTYYFFTSL
330 STYYYSML
Novel 
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number
Peptide sequence
UIS genes 
Matuschewski 2002 
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2004 (sg spz v 
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DSK hi (highly 
downregulated in 
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DSK lo (lowly 
downregulated in 
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+/- +/- +/- +/-
- - - -
- - - -
- - - -
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- - - -
- - - -
- - - -
- - - -
- - - -
- - - -
- - - -
- - - -
- - - -
- - - -
- - - -
- - - -
- - - -
- - - -
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- - - -
- - - -
- - - +
- - - -
- - - -
- - - +
- - - -
- - - +
- - - -
- - - -
- - - -
- - - -
P. berghei originorthologs of P. yoelii
Expression data
MicroarraySSH
331 ICFPFFNRL 0.014 no 0 2038 9 408 20.01962709 Kb 0.717 21.37 0.05
332 ICYKYFDVL 0.014 no 0 447 9 236 52.79642058 Kb 0.577 97.73 0.4
333 MCYDHCSAL 0.014 yes 1 2081 9 1757 84.43056223 Kb 0.545 136.67 0.5
334 SCYSYINTM 0.014 no 1 940 9 590 62.76595745 Kb 0.616 64.08 0.25
335 SVFDYFTSF 0.014 yes 1 2096 9 199 9.494274809 Kb 0.752 14.63 0.03
336 KMFVNLSGF 0.014 no 0 258 9 210 81.39534884 Kb 0.568 107.72 0.4
337 VLYLKFCNF 0.014 no 0 174 9 160 91.95402299 Kb 0.649 44.36 0.15
338 INYNFYSML 0.014 no 3 1115 9 1012 90.76233184 Kb 0.877 3.76 0.01
339 MAITNILTI 0.014 no 0 1153 9 968 83.95490026 Db 0.89 3.29 0.01
340 YNYTFQAL 0.014 yes 0 1272 8 525 41.27358491 Kb 0.804 8.29 0.01
341 ISLVNNYVYI 0.014 no 4 2562 10 1330 51.91256831 Db 0.821 6.9 0.01
342 VIYAHILNL 0.0135 yes 2 1349 9 446 33.06152706 Kb 0.75 15.03 0.03
343 LAYAYYSSL 0.0135 no 0 655 9 582 88.85496183 Kb 0.814 7.48 0.01
344 VSYTRYASEM 0.0135 no 0 70 10 6 8.571428571 Kb 0.679 32.24 0.1
345 INYNFINL 0.013485 yes 0 495 8 320 64.64646465 Kb 0.843 5.5 0.01
346 STYVFFPPI 0.01324 yes 5 420 9 406 96.66666667 Kb 0.818 7.16 0.01
347 SVYFFYAYL 0.013 no 4 3976 9 3108 78.16901408 Kb 0.863 4.38 0.01
348 MCYLYTLLL 0.013 no 4 1504 9 953 63.3643617 Kb 0.573 102.05 0.4
349 VCWRHFLAM 0.013 no 0 478 9 415 86.82008368 Kb 0.569 105.99 0.4
350 RGYDTFMNL 0.013 no 0 83 9 36 43.37349398 Kb 0.598 77.44 0.3
351 LSYKFFPEL 0.013 no 0 572 9 245 42.83216783 Kb 0.819 7.13 0.01
352 KAINNFEFM 0.013 no 12 1088 9 641 58.91544118 Db 0.862 4.45 0.01
353 ISIFHYPYL 0.013 no 0 915 9 675 73.7704918 Kb 0.805 8.2 0.01
354 AALCNQWYI 0.013 no 0 1249 9 623 49.87990392 Db 0.875 3.85 0.01
355 MSLVNNAYI 0.013 no 0 1801 9 462 25.65241532 Db 0.885 3.45 0.01
356 SSYFHFSFI 0.013 no 0 631 9 13 2.06022187 Kb 0.791 9.54 0.01
357 IAYFRSSNL 0.013 no 0 2840 9 770 27.11267606 Kb 0.797 8.94 0.01
358 VSFYKYNSM 0.013 no 0 811 9 381 46.97903822 Kb 0.82 7.01 0.01
359 IAFMFFLNSL 0.013 no 3 341 10 51 14.95601173 Kb 0.713 22.32 0.05
360 TSVINTDLL 0.013 yes 0 989 9 486 49.14054601 Db 0.803 8.38 0.03
361 VAYYFTYHSYM 0.013 no 0 1073 11 262 24.41752097 Kb 0.726 19.39 0.05
362 SSMFFYLSF 0.013 yes 0 2150 9 1579 73.44186047 Kb 0.75 15.03 0.03
363 FSFQFYHFTSF 0.013 yes 2 896 11 194 21.65178571 Kb 0.613 65.84 0.25
364 YANKNNNLQFL 0.013 no 0 343 11 87 25.36443149 Db 0.648 45.09 0.07
365 YSYFYFQNNL 0.012895 no 7 5611 10 3535 63.00124755 Kb 0.724 19.92 0.05
366 ITYSRQPHL 0.012665 no 0 167 9 103 61.67664671 Kb 0.786 10.18 0.01
367 RTLSNFTFI 0.01265 yes 0 1304 9 875 67.10122699 Db 0.816 7.32 0.01
368 SAIVNISLV 0.012525 no 16 988 9 362 36.63967611 Db 0.858 4.65 0.01
369 HSMSNHVPM 0.01219 no 0 3296 9 1074 32.58495146 Db 0.861 4.5 0.01
370 LAYAYYSSLL 0.012135 no 0 655 10 582 88.85496183 Kb 0.701 25.41 0.07
371 RALENYTNI 0.012105 no 0 1986 9 731 36.80765358 Db 0.875 3.89 0.01
372 CMFSFFSYL 0.012 yes 2 259 9 239 92.27799228 Kb 0.838 5.77 0.01
373 SSLVNREFI 0.012 no 0 1005 9 985 98.00995025 Db 0.915 2.51 0.01
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+/- +/- +/- +/- +/- +/- +/- +/- +/- +/- +/-
Kb 0.8342 6.015 0.0092 - + - - + - - - - - -
Kb 0.7062 24.008 0.0585 - - - - + - + - - - -
Kb 0.5326 157.0695 0.3795 - + + + + - - - - - -
Kb 0.649 44.5869 0.1115 - - - - + - - - - - -
Kb 0.7994 8.7614 0.0143 - - - - + - - - - - -
Kb 0.4877 255.3201 0.5884 + - - - - - - - - - -
Kb 0.6757 33.3991 0.0838 - + - - - - - - - - +
Kb 0.9404 1.9053 0.0033 - - - - - - - - - - +
Db 0.8657 4.2761 0.004 - + - - + - - - - - -
Kb 0.8442 5.3939 0.0086 + + - - + - - - - - -
Db 0.6688 35.9876 0.01 - - - - + - - - - - +
Kb 0.8192 7.0698 0.01 + - - - + - - - - - -
Kb 0.9052 2.7894 0.0052 - - - - - - + - - - -
Kb 0.7769 11.1745 0.0216 - + + - + - + - - - -
Kb 0.9222 2.3202 0.0043 - - - - - + - - - - -
Kb 0.8783 3.7304 0.0067 - - - - - - + - - - +
Kb 0.89 3.2885 0.0061 - - - - + - - - - - -
Kb 0.5592 117.9035 0.3006 + - - - - - - - - - -
Kb 0.5924 82.3221 0.2107 - - - - - - + - - - -
Kb 0.7266 19.2606 0.0446 - + + - + - + - - - -
Kb 0.8919 3.2218 0.006 - + - - + - - - - - -
Db 0.877 3.7845 0.0037 - + + + + - - - - - -
Kb 0.8625 4.4255 0.0076 - + - - + - - - - - -
Db 0.856 4.7513 0.0043 - + + + + - - - - - -
Db 0.8559 4.7562 0.0043 - - + - + - - - - - -
Kb 0.8495 5.0967 0.0083 - + + + + - - - - - -
Kb 0.8399 5.6536 0.0089 - + - - + - - - - - -
Kb 0.8219 6.8697 0.0099 - + - - + - - - - - -
Kb 0.8147 7.4251 0.011 - - + - + - - - - - -
Db 0.7496 15.0122 0.0076 - + - - + - - - - - -
Kb 0.7322 18.1357 0.0402 - + - - + - - - - - -
Kb 0.7221 20.2177 0.0481 - + - - - - - - - - -
Kb 0.5516 127.9255 0.3231 - + + - + - - - - - -
Db 0.5123 195.8389 0.0489 - + - - + - - - - - -
Kb 0.8214 6.9052 0.0099 - - - - - - - - - - +
Kb 0.776 11.2833 0.0219 + + - - + - + - - - -
Db 0.7682 12.2865 0.007 + - - - - + - - - - -
Db 0.8354 5.9341 0.005 + + - - + - - - - - -
Db 0.8386 5.7361 0.0049 - + + + + - - - - - -
Kb 0.7903 9.6666 0.017 - - - - - - + - - - -
Db 0.7955 9.1365 0.0062 + + + + + - - - - - -
Kb 0.8312 6.2133 0.0093 - - - - + - - - - - -
Db 0.8791 3.6988 0.0036 - - - - + - - - - - -
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374 VSYKYYDL 0.012 no 0 596 8 146 24.4966443 Kb 0.825 6.64 0.01
375 NCYYFYEI 0.012 no 4 608 8 137 22.53289474 Kb 0.319 1593.49 5
376 VCYIFFISF 0.012 no 22 3004 9 1391 46.30492676 Kb 0.583 91.09 0.4
377 IMYYFSIL 0.012 no 6 4789 8 296 6.180831071 Kb 0.83 6.33 0.01
378 YSIKNSYSL 0.012 no 2 519 9 479 92.29287091 Db 0.84 5.65 0.01
379 ANFNRYSFL 0.012 yes 0 255 9 1 0.392156863 Kb 0.782 10.52 0.01
380 YSIINNRFI 0.012 no 2 2434 9 1634 67.13229252 Db 0.841 5.56 0.01
381 NSMRNSETI 0.012 yes 0 786 9 367 46.69211196 Db 0.815 7.4 0.01
382 SSFLRLGLL 0.012 no 10 554 9 529 95.48736462 Kb 0.756 14.01 0.03
383 YAIKNSNYEIV 0.012 no 4 611 11 88 14.40261866 Db 0.713 22.32 0.05
384 YSIFNNDNEI 0.012 no 4 3053 10 2608 85.42417294 Db 0.801 8.61 0.03
385 VSYARHFLFM 0.012 yes 1 2081 10 1291 62.03748198 Kb 0.742 16.31 0.03
386 SSFLFLSNL 0.011905 no 0 1411 9 505 35.7902197 Kb 0.815 7.4 0.01
387 INYFAYYISYL 0.011585 yes 1 453 11 311 68.65342163 Kb 0.651 43.88 0.15
388 QTYPYYSTL 0.0115 no 0 243 9 174 71.60493827 Kb 0.806 8.11 0.01
389 ASYEFTTL 0.011 no 0 365 8 89 24.38356164 Kb 0.829 6.4 0.01
390 IIYRRYASL 0.011 no 0 146 9 56 38.35616438 Kb 0.832 6.19 0.01
391 SAMENYFVL 0.011 no 0 797 9 752 94.35382685 Db 0.884 3.51 0.01
392 SIYTFMRL 0.011 no 0 542 8 276 50.92250923 Kb 0.828 6.43 0.01
393 NCLIYSLL 0.011 no 0 349 8 232 66.4756447 Kb 0.27 2678.54 7
394 NCYNFGLV 0.011 no 0 501 8 219 43.71257485 Kb 0.304 1854.1 5
395 RCYSKYIYL 0.011 no 0 2418 9 728 30.10752688 Kb 0.622 59.73 0.25
396 SCFFFFYEM 0.011 no 0 1114 9 153 13.73429084 Kb 0.618 62.37 0.25
397 SCYSYSNLF 0.011 no 0 129 9 41 31.78294574 Kb 0.586 88.18 0.4
398 VNFFFMYL 0.011 no 1 918 8 119 12.96296296 Kb 0.838 5.77 0.01
399 KSIVNKDFI 0.011 no 0 649 9 242 37.28813559 Db 0.873 3.97 0.01
400 VMYFFGSSL 0.011 no 12 505 9 153 30.2970297 Kb 0.81 7.77 0.01
401 SSLQNVSFL 0.011 yes 3 628 9 75 11.94267516 Db 0.868 4.17 0.01
402 YSIPNSYSI 0.011 yes 0 1049 9 849 80.93422307 Db 0.824 6.75 0.01
403 STICNTDSI 0.011 no 0 2518 9 934 37.0929309 Db 0.788 9.91 0.03
404 FSFMNGVLI 0.011 no 13 585 9 222 37.94871795 Db 0.828 6.43 0.01
405 YSINNNEQL 0.011 yes 1 473 9 404 85.41226216 Db 0.767 12.44 0.03
406 YMYVNIFEI 0.011 no 10 2269 9 1278 56.32437197 Db 0.871 4.06 0.01
407 AAIHNANDLAL 0.011 yes 0 917 11 241 26.28135224 Db 0.648 45.09 0.07
408 FAFSFFNGL 0.01069 no 11 500 9 107 21.4 Kb 0.824 6.71 0.01
no peptide restimulation 0.010650367
409 YANKNYSSI 0.01064 yes 2 679 9 339 49.9263623 Db 0.786 10.07 0.03
410 VGYESFSPL 0.010625 no 0 131 9 15 11.45038168 Kb 0.782 10.58 0.01
411 FSYINYSNL 0.0103375 yes 1 1192 9 556 46.6442953 Kb 0.77 12.04 0.03
412 ICPSYYLKL 0.01 yes 0 908 9 229 25.22026432 Kb 0.556 122 0.5
413 NCIFYFLL 0.01 no 4 3976 8 176 4.426559356 Kb 0.296 2021.74 6
414 KSVENPTEI 0.01 yes 0 1406 9 94 6.685633001 Db 0.75 14.95 0.05
415 SSYIYFLL 0.01 yes 11 1035 8 899 86.85990338 Kb 0.846 5.29 0.01
331 ICFPFFNRL
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74 VSYKYYDL
375 NCYYFYEI
376 VCYIFFISF
377 IMYYFSIL
378 YSIKNSYSL
379 ANFNRYSFL
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383 YAIKNSNYEIV
384 YSIFNNDNEI
385 VSYARHFLFM
386 SSFLFLSNL
387 INYFAYYISYL
388 QTYPYYSTL
389 ASYEFTTL
390 IIYRRYASL
391 SAMENYFVL
392 SIYTFMRL
393 NCLIYSLL
394 NCYNFGLV
395 RCYSKYIYL
396 SCFFFFYEM
397 SCYSYSNLF
398 VNFFFMYL
399 KSIVNKDFI
400 VMYFFGSSL
401 SSLQNVSFL
402 YSIPNSYSI
403 STICNTDSI
404 FSFMNGVLI
405 YSINNNEQL
406 YMYVNIFEI
407 AAIHNANDLAL
408 FAFSFFNGL
no peptide restimulation
409 YANKNYSSI
410 VGYESFSPL
411 FSYINYSNL
412 ICPSYYLKL
413 NCIFYFLL
414 KSVENPTEI
415 SSYIYFLL
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Kb 0.8961 3.0762 0.0057 - - - - + - - - - - -
Kb 0.4334 459.5107 0.9427 - + - - + - - - - - -
Kb 0.4978 229.0651 0.5367 - - + + - - - - - - -
Kb 0.8813 3.6112 0.0066 - - + + + - - - - - -
Db 0.8388 5.7221 0.0049 - + - - + - - - - - -
Kb 0.8264 6.5408 0.0096 - + + + + - - - - - -
Db 0.8134 7.5271 0.0056 - + - - + - - - - - -
Db 0.8123 7.6178 0.0057 + + - - + - - - - - -
Kb 0.7581 13.7059 0.0283 - + - - - - - - - - -
Db 0.7283 18.9165 0.0082 - + - - + - - - - - -
Db 0.7228 20.0629 0.0084 - + - - + - - - - - -
Kb 0.7167 21.448 0.0519 - + + + + - - - - - -
Kb 0.904 2.8252 0.0053 - - - - - - - - - - +
Kb 0.7772 11.1472 0.0215 + + + - + - - - - - -
Kb 0.8685 4.1505 0.0073 + + + + + - - - - - -
Kb 0.9015 2.9032 0.0055 - + - - + - - - - - -
Kb 0.8753 3.8552 0.0069 - - - - + - - - - - -
Db 0.8911 3.2477 0.0033 - - - - + - - - - - -
Kb 0.9059 2.7677 0.0052 - + - - + + + - - - -
Kb 0.3542 1082.694 1.9291 + + + - + - - - - - -
Kb 0.3572 1047.956 1.8854 + + + + + - - - - - -
Kb 0.6131 65.7385 0.1672 - + - - + - - - - - -
Kb 0.6484 44.8802 0.1121 - - - - + - - - - - -
Kb 0.5492 131.3236 0.3303 - - - - - - + - - - -
Kb 0.9108 2.6254 0.0049 - + - - + - - - - - -
Db 0.8611 4.4935 0.0042 - - - - - - - - - - +
Kb 0.8493 5.1044 0.0083 - + - - + - + - - - -
Db 0.8457 5.3078 0.0047 - + + - + - + - - - -
Db 0.8223 6.8395 0.0054 - - + + - - - - - - -
Db 0.8183 7.1399 0.0055 - - - - - - - - - - +
Db 0.7852 10.2136 0.0065 - + + - + - - - - - -
Db 0.7673 12.406 0.007 - + - - + - - - - - -
Db 0.7601 13.4036 0.0072 - + - - + - - - - - +
Db 0.5566 121.2569 0.0345 + + - - + - - - - - -
Kb 0.8464 5.2669 0.0085 + + + - + - - - - - -
Db 0.7631 12.9754 0.0071 + - - - - - + - - - -
Kb 0.8498 5.081 0.0083 - + - - + + + - - - -
Kb 0.8319 6.2 0.0093 + + - - + - - - - - -
Kb 0.6753 33.5571 0.0842 + + + - + - - - - - -
Kb 0.3662 951.0274 1.7381 - - - - + - - - - - -
Db 0.7052 24.2862 0.0089 + - + - - - - - - - -
Kb 0.8986 2.994 0.0056 - + - - + - - - - - -
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416 VSYLFTPNM 0.01 no 5 1902 9 1744 91.69295478 Kb 0.81 7.77 0.01
417 TTFSFFFTL 0.01 no 5 399 9 379 94.98746867 Kb 0.794 9.24 0.01
418 TTYYFMLHL 0.01 no 0 3368 9 3183 94.50712589 Kb 0.806 8.16 0.01
419 SNYFRFRLAL 0.01 no 0 494 10 5 1.012145749 Kb 0.75 14.95 0.03
420 SAPNNNINPL 0.01 no 0 607 10 190 31.3014827 Db 0.77 11.98 0.03
421 KAMINDITI 0.00998 no 0 1192 9 703 58.97651007 Db 0.844 5.41 0.01
422 SSYKKFILL 0.009976667 no 0 5309 9 1102 20.75720475 Kb 0.823 6.79 0.01
423 YTILNDENM 0.00995 yes 1 2096 9 903 43.08206107 Db 0.736 17.49 0.05
424 SSYGKLMYFLM 0.00995 no 0 609 11 223 36.61740558 Kb 0.679 32.06 0.1
425 ISVENYPVI 0.00993 yes 1 1809 9 1280 70.75732449 Db 0.747 15.45 0.05
426 INYNYYLM 0.0099 no 0 1370 8 294 21.45985401 Kb 0.828 6.47 0.01
427 SNYRNFFLL 0.00986 no 0 4800 9 415 8.645833333 Kb 0.774 11.47 0.03
428 KNYNFIFL 0.00979 yes 4 1785 8 621 34.78991597 Kb 0.772 11.79 0.03
429 ITFLFYNIL 0.00979 yes 0 2150 9 1910 88.8372093 Kb 0.793 9.34 0.01
430 VNYHFSNYM 0.00978 yes 1 2081 9 811 38.97164825 Kb 0.826 6.61 0.01
431 YIYERYIRL 0.00974 no 0 2412 9 381 15.7960199 Kb 0.799 8.8 0.01
432 KIYGYFTLL 0.00972 no 0 1250 9 39 3.12 Kb 0.81 7.77 0.01
433 ASVVFQEL 0.00969 no 0 255 8 94 36.8627451 Kb 0.601 74.97 0.3
434 YGFKYYPL 0.00962 yes 1 1192 8 661 55.45302013 Kb 0.812 7.65 0.01
435 IGFNRFTTF 0.009615 no 0 541 9 490 90.57301294 Kb 0.76 13.35 0.03
436 VIFTFYHIL 0.00961 no 13 585 9 202 34.52991453 Kb 0.764 12.92 0.03
437 IVYYFYARM 0.00955 no 4 675 9 306 45.33333333 Kb 0.865 4.29 0.01
438 SSFYFFFNSL 0.00953 no 0 1415 10 472 33.35689046 Kb 0.79 9.7 0.01
439 VSFEFNNL 0.0095 no 6 4789 8 2356 49.19607434 Kb 0.836 5.93 0.01
440 HAIENIPAI 0.00945 no 0 349 9 155 44.41260745 Db 0.797 8.94 0.03
441 ISMSHYLYSTL 0.00943 no 12 1210 11 1119 92.47933884 Kb 0.629 55.08 0.2
442 INFNYFSLL 0.00938 no 2 524 9 441 84.16030534 Kb 0.864 4.36 0.01
443 ITYLYFNL 0.00934 no 0 2337 8 398 17.03038083 Kb 0.849 5.15 0.01
444 VSLSNLFYL 0.00932 no 0 1228 9 304 24.75570033 Db 0.827 6.5 0.01
445 IMFAFAGL 0.00927 no 6 283 8 199 70.3180212 Kb 0.833 6.09 0.01
446 YALENKSLL 0.00927 yes 0 479 9 257 53.65344468 Db 0.83 6.33 0.01
447 KTYLYYHTLL 0.00925 no 0 663 10 59 8.898944193 Kb 0.688 29.41 0.07
448 INYIHMCLFLL 0.00922 yes 0 748 11 544 72.72727273 Kb 0.617 63.05 0.25
449 KSYYFYISL 0.00918 no 0 1059 9 366 34.56090652 Kb 0.842 5.53 0.01
450 ITMSNIDYI 0.00915 no 0 410 9 387 94.3902439 Db 0.813 7.56 0.01
451 FAMKNNVDCI 0.00914 no 0 255 10 98 38.43137255 Db 0.779 10.93 0.03
452 FSLENNITEL 0.00907 yes 0 879 10 626 71.21729238 Db 0.792 9.44 0.03
453 MSYPFFPLL 0.00902 no 0 4287 9 3924 91.53254024 Kb 0.865 4.31 0.01
454 IMFERWNQL 0.00895 no 6 4789 9 3151 65.79661725 Kb 0.816 7.36 0.01
455 YSIFNVNAEII 0.00887 no 2 7126 11 1166 16.36261577 Db 0.657 40.68 0.07
456 KAVKNYVEI 0.008725 yes 0 776 9 472 60.82474227 Db 0.823 6.82 0.01
457 STYYYEYAM 0.00869 yes 0 3254 9 1912 58.75845114 Kb 0.737 17.21 0.05
458 VIFSRLSNF 0.008675 no 0 1384 9 843 60.91040462 Kb 0.748 15.28 0.03
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Kb 0.8832 3.5393 0.0065 - + - - + - - - - - -
Kb 0.86 4.5485 0.0077 - + + - + + - - - - -
Kb 0.8293 6.3383 0.0094 - + - - + - - - - - -
Kb 0.8169 7.2514 0.0105 - + - - - - - - - - -
Db 0.6424 47.8919 0.013 - - - - + - - - - - -
Db 0.8371 5.8243 0.0049 - + - - - - - - - - -
Kb 0.8357 5.9148 0.0091 + + - - + - - - - - -
Db 0.6846 30.3523 0.0095 - - - - + - - - - - -
Kb 0.5482 132.7579 0.3333 - + - - + - - - - - -
Db 0.7045 24.4579 0.0089 - - - - + - - - - - +
Kb 0.8719 3.9999 0.0071 - + - - + - - - - - -
Kb 0.8136 7.5158 0.0112 - + - - + - - - - - -
Kb 0.8367 5.8507 0.009 - - - - + - - - - - -
Kb 0.8518 4.9718 0.0082 - + - - - - - - - - -
Kb 0.8392 5.6943 0.0089 - + + + + - - - - - -
Kb 0.781 10.6944 0.0203 - + - - + - - - - - -
Kb 0.8425 5.4975 0.0087 - + + + + - - - - - -
Kb 0.702 25.123 0.0618 - + - - - - + - - - -
Kb 0.8332 6.0781 0.0092 + + - - + - - - - - -
Kb 0.7512 14.7576 0.0311 - + - - + - - + - - -
Kb 0.8715 4.0152 0.0071 - + + - + - - - - - -
Kb 0.899 2.983 0.0056 - + - - - - - - - - -
Kb 0.8426 5.4902 0.0087 - - - - - - - + - - -
Kb 0.9238 2.2811 0.0042 - - + + + - - - - - -
Db 0.7467 15.4925 0.0076 + + + - + - - - - - -
Kb 0.6648 37.5724 0.0952 - - + - - - - - - - -
Kb 0.9277 2.1872 0.004 - - + - - - - - - - -
Kb 0.9194 2.3906 0.0045 - - + + - - - - - - -
Db 0.8209 6.9409 0.0054 - + - - + - - - - - -
Kb 0.905 2.7937 0.0053 - + + + + - - - - - -
Db 0.809 7.8936 0.0058 - - + + + - - - - - -
Kb 0.7478 15.316 0.0327 - - + + - - - - - - -
Kb 0.5888 85.5336 0.2201 + + - - + - - - - - -
Kb 0.8912 3.2467 0.006 - + - - + - - - - - -
Db 0.8368 5.8443 0.0049 - + + + + - - - - - -
Db 0.723 20.0252 0.0084 - + - - - - + - - - -
Db 0.6862 29.8297 0.0095 - - + + - - - - - - -
Kb 0.904 2.8252 0.0053 - - + - - - - - - - -
Kb 0.7578 13.7455 0.0284 - - + + + - - - - - -
Db 0.7047 24.4137 0.0089 - - - - + - - - - - +
Db 0.7909 9.6097 0.0063 + + + + + - - - - - +
Kb 0.7242 19.7647 0.0464 + - - - - - - - - - -
Kb 0.711 22.7966 0.0555 + + - - + + - - - - -
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459 KSIKNNDFI 0.00864 no 2 7480 9 3533 47.23262032 Db 0.85 5.1 0.01
460 SSYLSYYLL 0.008565 yes 2 395 9 231 58.48101266 Kb 0.768 12.24 0.03
461 NSLLNVDEI 0.00853 no 0 622 9 336 54.0192926 Db 0.863 4.43 0.01
462 ISYNFYRIF 0.008525 no 0 787 9 75 9.529860229 Kb 0.796 9.09 0.01
463 RTFYYFHGL 0.0085 yes 2 1349 9 832 61.67531505 Kb 0.761 13.28 0.03
464 YANYNNTYI 0.00842 no 2 3724 9 311 8.351235231 Db 0.869 4.1 0.01
465 INYNKYIHL 0.00839 no 0 5249 9 3477 66.2411888 Kb 0.828 6.47 0.01
466 VSIENYHLI 0.00838 no 0 547 9 458 83.72943327 Db 0.826 6.57 0.01
467 VSFMYSRKL 0.00831 yes 1 3204 9 1982 61.86017478 Kb 0.744 16.04 0.03
468 CSISNPTYI 0.00811 no 0 1396 9 1344 96.27507163 Db 0.843 5.47 0.01
469 SLYNYFFNL 0.008 no 0 3018 9 1805 59.80781975 Kb 0.77 12.11 0.03
470 TGYARYFAL 0.008 no 0 256 9 168 65.625 Kb 0.776 11.35 0.01
471 SNYIKYNQL 0.008 yes 0 1354 9 295 21.7872969 Kb 0.792 9.44 0.01
472 YAQTNPLPL 0.008 no 0 1038 9 138 13.29479769 Db 0.806 8.16 0.01
473 KSIKNTDNI 0.008 yes 0 1109 9 982 88.54824166 Db 0.775 11.35 0.03
474 IIYNFFINNL 0.00795 no 0 6521 10 3221 49.39426468 Kb 0.717 21.37 0.05
475 ISYSFQNEL 0.00791 no 0 797 9 779 97.74153074 Kb 0.825 6.68 0.01
476 FALCNSNFHII 0.00783 no 0 2420 11 135 5.578512397 Db 0.689 28.93 0.07
477 YTMCNYTLM 0.00774 no 8 1272 9 950 74.68553459 Db 0.866 4.26 0.01
478 YNYYFSYL 0.00765 no 4 2996 8 2649 88.41789052 Kb 0.844 5.41 0.01
479 YSYLYTPL 0.00763 no 0 610 8 166 27.21311475 Kb 0.861 4.52 0.01
480 STFFFTLL 0.00763 no 2 533 8 270 50.65666041 Kb 0.821 6.97 0.01
481 ITYQRHIPF 0.00761 yes 3 1149 9 40 3.481288077 Kb 0.766 12.64 0.03
482 INYIYNGI 0.0076 yes 1 1809 8 1249 69.04367054 Kb 0.731 18.37 0.05
483 YALENKSLLPI 0.00758 yes 0 479 11 257 53.65344468 Db 0.685 30.05 0.07
484 ITYKYSLL 0.00752 yes 0 2773 8 415 14.96574107 Kb 0.852 4.96 0.01
485 LAIQNNMPTM 0.0075 yes 1 1791 10 890 49.69290899 Db 0.736 17.49 0.05
486 ASFEFISHL 0.00749 no 0 1168 9 502 42.97945205 Kb 0.779 10.93 0.01
487 SIFLFTPL 0.00746 no 9 1936 8 866 44.73140496 Kb 0.827 6.5 0.01
488 YAINNPNFNNL 0.00707 no 0 1388 11 788 56.77233429 Db 0.7 25.69 0.05
489 YSIVNEDIV 0.00678 no 0 415 9 404 97.34939759 Db 0.877 3.76 0.01
490 SSLLNEIEI 0.006725 no 0 219 9 91 41.55251142 Db 0.844 5.41 0.01
491 FTITNNHSPL 0.006665 no 0 154 10 46 29.87012987 Db 0.705 24.33 0.05
492 VSYALFALL 0.00649 yes 1 625 9 609 97.44 Kb 0.831 6.26 0.01
493 VSLLFFSYL 0.00647 no 13 585 9 530 90.5982906 Kb 0.823 6.79 0.01
494 KAISNFLPL 0.00644 no 0 3796 9 2645 69.67860906 Db 0.89 3.29 0.01
495 ASYERFINIL 0.00643 no 0 757 10 601 79.39233818 Kb 0.681 31.38 0.1
496 INYSRLFVSFL 0.00637 no 6 4789 11 600 12.52871163 Kb 0.641 48.37 0.17
497 IAYYFSVL 0.00636 no 0 659 8 332 50.37936267 Kb 0.841 5.59 0.01
498 YAISNFLSQTI 0.00635 no 0 1758 11 1653 94.02730375 Db 0.704 24.6 0.05
499 FSFCNSIPL 0.00633 no 0 2957 9 2413 81.60297599 Db 0.878 3.74 0.01
500 YSYNFYSTL 0.00632 no 0 1174 9 8 0.681431005 Kb 0.875 3.89 0.01
501 SIYYFFSKL 0.0063 yes 16 1292 9 649 50.23219814 Kb 0.849 5.12 0.01
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Db 0.8246 6.6708 0.0053 - + - - + - - - - - +
Kb 0.821 6.9344 0.0099 + + + + + - - - - - -
Db 0.8115 7.6908 0.0057 - + - - + - - - - - -
Kb 0.8295 6.3247 0.0094 + + + + + - - - - - -
Kb 0.8569 4.7022 0.0079 + - - - + - - - - - -
Db 0.8222 6.8464 0.0054 - - - - + - - - - - -
Kb 0.8812 3.6178 0.0066 + - - - - - - - - - -
Db 0.7775 11.103 0.0067 - - + + - - - - - - -
Kb 0.875 3.8661 0.0069 - - + + - - - - - - -
Db 0.8193 7.0642 0.0054 - - + + + - - - - - -
Kb 0.8577 4.6644 0.0079 - - - - - + - - - - -
Kb 0.8233 6.7637 0.0098 + + + + + - - - - - -
Kb 0.8195 7.046 0.01 + + - - + - - - - - -
Db 0.8029 8.4339 0.0059 + + + + + + - - - - -
Db 0.7668 12.4713 0.007 - - - - - - - - - - +
Kb 0.8281 6.4212 0.0095 - + - - + - - - - - -
Kb 0.8587 4.6115 0.0078 - - - - - - + - - - -
Db 0.7254 19.5102 0.0083 - + - - + - - - - - -
Db 0.834 6.0288 0.005 - - - - + - - - - - -
Kb 0.9059 2.7692 0.0052 - + - - + - - - - - -
Kb 0.9139 2.5374 0.0048 - + - - + - - - - - -
Kb 0.8904 3.2737 0.0061 - + - - + - - - - - -
Kb 0.7305 18.4742 0.0416 + - - - - - - - - - -
Kb 0.8573 4.6813 0.0079 - - - - + - - - - - +
Db 0.7592 13.5329 0.0073 - - + + + - - - - - -
Kb 0.9156 2.4912 0.0047 - + - - - - - - - - -
Db 0.6268 56.7162 0.0148 + - - - + - - - - - -
Kb 0.8672 4.2069 0.0074 - + - - + - - - - - -
Kb 0.8895 3.3053 0.0061 - - - - + - - - - - -
Db 0.6978 26.3118 0.0091 + + + + + - - - - - -
Db 0.8636 4.3749 0.0041 - + - - + - - - - - -
Db 0.7901 9.6927 0.0063 + + - - + - - - - - -
Db 0.6764 33.1679 0.0098 + - - - + - + - - - -
Kb 0.8875 3.3783 0.0062 - + + + + - - - - - -
Kb 0.8852 3.4629 0.0064 - + + - + - - - - - -
Db 0.8749 3.8719 0.0038 - - - - + - - - - - -
Kb 0.7217 20.3071 0.0484 - + + - - + - - - - -
Kb 0.7239 19.8297 0.0467 - - + + + - - - - - -
Kb 0.9011 2.9143 0.0055 - - - - - - + - - - -
Db 0.7878 9.9369 0.0064 - - + + + - - - - - -
Db 0.8716 4.0107 0.0039 - + + - + - - - - - +
Kb 0.924 2.2758 0.0042 - + - - + - - - - - -
Kb 0.9037 2.8355 0.0053 - + - - + - - - - - -
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502 NCYYPYTL 0.00629 no 0 420 8 127 30.23809524 Kb 0.248 3398.41 9
503 FSILNENEL 0.00627 no 0 2458 9 1121 45.60618389 Db 0.832 6.19 0.01
504 IIYSFYIYL 0.00625 no 3 970 9 904 93.19587629 Kb 0.838 5.8 0.01
505 STYYYSMLL 0.00625 no 0 426 9 359 84.27230047 Kb 0.814 7.52 0.01
506 TMYYFSISL 0.00622 no 0 1013 9 236 23.29713722 Kb 0.801 8.57 0.01
507 IGYYYYPYM 0.0062 no 0 870 9 850 97.70114943 Kb 0.84 5.68 0.01
508 VSMVNECFI 0.00617 no 0 2057 9 2004 97.42343218 Db 0.859 4.62 0.01
509 VSLSRFFSM 0.00616 no 5 245 9 50 20.40816327 Kb 0.757 13.86 0.03
510 FAFKNSCLAPM 0.00615 no 0 4800 11 1378 28.70833333 Db 0.72 20.58 0.05
511 MNYSKYLLL 0.00611 no 0 414 9 257 62.07729469 Kb 0.824 6.71 0.01
512 YTIQNKDEL 0.00608 no 0 1370 9 531 38.75912409 Db 0.8 8.66 0.03
513 YANLNMIHL 0.00607 no 0 739 9 361 48.84979702 Db 0.843 5.47 0.01
514 RSFIFYSAM 0.00605 no 0 368 9 37 10.05434783 Kb 0.809 7.9 0.01
515 VNYNKFLEL 0.00602 yes 8 592 9 257 43.41216216 Kb 0.813 7.56 0.01
516 LSLSNYLFL 0.006 yes 0 1354 9 597 44.0915805 Db 0.802 8.47 0.03
517 YALENNDSVL 0.00585 no 0 343 10 60 17.49271137 Db 0.806 8.16 0.01
518 YAYINLESL 0.00581 no 0 5434 9 2250 41.40596246 Db 0.86 4.55 0.01
519 VSLTNIDSI 0.00542 no 0 5317 9 5124 96.37013353 Db 0.847 5.24 0.01
520 YSYKYLAL 0.00536 no 0 383 8 365 95.3002611 Kb 0.825 6.68 0.01
521 SSLENMYEM 0.00526 no 0 551 9 168 30.49001815 Db 0.887 3.4 0.01
522 SIYLYYYL 0.00523 no 0 1471 8 662 45.00339905 Kb 0.824 6.75 0.01
523 YNFSSYFPLL 0.005 no 0 3183 10 407 12.78667923 Kb 0.677 32.94 0.1
524 FSYKRIGYL 0.00491 no 0 1067 9 76 7.122774133 Kb 0.712 22.68 0.05
525 FIYNFYQGL 0.00484 no 0 9556 9 4002 41.87944747 Kb 0.827 6.54 0.01
526 FSHRNLDHI 0.00467 no 3 4291 9 1167 27.1964577 Db 0.855 4.83 0.01
527 FSYSYYSNL 0.00466 no 0 677 9 41 6.056129985 Kb 0.855 4.83 0.01
528 YNYFYKPL 0.00463 yes 0 1272 8 1135 89.22955975 Kb 0.79 9.7 0.01
529 MSIMNFSYI 0.00462 no 4 2996 9 2193 73.1975968 Db 0.901 2.9 0.01
530 YSLINYYNL 0.00445 no 2 7126 9 2355 33.04799326 Db 0.877 3.76 0.01
531 VSYAKFPPI 0.00443 yes 0 786 9 455 57.88804071 Kb 0.815 7.4 0.01
532 VSFNPFSLL 0.0043 yes 2 246 9 202 82.11382114 Kb 0.803 8.38 0.01
533 SVMSNLCPI 0.0043 no 0 640 9 39 6.09375 Db 0.792 9.44 0.03
534 LSITNLSYI 0.00429 no 2 7126 9 4328 60.73533539 Db 0.841 5.62 0.01
535 MAYQNVEEI 0.00424 no 0 958 9 546 56.99373695 Db 0.812 7.6 0.01
536 ISMTNELPI 0.00423 no 4 1513 9 1338 88.43357568 Db 0.844 5.41 0.01
537 ITYQYYSIF 0.00411 no 0 309 9 130 42.07119741 Kb 0.772 11.72 0.03
538 HTYNFYSLM 0.00408 no 0 1415 9 913 64.5229682 Kb 0.809 7.9 0.01
539 FSILNNIIL 0.003895 yes 0 1478 9 1013 68.53856563 Db 0.77 11.98 0.03
540 KSISNGNTI 0.00329 no 0 990 9 58 5.858585859 Db 0.806 8.16 0.01
541 ISFYFYNNKL 0.00324 no 0 1194 10 838 70.18425461 Kb 0.732 18.27 0.05
542 VSYGKYSPI 0.00322 no 0 511 9 447 87.47553816 Kb 0.827 6.5 0.01
543 ISYVFKSYL 0.00318 yes 5 2248 9 252 11.20996441 Kb 0.831 6.22 0.01
544 IAYYRMPL 0.00315 no 1 1897 8 583 30.7327359 Kb 0.775 11.41 0.01
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Kb 0.3056 1831.71 2.9722 - + - - - - - - - - -
Db 0.8312 6.2134 0.0051 - - - - - - - - - - +
Kb 0.8392 5.6966 0.0089 - + - - + - - - - - -
Kb 0.8369 5.839 0.009 - + - - + - - - - - -
Kb 0.814 7.4804 0.0111 + + + - + - - - - - -
Kb 0.8992 2.9748 0.0056 - - + + - - - - - - -
Db 0.822 6.8636 0.0054 - - - - - - - - - - -
Kb 0.7539 14.3393 0.0298 - + + - + - - - - - -
Db 0.7426 16.2014 0.0078 - + - - + - - - - - -
Kb 0.8453 5.3351 0.0086 - + - - + - - - - - -
Db 0.7905 9.6491 0.0063 - + - - + - - - - - -
Db 0.7801 10.8029 0.0066 - + - - - - - - - - -
Kb 0.8703 4.0689 0.0072 - + + + + - - - - - -
Kb 0.8443 5.3932 0.0086 - + - - + - - - - - -
Db 0.7257 19.44 0.0083 + + - - + - - - - - -
Db 0.7371 17.1847 0.0079 - + - - - - - - - - -
Db 0.8657 4.2756 0.004 - + - - + - - - - - -
Db 0.8401 5.6389 0.0048 - + + - - - - - - - -
Kb 0.8777 3.7566 0.0068 - + - - + + - - - - -
Db 0.8305 6.256 0.0051 - + - - - - - - - - -
Kb 0.8517 4.9739 0.0082 - - - - + + - - - - -
Kb 0.71 23.0544 0.0561 + + - - + - - - - - -
Kb 0.7292 18.7241 0.0425 - + - - + - - - - - -
Kb 0.842 5.5273 0.0087 - + - - + - - - - - -
Db 0.8076 8.0223 0.0058 - - - - - - - - - + +
Kb 0.9269 2.2047 0.004 + + - - + - - - - - -
Kb 0.8789 3.7092 0.0067 + + - - + - - - - - -
Db 0.9005 2.9357 0.003 - + - - + - - - - - -
Db 0.8027 8.4576 0.006 - - - - + - - - - - +
Kb 0.8421 5.5224 0.0087 + + - - + - - - - - -
Kb 0.832 6.155 0.0093 - - - - - - + - - - -
Db 0.8021 8.5141 0.006 - - - - - - + - - - +
Db 0.8422 5.5124 0.0048 - - - - + - - - - - +
Db 0.825 6.6402 0.0053 - + - - + - - - - - -
Db 0.8278 6.4422 0.0052 - - - - - - - - - - +
Kb 0.8137 7.5051 0.0112 + + - - + - - - - - -
Kb 0.8177 7.1869 0.0104 - - - - - - - + - - -
Db 0.7509 14.8014 0.0075 - - - - + - - - - - -
Db 0.8052 8.2324 0.0059 - + - - + - - - - - -
Kb 0.8651 4.3041 0.0075 - - + - - - - - - - -
Kb 0.8331 6.084 0.0092 - + + + - - - - - - -
Kb 0.8994 2.9707 0.0056 - - + + + - - - - - -
Kb 0.8251 6.6326 0.0097 - - + - + - - - - - -
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545 NAMVNNFFTI 0.00311 no 0 3439 10 2017 58.65077057 Db 0.753 14.48 0.05
546 YGYTHYLQL 0.0031 no 0 5317 9 3369 63.36279857 Kb 0.762 13.06 0.03
547 YNILNSDTI 0.0031 no 0 1010 9 355 35.14851485 Db 0.864 4.36 0.01
548 YSYINENEI 0.00309 no 0 233 9 131 56.22317597 Db 0.788 9.91 0.03
549 KSMSNLDLL 0.00304 no 0 6521 9 5956 91.33568471 Db 0.808 8.03 0.01
550 HSLKNGDTI 0.00304 yes 3 583 9 180 30.87478559 Db 0.853 4.88 0.01
551 LSFIFYSLL 0.00273 no 10 541 9 497 91.86691312 Kb 0.824 6.75 0.01
552 FNYYHFYKPL 0.00259 no 0 529 10 36 6.805293006 Kb 0.711 22.93 0.05
553 VSYNFKSRL 0.00256 no 4 3350 9 236 7.044776119 Kb 0.829 6.4 0.01
554 VMFSRASAL 0.00254 no 0 264 9 211 79.92424242 Kb 0.792 9.54 0.01
555 INYTKFLSL 0.00251 no 0 455 9 241 52.96703297 Kb 0.792 9.44 0.01
556 KSYSKYILL 0.00247 no 0 1174 9 162 13.79897785 Kb 0.809 7.9 0.01
557 YSNANMATL 0.00216 no 4 2562 9 2082 81.264637 Db 0.879 3.72 0.01
558 NCYKYKNL 0.00215 no 2 3724 8 2733 73.38882922 Kb 0.428 487.32 2
559 INYFYLLL 0.002 no 8 4154 8 1606 38.66153105 Kb 0.824 6.71 0.01
560 YAFFFYPNL 0 no 6 951 9 436 45.84647739 Kb 0.818 7.2 0.01
561 INYERFNAL 0 no 0 439 9 98 22.32346241 Kb 0.842 5.53 0.01
562 YSFSNYYSI 0 no 2 3209 9 2638 82.2062948 Db 0.868 4.17 0.01
563 YSMFNLSII 0 yes 2 217 9 197 90.78341014 Db 0.853 4.91 0.01
564 YSYLNIDLL 0 no 0 1591 9 867 54.49402891 Db 0.871 4.06 0.01
565 YGLINITTI 0 yes 1 3204 9 3117 97.28464419 Db 0.904 2.83 0.01
566 YSYQNYSFL 0 no 0 252 9 51 20.23809524 Db 0.872 3.99 0.01
567 TALYNTETI 0 no 0 881 9 277 31.4415437 Db 0.873 3.93 0.01
568 FALYNVNIM 0 yes 0 2150 9 1665 77.44186047 Db 0.826 6.57 0.01
569 SSFNNMHYM 0 no 0 812 9 657 80.91133005 Db 0.817 7.24 0.01
570 YSISNDELI 0 no 0 1429 9 1356 94.89153254 Db 0.868 4.17 0.01
571 SSIKNVFSL 0 no 0 1214 9 343 28.25370675 Db 0.804 8.34 0.01
572 YSPLNYDVL 0 no 0 1218 9 724 59.44170772 Db 0.89 3.29 0.01
573 FAIENNMEI 0 yes 2 293 9 204 69.62457338 Db 0.855 4.78 0.01
574 YAYNNIFLI 0 no 13 2715 9 1866 68.72928177 Db 0.797 8.99 0.03
575 VAPTNITTI 0 no 0 655 9 152 23.20610687 Db 0.882 3.57 0.01
576 IALLNCDSI 0 no 0 784 9 569 72.57653061 Db 0.843 5.44 0.01
577 TSIANFYLL 0 no 0 1083 9 546 50.41551247 Db 0.83 6.29 0.01
578 YMIENLCVI 0 no 2 3209 9 1922 59.89404799 Db 0.839 5.68 0.01
579 FAIINVLLL 0 no 2 2091 9 1915 91.58297465 Db 0.865 4.31 0.01
580 YAPRNSDNI 0 no 0 581 9 233 40.10327022 Db 0.869 4.15 0.01
581 YGAHNYDPI 0 no 0 414 9 19 4.589371981 Db 0.821 6.97 0.01
582 RSMHNNIPI 0 no 0 1991 9 623 31.29080864 Db 0.81 7.77 0.01
583 YSFNFHVTYL 0 no 1 327 10 306 93.57798165 Kb 0.713 22.44 0.05
584 YQLKNVDEL 0 no 0 1591 9 1036 65.11627907 Db 0.857 4.72 0.01
585 TAIQNSNNFPI 0 no 0 1519 11 685 45.09545754 Db 0.704 24.47 0.05
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Db 0.669 35.9413 0.01 - + - - + - - - - - -
Kb 0.8291 6.3527 0.0095 - + + - - - - - - - -
Db 0.8255 6.6053 0.0053 - + - - - - - - - - -
Db 0.8228 6.8042 0.0053 - + - - + - + - - - -
Db 0.8233 6.762 0.0053 - + - - + - - - - - -
Db 0.818 7.1685 0.0055 - + - - - - - - - - -
Kb 0.8918 3.2248 0.006 - + - - + - - - - - -
Kb 0.7803 10.7751 0.0205 - + - - + - - - - - -
Kb 0.8897 3.2983 0.0061 - + - - + - - - - - -
Kb 0.7539 14.3285 0.0298 + + + + + - - - - - -
Kb 0.8691 4.1198 0.0072 - + - - + - + - - - -
Kb 0.7959 9.0994 0.015 - + - - + - - - - - -
Db 0.81 7.8129 0.0057 - - - - + - - - - - +
Kb 0.4468 397.7509 0.8498 - - - - + - - - - - -
Kb 0.9074 2.7246 0.0051 + - - - + - - - - - -
Kb 0.8944 3.1362 0.0058 - + - - + - - - - - -
Kb 0.8616 4.4681 0.0077 - + - - + + - - - - -
Db 0.8587 4.6117 0.0043 - + - - + - - - - - -
Db 0.8582 4.6393 0.0043 - + - - - - - - - - -
Db 0.8447 5.3654 0.0047 - + - - + - - - - - -
Db 0.844 5.4057 0.0047 - - + + - - - - - - -
Db 0.8411 5.5801 0.0048 - + - - + - - - - - -
Db 0.8353 5.9435 0.005 - + + - + + - - - - -
Db 0.8267 6.5198 0.0052 - + - - - - - - - - -
Db 0.8258 6.5824 0.0053 - + - - - - - - - - -
Db 0.8238 6.7288 0.0053 - + - - + + - - - - -
Db 0.8204 6.9838 0.0054 - + - - + - - - - - -
Db 0.8104 7.7827 0.0057 - + - - + - - - - - -
Db 0.8074 8.0367 0.0058 - - + - + - - - - - -
Db 0.8042 8.3181 0.0059 - - + - - - - - - - -
Db 0.8028 8.4432 0.0059 - + + - + - - - - - -
Db 0.8027 8.4525 0.006 - + - - - - - - - - -
Db 0.7961 9.0773 0.0061 - - + + + - - - - - -
Db 0.793 9.3859 0.0062 - + - - + - - - - - -
Db 0.7927 9.422 0.0063 - - - - - - - - - - +
Db 0.7883 9.8811 0.0064 - + - - - - - - - - -
Db 0.7826 10.5049 0.0066 - - + + + - - - - - -
Db 0.7681 12.2958 0.007 - + - - + - - - - - -
Kb 0.7602 13.3874 0.0275 - + + - + + - - - - -
Db 0.7593 13.5198 0.0073 - + - - + - - - - - -
Db 0.7231 19.9958 0.0083 - + - - + - - - - - -
